



US 20050026244A1

(19) **United States**(12) **Patent Application Publication****Ashley et al.**(10) **Pub. No.: US 2005/0026244 A1**(43) **Pub. Date: Feb. 3, 2005**(54) **RECOMBINANT NARBONOLIDE
POLYKETIDE SYNTHASE**(76) Inventors: **Gary Ashley**, Alameda, CA (US);
Melanie C. Betlach, San Francisco, CA
(US); **Mary Betlach**, San Francisco,
CA (US); **Robert McDaniel**, Palo Alto,
CA (US); **Li Tang**, Foster City, CA
(US)

Correspondence Address:

MORRISON & FOERSTER LLP
755 PAGE MILL RD
PALO ALTO, CA 94304-1018 (US)(21) Appl. No.: **10/468,828**(22) PCT Filed: **Feb. 22, 2002**(86) PCT No.: **PCT/US02/05642****Related U.S. Application Data**(60) Continuation of application No. 09/793,708, filed on
Feb. 22, 2001, which is a continuation-in-part of
application No. 09/657,440, filed on Sep. 7, 2000,now Pat. No. 6,509,455, which is a division of
application No. 09/320,878, filed on May 27, 1999,
now Pat. No. 6,117,659, which is a continuation-in-
part of application No. 09/141,908, filed on Aug. 28,
1998, now Pat. No. 6,503,741, which is a continua-
tion-in-part of application No. 09/073,538, filed on
May 6, 1998, now Pat. No. 6,558,942, which is a
continuation-in-part of application No. 08/846,247,
filed on Apr. 30, 1997, now Pat. No. 6,391,594.**Publication Classification**(51) **Int. Cl.⁷** **C12N 9/10**; C12N 9/16;
C07H 21/04; C12N 1/21
(52) **U.S. Cl.** **435/69.1**; 435/193; 435/196;
435/252.3; 435/320.1; 536/23.2(57) **ABSTRACT**Recombinant DNA compounds that encode all or a portion
of the narbonolide polyketide synthase are used to express
recombinant polyketide synthase genes in host cells for the
production of narbonolide, narbonolide derivatives, and
polyketides that are useful as antibiotics and as intermedi-
ates in the synthesis of compounds with pharmaceutical
value.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

RECOMBINANT NARBONOLIDE POLYKETIDE SYNTHASE

REFERENCE TO GOVERNMENT FUNDING

[0001] This invention was supported in part by SBIR grant 1R43-CA75792-01. The U.S. government has certain rights in this invention.

FIELD OF THE INVENTION

[0002] The present invention provides recombinant methods and materials for producing polyketides by recombinant DNA technology. The invention relates to the fields of agriculture, animal husbandry, chemistry, medicinal chemistry, medicine, molecular biology, pharmacology, and veterinary technology.

BACKGROUND OF THE INVENTION

[0003] Polyketides represent a large family of diverse compounds synthesized from 2-carbon units through a series of condensations and subsequent modifications. Polyketides occur in many types of organisms, including fungi and mycelial bacteria, in particular, the actinomycetes. There are a wide variety of polyketide structures, and the class of polyketides encompasses numerous compounds with diverse activities. Tetracycline, erythromycin, FK506, FK520, narbomycin, picromycin, rapamycin, spinocyn, and tylosin, are examples of such compounds. Given the difficulty in producing polyketide compounds by traditional chemical methodology, and the typically low production of polyketides in wild-type cells, there has been considerable interest in finding improved or alternate means to produce polyketide compounds. See PCT publication Nos. WO 93/13663; WO 95/08548; WO 96/40968; 97/02358; and 98/27203; U.S. Pat. Nos. 4,874,748; 5,063,155; 5,098,837; 5,149,639; 5,672,491; and 5,712,146; Fu et al., 1994, *Biochemistry* 33: 9321-9326; McDaniel et al., 1993, *Science* 262: 1546-1550; and Rohr, 1995, *Angew. Chem. Int. Ed. Engl.* 34(8): 881-888, each of which is incorporated herein by reference.

[0004] Polyketides are synthesized in nature by polyketide synthase (PKS) enzymes. These enzymes, which are complexes of multiple large proteins, are similar to the synthases that catalyze condensation of 2-carbon units in the biosynthesis of fatty acids. PKS enzymes are encoded by PKS genes that usually consist of three or more open reading frames (ORFs). Each ORF typically comprises two or more "modules" of ketosynthase activity, each module of which consists of at least two (if a loading module) and more typically three or more enzymatic activities or "domains." Two major types of PKS enzymes are known; these differ in their composition and mode of synthesis. These two major types of PKS enzymes are commonly referred to as Type I or "modular" and Type II "iterative" PKS enzymes.

[0005] Modular PKSs are responsible for producing a large number of 12, 14, and 16-membered macrolide antibiotics including methymycin, erythromycin, narbomycin, picromycin, and tylosin. These large multifunctional enzymes (>300,000 kDa) catalyze the biosynthesis of polyketide macrolactones through multistep pathways involving decarboxylative condensations between acyl thioesters followed by cycles of varying β -carbon process-

ing activities (see O'Hagan, D. *The polyketide metabolites*; E. Horwood: New York, 1991, incorporated herein by reference).

[0006] During the past half decade, the study of modular PKS function and specificity has been greatly facilitated by the plasmid-based *Streptomyces coelicolor* expression system developed with the 6-deoxyerythronolide B (6-dEB) synthase (DEBS) genes (see Kao et al., 1994, *Science*, 265: 509-512, McDaniel et al., 1993, *Science* 262: 1546-1557, and U.S. Pat. Nos. 5,672,491 and 5,712,146, each of which is incorporated herein by reference). The advantages to this plasmid-based genetic system for DEBS were that it overcame the tedious and limited techniques for manipulating the natural DEBS host organism, *Saccharopolyspora erythraea*, allowed more facile construction of recombinant PKSs, and reduced the complexity of PKS analysis by providing a "clean" host background. This system also expedited construction of the first combinatorial modular polyketide library in *Streptomyces* (see PCT publication No. WO 98/49315, incorporated herein by reference).

[0007] The ability to control aspects of polyketide biosynthesis, such as monomer selection and degree of β -carbon processing, by genetic manipulation of PKSs has stimulated great interest in the combinatorial engineering of novel antibiotics (see Hutchinson, 1998, *Curr. Opin. Microbiol.* 1: 319-329; Carreras and Santi, 1998, *Curr. Opin. Biotech.* 9: 403-411; and U.S. Pat. Nos. 5,712,146 and 5,672,491, each of which is incorporated herein by reference). This interest has resulted in the cloning, analysis, and manipulation by recombinant DNA technology of genes that encode PKS enzymes. The resulting technology allows one to manipulate a known PKS gene cluster either to produce the polyketide synthesized by that PKS at higher levels than occur in nature or in hosts that otherwise do not produce the polyketide. The technology also allows one to produce molecules that are structurally related to, but distinct from, the polyketides produced from known PKS gene clusters.

[0008] The present invention provides methods and reagents relating to the PKS gene cluster for the polyketide antibiotics known as narbomycin and picromycin. Narbomycin is produced in *Streptomyces narbonensis*, and both narbomycin and picromycin are produced in *S. venezuelae*. These species are unique among macrolide producing organisms in that they produce, in addition to the 14-membered macrolides narbomycin and picromycin (picromycin is shown in FIG. 1, compound 1), the 12-membered macrolides neomethymycin and methymycin (methymycin is shown in FIG. 1, compound 2). Based on the structural similarities between picromycin and methymycin, it was speculated that methymycin would result from premature cyclization of a hexaketide intermediate in the picromycin pathway.

[0009] Glycosylation of the C5 hydroxyl group of the polyketide precursor, narbonolide, is achieved through an endogenous desosaminyl transferase to produce narbomycin. In *Streptomyces venezuelae*, narbomycin is then converted to picromycin by the endogenously produced narbomycin hydroxylase. Thus, as in the case of other macrolide antibiotics, the macrolide product of the narbonolide PKS is further modified by hydroxylation and glycosylation.

[0010] Picromycin (FIG. 1, compound 1) is of particular interest because of its close structural relationship to

ketolide compounds (e.g. HMR 3004, **FIG. 1**, compound 3). The ketolides are a new class of semi-synthetic macrolides with activity against pathogens resistant to erythromycin (see Agouridas et al., 1998, *J. Med. Chem.* 41: 4080-4100, incorporated herein by reference). Thus, genetic systems that allow rapid engineering of the narbonolide PKS would be valuable for creating novel ketolide analogs for pharmaceutical applications. Furthermore, the production of picromycin as well as novel compounds with useful activity could be accomplished if the heterologous expression of the narbonolide PKS in *Streptomyces lividans* and other host cells were possible. The present invention meets these and other needs.

SUMMARY OF THE INVENTION

[0011] The present invention provides recombinant methods and materials for expressing PKSs derived in whole and in part from the narbonolide PKS and other genes involved in narbomycin and picromycin biosynthesis in recombinant host cells. The invention also provides the polyketides derived from the narbonolide PKS. The invention provides the complete PKS gene cluster that ultimately results, in *Streptomyces venezuelae*, in the production of picromycin. The ketolide product of this PKS is narbonolide. Narbonolide is glycosylated to obtain narbomycin and then hydroxylated at C12 to obtain picromycin. The enzymes responsible for the glycosylation and hydroxylation are also provided in recombinant form by the invention.

[0012] Thus, in one embodiment, the invention is directed to recombinant materials that contain nucleotide sequences encoding at least one domain, module, or protein encoded by a narbonolide PKS gene. The invention also provides recombinant materials useful for conversion of ketolides to antibiotics. These materials include recombinant DNA compounds that encode the C12 hydroxylase (the picK gene), the desosamine biosynthesis and desosaminyl transferase enzymes, and the beta-glucosidase enzyme involved in picromycin biosynthesis in *S. venezuelae* and the recombinant proteins that can be produced from these nucleic acids in the recombinant host cells of the invention.

[0013] In one embodiment, the invention provides a recombinant expression vector that comprises a heterologous promoter positioned to drive expression of the narbonolide PKS. In a preferred embodiment, the promoter is derived from a PKS gene. In a related embodiment, the invention provides recombinant host cells comprising the vector that produces narbonolide. In a preferred embodiment, the host cell is *Streptomyces lividans* or *S. coelicolor*.

[0014] In another embodiment, the invention provides a recombinant expression vector that comprises the desosamine biosynthetic genes as well as the desosaminyl transferase gene. In a related embodiment, the invention provides recombinant host cells comprising the vector that produces the desosamine biosynthetic gene products and desosaminyl transferase gene product. In a preferred embodiment, the host cell is *Streptomyces lividans* or *S. coelicolor*.

[0015] In another embodiment, the invention provides a method for desosaminylating polyketide compounds in recombinant host cells, which method comprises expressing the PKS for the polyketide and the desosaminyl transferase and desosamine biosynthetic genes in a host cell. In a preferred embodiment, the host cell expresses a beta-glucosidase gene as well. This preferred method is especially advantageous when producing desosaminylated polyketides

in *Streptomyces* host cells, because such host cells typically glucosylate desosamine residues of polyketides, which can decrease desired activity, such as antibiotic activity. By coexpression of beta-glucosidase, the glucose residue is removed from the polyketide.

[0016] In another embodiment, the invention provides the picK hydroxylase gene in recombinant form and methods for hydroxylating polyketides with the recombinant gene product. The invention also provides polyketides thus produced and the antibiotics or other useful compounds derived therefrom.

[0017] In another embodiment, the invention provides a recombinant expression vector that comprises a promoter positioned to drive expression of a hybrid PKS comprising all or part of the narbonolide PKS and at least a part of a second PKS. In a related embodiment, the invention provides recombinant host cells comprising the vector that produces the hybrid PKS and its corresponding polyketide. In a preferred embodiment, the host cell is *Streptomyces lividans* or *S. coelicolor*.

[0018] In a related embodiment, the invention provides recombinant materials for the production of libraries of polyketides wherein the polyketide members of the library are synthesized by hybrid PKS enzymes of the invention. The resulting polyketides can be further modified to convert them to other useful compounds, such as antibiotics, typically through hydroxylation and/or glycosylation. Modified macrolides provided by the invention that are useful intermediates in the preparation of antibiotics are of particular benefit.

[0019] In another related embodiment, the invention provides a method to prepare a nucleic acid that encodes a modified PKS, which method comprises using the narbonolide PKS encoding sequence as a scaffold and modifying the portions of the nucleotide sequence that encode enzymatic activities, either by mutagenesis, inactivation, insertion, or replacement. The thus modified narbonolide PKS encoding nucleotide sequence can then be expressed in a suitable host cell and the cell employed to produce a polyketide different from that produced by the narbonolide PKS. In addition, portions of the narbonolide PKS coding sequence can be inserted into other PKS coding sequences to modify the products thereof. The narbonolide PKS can itself be manipulated, for example, by fusing two or more of its open reading frames, particularly those for extender modules 5 and 6, to make more efficient the production of 14-membered as opposed to 12-membered macrolides.

[0020] In another related embodiment, the invention is directed to a multiplicity of cell colonies, constituting a library of colonies, wherein each colony of the library contains an expression vector for the production of a modular PKS derived in whole or in part from the narbonolide PKS. Thus, at least a portion of the modular PKS is identical to that found in the PKS that produces narbonolide and is identifiable as such. The derived portion can be prepared synthetically or directly from DNA derived from organisms that produce narbonolide. In addition, the invention provides methods to screen the resulting polyketide and antibiotic libraries.

[0021] The invention also provides novel polyketides and antibiotics or other useful compounds derived therefrom. The compounds of the invention can be used in the manufacture of another compound. In a preferred embodiment, the antibiotic compounds of the invention are formulated in a mixture or solution for administration to an animal or human.

[0022] These and other embodiments of the invention are described in more detail in the following description, the examples, and claims set forth below.

BRIEF DESCRIPTION OF THE FIGURES

[0023] FIG. 1 shows the structures of picromycin (compound 1), methymycin (compound 2), and the ketolide HMR 3004 (compound 3).

[0024] FIG. 2 shows a restriction site and function map of cosmid pKOS023-27.

[0025] FIG. 3 shows a restriction site and function map of cosmid pKOS023-26.

[0026] FIG. 4 has three parts. In Part A, the structures of picromycin (A(a)) and methymycin (A(b)) are shown, as well as the related structures of narbomycin, narbonolide, and methynolide. In the structures, the bolded lines indicate the two or three carbon chains produced by each module (loading and extender) of the narbonolide PKS. Part B shows the organization of the narbonolide PKS genes on the chromosome of *Streptomyces venezuelae*, including the location of the various module encoding sequences (the loading module domains are identified as sKS*, sAT, and sACP), as well as the picB thioesterase gene and two desosamine biosynthesis genes (picCII and picCIII). Part C shows the engineering of the *S. venezuelae* host of the invention in which the picAI gene has been deleted. In the Figure, ACP is acyl carrier protein; AT is acyltransferase; DH is dehydratase; ER is enoylreductase; KR is ketoreductase; KS is ketosynthase; and TE is thioesterase.

[0027] FIG. 5 shows the narbonolide PKS genes encoded by plasmid pKOS039-86, the compounds synthesized by each module of that PKS and the narbonolide (compound 4) and 10-deoxymethynolide (compound 5) products produced in heterologous host cells transformed with the plasmid. The Figure also shows a hybrid PKS of the invention produced by plasmid pKOS038-18, which encodes a hybrid of DEBS and the narbonolide PKS. The Figure also shows the compound, 3,6-dideoxy-3-oxo-erythronolide B (compound 6), produced in heterologous host cells comprising the plasmid.

[0028] FIG. 6 shows a restriction site and function map of plasmid pKOS039-104, which contains the desosamine biosynthetic, beta-glucosidase, and desosaminyl transferase genes under transcriptional control of actII-4.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The present invention provides useful compounds and methods for producing polyketides in recombinant host cells. As used herein, the term recombinant refers to a compound or composition produced by human intervention. The invention provides recombinant DNA compounds encoding all or a portion of the narbonolide PKS. The invention also provides recombinant DNA compounds encoding the enzymes that catalyze the further modification of the ketolides produced by the narbonolide PKS. The invention provides recombinant expression vectors useful in producing the narbonolide PKS and hybrid PKSs composed of a portion of the narbonolide PKS in recombinant host cells. Thus, the invention also provides the narbonolide PKS, hybrid PKSs, and polyketide modification enzymes in recombinant form. The invention provides the polyketides produced by the recombinant PKS and polyketide modification enzymes. In particular, the invention provides methods for producing the polyketides 10-deoxymethynolide,

narbonolide, YC17, narbomycin, methymycin, neomethymycin, and picromycin in recombinant host cells.

[0030] To appreciate the many and diverse benefits and applications of the invention, the description of the invention below is organized as follows. First, a general description of polyketide biosynthesis and an overview of the synthesis of narbonolide and compounds derived therefrom in *Streptomyces venezuelae* are provided. This general description and overview are followed by a detailed description of the invention in six sections. In Section I, the recombinant narbonolide PKS provided by the invention is described. In Section II, the recombinant desosamine biosynthesis genes, the desosaminyl transferase gene, and the beta-glucosidase gene provided by the invention are described. In Section III, the recombinant picK hydroxylase gene provided by the invention is described. In Section IV, methods for heterologous expression of the narbonolide PKS and narbonolide modification enzymes provided by the invention are described. In Section V, the hybrid PKS genes provided by the invention and the polyketides produced thereby are described. In Section VI, the polyketide compounds provided by use invention and pharmaceutical compositions of those compounds are described. The detailed description is followed by a variety of working examples illustrating the invention.

[0031] The narbonolide synthase gene, like other PKS genes, is composed of coding sequences organized in a loading module, a number of extender modules, and a thioesterase domain. As described more fully below, each of these domains and modules is a polypeptide with one or more specific functions. Generally, the loading module is responsible for binding the first building block used to synthesize the polyketide and transferring it to the first extender module. The building blocks used to form complex polyketides are typically acylthioesters, most commonly acetyl, propionyl, malonyl, methylmalonyl, and ethylmalonyl CoA. Other building blocks include amino acid like acylthioesters. PKSs catalyze the biosynthesis of polyketides through repeated, decarboxylative Claisen condensations between the acylthioester building blocks. Each module is responsible for binding a building block, performing one or more functions on that building block, and transferring the resulting compound to the next module. The next module, in turn, is responsible for attaching the next building block and transferring the growing compound to the next module until synthesis is complete. At that point, an enzymatic thioesterase activity cleaves the polyketide from the PKS.

[0032] Such modular organization is characteristic of the class of PKS enzymes that synthesize complex polyketides and is well known in the art. The polyketide known as 6-deoxyerythronolide B is a classic example of this type of complex polyketide. The genes, known as eryAI, eryAII, and eryAIII (also referred to herein as the DEBS genes, for the proteins, known as DEBS1, DEBS2, and DEBS3, that comprise the 6-dEB synthase), that code for the multi-subunit protein known as DEBS that synthesizes 6-dEB are described in U.S. Pat. No. 5,824,513, incorporated herein by reference. Recombinant methods for manipulating modular PKS genes are described in U.S. Pat. Nos. 5,672,491; 5,843,718; 5,830,750; and 5,712,146; and in PCT publication Nos. 98/49315 and 97/02358, each of which is incorporated herein by reference.

[0033] The loading module of DEBS consists of two domains, an acyl-transferase (AT) domain and an acyl

carrier protein (ACP) domain. Each extender module of DEBS, like those of other modular PKS enzymes, contains a ketosynthase (KS), AT, and ACP domains, and zero, one, two, or three domains for enzymatic activities that modify the beta-carbon of the growing polyketide chain. A module can also contain domains for other enzymatic activities, such as, for example, a methyltransferase or dimethyltransferase activity. Finally, the releasing domain contains a thioesterase and, often, a cyclase activity.

[0034] The AT domain of the loading module recognizes a particular acyl-CoA (usually acetyl or propionyl but sometimes butyryl) and transfers it as a thiol ester to the ACP of the loading module. Concurrently, the AT on each of the extender modules recognizes a particular extender-CoA (malonyl or alpha-substituted malonyl, i.e., methylmalonyl, ethylmalonyl, and carboxylglycolyl) and transfers it to the ACP of that module to form a thioester. Once the PKS is primed with acyl- and malonyl-ACPs, the acyl group of the loading module migrates to form a thiol ester (trans-esterification) at the KS of the first extender module; at this stage, extender module 1 possesses an acyl-KS adjacent to a malonyl (or substituted malonyl) ACP. The acyl group derived from the loading module is then covalently attached to the alpha-carbon of the malonyl group to form a carbon-carbon bond, driven by concomitant decarboxylation, and generating a new acyl-ACP that has a backbone two carbons longer than the loading unit (elongation or extension). The growing polyketide chain is transferred from the ACP to the KS of the next module, and the process continues.

[0035] The polyketide chain, growing by two carbons each module, is sequentially passed as covalently bound thiol esters from module to module, in an assembly line-like process. The carbon chain produced by this process alone would possess a ketone at every other carbon atom, producing a polyketone, from which the name polyketide arises. Most commonly, however, additional enzymatic activities modify the beta keto group of each two-carbon unit just after it has been added to the growing polyketide chain but before it is transferred to the next module. Thus, in addition to the minimal module containing KS, AT, and ACP domains necessary to form the carbon-carbon bond, modules may contain a ketoreductase (ICR) that reduces the keto group to an alcohol. Modules may also contain a KR plus a dehydratase (DH) that dehydrates the alcohol to a double bond. Modules may also contain a KR, a DH, and an enoylreductase (ER) that converts the double bond to a saturated single bond using the beta carbon as a methylene function. As noted above, modules may contain additional enzymatic activities as well.

[0036] Once a polyketide chain traverses the final extender module of a PKS, it encounters the releasing domain or thioesterase found at the carboxyl end of most PKSs. Here, the polyketide is cleaved from the enzyme and cyclized. The resulting polyketide can be modified further by tailoring enzymes; these enzymes add carbohydrate groups or methyl groups, or make other modifications, i.e., oxidation or reduction, on the polyketide core molecule.

[0037] While the above description applies generally to modular PKS enzymes, there are a number of variations that exist in nature. For example, some polyketides, such as epothilone, incorporate a building block that is derived from an amino acid. PKS enzymes for such polyketides include an

activity that functions as an amino acid ligase or as a non-ribosomal peptide synthetase (NRPS). Another example of a variation, which is actually found more often than the two domain loading module construct found in DEBS, occurs when the loading module of the PKS is not composed of an AT and an ACP but instead utilizes an inactivated KS, an AT, and an ACP. This inactivated KS is in most instances called KSQ, where the superscript letter is the abbreviation for the amino acid, glutamine, that is present instead of the active site cysteine required for activity. For example, the narbonolide PKS loading module contains aKS^Q. Yet another example of a variation has been mentioned above in the context of modules that include a methyltransferase or dimethyltransferase activity; modules can also include an epimerase activity. These variations will be described further below in specific reference to the narbonolide PKS and the various recombinant and hybrid PKSs provided by the invention.

[0038] With this general description of polyketide biosynthesis, one can better appreciate the biosynthesis of narbonolide related polyketides in *Streptomyces venezuelae* and *S. narbonensis*. The narbonolide PKS produces two polyketide products, narbonolide and 10-deoxymethynolide. Narbonolide is the polyketide product of all six extender modules of the narbonolide PKS. 10-deoxymethynolide is the polyketide product of only the first five extender modules of the narbonolide PKS. These two polyketides are desosaminylated to yield narbomycin and YC17, respectively. These two glycosylated polyketides are the final products produced in *S. narbonensis*. In *S. venezuelae*, these products are hydroxylated by the picK gene product to yield picromycin and either methymycin (hydroxylation at the C10 position of YC7) or neomethymycin (hydroxylation at the C12 position of YC17). The present invention provides the genes required for the biosynthesis of all of these polyketides in recombinant form.

[0039] Section 1: The Narbonolide PKS

[0040] The narbonolide PKS is composed of a loading module, six extender modules, and a thioesterase domain. **FIG. 4**, part B, shows the organization of the narbonolide PKS genes on the *Streptomyces venezuelae* chromosome, as well as the location of the module encoding sequences in those genes, and the various domains within those modules. In the Figure, the loading module is not numbered, and its domains are indicated as sKS*, sAT, and ACP. Also shown in the Figure, part A, are the structures of picromycin and methymycin.

[0041] The loading and six extender modules and the thioesterase domain of the narbonolide PKS reside on four proteins, designated PICAI, PICAI, PICAI, and PICAI. PICAI includes the loading module and extender modules 1 and 2 of the PKS. PICAI includes extender modules 3 and 4. PICAI includes extender module 5. PICAI includes extender module 6 and a thioesterase domain. There is a second thioesterase domain (TEII) on a separate protein, designated PICB. The amino acid sequences of these proteins are shown below.

Amino acid sequence of narbonolide synthase subunit 1, PICAI

1 MSTVSKSESE EFVSVSNDAG SAHGTAEPVA VVGISCRVPG ARDPPEFWEL LAAGGQAVTD

61 VPADRWNAGD FYDPRSAPG RSNSRWGGFI EDVDRFDAF FGISPREEAE MDPQQRLALE

121 LGWEALERAG IDPSSLTGTR TGVFAGAIWD DYATLKHRQG GAAITPHTVT GLHRGIIANR

181 LSYTLGLRGP SMVVDSGQSS SLVAVHLACE SLRRGESELA LAGGVS LNLV PDSIIGASKF

241 GGLSPDGRAY TFDARANGYV RGEGGGFVVL KRLSRAVADG DPVLAVIRGS AVNNGGAAQG

301 MTTFDAQAQE AVLREAHERA GTAPADVRYV ELHGTGTPVG DPEAAAALGA ALGTGRPAGQ

361 PLLVGSVKTN IGHLEGAAGI AGLIKAVLAV RGRALPASLN YETPNPAIPF EELNLRVNT

421 YLPWEPEHDG QRMVVGVS SF GMGGTNAHV LEEAPGVVEG ASVVESTVGG SAVGGGVVFW

481 VVSAKSAAAL DAQIERLA AF ASRDRTDGVD AGAVDAGAVD AGAVARVLAG GRAQFEHRAV

541 VVGSGPDDLA AALAAPEGLV RGVASGVGRV AFVFPQGQTQ WAGMGAELLD SSAVF AAMA

601 ECEAALSPYV DWSLEAVVRQ APGAPTLERV DVVQPVTFV MVSLARVWQH HGVTPQAVVG

661 HSQGEIAAAY VAGALSLDDA ARVVTLSRSK IAAHLGKGG MSLALSEDA VLERLAGFDG

721 LSVAAVNGPT ATVSGDPVQ IEELARACEA DGVRARVIPV DYASHSRQVE IIESELAEVL

781 AGLSPQAPRV PFFSTLEGAW ITEPVLDDGY WYRNLRRHVG FAPAVETLAT DEGFTHFVEV

841 SAHPVLTMAL PGTVTGLATL RRDNGGQDRL VASLAEAWAN GLAVDWSPLL PSATGHHS DL

901 PTYAFQTERH WLGEIEALAP AGEPAVQPAV LRTEAAEPAE LDRDEQLRVI LDKVRAQTAQ

961 VLGATYGGQI EVDRTFREAG CTSLTGVDLR NRINA AFVGR MAPSMIFDFP TPEALAEQLL

1021 LVVHGEEAAN PAGAEPAPVA AAGAVDEPVA IVGMACRLPG GVASPEDLWR LVAGGGDAIS

1081 EFPQDRGWDV EGLYHPDEH PGTSYVRQGG FIENVAGFDA AFGISPREA LAMPQQRL

1141 LETSWEAVED AGIDPTSLRG RQVGVFTGAM THEYGPSLRD GGEGLDGYLL TGNTASVMSG

1201 RVSYTLGLEG PALTVDTACS SSLVALHLAV QALRKGEVDM ALAGGVAVMP TPGMFVEFSR

1261 QRGLAGDGRS KAFAASADGT SWSEGVGVLL VERLSDARRN GHQVLAVVRG SAVNQDGASN

1321 GLTAPNGPSQ ORVIRRALAD ARLTTSDDV VEAHGTGTRL GDPIEAQALI ATYGQGRDDE

1381 QPLRLGSLKS NIGHTQAAAG VSGVIKMVQA MRHGLLPKTL HVDEPSDQID WSAGAVELLT

1441 EAVDWPEKQD GGLRRAAVSS FGISGTNAHV VLEEAPVVVE GASVVEPSVG GSAVGGGVTP

1501 WVVSAKSAAA LDAQIERLAA FASRDRTDDA DAGAVDAGAV AHVLADGRAQ FEHRAVALGA

1561 GADDLVQALA DPDGLIRGTA SGVGRVAFVF PGQGTQWAGM GAELLDSSAV FAAA MAECEA

1621 ALSPYVDWSL EAVVRQAPGA PTLERVDVVQ PVTFAVMVSL ARVWQH HGVTPQAVVGH SQG

1681 EIAAAAYAGA LPLDDAARVV TLRKSIAAH LAGKGM LSL ALNEDAVLER LSDFDGLSVA

1741 AVNGPTATVV SGDPVQIEEL AQACKADGFR ARIIPVDYAS HSRQVEIIES ELAQVLGLS

1801 PQAPRVPPFS TLEGTWITEP VLDGTYWYRN LRHRVGFAPA IETLAVDEGF THFVEVSAHP

1861 VLTMTLPETV TGLGTLRREQ GGQERLVTSL AEAWVNGLPV AWTSLLPATA SRPGLPTYAF

1921 QAERYWLENT PAALATGDDW RYRIDWKRLP AEGSERTGL SGRWLAVTPE DHSQAQAAVL

1981 TALVDAGAKV EVLTAGADDD REALAARLTA LTTGDGFTGV VSLLDGLVPQ VAWVQALGDA

2041 GIKAPLWSVT QGAVSVGRLD TPADPDRAML WGLGRVVALE HPERWAGLVD LPAQPDAAAL

2101 AHLVTALSGA TGEDQIAIRT TGLHARRLAR APLHGRRPTR DWQPHGTVLI TGGTGALGSH

2161 AARWMAHGA EHLLLVSRSG EQAPGATQLT AELTASGARV TIAACDVADP HAMRTLDAI

2221 PAETPLTAVV HTAGALDDGI VDTLTAEQVR RAHRAKAVGA SVLDELTRDL DLDAFVLFSS

-continued

2281 VSSTLGIPGQ GNYAPHNAYL DALAARRRAT GRSVSVAWG PWDGGGMAAG DGVAERLRNH
 2341 GVPGMDEPELA LAALESALGR DETAITVADI DWDRFYLAIS SGRPQPLVEE LPEVRRRIIDA
 2401 RDSATSGQGQ SSAQGANPLA RRLAAAAPGE RTEILLGLVR AQAAAVLRMR SPEDVAADRA
 2461 FKDIGFDSL A GVELNRNLTR ATGLQLPATL VFDHPTPLAL VSLLRSEFLG DEETADARRS
 2521 AALPATVGAG AGAGAGTDAD DDPIAIVAMS CRYPGDIRSP EDLWRMLSEG GEGITPFFPTD
 2581 RGWDL DGLYD ADPDALGRAY VREGGFLHDA AEFDAEFFGV SPREALAMDF QQRMLLTTSW
 2641 EAFERAGIEP ASLRGSSTGV FIGLSYQDYA ARVPNAPRGV EGYLLTGSTP SVASGRIAYT
 2701 FGLEGPATTV DTACSSSLTA LHLAVRALRS GECTMALAGG VAMMATPHMF VEF SRQRALA
 2761 PDGRSKAFSA DADGFGAAEG VGLLLVERLS DARRNGHPVL AVVRGTAVNQ DGASNGLTAP
 2821 NGPSQQRVIR QALADARLAP GDIDAVETHG TGTSLGDPIE AQGLQATYK ERPAERPLAI
 2881 GSVKSNIGHT QAAAGAAGII KMLAMRHGT LPKTLHADEP SPHVDWANS G LALVTEPIDW
 2941 PAGTGPRRAA VSSFGISGTN AHVVLEQAPD AAGEVLGADE VPEVSETVAM AGTAGTSEVA
 3001 EGSEASEAPA APGSREASLP GHLFWVLSAK DEQSLRGQAA ALHAWLSEPA ADLSDADGPA
 3061 RLRDVGYTLA TSRTAFAHRA AVTAADR DGF LDGLATLAQG GTSAHVHLDT ARDGT TAF LF
 3121 TGQGSQRPGA GRELYDRHPV FARALDEICA HLDGHLELPL LDVMFAAEGS AEAALLDETR
 3181 YTQCALFALE VALFRLVESW GMRPAALLGH SVGEIAAAHV AGVFSLADAA RLVAARGRLM
 3241 QELPAGGAML AVQAAEDEIR VWLETEERYA GRLDVAAVNG PEAAVLSGDA DAAREAEAYW
 3301 SGLGRRTRAL RVSHAFHSAH MDGMLDGFR A VLETVEFRRP SLTVVSNVTG LAAGPDDLCD
 3361 PEYWRHVRG TVRFLDGVRV LRD LGVRTCL ELGPDGVLTA MAADGLADTP ADSAAGSPVG
 3421 SPAGSPADSA AGALRPRPLL VALLRRKRSE TETVADALGR AHAHGTGPDW HAWFAGSGAH
 3481 RVDLPTYSFR RDRYWL DAPA ADTAVDTAGL GLGTADHPLL GAVVSLPDRD GLLLTGRLSL
 3541 RTHPWLDHA VLGSVLLPGA AMVELAAHAA ESAGLRDVRE LTLLEPLVLP EHG GVELRVT
 3601 VGAPAGEPGG ESAGDGARPV SLHSRLADAP AGTAWSCHAT GLLATDRPEL PVAPDRAAMW
 3661 PPQGAEVPL DGLYERLDGN GLAFGPLFQG LNAVWRYEGE VFADIALPAT TNATAPATAN
 3721 GGGSA A A A A A P Y G I H P A L L D A S L H A I A V G G L V D E P E L V R V P F H W S G V T V H A A G A A A A R V R L A
 3781 SAGTDAVSLS LTDGEGRLV SVERLTLRPV TADQAAASRV GGLMHRVAWR PYALASSGEQ
 3841 DPHATSYGPT AVLKDELKV AALESAGVE VGLYPLAAL SQDVAAGAPA PRTVLAPLPA
 3901 GPADGGAEGV RGT VARTLEL LQAWLADEHL AGTRLLLVTR GAVRDEPGSG ADDGGEDLSH
 3961 AAAGLVR TA Q TENPGRFGL LDLADDASSY RTLPSVLSDA GLRDEPQLAL HDGTIRLARL
 4021 ASVRPETGTA APALAPEGTV LLTGGTGGLG GLVARHVVE WGVRRLLLV S RRGTDAPGAD
 4081 ELVHELEALG ADVSVAACDV ADREALTAVL DAIPA EHPLT AVVHTAGVLS DGTLP SMTTE
 4141 DVEHVL RPKV DAAFLDEL T STPAYDLAAF VMFSSAAAVF GGAGQGAYAA ANATLDALAW
 4201 RRRAGLPAL SLGWLWAE T S GMTGELGQA DLRRMSRAGI GGISDAEGIA LLDAALRDDR
 4261 HPVLLPLRLD AAGLRDAAGN DPAGIPALFR DVVGARTVRA RPSAASASTT AGTAGTPGTA
 4321 DGAAETA AVT LADRAATVDG PARQRLLEF VVGEVAEVLG HARGHRIDAE RGFLDLGFDS
 4381 LTAVELNRNL NSAGGLALPA TLVFDHPSPA ALASHLDAEL PRGASDQDGA GNRNGNENG T
 4441 TASRSTAETD ALLAQLTRLE GALVLTGLSD APGSEEVLEH LRSLRSMVTG ETGTGTASGA
 4501 PDGAGSGAED RPWAAGDGAG GGS EDGAGVP DFMNASAEEL FGLLDQDPST D

Amino acid sequence of narbonolide synthase subunit 2, PICAI I

-continued

1 VSTVNEEKYL DYLRATADL HEARGRLREL EAKAGEPVAI VGMACRLPGG VASPEDLWRL
61 VAGGEDAISE FPQDRGWDVE GLYDPNPEAT GKSAREAGF LYEAGEFDAD FFGISPREAL
121 AMDPQQRLLL EASWEAFEHA GIPAATARGT SVGVFTGVMY HDYATRLTDV PEGIEGYLGT
181 GNSGSVASGR VAYTLGLEGP AVTVDTACSS SLVALHLAVQ ALRKGEVDMA LAGGVTVMST
241 PSTFVEFSRQ RGLAPDGRSK SFSSTADGTS WSEGVGVLLV ERLSDARRKG HRILAVVRGT
301 AVNQDGASSG LTAPNGPSQQ RVIRRALADA RLTTSDVDV V EAHGTGTRLG DPEAQAVIA
361 TYQGGRDGEQ PLRLGSLKSN IGHQAAGV SGVIKMQAM RHGVLPKTLH VEKPTDQVDW
421 SAGAVELLTE AMDWPKGDG GLRRAAVSSF GVSGTNAHV LEEAPAAEET PASEATPAVE
481 PSVGAGLVPV LVSAKTPAAL DAQIGRLAAF ASQGRDAD PGAVARVLG GRAEFEHRAV
541 VLGTGQDDFA QALTAPEGLI RGTPSDVGRV AFVFPQGQTQ WAGMGAELLD VSKEFAAAMA
601 ECESALSRYV DWSLEAVVRQ APGAPTLERV DVVQPVTFV MVS LAKVWQH HGVTPQAVVG
661 HSQGEIAAAY VAGALTLLDA ARVVTLSKS IAAHLAGKG MISLALSEE TRQRIENLHG
721 LSIAAVNGPT ATVVSGDPTQ IQELAQCEA DGVRARIIPV DYASHSAHVE TIESELAEVL
781 AGLSPRTPEV PFFSTLEGAW ITEPVLDTY WYRNLHRVG FAPAVETLAT DEGFTHFIEV
841 SAHPVLTMTL PETVTGLGTL RREQGGQERL VTS LAEAWN GLTIDWAPVL PTATGHHPEL
901 PTYAFQRRHY WLHDSAPVQG SVQDSWRYRI DWKRLAVADA SERAGLSGRW LVVVPEDRSA
961 EAAPVLAALS GAGADPVQLD VSPLGDRQL AATLGEALAA AGGAVDGVLS LLAWDESAHP
1021 GHPAPFTRGT GATLTLVQAL EDAGVAAPLW CVTHGAVSVG RADHVTSPAQ AMVWGMGRVA
1081 ALEHPERWGG LIDLPSDADR AALDRMTTVL AGGTGEDQVA VRASGLLARR LVASLPAHG
1141 TASPWWQADG TVLVTGAEEP AAAEAAARRLA RDGAGHLLH TTPSGSEGAE GTSGAAEDSG
1201 LAGLVAELAD LGATATVVT C DLTDAEAAAAR LLAGVSDAHP LSAVLHLPT VDSEPLAATD
1261 ADALARVVTA KATAALHLDR LLREAAAAGG RPPVLVLFSS VAAIWGGAGQ GAYAAGTAFI
1321 DALAGQHRAD GPTVTSVAWS PWEGRVTEG ATGERLRLRG LRPLAPATAL TALDTALGHG
1381 DTAVTIADVD WSSFAPGFTT ARPGTLLADL PEARRALDEQ QSTTAADDTV LSRELGALTG
1441 AEQQRRMQEL VREHLAVLN HPSPEAVDTG RAFRDLGFDS LTAVELRNRL KNATGLALPA
1501 TLVFDYPTPR TLAEFLLAEI LGEQAGAGEQ LPVDGGVDDE PVAIVGMACR LPGGVASPED
1561 LWRLVAGGED AISGFPQDRG WDVEGLYDPD PDASGRTYCR AGGFLEAGE FDADFFGISP
1621 REALAMPQQ RLLLETSWEA VEDAGIDPTS LQGGQGVFA GTNGPHYEPL LRNTAEDLEG
1681 YVGTGNAASI MSGRVSYTLG LEGPAVTVDT ACSSSLVALH LAVQALRKGE CGLALAGGV
1741 VMSTPTTFVE FSRQRLAED GRKAFASA DFGPAEGVG MLLVERLSA RRNGHRVLA
1801 VRGSVAVNDG ASNGLTAPNG PSQQRVIRRA LADARLTAD VDVVEAHGTG TRLDPIEAQ
1861 ALIATYGQGR DTEQPLRLGS LKSNIGHTQA AAGVSGIIM VQAMRHGVLP KTLHVDRPSD
1921 QIDWSAGTVE LLTEAMDWPR KQEGGLRRAA VSSFGISGTN AHIVLEEAPV DEDAPADEPS
1981 VGGVVPWLVS AKTPAALDAQ IGRLAASFASQ GRTDAADPGA VARVLAGGRA QFEHRAVALG
2041 TGQDDLAAAL AAPEGLVRGV ASGVGRVAFV FPGGTQWAG MGAELLDVSK EFAAAMAECE
2101 AALAPYVDWS LEAVVRQAPG APTLERVDV QPVTFAVMVS LAKVWQHHGV TPQAVVGHSQ
2161 GEIAAAYVAG ALSLDDAARV VTLRSKSGA HLAGQGMLS LALSEAAVVE RLAGFDGLSV
2221 AAVNGPTATV VSGDPTQIQE LAQACEADGV RARIIPVDYA SHSAHVETIE SELADVLAGL
2281 SPQTPQVFFF STLEGAWITE PALDGGYWYR NLRHRVGFAP AVETLATDEG FTHFVEVSAH

-continued

2341 PVLTMALPET VTGLGTLRRD NGGQHRLTTS LAEAWANGLT VDWasLLPTT TTHPDLPTYA
 2401 FQTERYWQPQ DLSAAGDITS AGLGAAEHPL LGAAVALADS DGCLLTGSLs LRTHPWLADH
 2461 AVAGTVLLPG TAFVELAFRA GDQVGC DLVE ELTLDAPLVL PRRGAVRVQL SVGASDESGR
 2521 RTFGLYAHPE DAPGEAEWTR HATGVLAARA DRTAPVADPE AWPPPGAEPV DVDGLYERFA
 2581 ANGYGYGPLF QGVRGVWRRG DEVFADVALP AEVAGAEGAR FGLHPALLDA AVQAAGAGGA
 2641 FGAGTRLPPA WSGISLYAVG ATALRVRLAP AGPDTVSVSA ADSSGQPVFA ADSLTVLPVD
 2701 PAQLAAFSDF TLDALHLEW TAWDGAAQAL PGAVVLGGDA DGLAAALRAG GTEVLSFPDL
 2761 TDLVEAVDRG ETPAPATVLV ACPAAGPGGP EHVREALHGS LALMQAWLAD ERFTDGRVLV
 2821 VTRDAVAARS GDGLRSTQQA AVWGLGRSAQ TESPGRFVLL DLAGEARTAG DATAGDGLTT
 2881 GDATVGGTSG DAALGSALAT ALGSSEPQLA LRDGALLVPR LARAAAPAAA DGLAADGLA
 2941 ALPLPAAPAL WRLEPGTDGS LESLTAAPGD AETLAPEPLG PGQVRIAIRA TGLNFRDVL I
 3001 ALGMYDPDPAL MGTEGAGVVT ATGPGVTHLA PGDRV MGLLS GAYAPVVVAD ARTVARMPEG
 3061 WTFAQGASVP VVFLTAVYAL RDLADV KPGE RLLVHSAAGG VGMAAVQLAR HWGVEVHGTA
 3121 SHGKWDALRA LGLDDAHIAS SRTLDFESAF RAASGGAGMD VVLNSLAREF VDASLRLLGP
 3181 GGRFVEMGKT DVRDAERVAA DHPGVGYRAF DLGEAGPERI GEMLAEVIAL FEDGVLRLHP
 3241 VTTWDVRRAR DAFRHVSQAR HTGKVVLTMP SGLDPEGTVL LTGGTGALGG IVARHVVGEW
 3301 GVRRLLLVSR RGTDAPGAGE LVHELEALGA DVSVAACDVA DREALTAVLD SIPAEHPLTA
 3361 VVHTAGVLSD GTLPSMTAED VEHVLRPKVD AAFLLDELTS TPGYDLAAV MFSSAAAVFG
 3421 GAGQGAYAAA NATLDALAWR RRTAGLPALS LGWGLWAETS GMTGGLSDTD RSRLARSGAT
 3481 PMDSELTLSL LDAAMRRDDP ALVPIALDVA ALRAQQRDGM LAPLLSGLTR GSRVGGAPVN
 3541 QRRAAAGGAG EADTDLGRL AAMTPDDRVA HLRDLVRTHV ATVLGHGTPS RVDLERAFRD
 3601 TGFDLSLTAVE LRNRLNAATG LRLPATLVFD HTPGELAGH LLELATAAG GSWAEGTSGG
 3661 DTASATDRQT TAALAE DLRL EGVLASLAPA AGGRPELAAR LRALAAALGD DGDDATDLDE
 3721 ASDDDLFSFI DKELGDSDF

Amino acid sequence of narbonolide synthase subunit 3, PICAI I
 1 MANNEDKLRD YLKRVTAE LQ QNTRRLREIE GRTHPEVAIV GMACRLPGGV ASPEDLWQLV

61 AGDGD AISEF PQDRGWDVEG LYDPDPDASG RTYCRSGGFL HDAGEFDADF FGISPREALA
 121 MDPQQRLSLT TAWEAIESAG IDPTALKGSG LGVFVGGWHT GYTSGQTTAV QSPELEGLV
 181 SGAALGFLSG RIAYVLGTDG PALTVDTACS SSLVALHLAV QALRKGECDM ALAGGVTVMP
 241 NADLFVQFSR QRGLAADGRS KAFATSADGF GPAEGAGVLL VERLSDARRN GHRILAVVRG
 301 SAVNQDGASN GLTAPHGPSQ QRVIRRALAD ARLAPGDVDV VEAHGTGTRL GDPIEAQALI
 361 ATYGQEKSS E QPLRLGALKS NIGHTQAAAG VAGVIKMVQA MRHGLLPKTL HVDEPSDQID
 421 WSAGTVELLT EAVDWPEKQD GGLRRAAVSS FGISGTNAHV VLEEAPAVED SPAVEPPAGG
 481 GVPWPVSAK TPAALDAQIG QLAAYADGRT DVDPAVAARA LVDSRTAMEH RAVAVGDSRE
 541 ALRDALRMPE GLVRGTSSDV GRVAFVFPQG GTQWAGMGAE LLDSSPEFAA SMAECETALS
 601 RYVDWSLEAV VRQEPGAPTL DRVDVVPVT FAVMVSLAKV WQHHGITPQA VVGHSQGEIA
 661 AAYVAGALTL DDAARVVTLR SKSIAAHLAG KGMISLALD EAAVLKRLSD FDGLSVAVN
 721 GPTATVVSGD PTQIEELART CEADGVRARI IPV DYASHSR QVEIIEKELA EVLAGLAPQA
 781 PHVPPFFSTLE GTWITEPVL D GTYWYRNL RH RVGFAPAVET LAVDGFTHFI EVSAHPVLT M

-continued

841 TLPETVTGLG TLRREQGGQE RLVTSLAEAW ANGLTIDWAP ILPTATGHHF ELPTYAFQTE
 901 RFWLQSSAPT SAADDWRYRV EWKPLTASGQ ADLSGRWIVA VGSEPEAELL GALKAGAEEV
 961 DVLEAGADDD REALAARLTA LTTGDGFTGV VSLDDLVLPQ VAWVQALGDA GIKAPLWSVT
 1021 QGAVSVGRDL TPADPDRAML WGLGRVVALE HPERWAGLVD LPAQPDAAAL AHLVTALSGA
 1081 TGEDQIAIRT TGLHARRLAR APLHGRRPTR DWQPHGTVLI TGGTGALGSH AARWMAHHGA
 1141 EHLLLVSRSG EQAPGATQLT AELTASGARV TIAACDVADP HAMRTLDAI PAETPLTAVV
 1201 HTAGAPGGDP LDVTGPDIA RILGAKTSGA EVLDDLLRGT PLDAFVLYSS NAGVWGSQSQ
 1261 GYVAAANHL DALAARRRAR GETATSVANG LWAGDGMGRG ADDAYWQRRG IRPMSPDRA
 1321 DELAKALSHD ETFVAVADV WERFAPAFV SRPSLLLDGV PEARQALAAP VGAPAPGDAA
 1381 VAPTQSSAL AAITALPEPE RRPALLTLVR THAAAVLGHS SPDRVAPGRA FTELGFDSL
 1441 AVQLRNQLST VVGNRLPATT VFDHPTPAL AAHLHEAYLA PAEPAPTWE GRVRRALAE
 1501 PLDRLRDAGV LDTVLRLTGI EPEPGSGSD GGAADPGAEP EASIDDLAE ALIRMALGPR
 1561 NT

Amino acid sequence of narbonolide synthase subunit 4, PICAIV
 1 MTSSNEQLVD ALRASLKENE ELRKESRRRA DRRQEPMAIV GMSCRFAGGI RSPEDLWDVA

61 AAGKDLVSEV PEERGWDIDS LYDPVPGRKG TTYVRNAAFL DDAAGFDAF FGISPREALA
 121 MDPQQRQLE ASWEVFERAG IDPASVRGTD VGVYVCGCYQ DYAPDIRVAP EGTGGYVVVG
 181 NSSAVASGRI AYSLGLEGA VTVDACSSS LVALHLALKG LRNGDCSTAL VGGVAVLATP
 241 GAFIEFSSQQ AMAADGRKKG FASAADGLAW GEGVAVLLE RLSDARRKGH RVLAVVRGSA
 301 INQDGASNGL TAPHGPSQOR LIRQALADAR LTSSDQDVVE GHGTGTRLGD PIEAQALLAT
 361 YGQGRAPGQP LRLGTLKSNL GHTQAASGVA GVIKMQALR HGVLPKTLHV DEPTDQVDWS
 421 AGSVELLTEA VDWPERPRL RRAGVSAGFV GGTNAHVLE EAPAVEESA VEPPAGGGVV
 481 PWPVSAKTS ALDAQIGQLA AYAEDRTDVD PAVAARALVD SRTAMEHRAV AVGDSREALR
 541 DALRMPEGLV RGTVTDPGRV AFVFPQGQTQ WAGMGAELLD SSPEFAAAMA ECETALSPYV
 601 DWSLEAVVRQ APSAPTLDRV DVVQPVTFV MVSIAKVWQH HGITPEAVIG HSQGEIAAAY
 661 VAGALTLLDA ARVVTLRKSK IAAHLAKGG MISLALSEE TRQRIENLHG LSIAAVNGPT
 721 ATVVSQDPTQ IQELAQACEA DGIRARIIPV DYASHSAHVE TIENELADVL AGLSPQTPQV
 781 PFFSTLEGTV ITEPALDGGY WYRNLRHRVG FAPAVETLAT DEGFTHFIEV SAHPVLTMTL
 841 PDKVTGLATL RREDGGQHRL TTSIAEAWAN GLALDWASLL PATGALSPAV PDLPTYAFQH
 901 RSYWISPAGP GEAPAHASG REAVAETGLA WGPGAEDLDE EGRSAVLAM VMRQAASVLR
 961 CDSPEEVPVD RPLREIGFDS LTAVDFRNRV NRTGLQLPP TVVFEHPTPV ALAERISDEL
 1021 AERNWAVEP SDHEQAEEK AAPAGARSG ADTGAGAGMF RALFRQAVED DRYGEFLDVL
 1081 AEASAFRPQF ASPEACSERL DPVLLAGGPT DRAEGRVLV GCTGTAANG PHEFLRLSTS
 1141 FQEERDFLAV PLPGYGTGTG TGTALLPADL DTALDAQARA ILRAAGDAPV VLLGHSGGAL
 1201 LAHELAFRLE RAHGAPPAGI VLVDPPYPGH QEPIEVWSRQ LGEGLFAGEL EPMSDARLLA
 1261 MGRYARFLAG PRPGRSSAPV LLVRASEPLG DWQEERGDWR AHWDLPHTV DVPGDHFTMM
 1321 RDHAPAVAEA VLSWLDATIEG IEGAGK

Amino acid sequence of typeII thioesterase, PICB
 1 VTDRLNVD GLWIRRFHPA PMSAVRLVCL PHAGGSASYF FRFSEELHPS VEALSVQYFG

-continued

61 RQDRRAEPCL ESVEELAEHV VAATEPWWQE GRLAFFGHSL GASVAFETAR ILEQRHGVRP
 121 EGLYVSGRRRA PSLAPDRLVH QLDDRAFLAE IRRLSGTDER FLQDDELLRL VLPALRSDYK
 181 AAETYLHRPS AKLTCPVMAL AGDRDPKAPL NEVAEWRRHT SGPFCLRAYS GGHFYLNDQW
 241 HEICNDISDH LLVTRGAPDA RVVQPPTSLI EGAARKWQNP R

[0042] The DNA encoding the above proteins can be isolated in recombinant form from the recombinant cosmid pKOS023-27 of the invention, which was deposited with the American Type Culture Collection under the terms of the Budapest Treaty on 20 Aug. 1998 and is available under accession number ATCC 203141. Cosmid pKOS023-27 contains an insert of *Streptomyces venezuelae* DNA of -38506 nucleotides. The complete sequence of the insert from cosmid pKOS023-27 is shown below. The location of the various ORFs in the insert, as well as the boundaries of the sequences that encode the various domains of the multiple modules of the PKS, are summarized in the Table below. FIG. 2 shows a restriction site and function map of pKOS023-27, which contains the complete coding sequence for the four proteins that constitute narbonolide PKS and four additional ORFs. One of these additional ORFs encodes the picB gene product, the type II thioesterase mentioned above. PICB shows a high degree of similarity to other type II thioesterases, with an identity of 51%, 49%, 45% and 40% as compared to those of *Amycolatopsis mediterranea*, *S. griseus*, *S. fradiae* and *Saccharopolyspora erythraea*, respectively. The three additional ORFs in the cosmid pKOS023-27 insert DNA sequence, from the picCII, picCIII, and picCVI, genes, are involved in desosamine biosynthesis and transfer and described in the following section.

From Nucleotide	To Nucleotide	Description
70	13725	picAI
70	13725	narbonolide synthase 1 (PICAI)
148	3141	loading module
148	1434	KS loading module
1780	2802	AT loading module
2869	3141	ACP loading module
3208	7593	extender module 1
3208	4497	KS1
4828	5847	AT1
6499	7257	KR1
7336	7593	ACP1
7693	13332	extender module 2
7693	8974	KS2

-continued

From Nucleotide	To Nucleotide	Description
9418	10554	AT2
10594	11160	DH2
12175	12960	KR2
13063	13332	ACP2
13830	25049	picAII
13830	25049	narbonolide synthase 2 (PICAI)
13935	18392	extender module 3
13935	15224	KS3
15540	16562	AT3
17271	18071	KR3 (inactive)
18123	18392	ACP3
18447	24767	extender module 4
18447	19736	KS4
20031	21050	AT4
21093	21626	DH4
22620	23588	ER4
23652	24423	KR4
24498	24765	ACP4
25133	29821	picAIII
25133	29821	narbonolide synthase 3 (PICAI)
25235	29567	extender module 5
25235	26530	KS5
26822	27841	AT5
28474	29227	KR5
29302	29569	ACP5
29924	33964	picAIV
29924	33964	narbonolide synthase 4 (PICAIV)
30026	32986	extender module 6
30026	31312	KS6
31604	32635	AT6
32708	32986	ACP6
33068	33961	PKS thioesterase domain
33961	34806	picB
33961	34806	type II thioesterase homolog
34863	36011	picCII
34863	36011	4-keto-6-deoxyglucose isomerase
36159	37439	picCIII
36159	37439	desosaminyl transferase
37529	38242	picCVI
37529	38242	3-amino dimethyltransferase

[0043]

Sequence of the Insert DNA in Cosmid pKOS023-27

1 GATCATGCGG AGCACTCCTT CTCTCGTGCT CCTACCGGTG ATGTGCGCGC CGAATTGATT
 61 CGTGAGAGAGA TGTCGACAGT GTCCAAGAGT GAGTCCGAGG AATTCGTGTC CGTGTGGAAC
 121 GACGCCGGTT CCGCGCACGG CACAGCGGAA CCCGTCGCCG TCGTCGCCAT CTCCTGCCGG
 181 GTGCCCCGGC CCCGGGACCC GAGAGAGTTC TGGGAATCC TGGCGGCAGG CGGCCAGGCC
 241 GTCACCGACG TCCCCGCGGA CCGCTGGAAC GCCGGCGACT TCTACGACCC GGACCGCTCC
 301 GCCCCCGGCC GCTCGAACAG CCGGTGGGGC GGGTTCATCG AGGACGTCGA CCGGTTCGAC

-continued

361 GCCGCCTTCT TCGGCATCTC GCCCCGCGAG GCCGCGGAGA TGGACCCGCA GCAGCGGCTC
421 GCCCTGGAGC TGGGCTGGGA GGCCCTGGAG CGCGCCGGGA TCGACCCGTC CTCGCTCACC
481 GGCACCCGCA CCGCGCTTCT CGCCGGCGCC ATCTGGGACG ACTACGCCAC CCTGAAGCAC
541 GCCCAGGGCG GCGCCGCGAT CACCCCGCAC ACCGTCACCG GCCTCCACCG CGGCATCATC
601 GCGAACCGAC TCTCGTACAC GCTCGGGCTC CGCGGCCCCA GCATGGTCGT CACTCCGGC
661 CAGTCCTCGT CGCTCGTCGC CGTCCACCTC GCGTGCGAGA GCCTGCGGCG CGGCGAGTCC
721 GAGCTCGCCC TCGCCGGCGG CGTCTCGCTC AACCTGGTGC CGGACAGCAT CATCGGGGCG
781 AGCAAGTTTC GCGGCCTCTC CCCCGACGGC CGCGCCTACA CCTTCGACGC GCGCGCCAAC
841 GGCTACGTAC GCGCGGAGGG CGGCGGTTTC GTCGTCCTGA AGCGCCTCTC CCGGGCCGTC
901 GCCGACGGCG ACCCGGTGCT CGCCGTGATC CGGGGCAGCG CCGTCAACAA CGGCGGCGCC
961 GCCCAGGGCA TGACGACCCC CGACGCGCAG GCGCAGGAGG CCGTGCTCCG CGAGGCCAC
1021 GAGCGGGCCG GGACCGCGCC GGCCGACGTG CGGTACGTGC AGCTGCACGG CACCGGCACC
1081 CCCGTGGGCG ACCCGATCGA GGCCGCTGCG CTCGGCGCCG CCCTCGGCAC CGGCCGCGCG
1141 GCCGGACAGC CGCTCCTGGT CGGCTCGGTC AAGACGAACA TCGGCCACCT GGAGGGCGCG
1201 GCCGGCATCG CCGGCCTCAT CAAGGCCGTC CTGGCGGTCC GCGGTGCGCG GCTGCCCGCC
1261 AGCCTGAAT ACAGAGACCCC GAACCGGCG ATCCCGTTTC AGGAATGAA CCTCCGGGTG
1321 AACACGGAGT ACCTGCCGTG GGAGCCGGAG CACGACGGGC AGCGGATGGT CGTCGGCGTG
1381 TCCTCGTTTC GCATGGGCGG CACGAACGCG CATGTCGTGC TCGAAGAGGC CCCGGGGTT
1441 GTCGAGGGTG CTTCCGTCTG GGAGTCGACG GTCGGCGGGT CGGCGGTCCG CGGCGGTGTG
1501 GTGCCGTGGG TGGTGTGCGC GAAGTCCGCT GCCGCGCTGG ACGCGCAGAT CGAGCGGCTT
1561 CCCGCGTTTC CCTCGCGGGA TCGTACGGAT GGTGTCGACG CGGGCGCTGT CGATGCGGGT
1621 GCTGTCGATG CGGGTGCTGT CGCTCGCGTA CTGGCCGGCG GCGGTGCTCA GTTCGAGCAC
1681 CGGGCCGTGC TCGTCGGCAG CGGGCCGGAC GATCTGGCGG CAGCGCTGGC CGCGCCTGAG
1741 GGTCTGGTCC GGGGCGTGGC TTCCGGTGTC GGGCGAGTGG CGTTCGTGTT CCCCAGGAG
1801 GGCACGCAGT GGGCCGGCAT GGGTGCCGAA CTGCTGGAAT CTCCGCGGT GTTCGCGGCG
1861 GCCATGGCCG AATGCGAGGC CGCACTCTCC CCGTACGTGC ACTGGTCTGT GGAGGCCGTC
1921 GTACGGCAGG CCCCCGGTGC GCCCAGCTG GAGCGGGTCG ATGTCGTGCA GCCTGTGACG
1981 TTCGCCGTC TGGTCTCGCT GGCTCGCGTG TGGCAGCACC ACGGGGTGAC GCCCCAGGCG
2041 GTCGTGCGCC ACTCGCAGGG CGAGATCGCC GCCGCGTACG TCGCCGTTGC CCTGAGCCTG
2101 GACGACGCCG CTCGTGTCTG GACCCTGCGC AGCAAGTCCA TCGCCGCCCA CCTCGCCGGC
2161 AAGGGCGGCA TGCTGTCCCT CGCGCTGAGC GAGGACGCCG TCCTGGAGCG ACTGGCCGGG
2221 TTCGACGGGC TGTCCGTCTC CGCTGTGAAC GGGCCACCG CCACCGTGGT CTCCGGTGAC
2281 CCCGTACAGA TCGAAGAGCT TGCTCGGGCG TGTGAGGCCG ATGGGGTCCG TGCGCGGGTC
2341 ATTCCTGTCG ACTACGCTC CCACAGCCGG CAGGTCGAGA TCATCGAGAG CGAGCTCGCC
2401 GAGGTCCTCG CCGGGCTCAG CCCGAGGCT CCGCGCGTGC CGTTCCTCTC GACACTCGAA
2461 GCGCCTGGA TCACCGAGCC CGTGCTCGAC GCGGGCTACT GGTACCGCAA CCTGCGCCAT
2521 CGTGTGGGCT TCGCCCCGCG CGTCGAGACC CTGGCCACCG ACAGGGGCTT CACCCACTTC
2581 GTCGAGGTCA CCGCCACCCC CGTCCTCACC ATGGCCCTCC CCGGGACCGT CACCGGTCTG

-continued

2641 GCGACCTGTC GTCGCGACAA CGGCGGTCAG GACCGCCTCG TCGCCTCCCT CGCCGAAGCA
2701 TGGGCCAACG GACTCGCGGT CGACTGGAGC CCGCTCCTCC CTCCCGCGAC CGGCCACCAC
2761 TCCGACCTCC CCACCTACGC GTTCCAGACC GAGCGCCACT GGCTGGGCGA GATCGAGGCG
2821 CTCGCCCCGG CGGGCGAGCC GGCGETGCAG CCCGCCGTCC TCCGCACGGA GGCGGCCGAG
2881 CCGGCGGAGC TCGACCGGGA CGAGCAGCTG CCGGTGATCC TGGACAAGGT CCGGGCGCAG
2941 ACGGCCCAGG TGCTGGGGTA CGCGACAGGC GGGCAGATCG AGGTCGACCG GACCTTCCGT
3001 GAGGCCGGTT GCACCTCCCT GACCGGCGTG GACCTGCACA ACCGGATCAA CGCCGCCTTC
3061 GGCCTACGGA TGGCGCCGTC CATGATCTTC GACTTCCCCA CCCCAGAGC TCTCGCGGAG
3121 CAGCTGCTCC TCGTCTGTGA CGGGGAGGCG GCGGCGAACC CGGCCGTGTC GGAGCCGGCT
3181 CCGGTGGCGG CGGCCGGTGC CGTCGACGAG CCGGTGGCGA TCGTCGGCAT GCCTGCCGC
3241 CTGCCCCGTG GGGTCGCCCTC GCCGAGGAC CTGTGGCGGC TGGTGGCCGG CGGCGGGGAC
3301 GCGATCTCGG AGTTCCCGCA GGACCGCGGC TGGGACGTGG AGGGGCTGTA CCACCCGGAT
3361 CCCGAGCACC CCGGCACGTC GTACGTCCGC CAGGGCGGTT TCATCGAGAA CGTCGCCGCG
3421 TTCGACGCGG CCTTCTTCGG GATCTCGCCG CGCGAGGCC TCGCCATGGA CCCGACGAG
3481 CGGCTCCTCC TCGAAACCTC CTGGGAGGCC GTCGAGGAC CGGGGATCGA CCCGACCTCC
3541 CTGCGGGGAC GGCAGGTGCG CGTCTTCACT GGGGCGATGA CCCACGAGTA CGGGCCGAGC
3601 CTGCGGGACG GCGGGGAAGG CCTCGACGGC TACCTGTGTA CCGGCAACAC GGCCAGCGTG
3661 ATGTGCGGCC GCGTCTCGTA CACACTCGGC CTTGAGGGCC CCGCCCTGAC GGTGGACACG
3721 GCCTGCTCGT CGTCGTGGT CGCCCTGCAC CTCGCCGTGC AGGCCCTGCG CAAGGGCGAG
3781 GTCGACATGG CGCTCGCCGG CGGCGTGGCC GTGATGCCCA CGCCCGGGAT GTTCGTGCGAG
3841 TTCAGCCGGC AGCGCGGGCT GGCCGGGAC GGCCGGTCGA AGCGTTCGC CGCGTCGGCG
3901 GACCGGACCA GCTGGTCCGA GGGCGTGGC GTCTCTCTCG TCGAGCGCCT GTCGGACGCC
3961 CGCCGCAACG GACACCAGGT CCTCGCGGTC GTCCCGGCA GGCCCGTGAA CCAGGACGGC
4021 GCGAGCAACG GCCTACAGGC TCCGAACGGG CCCTCGCAGC AGCGCGTCAT CCGCGCGCG
4081 CTGGCGGACG CCCGCTGAC GACCTCCGAC GTGGACGTGC TCGAGGCACA CGGCACGGGC
4141 ACGCGACTCG GCGACCCGAT CGAGGCGCAG GCCCTGATCG CCACCTACGG CCAGGGCCGT
4201 GACGACGAAC AGCCCTGCG CCTCGGGTCG TTGAAGTCCA ACATCGGGCA CACCCAGGCC
4261 GCGGCCGGCG TCTCCGGTGT CATCAAGATG GTCCAGGCGA TCGGCCACGG ACTGCTGCCG
4321 AAGACGCTGC ACGTCGACGA GCCCTCGGAC CAGATCGACT GGTGGGTGG CGCCGTGGAA
4381 CTCTCACCAG AGGCCGTGCA CTGGCCGGAG AAGCAGGAC GCGGGCTGCG CCGGGCCGCC
4441 GTCTCTCCT TCGGGATCAG CGGCACCAAT GCGCATGTGG TGCTCGAAGA GGCCCCGGTG
4501 GTTGTCGAGG GTGCTTCGGT CGTCGAGCCG TCGGTTGGCG GGTGGGCGGT CGGCGGCGGT
4561 GTGACGCCCT GGGTGGTGTG GCGAAGTCC GTCGCCGCG TCGACGCGCA GATCGAGCGG
4621 CTTGCCGCAT TCGCCTCGCG GGATCGTACG GATGACGCCG ACGCCGGTGC TGTCGACGCG
4681 GCGCTGTGTC CTCACGTACT GGCTGACGGG CGTGCTCAGT TCGAGCACCG GGCCGTGCGG
4741 CTCGGCGCCG GGGCGGACGA CCTCGTACAG GCGCTGGCCG ATCCGGACGG GCTGATACGC
4801 GGAACGGCTT CCGGTGTGCG GCGAGTGGCG TTCGTGTTCC CCGGTACGGG CACGCAGTGG
4861 GCTGGCATGG GTGCCGAACT GCTGGACTCT TCCGCGGTGT TCGGGCGGCG CATGGCCGAG
4921 TGTGAGGCCG CGCTGTCCCG GTACGTCGAC TGGTCGCTGG AGGCCGTCTG ACGGCAGGCC

-continued

4981 CCCGGTGC GC CCACGCTGGA GCGGGTCGAT GTCGTGCAGC CTGTGACGTT CGCCGTCATG
5041 GTCTCGCTGG CTCGCGTGTG GCAGCACCAC GGTGTGACGC CCCAGGCGGT CGTCGGCCAC
5101 TCGCAGGGCG AGATCGCCCG CGCGTACGTC GCCGGAGCCC TGCCCTTGA CGACGCCGCC
5161 CGCGTCGTCA CCCTGCGCAG CAAGTCCATC GCCGCCACC TCGCCGGCAA GGGCGGCATG
5221 CTGTCCCTCG CGCTGAACGA GGACGCCGTC CTGGAGCGAC TGAGTGACTT CGACGGGCTG
5281 TCCGTCGCCG CCGTCAACGG GCCCACC GCC ACTGTCTGT CGGGTGACCC CGTACAGATC
5341 GAAGAGCTTG CTCAGGCGTG CAAGGCGGAC GGATTCCGCG CGCGGATCAT TCCCGTCGAC
5401 TACGCGTCCC ACAGCCGCA GGTGAGATC ATCGAGAGCG AGCTCGCCA GGTCTCGCC
5461 GGTCTCAGCC CGCAGGCCCC GCGCGTGCCG TTCTTCTCGA CGCTCGAAGG CACCTGGATC
5521 ACCGAGCCCG TCCTCGACGG CACCTACTGG TACCGCAACC TCCGTACCG CGTCGGCTTC
5581 GCCCCGCCA TCGAGACCCT GGCCGTCGAC GAGGGCTTCA CGCACTTCGT CGAGGTCAGC
5641 GCCCACC CG TCCTCACCAT GACCTCCCC GAGACCGTCA CCGGCCTCG CACCTCCGT
5701 CGCGAACAGG GAGGCCAAGA GCGTCTGGTC ACCTCGCTCG CCAGGCGTG GGTCAACGGG
5761 CTTCCTGG CATGGACTT GCTCTGCCC GCCACGGCT CCGCCCCGG TCTGCCACC
5821 TACGCTTCC AGGCCGAGCG CTAAGGCTC GAGAACACT CCGCCGCCCT GGCCACCGGC
5881 GACGACTGGC GCTACCGCAT CGACTGGAAG CGCTCCCG CCGCGAGGG GTCCGAGCGC
5941 ACCGGCTGT CCGGCCGCTG GCTCGCCGTC ACGCCGAGG ACCACTCCG GCAGGCCGCC
6001 GCCGTGCTCA CCGCGCTGGT CGACGCCGG GCGAAGGTC AGGTGCTGAC GGCCGGGGCG
6061 GACGAGACC GTGAGGCCCT CGCCGCCCG CTCACCGCAC TGACGACCG TGACGGCTTC
6121 ACCGGCGTGG TCTCGCTCCT CGACGGACTC GTACCGCAG TCGCCTGGGT CCAGGCGCTC
6181 GCGCAGCCG GAATCAAGG GCCCTGTGG TCCGTACCC AGGGCGCGGT CTCCGTCGGA
6241 CGTCTCGACA CCCCCGCCA CCCCAGCCG GCCATGCTT GGGCCTCG CCGCGTCGTC
6301 GCCCTTGAG ACCCGAACG CTGGGCCGGC CTCGTGACC TCCCGCCCA GCCCGATGCC
6361 GCGCCCTCG CCCACTCGT CACCGCACTC TCCGGGCCA CCGCGAGGA CCAGATCGCC
6421 ATCCGACCA CCGGACTCCA CGCCGCCGC CTCGCCGCG CACCTTCCA CGGACGTCGG
6481 CCCACCGCG ACTGGCAGC CCACGGCACC GTCTCATCA CCGCGGCAC CGGAGCCCTC
6541 GGCAGCCAG CCGCAGCTG GATGGCCAC CACGAGCCG AACACCTCT CCTCGTCAGC
6601 CGCAGCGCG AACAGCCCC CGGAGCCACC CAACTACCG CCGAACTCAC CGCATCGGC
6661 GCGCGCTCA CCATCGCCGC CTGCGACGTC GCGACCCCC ACGCATGCG CACCTCTCTC
6721 GACGCCATCC CCGCCGAGC GCCCGTCACC GCGTCTGTC ACACCGCCG CGCGCTCGAC
6781 GACGGCATCG TGGACACGCT GACCGCCGAG CAGGTCCGG GGGCCACCG TCGAAGGCC
6841 GTCGGCGCCT CGGTGCTCGA CGAGCTGACC CGGACCTCG ACCTCGAGC GTTCGTGCTC
6901 TTCTCGTCCG TGTCGAGCAC TCTGGGCATC CCCGGTCAGG GCAACTACG CCGCACAAC
6961 GCCTACCTCG ACGCCCTCG GGCTGCCGC GGGGCCACCG GCGGTCCG CGTCTCGGTG
7021 GCCTGGGGAC CGTGGGACGG TGGCGGCATG GCCGCCGGT ACGCGGTGGC CGAGCGGCTG
7081 CGCAACCAG GCGTGCCCG CATGGACCG GAACTCGCC TGGCCGCACT GGAGTCCGCG
7141 CTCGGCCGGG ACGAGACCG GATACCGTC GCGGACATG ACTGGGACCG CTCTACCTC
7201 GCGTACTCCT CCGGTCGCCC GCAGCCCTC GTCGAGGAG TCGCCGAGGT GCGCGCATC

-continued

7261 ATCGACGCAC GGGACAGCGC CACGTCCGGA CAGGGCGGGA GCTCCGCCCA GGGCGCCAAC
7321 CCCCTGGCCG AGCGGCTGGC CGCCGCGGCT CCCGGCGAGC GTACGGAGAT CCTCCTCGGT
7381 CTCGTACGGG CGCAGGCCGC CGCCGTGCTC CGGATGCGTT CGCCGGAGGA CGTCGCCGCC
7441 GACCGCGCCT TCAAGGACAT CGGCTTCGAC TCGCTCGCCG GTGTCGAGCT GCGCAACAGG
7501 CTGACCCGGG CGACCCGGGT CCAGCTGCCC GCGACGCTCG TCTTCGACCA CCCGACGCCG
7561 CTGGCCCTCG TGTCGTGTGT CCGCAGCGAG TTCCTCGGTG ACGAGGAGAC GCGGACGCC
7621 CGGCGGTCCG CGGCGCTGCC CGCGACTGTC GGTGCCGGTG CCGGCGCCGG CGCCGGCACC
7681 GATGCCGACG ACGATCCGAT CGCGATCGTC GCGATGAGCT GCCGCTACCC CGGTGACATC
7741 CGCAGCCCGG AGGACCTGTG GCGGATGCTG TCCGAGGGCG GCGAGGGCAT CACGCCGTTC
7801 CCCACCGACC GCGGCTGGGA CCTCGACGGC CTGTACGACG CCGACCCGGA CGCGCTCGGC
7861 AGGGCGTACG TCCGCGAGGG CGGGTTCCTG CACGACGCGG CCGAGTTCGA CGCGGAGTTC
7921 TTCGGCGTCT CGCCGCGCGA GGCCTGGCC ATGGACCCGC AGCAGCGGAT GCTCCTGACG
7981 ACGTCCTGGG AGGCCTTTGA GCGGGCCGGC ATCGAGCCGG CATCGCTGCG CGGCAGCAGC
8041 ACCGGTGTCT TCATCGGCCT CTCCTACCAG GACTACGCGG CCCGCGTCCC GAACGCCCCG
8101 CGTGCGGTGG AGGGTTACCT GCTGACCGGC AGCACGCCGA GCGTCGCGTC GGGCCGTATC
8161 GCGTACACCT TCGGTCTCGA AGGGCCCGCG ACGACCGTCG ACACCGCCTG CTCGTCTGTCG
8221 CTGACCGCCC TGCACCTGGC GGTGCGGGCG CTGCGCAGCG GCGAGTGCAC GATGGCGCTC
8281 GCCGGTGGCG TGGCATGAT GGCAGCCCCG CACATGTTTCG TGGAGTTCAG CCGTCAGCGG
8341 GCGCTCGCCC CGGACGGCCG CAGCAAGGCC TTCTCGGCGG ACGCCGACGG GTTCGGCGCC
8401 GCGGAGGGCG TCGGCCTGCT GCTCGTGGAG CGGCTCTCGG ACGCGCGGCG CAACGGTCAC
8461 CCGGTGCTCG CCGTGGTCCG CGGTACCGCC GTCAACCAGG ACGGCGCCAG CAACGGGCTG
8521 ACCGCGCCCA ACGGACCTTC GCAGCAGCGG GTGATCCGGC AGGCGCTCGC CGACGCCCGG
8581 CTGGCACCCG GCGACATCGA CGCCGTCGAG ACGCACGGCA CGGGAACCTC GCTGGGCGAC
8641 CCCATCGAGG CCCAGGGCCT CCAGGCCACG TACGGCAAGG AGCGGCCCGC GGAACGGCCG
8701 CTCGCCATCG GCTCCGTGAA GTCCAACATC GGACACACCC AGGCCGCGGC CGGTGCGGCG
8761 GGCATCATCA AGATGGTCTT CGCGATGCGC CACGGCACCC TGCCGAAGAC CCTCCACGCC
8821 GACGAGCCGA GCCCGCACGT CGACTGGGCG AACAGCGGCC TGCCCTCTGT CACCGAGCCG
8881 ATCGACTGGC CGGCCGGCAC CGGTCCGCGC CGCGCCCGCG TCTCCTCCTT CGGCATCAGC
8941 GGGACGAACG CGCACGTCGT GCTGGAGCAG GCGCCGGATG CTGCTGGTGA GGTGCTTGGG
9001 GCCGATGAGG TGCCTGAGGT GTCTGAGACG GTAGCGATGG CTGGGACGGC TGGGACCTCC
9061 GAGGTCGCTG AGGGCTCTGA GGCCTCCGAG GCCCCGCGG CCCCCGCGAG CCGTGAGGCG
9121 TCCCTCCCCG GGCACCTGCC CTGGGTGCTG TCCGCCAAGG ACGAGCAGTC GCTGCGCGGC
9181 CAGGCCGCGG CCCTGCACGC GTGGCTGTCC GAGCCCGCCG CCACCTGTTC GGACGCGGAC
9241 GGACCGGCCC GCCTGCGGGA CGTCGGGTAC ACGCTCGCCA CGAGCCGTAC CGCCTTCGCG
9301 CACCGCGCCG CCGTGACCGC CGCCGACCGG GACGGGTTCG TGGACGGGCT GGCCACGCTG
9361 GCCCAGGGCG GCACCTCGGC CCACGTCCAC CTGGACACCG CCCGGGACGG CACCACGCG
9421 TTCTCTTTCA CCGGCCAGGG CAGTCAGCGC CCCGGCGCCG GCCGTGAGCT GTACGACCGG
9481 CACCCCGTCT TCGCCCGGGC GCTCGACGAG ATCTGCGCCC ACCTCGACGG TCACCTCGAA
9541 CTGCCCCTGC TCGACGTGAT GTTCGCGGCC GAGGGCAGCG CGGAGCCCGC GCTGCTCGAC

-continued

9601 GAGACGCGGT ACACGCAGTG CGCGCTGTTC GCCCTGGAGG TCGCGCTCTT CCGGCTCGTC
9661 GAGAGCTGGG GCATGCGGCC GGCCGCACTG CTCGGTCACT CGGTCGGCGA GATCGCCGCC
9721 GCGCACGTCG CCGGTGTGTT CTCGCTCGCC GACGCCGCCC GCCTGGTCGC CGCGCGCGGC
9781 CCGCTCATGC AGGAGCTGCC CGCCGGTGGC GCATGCTCG CCGTCCAGGC CGCGGAGGAC
9841 GAGATCCGCG TGTGGCTGGA GACGGAGGAG CGGTACGCGG GACGTCTGGA CGTCGCCGCC
9901 GTCAACGGCC CCGAGGCCCG CGTCCTGTCC GGCAGCGCG ACGCGGCGCG GGAGGCGGAG
9961 CGCTACTGGT CCGGGCTCGG CCGCAGGACC CGCGCGCTGC GGGTCAGCCA CGCCTTCCAC
10021 TCCGCGCACA TGGACGGCAT GCTCGACGGG TTCCGCGCCG TCCTGGAGAC GGTGGAGTTC
10081 CGGCGCCCCCT CCCTGACCGT GGTCTCGAAC GTCACCGGCC TGGCCGCCGG CCCGGACGAC
10141 CTGTGCGACC CCGAGTACTG GGTCCGGCAC GTCCGCGCA CCGTCCGCTT CCTCGACGGC
10201 GTCCGTGTCC TGGCGACCT CGGCGTGGG ACCTGCCTGG AGCTGGGCC CGACGGGGTC
10261 CTCACCGCCA TGGCGGCCGA CGGCCTCGCG GACACCCCCG CGGATTCCGC TGCCGGCTCC
10321 CCCGTGGCT CTCCCGCCG CTCTCCCGCC GACTCCGCG CGGCGCGCT CGGCCCCCG
10381 CCGCTGCTCG TGGCGCTGCT GCGCCGCAAG CGGTCGGAGA CCAGACCGT CGCGGACGCC
10441 CTCGGCAGGG CGCACGCCCA CGGCACCGGA CCCGACTGGC ACGCTGGTT CGCCGGCTCC
10501 GGGGCGCACC GCGTGACCT GCCACGTAC TCCTTCCGGC GCGACCGCTA CTGGCTGGAC
10561 GCCCCGGCGG CCGACACCGC GGTGGACACC GCCGGCCTCG GTCTCGGCAC CGCCGACCAC
10621 CCGTGCTCG GCGCGTGGT CAGCCTTCCG GACCGGGACG GCCTGCTGCT CACCGGCCGC
10681 CTCTCCCTGC GCACCCACCC GTGGCTCGCG GACCACGCG TCCTGGGGAG CGTCCTGCTC
10741 CCCGGCGCCG CGATGGTCGA ACTCGCCGCG CACGCTGCG AGTCCGCCG TCTGCGTGAC
10801 GTGCGGGAG TGACCTCCT TGAACCGCTG GACTGCCCC AGCACGGTGG CGTCGAGCTG
10861 CCGGTGACGG TCGGGGCGCC GGCCGGAGAG CCCGGTGGC AGTCGGCCG GGACGGCGCA
10921 CGGCCCGTCT CCCTCCACTC GCGGCTCGCC GACGCGCCG CCGGTACCG CTGGTCCTGC
10981 CACGCGACCG GTCTGTGGC CACCGACCG CCCGAGCTTC CCGTCGCGC CGACCGTGCG
11041 GCCATGTGGC CGCCCGAGG CGCCGAGGAG GTGCCGCTCG ACGGTCTCTA CGAGCGGCTC
11101 GACGGGAACG GCCTCGCCTT CGGTCCGCTG TTCCAGGGG TGAACGCGGT GTGGCGGTAC
11161 GAGGGTGAGG TCTTCGCCGA CATCGCGCTC CCCGCCACCA CGAATGCGAC CGCGCCCGCG
11221 ACCCGGAACG GCGGCGGGAG TGGGCGGCG GCCCCCTACG GCATCCACCC CGCCCTGCTC
11281 GACGCTTCGC TGCACGCCAT CGCGGTCGGC GGTCTCGTCG ACGAGCCGA GTCGTCCGC
11341 GTCCCTTCC ACTGGAGCGG TGTCACCGTG CACGCGGCCG GTGCCGCGC GGCCCGGGTC
11401 CGTCTCGCCT CCGCGGGGAC GGACGCCGTC TCCTGTGCC TGACGGACGG CGAGGGACGC
11461 CCGTGGTCT CCGTGGAACG GCTCACGCTG CGCCCGTCA CGCCGATCA GGCGGCGGCG
11521 AGCCGCGTCG GCGGGCTGAT GCACCGGGTG GCCTGGCGTC CGTACGCCCT CGCCTCGTCC
11581 GGCGAACAGG ACCCGCACGC CACTTCGTAC GGGCCGACCG CCGTCTCTCG CAAGGACGAG
11641 CTGAAGGTCG CCGCCGCCCT GGAGTCCGCG GCGGTCGAAG TCGGGCTCTA CCCCACCTG
11701 GCCGCGCTGT CCCAGGACGT GGGGCGCGC GCCCCGGCG CCCGTACCGT CCTTGCGCCG
11761 CTGCCCCGCG GTCCCGCCGA CGGCGGCGC GAGGGTGTAC GGGGCACGGT GGCCCGGACG
11821 CTGGAGCTGC TCCAGGCCCT GCTGGCCGAC GAGCACCTCG CGGGCACCCG CCTGCTCCTG

-continued

11881 GTCACCCGCG GTGCGGTGCG GGACCCCGAG GGGTCCGGCG CCGACGATGG CGGCGAGGAC
11941 CTGTGCGCAG CGGCCCGCTG GGGTCTCGTA CGGACCGCGC AGACCGAGAA CCCC GGCCGC
12001 TTCGGCCTTC TCGACTGGC CGACGACGCC TCGTCGTACC GGACCCTGCC GTCGGTGCTC
12061 TCCGACGCGG GCCTGCGCGA CGAACCGCAG CTCGCCCTGC ACGACGGCAC CATCAGGCTG
12121 GCCCGCCTGG CCTCCGTCCG GCCCGAGACC GGCACCGCCG CACCGGCGCT CGCCCCGAG
12181 GGCACGGTCC TGCTGACCGG CGGCACCGGC GGCCTGGGCG GACTGGTCGC CCGGCACGTG
12241 GTGGGCGAGT GGGGCGTACG ACGCCTGCTG CTGGTGAGCC GGC GGCGCAC GGACGCCCG
12301 GGC CGCGACG AGCTCGTGCA CGAGCTGGAG GCCTGGGAG CCGACGTCTC GGTGGCCGCG
12361 TGCGACGTCG CCGACCGCGA AGCCCTCACC GCCGTACTCG ACGCCATCCC CGCCGAACAC
12421 CCGCTCACCG CGGTCGTCCA CACGGCAGGC GTCCTCTCCG ACGGCACCCCT CCCGTCCATG
12481 ACGACGGAGG ACGTGGAACA CGTACTGCGG CCCAAGGTCG ACGCCGCGTT CCTCCTCGAC
12541 GAACTCACCT CGACGCCCGC ATACGACCTG GCAGCGTTGC TCATGTTCTC CTCCGCCGCC
12601 GCCGTCTTCG GTGGCGCGGG GCAGGGCGCC TACGCCGCCG CCAACGCCAC CCTCGACGCC
12661 CTCGCCTGGC GCCCGCGGGC AGCCGGACTC CCCGCCCTCT CCCTCGGCTG GGGCCTCTGG
12721 GCCGAGACCA GCGGCATGAC CGGCGAGCTC GGCAGGCGG ACCTGCGCCG GATGAGCCGC
12781 GCGGGCATCG GCGGGATCAG CGACGCCGAG GGCATCGCGC TCCTCGACGC CGCCCTCCGC
12841 GACGACCGCC ACCCGGTCTT GCTGCCCTTG CGGCTCGACG CGCCCGGGCT GCGGGACGCG
12901 GCCGGGAACG ACCCGGCCGG AATCCCGGCG CTCTTCCGGG ACGTCGTGCG CGCCAGGACC
12961 GTCCGGGCCC GGCCGTCCGC GGCCTCCGCC TCGACGACG CCGGGACGGC CGGCACGCCG
13021 GGGACGGCGG ACGGCGCGGC GGAAACGGCG GCGGTCACGC TCGCCGACCG GGCCGCCACC
13081 GTGGACGGGC CCGCACGGCA GCGCCTGCTG CTCGAGTTGC TCGTCGGCGA GGTGCGCGAA
13141 GTACTCGGCC ACGCCCGCGC TCACCGGATC GACGCCGAAC GGGGCTTCCT CGACCTCGGC
13201 TTCGACTCCC TGACCGCCGT CGAACTCCGC AACC GGCTCA ACTCCGCCG TGGCCTCGCC
13261 CTCCCGGCGA CCCTGGTCTT CGACCACCA AGCCCGGCG CACTCGCCTC CCACCTGGAC
13321 GCCGAGCTGC CGCGCGGCGC CTCGGACCAG GACGGAGCCG GGAACCGGAA CGGGAACGAG
13381 AACGGGACGA CGGCGTCCCG GAGCACC GCC GAGACGGACG CGTGCTGGC ACAACTGACC
13441 CGCCTGGAAG GCGCCTTGGT GCTGACGGGC CTCTCGGACG CCCCCGGAG CGAAGAAGTC
13501 CTGGAGCACC TGCGGTCCCT GCGCTCGATG GTCACGGGCG AGACCGGGAC CGGGACCGCG
13561 TCCGGAGCCC CGGACGGCGC CGGGTCCGGC GCCGAGGACC GGCCCTGGGC GGCCGGGGAC
13621 GGAGCCGGGG GCGGGAGTGA GGACGGCGCG GGAGTGCCGG ACTTCATGAA CGCCTCGGCC
13681 GAGGA ACTCT TCGGCTCCT CGACCAGGAC CCCAGCACGG ACTGATCCCT GCCGCACGGT
13741 CGCCTCCCGC CCCGGACCCC GTCCCGGGCA CCTCGACTCG AATCACTTCA TGCGCGCCTC
13801 GGGCGCCTCC AGGA ACTCAA GGGGACAGCG TGTCCACGGT GAACGAAGAG AAGTACCTCG
13861 ACTACTGCG TCGTGCCACG GCGGACCTCC ACGAGGCCCG TGGCCGCTC CGCGAGCTGG
13921 AGGCGAAGGC GGGCGAGCCG GTGGCGATCG TCGGCATGGC CTGCCGCTG CCCGGCGGCG
13981 TGCCTCGCC CGAGGACCTG TGGCGGCTGG TGCCCGGCG CGAGGACGCG ATCTCGGAGT
14041 TCCCCAGGA CCGCGGCTGG GACGTGGAGG GCCTGTACGA CCCGAACCCG GAGGCCACGG
14101 GCAAGAGTTA CGCCCGCGAG GCCGGATTCC TGTACGAGGC GGGCGAGTTC GACGCCGACT
14161 TCTTCGGGAT CTCGCCGCGC GAGGCCCTCG CCATGGACCC GCAGCAGCGT CTCCTCCTGG

-continued

14221 AGGCCTCCTG GGAGGCGTTC GAGCACGCCG GGATCCCGGC GGCCACCGCG CGCGGCACCT
14281 CGGTCGGCGT CTTACCCGGC GTGATGTACC ACGACTACGC CACCCGTCTC ACCGATGTCC
14341 CGGAGGGCAT CGAGGGGTAC CTGGGCACCG GCAACTCCGG CAGTGTCCGC TCGGGCCGCG
14401 TCGCGTACAC GCTTGGCCTG GAGGGGCCGG CCGTCACGGT CGACACCGCC TGCTCGTCCT
14461 CGCTGGTCGC CCTGCACCTC GCCGTGCAGG CCCTGCGCAA GGCGGAGGTC GACATGGCGC
14521 TCGCCGGCGG CGTGACGGTC ATGTCGACGC CCAGCACCTT CGTCGAGTTC AGCCGTCAGC
14581 GCGGGCTGGC GCCGACGGC CGGTCGAAGT CTTCTCGTC GACGGCCGAC GGCACCAGCT
14641 GGTCCGAGGG CGTCGGCGTC CTCCTCGTCG AGCGCCTGTC CGACGCGCGT CGCAAGGGCC
14701 ATCGGATCCT GCCTGTGGTC CGGGGCACCG CCGTCAACCA GGACGGCGCC AGCAGCGGCC
14761 TCACGGCTCC GAACGGGCCG TCGCAGCAGC GCGTCATCCG ACGTGCCCTG GCGGACGCCC
14821 GGCTCACGAC CTCGACGTG GACGTCGTCG AGGCCACCG CACGGGTACG GACTCGGCG
14881 ACCCGATCGA GGCGCAGGCC GTCATCGCCA CGTACGGGCA GGCCCGTGAC GGCGAACAGC
14941 CGCTGCGCCT CGGGTCGTTG AAGTCCAACA TCGGACACAC CCAGGCCGCC GCCGGTGTCT
15001 CCGGCGTGAT CAAGATGGTC CAGGCGATGC GCCACGGCGT CCGCCGAAG ACGCTCCACG
15061 TGGAGAAGCC GACGGACGAG GTGGAAGGT CCGCGGGCGC GGTGAGCTG CTCACCGAGG
15121 CCATGGACTG GCCGACAAG GCGACGGCG GACTGCGCAG GGCCGCGGTC TCCTCCTTCG
15181 GCGTCAGCGG GACGAACGCG CACGTCGTGC TCGAAGAGGC CCGGCGGCC GAGGAGACCC
15241 CTGCCTCCGA GGCGACCCCG GCCGTCGAGC CGTCGGTCGG CGCCGGCCTG GTGCCGTGGC
15301 TGGTGTGCGC GAAGACTCCG GCCGCGCTGG ACGCCAGAT CGGACGCTC GCCGCGTTCG
15361 CCTCGCAGGG CCGTACGGAC GCCCGCATC CGGGCGCGGT CGCTCGCGTA CTGGCCGGCG
15421 GGCGCGCCGA GTTCGAGCAC CGGGCCGTCG TGCTCGGCAC CGGACAGGAC GATTTCGCGC
15481 AGGCGCTGAC CGCTCCGGA GGAATGATAC GCGGCACGCC CTCGGACGTG GGCCGGGTGG
15541 CGTTCTGTGT CCCCAGTCAG GGCACGAGT GGGCCGGAT GGCGCGCAA CTCCTCGACG
15601 TGTCGAAGGA GTTCGCGCGC GCCATGGCCG AGTGCAGAG CGCGCTCTCC CGCTATGTGC
15661 ACTGGTCGCT GGAGGCCGTC GTCCGCGAG CGCCGGCGC GCCACGCTG GAGCGGGTCG
15721 ACGTCGTCCA GCCCGTAGC TTCGCTGTCA TGGTTTCGCT GGCGAAGGTC TGGCAGCACC
15781 ACGGCGTGAC GCCGAGGCC GTCGTCGGC ACTCGCAGG CGAGATCGCC GCCGCGTACG
15841 TCGCCGGTGC CCTCACCTC GACGACGCC CCGCGTCGT CACCTGCGC AGCAAGTCCA
15901 TCGCCGCCCA CCTCGCCGGC AAGGGCGCA TGATCTCCT CGCCCTCAGC GAGGAAGCCA
15961 CCCGCGAGCG CATCGAGAAC CTCCACGGAC TGTCGATCGC CGCCGTCAAC GGCCCCACCG
16021 CCACCTGGT TTCGGGCGAC CCCACCCAGA TCCAAGAGCT CGCTCAGGCG TGTGAGGCG
16081 ACGGGTCCG CGCAGCGAT ATCCCCGTCG ACTACGCCTC CCACAGCGCC CACGTCGAGA
16141 CCATCGAGAG CGAACTCGCC GAGGTCCTCG CCGGGCTCAG CCCGCGGACA CCTGAGGTGC
16201 CGTTCTTCTC GACACTCGAA GCGCCTGGA TCACCGAGCC GGTGCTCGAC GGCACCTACT
16261 GGTACGCAA CCTCGGCCAC CGCGTCGGT TCGCCCCGC CGTCGAGACC CTCGCCACCG
16321 ACGAAGGCTT CACCCACTTC ATCGAGGTCA GCGCCACCC CGTCCTCACC ATGACCTTCC
16381 CCGAGACCGT CACCGGCTC GGCACCTCC GCGCGAACA GGAGGCCAG GAGCGTCTGG
16441 TCACCTCACT CGCCGAAGCC TGGACCAACG GCCTCACCAT CACTCGGCG CCCGTCCTCC

-continued

16501 CCACCGCAAC CGGCCACCAC CCCGAGCTCC CCACCTACGC CTTCCAGCGC CGTCACTACT
16561 GGCTCCACGA CTCCCCCGCC GTCCAGGGCT CCGTGCAGGA CTCCTGGCGC TACCGCATCG
16621 ACTGGAAGCG CCTCGCGGTC GCCGACGCGT CCGAGCGCGC CGGGCTGTCC GGGCGCTGGC
16681 TCGTCGTCGT CCCCAGGAC CGTTCCGCCG AGGCCGCCCC GTTGCTCGCC GCGCTGTCCG
16741 GCGCCGGCGC CGACCCCGTA CAGCTGGACG TGTCCCCGCT GGGCGACCGG CAGCGGCTCG
16801 CCGCGACGCT GGGCGAGGCC CTGGCGGCGG CCGGTGGAGC CGTCGACGGC GTCTCTCGC
16861 TGCTCGCGTG GGACGAGAGC GCGCACCCCG GCCACCCCGC CCCCTTACC CGGGGCACCG
16921 GCGCCACCTT CACCTTGGTG CAGGCGCTGG AGGACGCCGG CGTCGCCGCC CCGCTGTGGT
16981 GCGTGACCCA CGGCGCGGTG TCCGTGCGCC GGGCCGACCA CGTCACCTCC CCCGCCAGG
17041 CCATGGTGTG GGGCATGGGC CGGGTCGCCG CCCTGGAGCA CCCCAGCGCG TGGGGCGGCC
17101 TGATCGACCT GCCCTCGGAC GCCGACCGGG CGGCCCTGGA CCGCATGACC ACGGTCTCTG
17161 CCGGCGGTAC GGGTGAGGAC CAGGTGCGGG TACGCGCCTC CGGGCTGCTC GCGCGCGGCC
17221 TCGTCCGCGC CTCCCTCCCG GCGCACGGCA CGGCTTCGCC GTGGTGCGAG GCCGACGGCA
17281 CGGTGCTCGT CACCGGTGCC GAGGAGCCTG CGGCCGCCGA GGCCGCACGC CGGCTGGCCC
17341 GCGACGGCGC CGGACACCTC CTCCTCCACA CCACCCCTC CGGCAGCGAA GCGCCGAAG
17401 GCACCTCCGG TGCCGCCGAG GACTCCGGCC TCGCCGGGCT CGTCGCCGAA CTCGCGGACC
17461 TGGGCGCGAC GGCCACCGTC GTGACCTGCG ACCTCACGGA CGCGGAGCGG GCCGCCCGGC
17521 TGCTCGCCGG CGTCTCCGAC GCGCACCCGC TCAGCGCCGT CCTCCACCTG CCGCCCACCG
17581 TCGACTCCGA GCCGCTCGCC GCGACCGACG CGGACGCGCT CGCCCGTGTC GTGACCGCGA
17641 AGGCCACCGC CGCGCTCCAC CTGGACCGCC TCCTGCGGGA GGCCGCGGCT GCCGGAGGCC
17701 GTCCGCCCGT CCTGGTCTTC TTCTCCTCGG TCGCCCGCAT CTGGGGCGGC GCCGGTCAGG
17761 GCGCGTACGC CGCCGGTACG GCCTTCCTCG ACGCCCTCGC CGGTACGAC CGGGCCGACG
17821 GCCCCACCGT GACCTCGGTG GCCTGGAGCC CTTGGGAGGG CAGCCCGCTC ACCGAGGGTG
17881 CGACCGGGGA GCGGCTGCGC GGCCTCGGCC TGCGCCCTT CGCCCCGCGC ACGGCGCTCA
17941 CCGCCCTGGA CACCGCGCTC GGCCACGGCG ACACCGCGT CACGATCGCC GACGTCGACT
18001 GGTGAGCTT CGCCCCCGGC TTCACACGG CCCGGCCGGG CACCTCCTC GCCGATCTGC
18061 CCGAGGCGCG CCGCGCGCTC GACGAGCAGC AGTCGACGAC GGCCGCCGAC GACACCGTCC
18121 TGAGCCGCGA GCTCGGTGCG CTCACCGCGC CCGAACAGCA GCGCCGTATG CAGGAGTTGG
18181 TCCGCGAGCA CCTCGCCGTG GTCCTCAACC ACCCTCCCC CGAGGCCGTC GACACGGGGC
18241 GGGCCTTCG TGACCTCGGA TTCGACTCGC TGACGGCGGT CGAGCTCCG AACC GCCTCA
18301 AGAACGCCAC CGGCCGTGCC CTCGCCGCCA CTCTGCTCTT CGACTACCCG ACCCCCCGGA
18361 CGCTGGCGGA GTTCTCTCTC GCGGAGATCC TGGGCGAGCA GGCCGGTGCC GCGGAGCAGC
18421 TTCCGGTGGA CGCGGGGTC GACGACGAGC CCGTCGCGAT CGTCGGCATG GCGTGCCGCC
18481 TGCCGGGCGG TGTGCGCTCG CCGGAGGACC TGTGGCGGCT GGTGGCCGGC GCGGAGGACG
18541 CGATCTCCGG CTTCGCCGAG GACCGCGGCT GGGACGTGGA GGGGCTGTAC GACCCGGACC
18601 CCGACGCGTC CGGCGGAGC TACTGCCGTG CCGGTGGCTT CCTCGACGAG GCGGGCGAGT
18661 TCGACGCCGA CTTCTTCGGG ATCTCGCCGC GCGAGGCCCT CGCCATGGAC CCGCAGCAGC
18721 GGCTCCTCCT GGAGACCTCC TGGGAGGCCG TCGAGGACGC CGGGATCGAC CCGACCTCCC
18781 TTCAGGGGCA CGAGGTGCGG GTGTTGCGCG GCACCAACGG CCCCCACTAC GAGCCGCTGC

-continued

18841 TCCGCAACAC CGCCGAGGAT CTTGAGGGTT ACGTCGGGAC GGGCAACGCC GCCAGCATCA
18901 TGTCGGGCCG TGTCTCGTAC ACCCTCGGCC TGGAGGGCCC GGCCGTCACG GTCGACACCG
18961 CCTGCTCCTC CTCGCTGGTC GCCCTGCACC TCGCCGTGCA GGCCCTGCGC AAGGGCGAAT
19021 GCGGACTGGC GCTCGGGGCG GGTGTGACGG TCATGTCGAC GCCACGACG TTCGTGGAGT
19081 TCAGCCGGCA GCGCGGGCTC GCGGAGGACG GCCGGTCGAA GGCGTTCGCC GCGTCGGCGG
19141 ACGGCTTCGG CCCGGCGGAG GGCCTCGGCA TGCTCCTCGT CGAGCGCCTG TCGGACGCCC
19201 GCCGCAACGG ACACCGTGTG CTGGCGGTCG TGGCGGCGAG CGCGGTCAAC CAGGACGGCG
19261 CGAGCAACGG CCTGACCGCC CCGAACGGGC CCTCGCAGCA GCGCGTCATC CGCGCGCGCG
19321 TCGCGGACGC CCGACTGACG ACCGCCGACG TGGACGTCGT CGAGGCCAC GGCACGGGCA
19381 CCGGACTCGG CGACCCGATC GAGGCACAGG CCCTCATCGC CACCTACGGC CAGGGGCGCG
19441 ACACCGAACA GCCGCTGCGC CTGGGGTCGT TGAAGTCAA CATCGGACAC ACCCAGGCCG
19501 CCGCCGGTGT CTCGGGCATC ATCAAGATGG TCCAGGCGAT GCGCCACGGC GTCCTGCCGA
19561 AGACGCTCCA CGTGGACCGG CCGTCGGACC AGATCGACTG GTCGCCGGGC ACGGTCGAGC
19621 TGCTCACCBA GGCCATGGAC TGGCCGAGGA AGCAGGAGGG CGGGCTGCGC CGCGCGGCCG
19681 TCTCCTCCTT CGGCATCAGC GGCACGAACG CGCACATCGT GCTCGAAGAA GCGCCGGTCG
19741 ACGAGGACGC CCCGGCGGAC GAGCCGTCGG TCGCGGTGTG GTGCGCGTGG CTCGTGTCCG
19801 CGAAGACTCC GGCCGCGCTG GACGCCAGA TCGGACGCCT CGCCGCGTTC GCCTCGCAGG
19861 GCCGTACGGA CGCCGCCGAT CCGGGCGCGG TCCTCGCGT ACTGGCCGGC GGGCGTGCGC
19921 AGTTCGAGCA CCGGGCCGTC GCGCTCGGCA CCGGACAGGA CGACCTGGCG GCCGCACTGG
19981 CCGCGCCTGA GGGTCTGGTC CGGGGTGTGG CCTCCGTTGT GGGTCGAGTG GCGTTCGTGT
20041 TCCCGGGACA GGGCACGCGAG TGGGCCGGGA TGGGTGCCGA ACTCCTCGAC GTGTCAAGG
20101 AGTTCGCGGC GGCCATGGCC GAGTGCAGG CCGCGCTCGC TCCGTACGTG GACTGGTCGC
20161 TGGAGGCCGT CGTCCGACAG GCCCCGCGC CGCCACGCT GGAGCGGGTC GATGTCGTCC
20221 AGCCCGTGAC GTTCGCCGTC ATGGTCTCGC TGGCGAAGGT CTGGCAGCAC CACGGGGTGA
20281 CCCCGCAAGC CGTCGTCGGC CACTCGCAGG GCGAGATCGC CGCCGCGTAC GTCGCCGGTG
20341 CCCTGAGCCT GGACGACGCC GCTCGTGTG TGACCCTGCG CAGCAAGTCC ATCGGCGCCC
20401 ACCTCGCGGG CCAGGGCGGC ATGCTGTCCC TCGCGCTGAG CGAGGCGGCC GTTGTGGAGC
20461 GACTGGCCGG GTTCGACGGG CTGTCCGTCG CCGCCGTCGA CGGGCCTACC GCCACCGTGG
20521 TTTCGGGCGA CCCGACCCAG ATCCAAGAGC TCGCTCAGGC GTGTGAGGCC GACGGGGTCC
20581 GCGCACGGAT CATCCCCGTC GACTACGCCT CCCACAGCGC CCACGTCGAG ACCATCGAGA
20641 GCGAACTCGC CGACGTCCTG GCGGGGTGTG CCCCCAGAC ACCCCAGGTC CCCTTCTTCT
20701 CCACCTCGA AGGCGCCTGG ATCACCGAAC CCGCCCTCGA CGGCGGTAC TGGTACCGCA
20761 ACCTCCGCCA TCGTGTGGGC TTCGCCCCGG CCGTCGAAAC CCTGGCCACC GACGAAGGCT
20821 TCACCCACTT CGTCGAGGTC AGCGCCACC CCGTCCTCAC CATGGCCCTG CCCGAGACCG
20881 TCACCGGCCT CGGCACCTC CGCCGTGACA ACGGCGGACA GCACCGCCTC ACCACCTCCC
20941 TCGCCGAGGC CTGGGCCAAC GGCCTACCG TCGACTGGGC CTCTCTCCTC CCCACCACGA
21001 CCACCCACCC CGATCTGCC ACCTACGCCT TCCAGACCGA GCGCTACTGG CCGCAGCCCG
21061 ACCTCTCCGC CGCCGGTGAC ATCACCTCCG CCGGTCTCGG GCGGCGCGAG CACCCGCTGC

-continued

21121 TCGGCGCGGC CGTGGCGCTC GCGGACTCCG ACGGCTGCCT GCTCACGGGG AGCCTCTCCC
21181 TCCGTACGCA CCCCTGGCTG GCGGACCACG CGGTGGCCGG CACCGTGTCTG CTGCCGGGAA
21241 CGGCGTTCGT GGAGCTGGCG TTCCGAGCCG GGGACCAGGT CGGTTGCGAT CTGGTCGAGG
21301 AGCTCACCTT CGACGCGCCG CTCGTGCTGC CCCGTCTGGG CGCGGTCCGT GTGCAGCTGT
21361 CCGTCGGGCG GAGCGACGAG TCCGGGCGTC GTACCTTCGG GCTCTACCGG CACCCGGAGG
21421 ACGCGCCGGG CGAGGCGGAG TGGACGCGGC ACGCCACCGG TGTGCTGGCC GCCCGTGC GG
21481 ACCGCACCGC CCCCGTCGCC GACCCGGAGG CCTGGCCGCC GCCGGGCGCC GAGCCGGTGG
21541 ACGTGGACGG TCTGTACGAG CGCTTCGCGG CGAACGGCTA CGGCTACGGC CCCCTCTTCC
21601 AGGCGTCCG TGGTGTCTGG CGGCGTGGCG ACGAGGTGTT CGCCGACGTG GCCCTGCCGG
21661 CCGAGGTCGC CGGTGCCGAG GGC GCGCGGT TCGGCCTTCA CCCGGCGCTG CTCGACGCCG
21721 CCGTGCAAGC GGCCGGTGCG GGC GGGGCGT TCGGCGCGGG CACGCGGCTG CCGTTCGCCT
21781 GGAGCGGGAT CTCCCTGTAC GCGGTGCGCG CCACCGCCCT CGCGGTGCGG CTGGCCCCCG
21841 CCGGCCCGGA CACGGTGTCG GTGAGCGCCG CCGACTCCTC CGGGCAGCCG GTGTTGCGCG
21901 CCGACTCCCT CACGGTGCTG CCCGTCGACC CCGCGCAGCT GCGCGCCTTC AGCGACCCGA
21961 CTCTGGACGC GCTGCACCTG CTGGAGTGA CCGCCTGGGA CGGTGCGCGG CACGCCCTGC
22021 CCGGCGCGGT CGTGCTGGGC GGC GACGCCG ACGGTCTCGC CGCGGCGCTG CGCGCCGGTG
22081 GCACCGAGGT CCTGTCCCTT CCGGACCTTA CGGACCTGGT GGAGGCCGTC GACCGGGGCG
22141 AGACCCCGGC CCCGCGACC GTCCTGGTGG CTGCCCCGCG CGCCGGCCCC GGTGGGCGCG
22201 AGCATGTCCG CGAGGCCCTG CACGGGTCGC TCGCGCTGAT GCAGGCCTGG CTGGCCGACG
22261 AGCGGTTTAC CGATGGGCGC CTGGTGCTCG TGACCCGCGA CGCGGTGCGC GCCCGTTCCG
22321 GCGACGGCCT GCGGTCCACG GGACAGGCCG CCGTCTGGGG CCTCGGCGCG TCCGCGCAGA
22381 CGGAGAGCCC GGGCCGGTTC GTCCTGCTCG ACCTCGCCGG GGAAGCCCGG ACGGCCGGGG
22441 ACGCCACCGC CGGGGACGGC CTGACGACCG GGGACGCCAC CGTCGGCGGC ACCTCTGGAG
22501 ACGCCGCCCT CGGCAGCGCC CTCGCGACCG CCCTCGGCTC GGGCGAGCCG CAGCTCGCCC
22561 TCCGGGACGG GGCCTCTCTC GTACCCCGCC TGGCGCGGGC CGCCGCGCCC GCCGCGGCCG
22621 ACGGCTCTGC CGCGGCCGAC GGCCTCGCCG CTCTGCCGCT GCCCGCCGCT CCGGCCCTCT
22681 GGCCTCTGGA GCCCGGTACG GACGGCAGCC TGGAGAGCCT CACGGCGGCG CCCGGCGACG
22741 CCGAGACCCT CGCCCCGGAG CCGCTCGGCC CGGGACAGGT CCGCATCGCG ATCCGGGCCA
22801 CCGGTCTCAA CTTCGCGGAC GTCCTGATCG CCCTCGGCAT GTACCCCGAT CCGGCGCTGA
22861 TGGGCACCGA GGGAGCCGGC GTGGTCACCG CGACCGGCC CGGCGTCACG CACCTCGCCC
22921 CCGGCGACCG GGTATGCGC CTGCTCTCCG GCGCGTACGC CCCGGTCTGT GTGGCGGACG
22981 CGCGGACCGT CGCGCGGATG CCCGAGGGGT GGACGTTCTG CCAGGGCGCC TCCGTGCCGG
23041 TGGTGTTCCT GACGGCCGTC TACGCCCTGC GCGACCTGGC GGACGTCAAG CCCGGCGAGC
23101 GCCTCTGGT CCACTCCGCC GCCGGTGGCG TGGCATGGC CGCCGTGCGC CTCGCCCGGC
23161 ACTGGGGCGT GGAGGTCCAC GGCACGGCGA GTCACGGGAA GTGGGACGCC CTGCGCGCGC
23221 TCGGCTTGA CGACGCGCAC ATCGCCTCCT CCCGACCTT GACTTTCGAG TCCGCGTTCC
23281 GTGCCGCTTC CGCGGGGGCG GGCATGGACG TCGTACTGAA CTCGCTCGCC CGCGAGTTCT
23341 TCGACGCTC GCTGCGCCTG CTCGGGCCGG GCGGCCGGTT CGTGGAGATG GGAAGACCG
23401 ACGTCCGCGA CGCGGAGCGG GTCGCCGCCG ACCACCCCGG TGTGCGCTAC CGCGCCTTCG

-continued

23461 ACCTGGGCGA GGCCGGGCGG GAGCGGATCG GCGAGATGCT CGCCGAGGTC ATCGCCCTCT
23521 TCGAGGACGG GGTGCTCCGG CACCTGCCCG TCACGACCTG GGACGTGCGC CGGGCCCGCG
23581 ACGCCTTCCG GCACGTCAGC CAGGCCCGCC ACACGGGCAA GGTGCTCCTC ACGATGCCGT
23641 CGGGCTCTGA CCCGAGGGT ACGGTCCTGC TGACCGCGCG CACCGGTGCG CTGGGGGGCA
23701 TCGTGGCCCG GCACGTGGTG GCGGAGTGGG GCGTACGACG CCTGCTGCTC GTGAGCCGGC
23761 GGGGCACGGA CGCCCCGGG GCCCGCGAGC TCGTGACAGA GCTGGAGGCC CTGGGAGCCG
23821 ACGTCTCGGT GGCCGCGTGC GACGTGCGCG ACCGCGAAGC CCTCACCGCC GTACTCGACT
23881 CGATCCCCGC CGAACACCCG CTCACCGCGG TCGTCCACAC GGCAGGCGTC CTCTCCGACG
23941 GCACCTCCC CTCGATGACA GCGGAGGATG TGGAACACGT ACTGCGTCCC AAGGTCGACG
24001 CGCGTTTCCT CCTCGACGAA CTCACCTCGA CGCCCGGCTA CGACCTGGCA GCGTTCGTCA
24061 TGTTCCTCTC CGCCGCCGCC GTCTTCGGTG GCGCGGGGCA GGCGCCTAC GCCCGGCCA
24121 ACGCCACCTT CGAGCCCTTC GCCTGGCGCC GCCGGACAGC CGGACTCCCC GCCCTCTCCC
24181 TCGGCTGGGG CCTCTGGGCC GAGACCAGCG GCATGACCGG CGGACTCAGC GACACCGACC
24241 GCTCGCGGCT GGCCCGTTCC GGGGCGACGC CCATGGACAG CGAGCTGACC CTGTCCCTCC
24301 TGGACGCGGC CATGCGCCGC GACGACCCGG CGCTCGTCCC GATCGCCCTG GACGTCGCCG
24361 CGCTCCGCGC CCAGCAGCGC GACGGCATGC TGGCGCCGCT GCTCAGCGGG CTCACCCGCG
24421 GATCGCGGGT CGCGGCGCGC CCGGTCAACC AGCGCAGGGC AGCCGCCGGA GGCGGGGCG
24481 AGGCGACAC GGACCTCGGC GGGCGGCTCG CCGCATGAC ACCGGACGAC CGGGTCGCGC
24541 ACCTGCGGGA CCTCGTCCGT ACGCACGTGG CGACCGTCTT GGGACACGGC ACCCCGAGCC
24601 GGTGGACCT GGAGCGGGCC TTCCGCGACA CCGGTTTCGA CTCGCTCACC GCCGTGAAAC
24661 TCCGCAACCG TCTCAACGCC GCGACCGGGC TGCGGCTGCC GGCCACGCTG GTCTTCGACC
24721 ACCCCACCCC GGGGAGCTC GCCGGGCACC TGCTCGACGA ACTCGCCACG GCCGCGGGCG
24781 GGTCTGGGC GGAAGGCACC GGGTCCGAG ACACGGCCTC GCGGACCGAT CGGCAGACCA
24841 CGGCGGCCCT CGCCGAATC GACCGGCTGG AAGGCGTGCT CGCCTCCCTC GCGCCCGCCG
24901 CGGCGGGCG TCCGAGCTC GCCCGCGGC TCAGGGCGCT GGCCGCGGCC CTGGGGGACG
24961 ACGGCGACGA GCCCACCACG CTGGACGAGG CGTCCGACGA CGACCTCTTC TCCTTCATCG
25021 ACAAGGAGCT GGGCGACTCC GACTTCTGAC CTGCCCACGA CCACCGGCAC CACCGGCACC
25081 ACCAGCCCC CTCACACAG GAACACGAA CGGACAGGCG AGAACGGGAG CCATGGCGAA
25141 CAACGAAGAC AAGCTCCGCG ACTACCTCAA GCGCGTCACC GCCGAGCTGC AGCAGAACAC
25201 CAGGCGTCTG CGCGAGATCG AGGGACGCAC GCACGAGCCG GTGGCGATCG TGGGCATGGC
25261 CTGCCGCTG CCGGGCGGTG TCGCCTCGCC CGAGGACCTG TGGCAGCTGG TGGCCGGGA
25321 CGGGGACGCG ATCTCGAGT TCCCGCAGGA CCGCGGCTGG GACGTGGAGG GGCTGTACGA
25381 CCCCACCCG GACGCGTCCG GCAGGACGTA CTGCCGTCC GCGGATTC TGCACGACGC
25441 CGGCGAGTTC GACGCCACT TCTTCGGGAT CTCGCCGCGC GAGGCCCTCG CCATGGACCC
25501 GCAGCAGCGA CTGTCCCTCA CCACCGCGTG GGAGGCGATC GAGAGCGCG GCATCGACCC
25561 GACGGCCCTG AAGGGCAGCG GCCTCGGCGT CTTCGTCGGC GGCTGGCACA CCGGCTACAC
25621 CTCGGGGCAG ACCACCGCCG TGCACTCGCC CGAGCTGGAG GGCCACCTGG TCAGCGCGC
25681 GCGCGTGGG TTCTGTCCG GCCGTATCG GTACGTCCTC GTACGAGC GACCGGCCCT

-continued

25741 GACCGTGGAC ACGGCCTGCT CGTCCTCGCT GGTCGCCCTG CACCTCGCCG TGCAGGCCCT
25801 CCGCAAGGGC GAGTGCGACA TGGCCCTCGC CGGTGGTGTC ACGGTCATGC CCAACGCGGA
25861 CCTGTTCTGT CAGTTCAGCC GGCAGCGCGG GCTGGCCGCG GACGGCCGGT CGAAGGCGTT
25921 CGCCACCTCG GCGGACGGCT TCGGCCCCGC GGAGGGCGCC GGAGTCTGTC TGGTGGAGCG
25981 CCTGTCGGAC GCGCCGCCGA ACGGACACCG GATCCTCGCG GTCGTCCGCG GCAGCGCGGT
26041 CAACCAGGAC GGCGCCAGCA ACGGCCTCAC GGCTCCGCAC GGGCCCTCCC AGCAGCGCGT
26101 CATCCGACGG GCCCTGGCGG ACGCCCGGCT CGCGCCGGGT GACGTGGACG TCGTCGAGGC
26161 GCACGGCACG GGCACGCGGC TCGGCGACCC GATCGAGGCG CAGGCCCTCA TCGCCACCTA
26221 CGGCCAGGAG AAGAGCAGCG AACAGCCGCT GAGGCTGGGC GCGTTGAAGT CGAACATCGG
26281 GCACACGCAG GCCGCGGCGG GTGTCGCAGG TGTCATCAAG ATGGTCCAGG CGATGCGCCA
26341 CGGACTGCTG CCGAAGACGC TGCACGTCGA CGAGCCCTCG GACCAGATCG ACTGGTCGGC
26401 GGGCACGGTG GAACTCCTCA CCGAGGCCGT GACTGGCCG GAGAAGCAGG ACGCGGGGCT
26461 GCGCCGCGCG GCTGTCTCCT CCTTCGGCAT CAGCGGGACG AACGCGCAGC TCGTCCTGGA
26521 GGAGGCCCCG GCGGTCGAGG ACTCCCCGGC CGTCGAGCCG CCGGCCGGTG GCGGTGTGGT
26581 GCCGTGGCCG GTGTCCGCGA AGACTCCGGC CGCGCTGGAC GCCCAGATCG GGCAGCTCGC
26641 CGCGTACGCG GACGGTCGTA CGGACGTGGA TCCGGCGGTG GCCGCCCGCG CCCTGGTCGA
26701 CAGCCGTACG GCGATGGAGC ACCGCGCGGT CGCGGTCCGC GACAGCCGGG AGGCACTGCG
26761 GGAGCCCTG CGGATGCCGG AAGGACTGGT ACGCGGCACG TCCTCGGACG TGGGCCGGGT
26821 GGCGTTCGTC TTCCCCGGCC AGGGCACGCA GTGGGCGGCG ATGGGCGCCG AACTCCTTGA
26881 CAGCTACCG GAGTTCGCTG CCTCGATGGC CGAATGCGAG ACCGCGCTCT CCCGCTACGT
26941 CGACTGGTCT CTTGAAGCCG TCGTCCGACA GGAACCCGGC GCACCCACGC TCGACCGCGT
27001 CGACGTCGTC CAGCCCGTGA CCTTCGCTGT CATGGTCTCG CTGGCGAAGG TCTGGCAGCA
27061 CCACGGCATC ACCCCCCAGG CCGTCGTCGG CCACTCGCAG GGCAGATCG CCGCCGCGTA
27121 CGTCGCCGGT GCACCTACCC TCGACGACGC CGCCCGCGTC GTCACCTGCG GCAGCAAGTC
27181 CATCGCCGCC CACCTCGCCG GCAAGGGCGG CATGATCTCC CTCGCCCTCG ACGAGGCGGC
27241 CGTCTGAAG CGACTGAGCG ACTTCGACGG ACTCTCCGTC GCCGCCGTCA ACGGCCCCAC
27301 CGCCACCGTC GTCTCCGGCG ACCCGACCCA GATCGAGGAA CTCGCCCGCA CCTGCGAGGC
27361 CGACGGCGTC CGTGCGCGGA TCATCCCGGT CGACTACGCC TCCCACAGCC GGCAGGTCGA
27421 GATCATCGAG AAGGAGCTGG CCGAGGTCCT CGCCGGACTC GCGCCGAGG CTCCGCACGT
27481 GCCGTTCTTC TCCACCCTCG AAGGCACCTG GATCACCGAG CCGGTGCTCG ACGGCACCTA
27541 CTGGTACCGC AACCTGCGCC ATCGCGTGGG CTTGCGCCCC GCCGTGGAGA CCTTGGCGGT
27601 TGACGGCTTC ACCCACTTCA TCGAGGTCAG CGCCACCCCC GTCCTCACCA TGACCCTCCC
27661 CGAGACCGTC ACCGGCCTCG GCACCTCCG CCGCGAACAG GGAGGCCAGG AGCGTCTGGT
27721 CACCTCACTC GCGGAAGCCT GGGCCAACGG CCTCACCATC GACTGGGCGC CCATCCTCCC
27781 CACCGCAACC GGCCACCACC CCGAGCTCCC CACCTACGCC TTCCAGACCG AGCGCTTCTG
27841 GCTGCAGAGC TCCGCGCCCA CCAGCGCCG CGACGACTGG CGTTACCGCG TCGAGTGGA
27901 GCCGCTGACG GCCTCCGGCC AGGCGGACCT GTCCGGGCGG TGGATCGTCG CCGTCGGGAG
27961 CGAGCCAGAA GCCGAGCTGC TGGGCGCGCT GAAGGCCGCG GGAGCGGAGG TCGACGTACT
28021 GGAAGCCGGG GCGGACGACG ACCGTGAGGC CCTCGCCGCC CGGCTACCG CACTGACGAC

-continued

28081 CGGCGACGGC TTCACCGGCG TGGTCTCGCT CCTCGACGAC CTCGTGCCAC AGGTCGCCCTG
28141 GGTGCAGGCA CTCGGCGACG CCGGAATCAA GGCGCCCTG TGGTCCGTCA CCCAGGGCGC
28201 GGTCTCCGTC GGACGTCTCG ACACCCCGC CGACCCCGAC CGGGCCATGC TCTGGGGCCT
28261 CGGCGCGTC GTCGCCCTTG AGCACCCGA ACCTGCGGC GGCCTCGTCG ACCTCCCCG
28321 CCAGCCCGAT GCCGCGGCC TCGCCACCT CGTCACGCA CTCTCCGGC CCACCGGCGA
28381 GGACCAGATC GCCATCCGCA CCACCGGACT CCACGCCCGC CGCTCGCCC GCGCACCCCT
28441 CCACGGACGT CGGCCACCC GCGACTGGCA GCGCCACGGC ACCGTCTCA TCACCGGCGG
28501 CACCGGAGCC CTCGGCAGCC ACGCCGACG CTGGATGGCC CACCACGGAG CCGAACACCT
28561 CCTCTCGTC AGCCGACGCG GCGAACAGC CCGCGAGCC ACCCAACTCA CCGCCGAACCT
28621 CACCGCATCG GCGCCCGCG TACCATCGC CGCTCGGAC GTCGCGGACC CCCACGCCAT
28681 GCGCACCTC CTCGACGCA TCCCGCCGA GACGCCCTC ACCGCCGTCG TCCACACCGC
28741 CGGCGACCG GCGCGCATC CGCTGGACGT CACCGGCCC GAGGACATCG CCCGATCCT
28801 GGGCGGAAG ACGAGCGCG CCGAGGTCCT CGACGACCTG CTCGCGGCA CTCGCTGGA
28861 CGCCTTCGTC CTCTACTCCT CGAACGCCG GGTCTGGGC AGCGGCAGCC AGGGCGCTA
28921 CGCGCGGCG AACGCCACC TCGACGCGT CGCGCCCGG CGCGCGCCC GGGCGGAGAC
28981 GCGACCTCG GTCGCTGGG GCCTCTGGG CGCGACGGC ATGGCCGGG GCGCCGACGA
29041 CGCGTACTG CAGCGTCGCG GCATCCGTCC GATGAGCCC GACCGCGCCC TGGACGAACT
29101 GGCCAAGGCC CTGAGCCACG ACGAGACCTT CGTCGCCGTG GCCGATGTCG ACTGGGAGCG
29161 GTTCGCGCCC GCGTTCACGG TGTCCCGTCC CAGCCTTCTG CTCGACGGCG TCCCGGAGGC
29221 CCGGCAGGCG CTCGCCGAC CCGTCGGTGC CCCGGCTCCC GCGGACGCC CCGTGGCGCC
29281 GACCGGGCAG TCGTCGGCG TGGCCGCGAT CACCGCGCTC CCGAGCCCG AGCGCCGGCC
29341 GCGCTCCTC ACCCTCGTCC GTACCCACGC GCGGCCGTA CTCGGCCATT CCTCCCCGA
29401 CCGGGTGGCC CCCGCCGTG CCTTCACGA GCTCGGCTT GACTCGTGA CGGCCGTGCA
29461 GCTCCGAAC CAGCTCTCCA CGGTGGTCGG CAACAGGCTC CCCGCCACCA CGGTCTTCGA
29521 CCACCCGACG CCCGCCGAC TCGCCGCGA CCTCCACGAG GCGTACCTCG CACCGGCCGA
29581 GCGCGCCCG ACGGACTGGG AGGGGCGGGT GCGCGGGCC CTGGCCGAAC TGCCCTCGA
29641 CCGGTGCGG GACGCGGGG TCCTCGACAC CGTCTGCGC CTCACCGGCA TCGAGCCGA
29701 GCGGGTTCC GCGGTTTCG ACGCGGCGC CGCCGACCT GTGCGGAGC CGGAGGCGTC
29761 GATCGACGAC CTGACGCGG AGGCCCTGAT CCGGATGGCT CTCGGCCCC GTAACACCTQ
29821 ACCCGACCGC GGTCTTGCCC CACGCGCGC ACCCGCGCA TCCCGCGAC CACCGCCCC
29881 CACACGCCA CAACCCATC CACGAGCGA AGACCACAC CAGATGACGA GTTCCAACGA
29941 ACAGTTGGTG GACGCTCTG CCGCTCTCT CAAGGAGAAC GAAGAACTCC GGAAAGAGAG
30001 CCGTCGCCG GCCGACCGTC GGCAGGAGC CATGGCGATC GTCGGCATGA GCTGCCGGTT
30061 CGCGGGCGGA ATCCGGTCCC CCGAGGACCT CTGGGACGCC GTCGCCGCG GCAAGGACCT
30121 GGTCTCCGAG GTACCGGAG AGCGCGGCTG GGACATCGAC TCCTCTACG ACCCGGTGCC
30181 CGGGCGAAG GGCACGACGT ACGTCCGCA CGCCGCGTTC CTCGACGAC CCGCCGATT
30241 CGACGCGCC TTCTTCGGGA TCTCGCCGCG CGAGGCCCTC GCGATGACG CCGAGCAGCG
30301 GCAGCTCCTC GAAGCCTCCT GGGAGGTCTT CGAGCGGGC GGCATCGACC CCGCTCGGT

-continued

30361 CCGCGGCACC GACGTCGGCG TGTACGTGGG CTGTGGCTAC CAGGACTACG CGCCGGACAT
30421 CCGGGTCGCC CCCGAAGGCA CCGGCGGTTA CGTCGTCACC GGCAACTCCT CCGCCGTGGC
30481 CTCGGGGCGC ATCGCGTACT CCCTCGGCCT GGAGGGACCC GCCGTGACCG TGGACACGGC
30541 GTGCTCCTCT TCGCTCGTCG CCCTGCACCT CGCCCTGAAG GGCTGCGGA ACGGCGACTG
30601 CTCGACGGCA CTCGTGGGCG GCGTGCCCGT CCTCGCGACG CCGGCGCGCT TCATCGAGTT
30661 CAGCAGCCAG CAGGCCATGG CCGCCGACGG CCGGACCAAG GGCTTCGCCT CGGCGGCGGA
30721 CGGCCTCGCC TGGGGCGAGG GCGTCGCCGT ACTCCTCCTC GAACGGCTCT CCGACGCGCG
30781 GCGCAAGGGC CACCGGGTCC TGGCCGTCGT GCGCGGCAGC GCCATCAACC AGGACGGCGC
30841 GAGCAACGGC CTCACGGCTC CGCACGGGCC CTCCAGCAG CGCCTGATCC GCCAGGCCCT
30901 GGCCGACGCG CGGCTCACGT CGAGCGACGT GGACGTCGTG GAGGGCCACG GCACGGGGAC
30961 CCGTCTCGGC GACCCGATCG AGGCGCAGGC GCTGCTCGCC ACGTACGGGC AGGGGCGCGC
31021 CCCGGGGCAG CCGCTGCGGC TGGGGACGCT GAAGTCGAAC ATCGGGCACA CGCAGGCCGC
31081 TTCGGGTGTC GCCGTTGTCA TCAAGATGGT GCAGGCGCTG CGCCACGGGG TGCTGCCGAA
31141 GACCTTGCAC GTGGACGAGC CGACGGACCA GGTGACTGG TCGGCCGGTT CGGTGAGCT
31201 GCTCACCGAG GCCGTGGACT GGCCGGAGCG GCCGGGCGG CTCCGCCGG CGGGCGTCTC
31261 CGCGTTCGGC GTGGGCGGGA CGAACGCGCA CGTCGTCCTG GAGGAGGCC CGGCGGTCGA
31321 GGAGTCCCCT GCCGTCGAGC CGCCGGCCGG TGGCGGCGTG GTGCCGTGGC CGGTGTCCGC
31381 GAAGACCTCG GCCGCACTGG ACGCCAGAT CGGGCAGCTC GCCGCATACG CGGAAGACCG
31441 CACGGACGTG GATCCGGCGG TGGCCGCCCG CGCCCTGGTC GACAGCCGTA CGGCGATGGA
31501 GCACCGCGCG GTCGCGGTG GCGACAGCCG GGAGGCACCTG CCGGACGCCC TCGGATGCC
31561 GGAAGACTG GTACGGGCA CGGTCACCA TCCGGGCCGG GTGGCGTTG TCTTCCCGG
31621 CCAGGGCAGC CAGTGGGCG GCATGGGCGC CGAACTCCTC GACAGCTCAC CCGAATTCGC
31681 CGCCGCCATG GCCGAATGCG AGACCGCACT CTCCCCGTAC GTCGACTGGT CTCTCGAAGC
31741 CGTCGTCCGA CAGGCTCCCA CGGCACCGAC ACTCGACCGC GTCGACGTCG TCCAGCCCGT
31801 CACCTTCGCC GTCATGGTCT CCCTCGCCAA GGTCTGGCAG CACCACGGCA TCACCCCGA
31861 GGCCGTCATC GGCCACTCCC AGGGCGAGAT CGCCGCCGCG TACGTCGCCG GTGCCCTCAC
31921 CCTCGACGAC GCCGCTCGTG TCGTGACCT CCGCAGCAAG TCCATCGCCG CCCACCTCGC
31981 CGGCAAGGGC GGCATGATCT CCCTCGCCCT CAGCGAGGAA GCCACCCGGC AGCGCATCGA
32041 GAACCTCCAC GGAATGTGTA TCGCCGCCGT CAACGGGCCT ACCGCCACCG TGGTTTCGGG
32101 CGACCCACCC CAGATCCAAG AACTTGCTCA GCGGTGTGAG GCCGACGGCA TCCGCGCAG
32161 GATCATCCCC GTCGACTACG CCTCCACAG CGCCACGTC GAGACCATCG AGAACGAACT
32221 CGCCGACGTC CTGGCGGGGT TGTCCTCCCA GACACCCAG GTCCCTTCT TCTCCACCCT
32281 CGAAGGCACC TGGATCACCG AACCCGCCCT CGACGGCGGC TACTGGTACC GCAACCTCCG
32341 CCATCGTGTG GGCTTCGCCC CGGCCGTCGA GACCCTCGCC ACCGACGAAG GCTTCACCCA
32401 CTTTCATCGAG GTCAGCGCCC ACCCCGTCCT CACCATGACC CTCCCCGACA AGGTCACCGG
32461 CCTGGCCACC CTCGACGCG AGGACGGCG ACAGACCGC CTCACCACCT CCCTTGCCGA
32521 GGCTTGGGCC AACGGCCTCG CCCTCGACTG GGCTTCCTC CTGCCCGCCA CGGGCGCCCT
32581 CAGCCCCGCC GTCCCCGACC TCCCGACGTA CGCCTTCCAG CACCGCTCGT ACTGGATCAG
32641 CCCC GCGGGT CCGGCGAGG CGCCGCGCA CACCGCTTCC GGGCGCGAG CCGTCGCCGA

-continued

32701 GACGGGGCTC GCGTGGGGCC CGGCTGCCGA GGACCTCGAC GAGGAGGGCC GCGCGAGCGC
32761 CGTACTCGCG ATGGTGATGC GGCAGGCGGC CTCCGTGCTC CGGTGCGACT CGCCCGAAGA
32821 GGTCCCCGTC GACCGCCCGC TGC GGAGAT CGGCTTCGAC TCGCTGACCG CCGTCGACTT
32881 CCGCAACCGC GTCAACCGC TGACCGGTCT CCAGCTGCCG CCCACCGTCG TGTTTCGAGCA
32941 CCCGACGCCC GTCGCGCTCG CCGAGCGCAT CAGCGACGAG CTGGCCGAGC GGAAC TGGGC
33001 CGTCGCCGAG CCGTCGGATC ACGAGCAGGC GGAGGAGGAG AAGGCCGCCG CTCGGCGGG
33061 GGGCCGCTCC GGGGCGGACA CCGGCGCCGG CGCCGGGATG TTCCGCGCCC TGTTCCGGCA
33121 GGCCGTGGAG GACGACCGGT ACGGCGAGTT CCTCGACGTC CTCGCCGAAG CCTCCGCGTT
33181 CCGCCCGCAG TTCGCCTCGC CCGAGGCCTG CTCGGAGCGG CTCGACCCGG TGCTGCTCGC
33241 CGGCGGTCCG ACGGACCGGG CGGAAGGCCG TGCCGTTCTC GTCGGCTGCA CCGGCACCGC
33301 GGCGAACGGC GGCCCGCACG AGTTCCTGCG GCTCAGCACC TCCTTCCAGG AGGAGCGGGA
33361 CTTCTCGCC GTACCTCTCC CCGGCTACGG CACGGGTACG GGCACCGGCA CGGCCCTCCT
33421 CCCGGCCGAT CTCGACACCG CGCTCGACGC CCAGGCCCGG GCGATCTCC GGGCCCGCG
33481 GGACGCCCCG GTCGTCCTGC TCGGGCACTC CGGCGGCGCC CTGCTCGCGC ACGAGCTGGC
33541 CTTCCGCCGT GAGCGGGCGC ACGGCGCGCC GCCGGCCGGG ATCGTCTTG TCGACCCCTA
33601 TCCGCCGGGC CATCAGCAGC CCATCGAGGT GTGGAGCAGG CAGCTGGGCG AGGGCCTGTT
33661 CGCGGGCGAG CTGGAGCCGA TGTCCGATGC GCGGCTGCTG GCCATGGGCC GTACGCGCG
33721 GTTCTCGCC GGCCCGCGGC CGGGCCGAG CAGCGCGCCC GTGCTTCTGG TCCGTGCCTC
33781 CGAACCGTG GGGGACTGGC AGGAGGAGCG GGGCGACTGG CGTGCCCACT GGGACCTTCC
33841 GCACACCGTC GCGACGCTGC CGGGCGACCA CTTACGATG ATGCGGGACC ACGCGCCGCG
33901 CGTCGCCGAG GCCCTCTCT CCTGGCTCGA CGCCATCGAG GGCATCGAGG GGGCGGGCAA
33961 GTGACCGACA GACCTCTGAA CGTGGACAGC GGA CTGTGGA TCCGGCGCTT CCACCCCGC
34021 CCGAACAGCG CGGTGCGGCT GGTCTGCCTG CCGCACGCCG GCGGCTCCGC CAGCTACTTC
34081 TTCCGTTCT CGGAGGAGCT GCACCCCTCC GTCGAGGCC TGTCGGTGCA GTATCCGGGC
34141 CGCCAGGACC GCGGTGCCGA GCCGTGTCTG GAGAGCGTCG AGGAGCTCGC CGAGCATGTG
34201 GTCGCGGCCA CCGAACCTG GTGGCAGGAG GGCGGCTGG CTTCTTCG GACAGCCTC
34261 GGGCCTCCG TCGCCTTCGA GACGGCCGC ATCCTGGAAC AGCGGCACGG GTACGGCCC
34321 GAGGGCCTGT ACGTCTCCG TCGGCGCGCC CCGTCGCTGG CGCCGGACCG GCTCGTCCAC
34381 CAGCTGGACG ACCGGCGGTT CCTGGCCGAG ATCCGGCGGC TCAGCGGCAC CGACGAGCGG
34441 TTCTCCAGG ACGACGAGCT GCTGCGGCTG GTGCTGCCC CGCTGCGCAG CACTACAAG
34501 GCGGCCGAGA CGTACCTGCA CCGCCGCTCC GCCAAGCTCA CTGCCCCTG GATGGCCCTG
34561 GCCGGCCACC GTGACCCGAA GGGCGCGCTG AACGAGGTGG CCGAGTGGCG TCGGCACACC
34621 AGCGGGCCGT TCTGCCTCCG GCGTACTCC GCGGCCACT TCTACCTCAA CGACAGTGG
34681 CACGAGATCT GCAACGACAT CTCGACCAC CTGCTCGTCA CCCGCGCGC GCCCGATGCC
34741 CGCGTCGTGC AGCCCCGAC CAGCCTTATC GAAGGAGCG CGAAGAGATG GCAGAACCCA
34801 CGGTGACCGA CGACCTGACG GGGGCCCTCA CGCAGCCCC GCTGGGCCG ACCGTCCGCG
34861 CGGTGGCCGA CCGTGAATC GGCACCCACC TCCTGGAGAC CGCGGCATC CACTGGATCC
34921 ACGCCCGCAA CGGCGACCCG TACGCCACCG TGCTGCGCG CCAGGCGGAC GACCCGTATC

-continued

34981 CCGCGTACGA GCGGGTGCCT GCCCGCGGCG CGCTCTCCTT CAGCCCGACG GGCAGCTGGG
35041 TCACCGCCGA TCACGCCCTG GCGGCGAGCA TCCTCTGCTC GACGGACTTC GGGGTCTCCG
35101 GCGCCGACGG CGTCCCGGTG CCGCAGCAGG TCCTCTCGTA CGGGGAGGGC TGTCCGCTGG
35161 AGCGCGAGCA GGTGCTGCCG GCGGCCGGTG ACGTGCCGGA GGGCGGGCAG CGTGCCGTGG
35221 TCGAGGGGAT CCACCGGGAG ACGCTGGAGG GTCTCGCGCC GGACCCGTCG GCGTCGTACG
35281 CCTTCGAGCT GCTGGGCGGT TTCGTCCGCC CGGCGGTGAC GGCCGCTGCC GCCGCCGTGC
35341 TGGGTGTTCC CGCGGACCGG CGCGCGGACT TCGCGGATCT GCTGGAGCGG CTCGGGCCGC
35401 TGTCCGACAG CCTGCTGGCC CCGCAGTCCC TCGGACGGT ACGGCGGGC GACGGCGCGC
35461 TGGCCGAGCT CACGGCGGTG CTCGCCGATT CGGACGACTC CCCCCGGGCC CTGCTGTCGG
35521 CGCTCGGGGT CACCGCAGCC GTCCAGCTCA CCGGGAACGC GGTGCTCGCG CTCTCGCGC
35581 ATCCCCGAGCA GTGGCGGGAG CTGTGCGACC GGGCCGGGCT CGCGCGGGCC GCGGTGGAGG
35641 AGACCTCCG CTACGACCCG CCGGTGCAGC TCGACGCCG GGTGGTCCGC GGGGAGACGG
35701 AGCTGGCGGG CCGGCGGGTG CCGGCCGGGG CGCATGTCTG CTCTCTGACC GCCGCGACCG
35761 GCCGGGACCC GGAGGTCCTT ACGGACCCGG AGCGCTTCGA CCTCGCGCGC CCCGACGCCG
35821 CCGCGCACCT CGCGCTGCAC CCCGCCGGTC CGTACGGCCC GGTGGCGTCC CTGGTCCGGC
35881 TTCAGCGGGA GGTGCGCGTG CGGACCCCTG CCGGGCGTTT CCCCCGGGCTG CGGCAGGCGG
35941 GGGACGTGCT CCGCCCCCGC CGCGCGCCTG TCGGCCGCGG GCCGCTGAGC GTCCCGGTCA
36001 GCAGCTCCTG AGACACCGGG GCCCCGGTCC GCGCGGCCCC CCTTCGGACG GACCGGACGG
36061 CTCGGACCAC GGGGACGGCT CAGACCGTCC CGTGTGTCCC CGTCCGGCTC CCGTCCGCCC
36121 CATCCGCCC CTCCACCGGC AAGGAAGGAC ACGACGCCAT GCGCGTCCGT CTGACCTCGT
36181 TCGCACATCA CACGCACTAC TACGGCCTGG TGCCCTTGGC CTGGGCGCTG CTCGCCGCCG
36241 GGCACGAGGT GCGGGTCGCC AGCCAGCCCG CGCTCACGGA CACCATCACC GGGTCCGGGC
36301 TCGCCGCGGT GCCGTCGGC ACCGACCACC TCATCCACGA GTACCGGGTG CGGATGGCGG
36361 GCGAGCCGCG CCCGAACCAT CCGGCGATCG CCTTCGACGA GGCCCGTCCC GAGCCGCTGG
36421 ACTGGGACCA CGCCCTCGGC ATCGAGGCGA TCCTCGCCCC GTACTTCTAT CTGCTCGCCA
36481 ACAACGACTC GATGGTCGAC GACCTCGTCG ACTTCGCCCC GTCTTGCGAG CCGGACCTGG
36541 TGCTGTGGGA GCCGACCACC TACGCGGGCG CCGTCGCCCG CCAGGTCACC GGTGCCCGGC
36601 ACGCCCGGGT CCTGTGGGGG CCCGACGTGA TGGGACGCGC CCGCCGCAAG TTCGTGCGCG
36661 TGCGGGACCG GCAGCCGCCC GAGCACCAGG AGGACCCAC CGCGGAGTGG CTGACGTGGA
36721 CGCTCGACCG GTACGGCGCC TCCTTCGAAG AGGAGCTGCT CACCGGCCAG TTCACGATCG
36781 ACCCGACCCC GCCGAGCCTG CGCCTCGACA CGGGCCTGCC GACCGTCGGG ATGCGTTATG
36841 TTCCGTACAA CGGCACGTCG GTCGTGCCGG ACTGGCTGAG TGAGCCGCCC GCGCGGCCCC
36901 GGGTCTGCCT GACCCTCGGC GTCTCCGCGC GTGAGTCTCT CGGCGGCGAC GCGTCTCGC
36961 AGGGCGACAT CCTGGAGGCG CTCGCCGACC TCGACATCGA GCTCGTCGCC ACGCTCGACG
37021 CGAGTCAGCG CGCCGAGATC CGCAACTACC CGAAGCACAC CCGGTTACAG GACTTCGTGC
37081 CGATGCACGC GCTCTGGCCG AGCTGCTCGG CGATCATCCA CCACGGCGGG GCGGGCACCT
37141 ACGCGACCGC CGTGATCAAC GCGGTGCCCG AGGTCATGCT CGCCGAGCTG TGGGACGCGC
37201 CGGTCAAGGC GCGGGCCGTC GCCGAGCAGG GGGCGGGGTT CTTCCTGCCG CCGGCCGAGC
37261 TCACGCCGCA GGCCGTGCGG GACGCCGTCG TCCGCATCCT CGACGACCCC TCGGTGCGCA

-continued

37321 CCGCCGCGCA CCGGCTGCGC GAGGAGACCT TCGGCGACCC CACCCCGGCC GGGATCGTCC
 37381 CCGAGCTGGA GCGGCTCGCC GCGCAGCACC GCCGCCGCC GGCCGACGCC CGGCACTGAG
 37441 CCGCACCCCT CGCCCCAGGC CTCACCCCTG TATCTGCGCC GGGGACGCC CCCGGCCAC
 37501 CCTCCGAAAG ACCGAAAGCA GGAGCACCGT GTACGAAGTC GACCACGCCG ACGTCTACGA
 37561 CCTCTTCTAC CTGGGTCGCG GCAAGGACTA CGCCGCCGAG GCCTCCGACA TCGCCGACCT
 37621 GGTGCGCTCC CGTACCCCCG AGGCCTCCTC GTCCTGGAC GTGGCCTGCG GTACGGGCAC
 37681 GCATCTGGAG CACTTCACCA AGGAGTTCGG CGACACGCC GGCTGGAGC TGTCCGAGGA
 37741 CATGCTCACC CACGCCCGCA AGCGGCTGCC CGACGCCACG CTCCACCAGG GCGACATGCG
 37801 GGACTTCCGG CTCGGCCGGA AGTTCTCCGC CGTGGTCAGC ATGTTTCACT CCGTCGGCTA
 37861 CCTGAAGACG ACCGAGGAAC TCGGCGCGGC CGTCGCCTCG TTCGCGGAGC ACCTGGAGCC
 37921 CGGTGGCGTC GTCGTCGTCG AGCCGTGGTG GTTCCCGGAG ACCTTCGCCG ACGGCTGGGT
 37981 CAGCGCCGAC GTCGTCCGCC GTGACGGGCG CACCGTGCCG CGTGTCTCGC ACTCGGTGCG
 38041 GGAGGGGAAC GCGACGCGCA TGGAGGTCCA CTTACCGTG GCCGACCCGG GCAAGGGCGT
 38101 GCGGCACTTC TCCGACGTCC ATCTCATCAC CCTGTTCCAC CAGGCCGAGT ACGAGGCCGC
 38161 GTTCACGGCC GCCGGGCTGC GCGTCGAGTA CTTGGAGGGC GGCCCGTCGG GCCGTGGCCT
 38221 CTTGTCGGC GTCCCCGCCT GAGCACCGCC CAAGACCCCG CGGGCGGGA CGTCCCGGT
 38281 GCACCAAGCA AAGAGAGAGA AACGAACCGT GACAGGTAAG ACCCGAATAC CGCGTGTCCG
 38341 CCGCGGCCGC ACCACGCCCA GGGCCTTCAC CTTGGCCGTC GTCGGCACCC TGCTGGCGGG
 38401 CACCACCGTG GCGGCCCGCG CTCCTGGCGC CGCCGACAG GCCAATGTTC AGTACACGAG
 38461 CCGGGCGGCG GAGCTCGTCG CCCAGATGAC GCTCGACGAG AAGATC

[0044] Those of skill in the art will recognize that, due to the degenerate nature of the genetic code, a variety of DNA compounds differing in their nucleotide sequences can be used to encode a given amino acid sequence of the invention. The native DNA sequence encoding the narbonolide PKS of *Streptomyces venezuelae* is shown herein merely to illustrate a preferred embodiment of the invention, and the invention includes DNA compounds of any sequence that encode the amino acid sequences of the polypeptides and proteins of the invention. In similar fashion, a polypeptide can typically tolerate one or more amino acid substitutions, deletions, and insertions in its amino acid sequence without loss or significant loss of a desired activity. The present invention includes such polypeptides with alternate amino acid sequences, and the amino acid sequences shown merely illustrate preferred embodiments of the invention.

[0045] The recombinant nucleic acids, proteins, and peptides of the invention are many and diverse. To facilitate an understanding of the invention and the diverse compounds and methods provided thereby, the following description of the various regions of the narbonolide PKS and corresponding coding sequences is provided.

[0046] The loading module of the narbonolide PKS contains an inactivated KS domain, an AT domain, and an ACP domain. The AT domain of the loading module binds propionyl CoA. Sequence analysis of the DNA encoding the KS domain indicates that this domain is enzymatically inactivated, as a critical cysteine residue in the motif TVDAC-

SSSL, which is highly conserved among KS domains, is replaced by a glutamine and so is referred to as a KSQL domain. Such inactivated KS domains are also found in the PKS enzymes that synthesize the 16-membered macrolides carbomycin, spiromycin, tylosin, and niddamycin. While the KS domain is inactive for its usual function in extender modules, it is believed to serve as a decarboxylase in the loading module.

[0047] The present invention provides recombinant DNA compounds that encode the loading module of the narbonolide PKS and useful portions thereof. These recombinant DNA compounds are useful in the construction of PKS coding sequences that encode all or a portion of the narbonolide PKS and in the construction of hybrid PKS encoding DNA compounds of the invention, as described in the section concerning hybrid PKSs below. To facilitate description of the invention, reference to a PKS, protein, module, or domain herein can also refer to DNA compounds comprising coding sequences therefor and vice versa. Also, reference to a heterologous PKS refers to a PKS or DNA compounds comprising coding sequences therefor from an organism other than *Streptomyces venezuelae*. In addition, reference to a PKS or its coding sequence includes reference to any portion thereof.

[0048] The present invention provides recombinant DNA compounds that encode one or more of the domains of each of the six extender modules (modules 1-6, inclusive) of the narbonolide PKS. Modules 1 and 5 of the narbonolide PKS

are functionally similar. Each of these extender modules contains a KS domain, an AT domain specific for methylmalonyl CoA, a KR domain, and an ACP domain. Module 2 of the narbonolide PKS contains a KS domain, an AT domain specific for malonyl CoA, a KR domain, a DH domain, and an ACP domain. Module 3 differs from extender modules f and 5 only in that it contains an inactive ketoreductase domain. Module 4 of the narbonolide PKS contains a KS domain, an AT domain specific for methylmalonyl CoA, a IR domain, a DH domain, an ER domain, and an ACP domain. Module 6 of the narbonolide PKS contains a KS domain, an AT domain specific for methylmalonyl CoA, and an ACP domain.

[0049] In one important embodiment, the invention provides a recombinant narbonolide PKS that can be used to express only narbonolide (as opposed to the mixture of narbonolide and 10-deoxymethynolide that would otherwise be produced) in recombinant host cells. This recombinant narbonolide PKS results from a fusion of the coding sequences of the picAIII and picAIV genes so that extender modules 5 and 6 are present on a single protein. This recombinant PKS can be constructed on the *Streptomyces venezuelae* or *S. narbonensis* chromosome by homologous recombination. Alternatively, the recombinant PKS can be constructed on an expression vector and introduced into a heterologous host cell. This recombinant PKS is preferred for the expression of narbonolide and its glycosylated and/or hydroxylated derivatives, because a lesser amount or no 10-deoxymethynolide is produced from the recombinant PKS as compared to the native PKS. In a related embodiment, the invention provides a recombinant narbonolide PKS in which the picAIV gene has been rendered inactive by an insertion, deletion, or replacement. This recombinant PKS of the invention is useful in the production of 10-deoxymethynolide and its derivatives without production of narbonolide.

[0050] In similar fashion, the invention provides recombinant narbonolide PKS in which any of the domains of the native PKS have been deleted or rendered inactive to make the corresponding narbonolide or 10-deoxymethynolide derivative. Thus, the invention also provides recombinant narbonolide PKS genes that differ from the narbonolide PKS gene by one or more deletions. The deletions can encompass one or more modules and/or can be limited to a partial deletion within one or more modules. When a deletion encompasses an entire module, the resulting narbonolide derivative is at least two carbons shorter than the polyketide produced from the PKS encoded by the gene from which deleted PKS gene and corresponding polyketide were derived. When a deletion is within a module, the deletion typically encompasses a KR, DH, or ER domain, or both DH and ER domains, or both KR and DH domains, or all three KR, DH, and ER domains.

[0051] This aspect of the invention is illustrated in FIG. 4, parts B and C, which shows how a vector of the invention, plasmid pKOS039-16 (not shown), was used to delete or "knock out" the picAI gene from the *Streptomyces venezuelae* chromosome. Plasmid pKOS039-16 comprises two segments (shown as cross-hatched boxes in FIG. 4, part B) of DNA flanking the picAI gene and isolated from cosmid pKOS023-27 (shown as a linear segment in the Figure) of the invention. When plasmid pKOS039-16 was used to transform *S. venezuelae* and a double crossover homologous

recombination event occurred, the picAI gene was deleted. The resulting host cell, designated K039-03 in the Figure, does not produce picromycin unless a functional picAI gene is introduced.

[0052] This *Streptomyces venezuelae* K039-03 host cell and corresponding host cells of the invention are especially useful for the production of polyketides produced from hybrid PKS or narbonolide PKS derivatives. Especially preferred for production in this host cell are narbonolide derivatives produced by PKS enzymes that differ from the narbonolide PKS only in the loading module and/or extender modules 1 and/or 2. These are especially preferred, because one need only introduce into the host cell the modified picAI gene or other corresponding gene to produce the desired PKS and corresponding polyketide. These host cells are also preferred for desosaminylating polyketides in accordance with the method of the invention in which a polyketide is provided to an *S. venezuelae* cell and desosaminylated by the endogenous desosamine biosynthesis and desosaminyl transferase gene products.

[0053] The recombinant DNA compounds of the invention that encode each of the domains of each of the modules of the narbonolide PKS are also useful in the construction of expression vectors for the heterologous expression of the narbonolide PKS and for the construction of hybrid PKS expression vectors, as described further below.

[0054] Section II: The Genes for Desosamine Biosynthesis and Transfer and for Beta-glucosidase

[0055] Narbonolide and 10-deoxymethynolide are desosaminylated in *Streptomyces venezuelae* and *S. narbonensis* to yield narbomycin and YC-17, respectively. This conversion requires the biosynthesis of desosamine and the transfer of the desosamine to the substrate polyketides by the enzyme desosaminyl transferase. Like other *Streptomyces*, *S. venezuelae* and *S. narbonensis* produce glucose and a glucosyl transferase enzyme that glucosylates desosamine at the 2' position. However, *S. venezuelae* and *S. narbonensis* also produce an enzyme called beta-glucosidase, which removes the glucose residue from the desosamine. The present invention provides recombinant DNA compounds and expression vectors for each of the desosamine biosynthesis enzymes, desosaminyl transferase, and beta-glucosidase.

[0056] As noted above, cosmid pKOS023-27 contains three ORFs that encode proteins involved in desosamine biosynthesis and transfer. The first ORF is from the picCII gene, also known as des VIII, a homologue of enyCII, believed to encode a 4-keto-6-deoxyglucose isomerase. The second ORF is from the picCIII gene, also known as des VII, a homologue of eryCIII, which encodes a desosaminyl transferase. The third ORF is from the picCVI gene, also known as desVI, a homologue of eryCVI, which encodes a 3-amino dimethyltransferase.

[0057] The three genes above and the remaining desosamine biosynthetic genes can be isolated from cosmid pKOS023-26, which was deposited with the American Type Culture Collection on 20 Aug. 1998 under the Budapest Treaty and is available under the accession number ATCC 203141. FIG. 3 shows a restriction site and function map of cosmid pKOS023-26. This cosmid contains a region of overlap with cosmid pKOS02327 representing nucleotides 14252 to nucleotides 38506 of pKOS023-27.

[0058] The remaining desosamine biosynthesis genes on cosmid pKOS023-26 include the following genes. ORF11, also known as desR, encodes beta-glucosidase and has no ery gene homologue. The picCI gene, also known as desV, is a homologue of eryCI. ORF14, also known as desIV, has no known ery gene homologue and encodes an NDP glucose 4,6-dehydratase. ORF13, also known as desIII, has no known ery gene homologue and encodes an NDP glucose synthase. The picCV gene, also known as desII, a homologue of eryCV is required for desosamine biosynthesis. The picCIV gene also known as desI, is a homologue of eryCIV, and its product is believed to be a 3,4-dehydratase. Other ORFs on cosmid pKOS02326 include ORF12, believed to

be a regulatory gene; ORF15, which encodes an S-adenosyl methionine synthase; and ORF16, which is a homolog of the *M. tuberculosis* cbhK gene. Cosmid pKOS023-26 also encodes the picK gene, which encodes the cytochrome P450 hydroxylase that hydroxylates the C12 of narbomycin and the C10 and C12 positions of YC-17. This gene is described in more detail in the following section.

[0059] Below, the amino acid sequences or partial amino acid sequences of the gene products of the desosamine biosynthesis and transfer and beta-glucosidase genes are shown. These amino acid sequences are followed by the DNA sequences that encode them.

Amino acid sequence of PICCI

```
1VSSRAETPRV PFLDLKAAYE ELRAETDAAI ARVLDSGRYL LGPELEGFEA EFAAYCETDH
61AVGVNSGMDA LQLALRGLGI GPGDEVIVPS HTYIASWLAV SATGATPVVPV EPHEDHPTLD
121PLLVEKAITP RTRALLPVHL YGHPADMDAL RELADRHGLH IVEDAAQAHG ARYRGRRIGA
181GSSVAAFSFI PGKNLGCFGD GGAVVTGDPE LAERLRMLRN YGSRQKYSHE TKGTNSRLDE
241MQAAVLRIRL XHLD SWNGRR SALAAEYLSG LAGLPGIGLP VTAPDTPVW HLFTVTRTERR
301DELRSHLDAR GIDTLTHYPV PVHLSPAYAG EAPPEGSLPR AESFARQVLS LPIGPHLERP
361QALRVIDAVR EWAERVDQA
```

Amino acid sequence of 3-keto-6-deoxyglucose isomerase, PICCII

```
1VADRELGTHL LETRGIHWIH AANGDPYATV LRGQADDPYP AYERVRARGA LSFSPGTSWV
61TADHALAASI LCSTDFGVSG ADGVPVPQOV LSYGEGCPLR REQVLPAAGD VPEGGQRAVV
121EGIHRETLEG LAPDPSASYA FELLGGFVRP AVTAAAAAVL GVPADRRADF ADLLERLRPL
181SDSLLAPQSL RTVRAADGAL AELTALLADS DDSPGALLSA LGVTAAVQLT GNAVLALLAH
241PEQWRELCDR PGLAAA AVEE TLRYPVPVQL DARVVRGETE LAGRRLPAGA HVVVLTAATG
301RDPEVFTDPE RFDLARPDA AHLALHPAGP YGPVASLVR LQAEVALRTLA GRFPGLRQAG
361DVLRRRAPV GRGPLSVVPS SS
```

Amino acid sequence of desosaminyl transferase, PICCIII

```
1MRVLLTSFAH HTHYGLVPL AWALLAAGHE VRVASQPALT DTITGSLGAA VPGVTDHLIH
61EYRVRMAGEP RPNHPAIAFD EARPEPLDWD HALGIEAILA PYFYLLANN D SMVDDLVDFA
121RSWQPDVLW EPITYAGAVA AQVTGAHAR VLWGPDMVMS ARKRFVALRD RQPPEHREDP
181TAEWLTWILD RYGASFEEEL LTGQFTIDPT PPSLRDLTGL PTVMGRYVPY NGTSVVPDWL
241SEPPARPRVC LTLGVSAREV LGGDGVVSQGD ILEALADLDI ELVATLDASQ RAEIRNYPKH
301TRFTDFVPMH ALLPSCSAII HHGGAGTYAT AVINAVPQVM LAELWDAPVK ARAVAEQGAG
361FFLPPAELTP QAVRDAVVRI LDDPSVATAA HRLREETFGD PTPAGIVPEL ERLAAQHRRP
421PADARH
```

Partial amino acid sequence of aminotransferase-dehydrase, PICCIV

```
1VKSALSDLAF FGGPAAFDQP LLVGRPNRID RARLYERLDR ALDSQWLSNG GPLVREFEER
61VAGLAGVRHA VATCNATAGL QLLAHAAGLT GEVIMPSMTF AATPHALRWI GLTPVFADID
121PDTGNLDPDQ VAAAVTPRTS AVVGVHLWGR PCAADQLRKV ADEHGLRLYF DAAHALGCAV
181DGRPAGSLGD AEVFSFHATK AVNAFEGGAV VTDDADLAAR IRALHNFPGFD LPGGSPAGGT
241NAKMSEAAAA MGLTSLDAFP EVIDRNRNRH AXYPEHLADL PGVLVADHDR HGLNNHQYVI
301VEIDEATTGI HRDLVMEVLK AEGVHTRAYF S
```


-continued

Amino acid sequence of PICCV

1MTAPALSATA PAERCAHPGA DLGAHVAVG QTLAAGGLVP PDEAGTTARH LVRLAVRYGN
 61SPFTPLEEAR HDLGVD RDAF RLLALFGQV PELRTAVETG PAGAYWKNTL LPLEQRGVFD
 121AALARKPVFP YSVGLYPGPT CMFRCHFCVR VTGARYDPSA LDAGNAMFRS VIDEIPAGNP
 181SAMYFSGGLE PLTNPGLGSL AAHATDHGLR PTVYTNSFAL TERTLERQPG LWGLHAIRTS
 241LYGLNDEEYE QTTGKKAAPR RVRENLRRFQ QLRAERESPI NLGFAYIVLP GRASRLDLV
 301DFIADLNAG QGRTIDFVNI REDYSGRDDG KLPQEERAEL QEALNAFEER VRERTPGLHI
 361DYGYALNSLR TGADAELLRI KPATMRPTAH PQVAVQVDLL GDVYLYREAG FPDLDGATRY
 421IAGRVTPDTS LTEVVRDFVE RGGEVAAVDG DEYFMDGFDQ VVTARLNQLE RDAADGWEEA
 481RGFLR

Amino acid sequence of 3-amino dimethyl transferase, PICCVI

1VYEVHDADV DLFYLGKGD YAAEASDIAD LVRSTPEAS SLLDVACGTG THLEHFTKEF
 61GDTAGLELSE DMLTHARKRL PDATLHQGDM RDFRLGRKFS AVVSMFSSVG YLKTTEELGA
 121AVASFAEHLE PGGVVVVEPW WFPETFADGW VSADVVRDGD RTVARVSHSV REGNATRMEV
 181HFTVADPGKG VRHFSVHLI TLFHQAEYEA AFTAAGLRVE YLEGGPSGRG LFVGVPA

Partial amino acid sequence of beta-glucosidase, ORF11

1MTLDEKISFV HVALDPPRQN VGYPGVPR L GIPELRAADG PNGIRLVGQT ATALPAPVAL
 61ASTFDDTMAD SYGKVMGRDG RALNQDMVLG PMMNNIRVPH GGRNYETFSE DPLVSSRTAV
 121AQIKGIQAG LMTAKHFAA NNQENNRFSV NANVDEQTLR EIEFPAFEAS SKAGAGSFCM
 181AYNGLNGKPS CGNDELLNNV LRTQWGFQGW VMSDWLATPG TDAITKGLDQ EMGVELPGDV
 241PKGEPSPPAK FFGEALKTAV LNGTVPEAAV TRSAERIVGQ MEKFGLLLAT PAPRPERDKA
 301GAQAVSRKVA ENGAVLLRNE GQALPLAGDA GKSIAVIGPT AVDPKVTGLG SAHVVPDSAA
 361APLDTIKARA GAGATVTYET GEETFGTQIP AGNLSPAFNQ GHQLEPGKAG ALYDGTTLTV
 421ADGEYRIAVR ATGGYATVQL GSHTIEAGQV YGKVSSPLLK LTKGTHKLT I SGFAMSATPL
 481SLELGWVTPA AADATIAKAV ESARKARTAV VFAYDDGTEG VDRPNLSLPG TQDKLISAVA
 541DANPNTIVVL NTGSSVLMWP LSKTRAVLDM WYPGQAGAEA TAAALYGDVN PSGKLTQSFP
 601AAENQHAVAG DPTSYPVDN QQTYREGIHV GYRWFDEKENV KPLFPFGHGL SYTSFTQSAP
 661TVVRTSTGGL KVTVTVRNSG KRAGQEVVQA YLGASPNVTA PQAKKKLVGY TKVSLAAGEA
 721KTVTVNVDRR QLQFWDAAATD NWKTGTGNRL LQTGSSSADL RGSATVNVW

Amino acid sequence of transcriptional activator, ORF12

1MNLVERDGEI AHLRAVLDA AAGDGTLLLV SGPAGSGKTE LLRSLRRLAA ERETPVWSVR
 61ALPGDRDIPL GVLQCLLRSA EQHGADTSV RDLDAASRR AGTSPPPPTR RASSTRHTAC
 121TTGCSPPAG TPFLVAVDDL THADTASLRF LLYCAAHHDQ GGIGFVMTER ASQRAGYRVF
 181RAELLRQPHC RNMWLSGLPP SGVRQLLAHY YGPEAAERRA PAYHATTGGN PLLLRALTQD
 241RQASHTTLGA AGGDEPVHGD AFAQAVLDCL HRSAGTLET ARWLAVLEQS DPLLVERLTG
 301TTAAAVERHI QELAAIGLLD EDGTLGQPAI REAALQDLPA GERTELHRR A EQLRHDGAD
 361EDTVARHLLV GGAPDAPWAL PLLERGAQQA LFDDRLLDADF RILEFAVRSS TDNTQLARLA
 421PHLVAASWRM NPHMTTRALA LFDRLLSGEL PPSHPVMALI RCLVWYGRLP EAADALSRLR
 481PSSDNDALEL SLTRMWLAAL CPPLLESIPA TPEPERGPVP VRLAPRTTAL QAQAGVFQRG
 541PDNASVAQAE QILQGCRLSE ETYEALETAL LVLVHADRLD RALFWSDAL AEAVERRS LG
 601WEAVFAATRA MIAIRCGLP TARERAELAL SHAAPESWGL AVGMPLSALL LACTEAGEYE

-continued

661QAERVLRQPV PDAMFDSRHG MEYMHARGRY WLAXGRLHAA LGEFMLCGEI LGSWNLDQPS
 721IVPWRTSAAE VYLRLGNRQK ARALAEAQLA LVRPGRSRTR GLTLRVLAAA VDGQQAERLH
 781AEAVDMLHDS GDRLEHARAL AGMSRHQQAQ GDNYRARMTA RLAGDMAWAC GAYPLAEEIV
 841PGRGRRRAKA VSTELELPGG PDVGLLSEAE RRVAALAARG LTNRQIARRL CVTASTVEQH
 901LTRVYRKLNV TRRADLPISL AQDKSVTA

Amino acid sequence of dNDP-glucose synthase
 (glucose-1-phosphate thymidyl transferase), ORF13
 1MKGIVLAGGS GTRLHPATSV ISKQILPVYN KPMIYYPLSV LMLGGIREIQ IISTPQHIEL
 61FQSLGNGRH LGIELDYAVQ KEPAGIADAL LVGAEHIGDD TCALILGDNI FHGPGLYTLL
 121RDSIARLDGC VLFQYPVKDP ERYGVAEVDA TGRLTDLVEK PVKPRSNLAV TGLYLYDNV
 181VDIAKNIRPS PRGELEITDV NRVYLERGRA ELVNLGRGFA WLDTGTHDSL LRAAQYVQVL
 241EERQGVWIAQ LEEIAFRMGF IDAEACHGLG EGLSRTEYGS YLMEIAGREG AP

Amino acid sequence of dNDP-glucose 4,6-dehydratase, ORF14
 1VRLLVTGGAG FIGSHFVRQL LAGAYPDVPA DEVIVLDSL T YAGNRANLAP VDADPRLRFV
 61HGDIRDAGLL ARELRGVDAI VHFAAESHVD RSIAGASVFT ETNVQGTQTL LQCAVDAGVG
 121RVVHVSTDEV YGSDISGWSW ESSPLEPNSP YAASKAGSDL VARAYHRTYG LDVRI TRCCN
 181NYGPYQHPK LIPLFVTNLL DGGTLPYGD GANVREWVHT DDHCRGIALV LAGGRAGEIY
 241HIGGGLELTN RELTGILLDS LGADWSSVRK VADRKGHDLR YSLDGGKIER ELGYRPQVSF
 301ADGLARTVRW YRENRGWEP LKATAPQLPA TAVEVSA

Partial amino acid sequence of S-adenosylmethionine
 synthase, ORF15
 1IGYDSSKKGF DGASCGVSVS IGSQSPDIAQ GVD TAYEKRV EGASQRDEGD ELDKQGAGDQ
 61GLMFGYASDE TPELMPLPIH LAHRLSRRLT EVRKNGTIPY LRPDGKTQVT IEYDGDRAVR
 121LDTVVVSSQH ASDIDLESLL APDVRKFVVE HVLAQLVEDG IKLDTDGYRL LVNPTGRFEI
 181GGPMGDAGLT GRKIIIDTYG GMARHGGGAF SGKDPSKVDR SAAYAMRWVA KNVVAAGLAS
 241RCEVQVAYAI GKAEPVGLFV ETPGTHKIET EKIENAIGEV FDLRPAAIIR DLDLLRPIYS
 301QTAAYGHFGR ELPDFTWERT DRVDALKKAA GL

Partial amino acid sequence of ORF16
 (homologous to *M. tuberculosis cbhK*)
 1MRIAVTGSIA TDHLMTPFGR FAEQILPDQL AHVSLSFLVD TLDIRHGGVA ANIAYGLGLL
 61GRRPVLVGAV GKDFDGYQL LRAAGVDTDS VRVSDRQHTA RFMCTTDEDG NQLASFYAGA
 121MAEARDIDLG ETAGRPGGID LVLVGADDPE AMVRHTRVCR ELGLRPAADP SQQARLEGD
 181SVRELVDGAE LLFTNAYERA LLLSKTGWTE QEVLARVGTW ITTLGAKGCR

[0060] While not all of the insert DNA of cosmid pKOS02326 has been sequenced, five large contigs shown of FIG. 3 have been assembled and provide sufficient sequence information to manipulate the genes therein in accordance with the methods of the invention. The sequences of each of these five contigs are shown below.

[0061] Contig 001 from cosmid pKOS023-26 contains 2401 nucleotides, the first 100 bases of which correspond to 100 bases of the insert sequence of cosmid pKOS023-27. Nucleotides 80-2389 constitute ORF11, which encodes 1 beta glucosidase.

1 CGTGGCGGCC GCCGCTCCCG GCGCCGCCGA CACGGCCAAT GTTCAGTACA CGAGCCGGGC
 61 GGCGGAGCTC GTCGCCAGA TGACGCTCGA CGAGAAGATC AGCTTCGTCC ACTGGGCGCT
 121 GGACCCCGAC CGGCAGAACG TCGGCTACCT TCCCGCGGTG CCGCGCTTGG GCATCCCGGA

-continued

181 GCTGCGTGCC GCCGACGGCC CGAACGGCAT CCGCCTGGTG GGGCAGACCG CCACCGCGCT
241 GCCCCGCGCG GTCGCCCTGG CCAGCACCTT CGACGACACC ATGGCCGACA GCTACGGCAA
301 GGTCAATGGGC CGCGACGGTC GCGCGCTCAA CCAGGACATG GTCTTGGGCC CGATGATGAA
361 CAACATCCGG GTGCCGCACG GCGGCCGGAA CTACGAGACC TTCAGCGAGG ACCCCCTGGT
421 CTCCTCGCGC ACCGCGGTGCG CCCAGATCAA GGGCATCCAG GGTGCGGGTC TGATGACCAC
481 GGCCAAGCAC TTCGCGGCCA ACAACCAGGA GAACAACCGC TTCTCCGTGA ACGCCAATGT
541 CGACGAGCAG ACGCTCCGCG AGATCGAGTT CCCGGCGTTC GAGGCGTCCT CCAAGGCCGG
601 CGCGGGCTCC TTCATGTGTG CCTACAACGG CCTCAACGGG AAGCCGTCCT GCGGCAACGA
661 CGAGTCCTC AACACGTGC TGCACACGCA GTGGGGCTTC CAGGGCTGGG TGATGTCCGA
721 CTGGCTCGCC ACCCCGGGCA CCGACGCCAT CACCAAGGGC CTCGACCAGG AGATGGGCGT
781 CGAGTCCCC GGCACGTCC CGAAGGGCGA GCCCTCGCCG CCGGCCAAGT TCTTCGGCGA
841 GCGGTGAAG ACGCCGTCC TGAACGGCAC GGTCCCCGAG GCGGCCGTGA CGCGGTCGGC
901 GGAGCGGATC GTCGGCCAGA TGGAGAAGTT CGGTCTGCTC CTCGCCACTC CGGCCCCGCG
961 GCCCAGCGC GACAAGGCGG GTGCCCAGGC GGTGTCCCGC AAGGTCGCCG AGAACGGCGC
1021 GGTGCTCCTG CGCAACGAGG GCCAGGCCCT GCCGCTCGCC GGTGACGCCG GCAAGAGCAT
1081 CGCGGTCATC GGGCCGACGG CCGTCGACCC CAAGGTCACC GGCTTGGGCA GCGCCACGT
1141 CGTCCCGGAC TCGCGCGCGG CGCCACTCGA CACCATCAAG GCCCGCGCGG GTGCGGGTGC
1201 GACGGTGACG TACGAGACGG GTGAGGAGAC CTTGCGGACG CAGATCCCGG CGGGGAACCT
1261 CAGCCCGGCG TTCAACCAGG GCCACCAGCT CGAGCCGGGC AAGGCGGGGG CGCTGTACGA
1321 CGGCACGCTG ACCGTGCCCG CCGACGGCGA GTACCGCATC GCGGTCCGTG CCACCGGTGG
1381 TTACGCCACG GTGCACTCG GCAGCCACAC CATCGAGGCC GGTGAGGTCT ACGGCAAGGT
1441 GAGCAGCCCG CTCCTCAAGC TGACCAAGGG CACGCACAAG CTCACGATCT CGGGCTTCGC
1501 GATGAGTGCC ACCCCGCTCT CCCTGGAGCT GGGCTGGGTN ACGCCGGCGG CGGCCGACGC
1561 GACGATCGCG AAGGCCGTGG AGTCGGCGCG GAAGGCCCGT ACGGCGGTG TCTTCGCCTA
1621 CGACGACGGC ACCGAGGGCG TCGACCGTCC GAACCTGTCG CTGCCGGGTA CGCAGGACAA
1681 GCTGATCTCG GCTGTCGCGG ACGCCAACCC GAACACGATC GTGGTCTCA ACACCGGTTT
1741 GTCGGTGCTG ATGCCGTGGC TGTCCAAGAC CCGCGCGGTC CTGGACATGT GGTACCCGGG
1801 CCAGGCGGGC GCCGAGGCCA CCGCCGCGCT GCTCTACGGT GACGTCAACC CGAGCGGCAA
1861 GCTCACGCG AGCTTCCCGG CCGCCGAGAA CCAGCACGCG GTCGCCGCGG ACCCGACCAG
1921 CTACCCGGGC GTCGACAACC AGCAGACGTA CCGCGAGGGC ATCCACGTG GGTACCGCTG
1981 GTTCGACAAG GAGAACGTCA AGCCGCTGTT CCCGTTCTGG CACGGCCTGT CGTACACCTC
2041 GTTCACGCG AGCGCCCCGA CCGTCGTGCG TACGTCCACG GGTGGTCTGA AGGTCACGGT
2101 CACGGTCCG AACAGCGGGA AGCGCGCCGG CCAGGAGGTC GTCCAGGCGT ACCTCGGTGC
2161 CAGCCCGAAG GTGACGGGTC CGCAGGCGAA GAAGAAGCTC GTGGGCTACA CGAAGGTCTC
2221 GCTCGCCGCG GGCAGGCGA AGACGGTGAC GGTGAACGTC GACCGCCGTC AGCTGCAGTT
2281 CTGGGATGCC GCCACGGACA ACTGGAAGAC GGAACGGGC AACCGCCTCC TGCAGACCGG
2341 TTCGTCTCC GCCGACCTGC GGGGCAGCGC CACGGTCAAC GTCTGGTGAC GTGACGCCGT
2401 G

[0062] Contig 002 from cosmid pKOS023-26 contains 5970 nucleotides and the following ORFs: from nucleotide 995 to 1 is an ORF of picCIV that encodes a partial sequence of an amino transferase-dehydrase; from nucleotides 1356 to

2606 is an ORF of picK that encodes a cytochrome P450 hydroxylase; and from nucleotides 2739 to 5525 is ORF12, which encodes a transcriptional activator.

```

1  GGCAGAGAGT AGGCGCGGGT GTGCACGCCT TCGGCCTTCA GGACCTCCAT GACGAGGTCTG
61 CGGTGGATGC CGGTGGTGGC CTCGTCGATC TCGACGATCA CGTACTGGTG GTTGTGAGG
121 CCGTGGCGGT CGTGGTCGGC GACGAGGACG CCGGGGAGGT CCGCGAGGTG CTCGCGGTAG
181 SCGGCGTGGT TGGCCCGGTT CCGGTCGATG ACCTCGGGAA ACGCGTCGAG GGAGGTGAGG
241 CCCATGGCGG CGCGGGCCTC GCTCATCTTG GCGTTGGTCC CGCCGGCGGG GCTGCCGCCG
301 GGCAGGTCGA AGCCGAAGTT GTGGAGGGCG CGGATCCGGG CCGCGAGGTC GGCGTCGTCTG
361 GTGACGACGG CGCCGCCCTC GAAGGCGTTG ACGGCCTTGG TGGCGTGAA GCTGAAGACC
421 TCGGCGTCGC CGAGGCTGCC GCGGGGCCGG CCGTCGACCG CGCAGCCGAG GCGGTGCGCG
481 GCGTCGAAGT ACAGCCGAGG GCCGTGCTCG TCGGCGACCT TCCGCGAGCTG GTCGCGGGCG
541 CAGGGGCGGC CCCAGAGGTG GACGCGGACG ACGGCCGAGG TCGGGGTGT GACCGCGGGC
601 GCCACCTGGT CCGGTCGAG GTTGCCGGTG TCCGGGTCGA TGTCGGCGAA GACCGGGGTG
661 AGGCCGATCC AGCGCAGTGC GTGCGGGGTG GCGGCGAAGC TCATCGACGG CATGATCACT
721 TCGCCGGTGA GGCGGGCGGC GTGCGCGAGG AGCTGGAGCC CGGCCGTGGC GTTGCAGGTG
781 GCCACGGCAT GCCGGACCCC GCGAGAGCCG GCGACGCGCT CCTCGAACTC GCGGACGAGC
841 GGGCCGCCGT TGGACAGCCA CTGGCTGTCTG AGGGCCCCGT CGAGCCGCTC GTACAGCCTG
901 GCGCGGTCTGA TGGGTTGGG CCGCCCCACG AGGAGCGGCT GGTCAAAGC GCGGGGGCCG
961 CCGAAGAATG CGAGGTCGGA TAAGGCGCTT TTCACGGATG TTCCCTCCGG GCCACCGTCA
1021 CGAAATGATT CGCCGATCCG GGAATCCCGA ACGAGGTCGC CGCGCTCCAC CGTGACGTAC
1081 GACGAGATGG TCGATTGTGG TGGTCGATTT CGGGGGGACT CTAATCCGCG CGGAACGGGA
1141 CCGACAAGAG CACGCTATGC GCTCTCGATG TGCTTCGGAT CACATCCGCC TCCGGGTAT
1201 TCCATCGGCG GCCCGAATGT GATGATCCTT GACAGGATCC GGAATCAGC CGAGCCGCCG
1261 GGAGGGCCGG GCGCGCTCC CCGGAAGAGT ACGTGTGAGA AGTCCCGTTC CTCTTCCCGT
1321 TTCCGTTCCG CTTCCGGCCC GGTCTGGAGT TCTCCGTGCG CCGTACCCAG CAGGGAACGA
1381 CCGCTCCTCC CCCGTACTC GACCTCGGGG CCCTGGGGCA GGATTTCGCG GCCGATCCGT
1441 ATCCGACGTA CGCGAGACTG CGTGCCGAGG GTCCGGCCCA CCGGTGCGC ACCCCGAGG
1501 GGGACGAGGT GTGGCTGGTC GTCGCTACG ACCGGGCGCG GCGGTCCCTC GCCGATCCCC
1561 GGTTCAAGAA GGAATGGCGC AACTCCACGA CTCCCCTGAC CGAGGCCGAG GCCGCGCTCA
1621 ACCACAACAT GCTGGAGTCC GACCCGCCGC GGCACACCCG GCTGCGCAAG CTGGTGGCCC
1681 GTGAGTTTAC CATGCGCCGG GTCGAGTTGC TGGGCCCCG GGTCCAGGAG ATCGTCGACG
1741 GGTCGTGGA CGCCATGCTG GCGGCGCCCC ACGCCGCGC CGATCTGATG GAGTCCCTGG
1801 CCTGGCGCT GCCGATCACC GTGATCTCCG AACTCCTCGG CGTGCCGAG CCGGACCGCG
1861 CCGCCTTCCG CGTCTGGACC GACGCTTCG TCTTCCCGGA CGATCCCGCC CAGGCCCAGA
1921 CCGCATATGG CGAGATGAGC GGCTATCTCT CCCGGCTCAT CGACTCCAAG CGCGGCAGG
1981 ACGGCGAGGA CCTGCTCAGC GCGCTCGTGC GGACCAGCGA CGAGGACGGC TCCCGGCTGA
2041 CCTCCGAGGA GCTGCTCGGT ATGGCCACA TCCTGCTCGT CGCGGGGCAC GAGACCACGG
2101 TCAATCTGAT CGCAACGGC ATGTACGCGC TGCTCTCGCA CCCCAGCAG CTGGCCGCC

```

-continued

2161 TCGGGGCCGA CATGACGCTC TTGGACGGCG CGGTGGAGGA GATGTTGCGC TACGAGGGCC
2221 CGGTGGAATC CGCGACCTAC CGCTTCCCGG TCGAGCCCGT CGACCTGGAC GGCACGGTCA
2281 TCCCGGCCGG TGACACGGTC CTCGTCGTCC TGGCCGACGC CCACCGCACC CCCGAGCGCT
2341 TCCCGGACCC GCACCGCTTC GACATCCGCC GGGACACCGC CGGCCATCTC GCCTTCGGCC
2401 ACGGCATCCA CTTCTGCATC GGCGCCCCCT TGGCCCGGTT GGAGGCCCGG ATCGCCGTCC
2461 GCGCCCTTCT CGAACGCTGC CCGGACCTCG CCCTGGACGT CTCCTCCCGC GAACTCGTGT
2521 GGTATCCGAA CCCGATGATC CGCGGGCTCA AGGCCCTGCC GATCCGGTGG CGGCAGGAC
2581 GGGAGGCGGG CCGCCGTACC GGTGAACCC GCACGTCACC CATTACGACT CCTTGTCACG
2641 GAAGCCCGG ATCGGTCCCC CCTCGCCGTA ACAAGACCTG GTTAGAGTGA TGGAGGACGA
2701 CGAAGGGTTC GGCGCCCGGA CGAGGGGGGA CTCCCGCAT GAATCTGGTG GAACGCGACG
2761 GGGAGATAGC CCATCTCAGG GCCGTTCTTG ACGCATCCGC CGCAGGTGAC GGGACGCTCT
2821 TACTCGTCTC CGGACCGGCC GGCAGCGGGA AGACGGAGCT GCTGCGGTCTG CTCCGCCGGC
2881 TGGCCGCCGA GCGGGAGACC CCCGTCTGGT CGGTCCGGGC GCTGCCGGGT GACCGCGACA
2941 TCCCCCTGGG CGTCTCTGCG CAGTTACTCC GCAGCGCCGA ACAACACGGT GCCGACACCT
3001 CCGCCGTCCG CGACCTGCTG GACGCCGCCT CGCGGCGGGC CGGAACCTCA CCTCCCCCGC
3061 CGACGCGCCG CTCGCGCTCG ACGAGACACA CCGCCTGCAC GACTGGCTGC TCTCCGTCTC
3121 CCGCCGGCAC CCCGTTCTCT GTCGCCGTCTG ACGACCTGAC CCACGCCGAC ACCGCGTCCC
3181 TGAGGTTTCT CCTGTACTGC GCCGCCACC ACGACCAGGG CGGCATCGGC TTCGTCATGA
3241 CCGAGCGGGC CTCGACGCGC GCCGGATACC GGTGTTCCG CGCCGAGTCT CTCCGCCAGC
3301 CGCACTGCGG CAACATGTGG CTCTCCGGGC TTCCCCCAG CGGGGTACGC CAGTTACTCG
3361 CCCACTACTA CGGCCCCGAG GCCGCCGAGC GCGGGGCCCC CGCGTACCAC GCGACGACCG
3421 GCGGGAACCC GCTGCTCTCT GCGGCGCTGA CCCAGGACCG GCAGGCCTCC CACACCACCC
3481 TCGGCGCGGC CGGCGCGCAC GAGCCCGTCC ACGGCGACGC CTTGCGCCAG GCCGTCCTCG
3541 ACTGCCTGCA CCGCAGCGCC GAGGGCACAC TGGAGACCGC CCGCTGGCTC GCGGTCCTCG
3601 AACAGTCCGA CCCGCTCTCT GTGGAGCGGC TCACGGGAAC GACCGCCGCC GCCGTCGAGC
3661 GCCACATCCA GGAGCTCGCC GCCATCGGCC TCCTGGACGA GGACGGCACC CTGGGACAGC
3721 CCGCGATCCG CGAGGCCGCC CTCCAGGACC TGCCGGCCGG CGAGCGCACC GAACTGCACC
3781 GCGCGGCCCG GGAGCAGCTG CACCGGGACG GCGCCGACGA GGACACCGTG GCCCGCACCC
3841 TGCTGGTCTG CGGCGCCCCC GACGCTCCCT GGGCGCTGCC CCGCTCGAA CGGGGCGCGC
3901 AGCAGGCCCT GTTCGACGAC CGACTCGACG ACGCCTTCCG GATCCTCGAG TTCGCCGTGC
3961 GGTGAGCAC CGACAACACC CAGCTGGCCC GCCTCGCCCC ACACCTGGTC GCGGCCTCCT
4021 GCGGATGAA CCCGCACATG ACGACCCGGG CCCTCGCACT CTTGACCGG CTCTGAGCG
4081 GTGAACTGCC GCCCAGCCAC CCGGTCATGG CCCTGATCCG CTGCCTCGTC TGGTACGGNC
4141 GGCTGCCCCG GCGCGCCGAC GCGCTGTCCC GGCTGCGGCC CAGCTCCGAC AACGATGCCT
4201 TGGAGCTGTC GCTCACCCGG ATGTGGCTCG CGGCGCTGTG CCCGCCGCTC CTGGAGTCCC
4261 TGCCGGCCAC GCCGAGCCG GAGCGGGGTC CCGTCCCCGT ACGGCTCGCG CCGCGGACGA
4321 CCGCGCTCCA GCGCCAGGCC GCGCTCTTCC AGCGGGGCCG GGACAACGCC TCGGTCGCGC
4381 AGGCCGAACA GATCTGCAG GGCTGCCGGC TGTCGGAGGA GACGTACGAG GCCCTGGAGA

-continued

4441 CGGCCCTCTT GCTCTCGTC CACGCCGACC GGCTCGACCG GCGCTGTTC TGGTCGGACG
 4501 CCCTGCTCGC CGAGGCCGTG GAGCGGCGGT CGCTCGGCTG GGAGGCGGTC TTCGCCGCGA
 4561 CCCGGGGGAT GATCGCGATC CGCTGCGGCG ACCTCCCGAC GCGCGGGGAG CGGGCCGAGC
 4621 TGGCGCTCTC CCACGCGGCG CCGGAGAGCT GGGGCCTCGC CGTGGGCATG CCCCTCTCCG
 4681 CGCTGCTGCT CGCCTGCACG GAGGCCGCG AGTACGAACA GCGGAGCGG GTCCTGCGGC
 4741 AGCCGGTGCC GGACGCGATG TTCGACTCGC GGCACGGCAT GGAGTACATG CACGCCCGGG
 4801 GCCGCTACTG GCTGGCGANC GGCCGGCTGC ACGCGGCGCT GGGCGAGTTC ATGCTCTGCG
 4861 GGGAGATCCT GGGCAGCTGG AACCTCGACC AGCCCTCGAT CGTGCCCTGG CGGACCTCCG
 4921 CCGCCGAGGT GTACCTGCGG CTCGGCAACC GCCAGAAGGC CAGGGCGCTG GCCGAGGCCC
 4981 AGCTCGCCCT GGTGCGGCC GGGCGCTCCC GCACCCGGG TCTACCCCTG CGGGTCCTGG
 5041 CGGCGGCGGT GGACGGCCAG CAGGCGGAGC GGCTGCACGC CGAGGCGGTC GACATGCTGC
 5101 ACGACAGCGG CGACCGGCTC GAACACGCCC GCGCGCTCGC CGGGATGAGC CGCCACCAGC
 5161 AGGCCCAGGG GGACAACCTAC CGGGCGAGGA TGACGGCGCG GCTCGCCGCG GACATGGCGT
 5221 GGGCTGCGG CGCGTACCCG CTGGCCGAGG AGATCGTGCC GGGCCGCGG GGGCCCGGG
 5281 CGAAGGCGGT GAGCACGGAG CTGGAACCTG CGGGCGGCC GACGTCGGC CTGCTCTCGG
 5341 AGGCCGAACG CCGGTGGCG GCCCTGGCAG CCCGAGGATT GACGAACCGC CAGATAGCGC
 5401 GCCGCTCTG CGTCACCGCG AGCACGGTCG AACAGCACCT GACGCGCGTC TACC GCAAAAC
 5461 TGAACGTGAC CCGCCGAGCA GACCTCCCGA TCAGCCTCGC CCAGGACAAG TCCGTCACGG
 5521 CCTGAGCCAC CCCCGGTGTC CCCGTGCGAC GACCCGCGC ACGGGCCACC GGGCCGCGG
 5581 GGACACGCGG GTGCGACACG GGGCGCGCC AGGTGCCATG GGGACCTCCG TGACCGCCCG
 5641 AGGCGCCCGA GGCGCCCGT GCGGCACCG GAGACGCCAG GACCGCCGGG ACCACCGGAG
 5701 ACGCCAGGGA CCGCTGGGGA CACCGGGACC TCAGGGACCG CCGGACCGC CCGAGTTGCA
 5761 CCCGTGCGC CCGGGGACAC CAGACCGCCG GGACCACCG AGGGTGCCCG GTGTGGCCCC
 5821 GCGGCGCGG GTGTCTTCA TCGGTGGGCC TTCATCGCA GGAGGAAGCG ACCGTGAGAC
 5881 CCGTCGTGCC GTCGGCGATC AGCCGCCTGT ACGGCGCTG GACTCCCTGG CGGTCCCGA
 5941 CCCGTCGTAC GGGCTCGCG GACCCGGTGC

[0063] Contig 003 from cosmid pKOS023-26 contains 3292 nucleotides and the following ORFs: from nucleotide 104 to 982 is ORF13, which encodes dNDP glucose synthase (glucose-1-phosphate thymidyl transferase); from

nucleotide 1114 to 2127 is ORF14, which encodes dNDP-glucose 4,6-dehydratase; and from nucleotide 2124 to 3263 is the picCI ORF.

1 ACCCCCCAAA GGGGTGGTGA CACTCCCCCT GCGCAGCCCC TAGCGCCCC CTAACGCGC
 61 ACGCCGACCG TTATCACCAG CGCCCTGCTG CTAGTTTCCG ACAATGAAGG GAATAGTCCT
 121 GGCCGGCGGG AGCGGAACTC GGCTGCATCC GCGACCTCG GTCATTTCGA AGCAGATTCT
 181 TCCGTCTAC AACAAACCGA TGATCTACTA TCCGCTGTCG GTTCTCATGC TCGGCGGTAT
 241 TCGCGAGATT CAAATCATCT CGACCCCCCA GCACATCGAA CTCTTCCAGT CGCTTCTCGG
 301 AAACGGCAGG CACCTGGGAA TAGAACTCGA CTATGCGGTC CAGAAAGAGC CCGCAGGAAT
 361 GCGGACGCA CTTCTCGTCG GAGCCGAGCA CATCGGCGAC GACACCTGCG CCCTGATCCT
 421 GGGCGACAAC ATCTTCCACG GGCCCGGCCT CTACACGCTC CTGCGGGACA GCATCGCGCG

-continued

481 CCTCGACGGC TGC GTGCTCT TCGGCTACCC GGTC AAGGAC CCCGAGCGGT ACGGCGTCGC
541 CGAGGTGGAC GCGACGGGCC GGCTGACCGA CCTCGTCGAG AAGCCCGTCA AGCCGCGCTC
601 CAACCTCGCC GTCACCGGCC TCTACCTCTA CGACAACGAC GTCGTCGACA TCGCCAAGAA
661 CATCCGGCCC TCGCCGCGCG GCGAGCTGGA GATCACCGAC GTCAACCGCG TCTACCTGGA
721 GCGGGGCCGG GCCGAACTCG TCAACCTGGG CCGCGGCTTC GCCTGGCTGG ACACCGGCAC
781 CCACGACTCG CTCCTGCGGG CCGCCCAGTA CGTCCAGGTC CTGGAGGAGC GGCAGGGCGT
841 CTGGATCGCG GGCCTTGAGG AGATCGCCTT CCGCATGGGC TTCATCGACG CCGAGGCCTG
901 TCACGGCCTG GGAGAAGGCC TCTCCCGCAC CGAGTACGGC AGCTATCTGA TGGAGATCGC
961 CGGCCGCGAG GGAGCCCGT GAGGGCACCT CCGCGCCGAC CGCTTCCAC GACCGACAGC
1021 GCCACCGACA GTGCGACCCA CACCGCGACC CGCACCGCCA CCGACAGTGC GACCCACACC
1081 GCGACCTACA GCGCGACCGA AAGGAAGACG GCAGTGC GGC TTCTGGTGAC CGGAGGTGCG
1141 GGCTTCATCG GCTCGCACTT CGTGCGGCAG CTCCTCGCCG GGGCGTACCC CGACGTGCCC
1201 GCCGATGAGG TGATCGTCCT GGACAGCCTC ACCTACGCGG GCAACCGCGC CAACCTCGCC
1261 CCGGTGGACG CGGACCCGCG ACTGCGCTTC GTCCACGGCG ACATCCGCGA CGCCGGCCTC
1321 CTCGCCCCGG AACTGCGCGG CGTGGACGCC ATCGTCCACT TCGCGGCCGA GAGCCACGTG
1381 GACCGCTCCA TCGCGGGCGC GTCCGTGTTT ACCGAGACCA ACGTGCAGGG CACGCAGACG
1441 CTGCTCCAGT GCGCCGTCGA CGCCGGCGTC GGCCGGGTCG TGCACGTCTC CACCGACGAG
1501 GTGTACGGGT CGATCGACTC CGGCTCCTGG ACCGAGAGCA GCCCGCTGGA GCCCAACTCG
1561 CCCTACGCGG CGTCCAAGGC CGGCTCCGAC CTCGTTGCCG GCGCCTACCA CCGGACGTAC
1621 GGCCTCGACG TACGGATCAC CCGCTGCTGC AACAACTACG GGCCGTACCA GCACCCCGAG
1681 AAGCTCATCC CCCTCTTCGT GACGAACCTC CTCGACGGCG GGACGCTCCC GCTGTACGGC
1741 GACGGCGCGA ACGTCCGCGA GTGGGTGCAC ACCGACGACC ACTGCCGGG CATCGCGCTC
1801 GTCCTCGCGG GCGGCCGGGC CGGCGAGATC TACCACATCG GCGGCGGCCT GGAGCTGACC
1861 AACCGCGAAC TCACCGGCAT CCTCCTGGAC TCGCTCGGCG CCGACTGGTC CTCGGTCCGG
1921 AAGGTCGCGG ACCGCAAGGG CCACGACCTG CGTACTTCCC TCGACGGCGG CAAGATCGAG
1981 CGCGAGCTCG GCTACCGCCC GCAGGTCTCC TTCGCGGACG GCCTCGCGCG GACCGTCCGC
2041 TGGTACCGGG AGAACCGCGG CTGGTGGGAG CCGCTCAAGG CGACCGCCCC GCAGCTGCCC
2101 GCCACCGCCG TGGAGGTGTC CGCGTGAGCA GCCGCGCCGA GACCCCCCGC GTCCCTTCC
2161 TCGACCTCAA GGCCGCCTAC GACGAGCTCC GCGCGGAGAC CGACGCGCG ATCGCCCGCG
2221 TCCTCGACTC GGGCGCTAC CTCCTCGGAC CCGAACTCGA AGGATTCGAG GCGGAGTTCG
2281 CCGCGTACTG CGAGACGGAC CACGCCGTCG GCGTGAACAG CGGGATGGAC GCCCTCCAGC
2341 TCGCCCTCCG CGGCCTCGGC ATCGGACCCG GGGACGAGGT GATCGTCCCC TCGCACACGT
2401 ACATCGCCAG CTGGCTCGCG GTGTCCGCCA CCGCGCGGAC CCCCCTGCCC GTCGAGCCGC
2461 ACGAGGACCA CCCCACCTG GACCCGCTGC TCGTCGAGAA GGCGATCACC CCCCACCC
2521 GGGCGCTCCT CCCCCTCCAC CTCTACGGG ACCCGCCGA CATGGACGCC CTCCGCGAGC
2581 TCGCGGACCG GCACGGCTG CACATCGTCG AGGACGCCG GCAGGCCAC GCGCCCGCT
2641 ACCGGGGCCG GCGGATCGGC GCCGGGTCGT CGGTGGCCG GTTCAGCTTC TACCCGGGCA
2701 AGAACCTCG CTGCTTCGGC GACGGCGGCG CCGTCGTCAC CGGCGACCCC GAGCTCGCCG
2761 AACGGCTCCG GATGCTCCG AACTACGGCT CCGCGCAGAA GTACAGCCAC GAGACGAAGG

-continued

2821 GCACCAACTC CCGCCTGGAC GAGATGCAGG CCGCCGTGCT GCGGATCCGG CTCGNCCACC
 2881 TGGACAGCTG GAACGGCCGC AGGTCGGCGC TGGCCGCGGA GTACCTCTCC GGGCTCGCCG
 2941 GACTGCCCCG CATCGGCCTG CCGGTGACCG CGCCCGACAC CGACCCGGTC TGGCACCTCT
 3001 TCACCGTGCG CACCGAGCGC CGCGACGAGC TGCAGAGCCA CCTCGACGCC CGCGGCATCG
 3061 ACACCCTCAC GCACTACCCG GTACCCGTGC ACCTCTCGCC CGCCTACGCG GCGAGGCAC
 3121 CGCCGGAAGG CTCGCTCCCG CGGGCCGAGA GCTTCGCGCG GCAGGTCCTC AGCCTGCCGA
 3181 TCGGCCCGCA CCTGGAGCGC CCGCAGGCGC TCGGGGTGAT CGACGCCGTG CGCGAATGGG
 3241 CCGAGCGGGT CGACCAGGCC TAGTCAGGTG GTCCGGTAGA CCCAGCAGGC CG

[0064] Contig 004 from cosmid pKOS023-26 contains 1693 nucleotides and the following ORFs: from nucleotide 1692 to 694 is ORF15, which encodes a part of S-adenosylmethionine synthetase; and from nucleotide 692 to 1 is ORF16, which encodes a part of a protein homologous to the *M. tuberculosis* cbhK gene.

1 ATGCGGCACC CCTTGGCGCC GAGCGTGGTG ATCCAGGTGC CGACCCGGGC GAGCACCTCC
 61 TGCTCGGTCC AGCCCGTCTT GCTGAGCAGC AGCGCCCGCT CGTAGCGGTT CGTGAACAGC
 121 AGCTCGGCTC CGTCGACGAG CTCCCGGACG CTGTCGCCCT CCAGCCGGGC GAGCTGCTGC
 181 GAGGGGTCCG CGGCCCGCGC GAGGCCAGC TCGCGGCAGA CCCGCGTGTG CCGCACCATC
 241 GCCTCGGGGT CGTCCGCGCC GACGAGGACG AGGTCGATCC CGCCGGGCGC GCCGGCCGTC
 301 TCGCCCAGGT CGATGTCGCG CGCCTCGGCC ATCGCGCCCG CGTAGAACGA GCGGAGCTGA
 361 TTGCCGTCCT CGTCGGTGGT GCACATGAAG CGGCGGTGTG GCTGACGGTC CGACACCCGC
 421 ACGGAGTCGG TGTCGACGCC CGCGGCGCGG AGCAGCTGCC CGTACCCGTC GAAGTCCTTG
 481 CCGACGGCGC CGACGAGGAC GGGGCGGCGA CCGAGCAGGC CGAGGCCGTA CGCGATGTTG
 541 GCGGCGACGC CGCCGTGCGG GATGTCCAGG GTGTCGACGA GGAACGACAG GGACACGTGG
 601 GCGAGCTGGT CCGGCAGGAT CTGCTCGGCG AAGCGGCCCC GGAAGGTCAT CAGGTGGTGC
 661 GTGGCGATCG ACCCGGTGAC GGCTATACGC ATGTCAGAGC CCCGCGGCCT TCTTCAGGGC
 721 GTCCACGCGG TCGGTGCGCT CCCAGGTGAA GTCCGGCAGC TCGCGGCCGA AGTGGCCGTA
 781 GCGGCGGTC TGGGAGTAGA TCGGGCGGAG CAGGTCGAGG TCGCGGATGA TCGCGCCGG
 841 GCGGAGGTCG AAGACCTCGC CGATGGCGTT CTCGATCTTC TCGGTCTCGA TCTTGTGGGT
 901 GCCGAAGGTC TCGACGAAGA GGCCGACGGG CTCGGCCTTG CCGATCGCGT ACGCGACCTG
 961 GACCTCGCAG CGCGAGGCGA GACCGGCGGC GACGACGTTT TTCGCCACCC AGCGCATCGC
 1021 GTACGCGCGG GAGCGGTGCA CCTTCGACGG GTCCTTGCCG GAGAAGGCGC CGCCACCGTG
 1081 GCGGGCCATG CCGCCGTAGG TGTCGATGAT GATCTTGCGG CCGGTGAGGC CGGCGTCGCC
 1141 CATCGGGCCG CCGATCTCGA AGCGACCGGT CGGGTTCACG AGCAGGCGGT AGCCGTGCGT
 1201 GTCGAGCTTG ATGCCGTCCT CGACGAGCTG CGCAAGCACG TGCTCGACGA CGAACTTCCG
 1261 CACGTCGGGG GCGAGCAGCG ACTCCAGGTC GATGTCCGAG GCGTGCTCGG AGGAGACGAC
 1321 GACCGTGTCG AGACGGACCG CCCTGTGCGC GTCGTACTCG ATGGTGACCT GGGTCTTGCC
 1381 GTCGGGACGC AGGTACGGGA TGGTCCCGTT CTTGCGGACC TCGGTCAGGC GCGCGGAGAG
 1441 ACGGTGCGCG AGGTGGATCG GCAGCGGCAT CAGCTCGGGC GTCTCGTCCG AGGCATAGCC
 1501 GAACATCAGG CCCTGGTCAC CGGCGCCCTG CTTGTCGAGC TCGTCCCCCT CGTCCCGCTG

-continued

1561 GGAGGCACCC TCGACCCGCT TCTCGTACGC GGTGTCGACA CCCTGGGCGA TGTCGCGGGA
 1621 CTGCGACCCG ATGGACACCG ACACGCCGCA GGAGGCGCCG TCGAAGCCCT TCTTCGAGGA
 1681 GTCGTACCCG ATC

[0065] Contig 005 from cosmid pKOS023-26 contains 1565 nucleotides and contains the ORF of the picCV gene that encodes PICCV, involved in desosamine biosynthesis.

1 CCCCCTCGC GGGCCCCCAG ACATCCACGC CCACGATTGG ACGCTCCCGA TGACCGCCCC
 61 CGCCCTCTCC GCCACCGCCC CGGCCGAACG CTGCGCGCAC CCCGGAGCCG ATCTGGGGGC
 121 GGCGGTCCAC GCCGTCGGCC AGACCTTCGC CGCCGGCGGC CTCGTGCCGC CCGACGAGGC
 181 CGGAACGACC GCCCGCCACC TCGTCCGGCT CGCCGTGCGC TACGGCAACA GCCCCTTCAC
 241 CCCGCTGGAG GAGGCCCGCC ACGACCTGGG CGTCGACCGG GACGCCTTCC GGCGCTCCT
 301 CGCCCTGTTC GGGCAGGTCC CCGAGCTCCG CACCGCGGTC GAGACCGGCC CCGCCGGGGC
 361 GTACTGGAAC AACACCTGTC TCCCGCTCGA ACAGCGCGGC GTCTTCGACG CGGCCTCGC
 421 CAGGAAGCCC GTCTTCCCGT ACAGCGTCGG CCTCTACCCC GGCCCGACCT GCATGTTCCG
 481 CTGCCACTTC TGCCTCCGTG TGACCGGCGC CCGCTACGAC CCGTCCGCC TCGACGCGG
 541 CAACGCCATG TTCCGGTCGG TCATCCACGA GATACCCGCG GGCAACCCCT CGGCATGTA
 601 CTTCTCCGGC GGCCTGGAGC CGCTCACCAA CCCCAGCCTC GGGAGCCTGG CCGCGCACGC
 661 CACCGACCAC GGCCTGCGGC CCACCGTCTA CACGAACTCC TTCGCGCTCA CCGAGCGCAC
 721 CCTGGAGCGC CAGCCCGGCC TCTGGGGCCT GCACGCCATC CCCACCTCGC TCTACGGCCT
 781 CAACGACGAG GAGTACGAGC AGACCACCGG CAAGAAGGCC GCCTTCCGCC GCGTCCGGA
 841 GAACCTGCGC CGCTTCCAGC AGCTGCGCGC CGAGCGCGAG TCGCCGATCA ACCTCGGCTT
 901 CGCCTACATC GTGCTCCCGG GCCGTGCCTC CCGCCTGCTC GACCTGGTCG ACTTCATCGC
 961 CGACCTCAAC GACGCCGGGC AGGCGAGGAC GATCGACTTC GTCAACATTC GCGAGGACTA
 1021 CAGCGGCCGT GACGACGGCA AGCTGCCGCA GGAGGAGCGG GCCGAGCTCC AGGAGGCCCT
 1081 CAACGCCCTC GAGGAGCGGG TCCGCGAGCG CACCCCGGA CTCACATCG ACTACGGCTA
 1141 CGCCCTGAAC AGCCTGCGCA CCGGGGCCGA CGCCGAACTG CTGCCGATCA AGCCCGCCAC
 1201 CATGCGGCCC ACCCGCGACC CGCAGGTCGC GGTGCAGGTC GATCTCCTCG GCGACGTGTA
 1261 CCTGTACCGC GAGGCCGGCT TCCCCGACCT GGACGGCGCG ACCCGCTACA TCGCGGGCCG
 1321 CGTGACCCCC GACACCTCCC TCACCGAGGT CGTCAGGGAC TTCGTGAGC GCGGCGGCGA
 1381 GGTGGCGGCC GTGACGGCG ACGAGTACTT CATGGACGGC TTCGATCAGG TCGTCACCGC
 1441 CCGCCTGAAC CAGCTGGAGC GCGACGCCGC GGACGGCTGG GAGGAGGCC CCGGCTTCCT
 1501 GCGCTGACCC GCACCCGCC CGATCCCC GATCCCCC CCACGATCCC CCCACCTGAG
 1561 GGCCC

[0066] The recombinant desosamine biosynthesis and transfer and beta-glucosidase genes and proteins provided by the invention are useful in the production of glycosylated polyketides in a variety of host cells, as described in Section IV below.

[0067] Section III. The picK Hydroxylase Gene

[0068] The present invention provides the picK gene in recombinant form as well as recombinant PicK protein. The availability of the hydroxylase encoded by the picK gene in

recombinant form is of significant benefit in that the enzyme can convert narbomycin into picromycin and accepts in addition a variety of polyketide substrates, particularly those related to narbomycin in structure. The present invention also provides methods of hydroxylating polyketides, which method comprises contacting the polyketide with the recombinant PicK enzyme under conditions such that hydroxylation occurs. This methodology is applicable to large numbers of polyketides.

[0069] DNA encoding the picK gene can be isolated from cosmid pKOS023-26 of the invention. The DNA sequence of the picK gene is shown in the preceding section. This DNA sequence encodes one of the recombinant forms of the enzyme provided by the invention. The amino acid sequence of this form of the picK gene is shown below. The present invention also provides a recombinant picK gene that encodes a picK gene product in which the PicK protein is fused to a number of consecutive histidine residues, which facilitates purification from recombinant host cells.

Amino acid sequence of picromycin/methymycin
cytochrome P450 hydroxylase, PicK

```

1VVRTQQGTTA SPPVLDLGLA GQDFAADFPY TYARLRAEGP AHRVRTPEGD EVWLTVGYDR
61ARAVLADPRF SKDWRNSTTP LTEAEALNH NMLESPPRH TRLRKLVARE FTMRRVELLR
121PRVQEIVDGL VDAMLAAPDG RADLMESLAW PLPITVISEL LGVPEPDRAA FRVWIDAFVF
181PDDPAQAQTA MAEMSGYLSR LIDSKRGQDG EDLLSALVRT SDEGSRSLTS EELGMAHIL
241LVAGHETTVN LIANGMYALL SHPDQLAALR ADMTLLDGAV EEMLRYPGPV ESATYRFPVE
301PVDLDGTVIP AGDTVLVVLA DAHRTPERFP DPHRFDIRRD TAGHLAFGHG IHFCIGAPLA
361RLEARIAVRA LLERCPDLAL DVSPGELVWY PNPIMIRGLKA LPIRWRRGRE AGRRTG

```

[0070] The recombinant PicK enzyme of the invention hydroxylates narbomycin at the C12 position and YC-17 at either the C10 or C12 position. Hydroxylation of these compounds at the respective positions increases the antibiotic activity of the compound relative to the unhydroxylated compound. Hydroxylation can be achieved by a number of methods. First, the hydroxylation may be performed in vitro using purified hydroxylase, or the relevant hydroxylase can be produced recombinantly and utilized directly in the cell that produces it. Thus, hydroxylation may be effected by supplying the nonhydroxylated precursor to a cell that expresses the hydroxylase. These and other details of this embodiment of the invention are described in additional detail below in Section IV and the examples.

[0071] Section IV: Heterologous Expression of the Narbonolide PKS; the Desosamine Biosynthetic and transferase Genes; the Beta-Glucosidase Gene; and the picK Hydroxylase Gene

[0072] In one important embodiment, the invention provides methods for the heterologous expression of one or more of the genes involved in picromycin biosynthesis and recombinant DNA expression vectors useful in the method. Thus, included within the scope of the invention in addition to isolated nucleic acids encoding domains, modules, or proteins of the narbonolide PKS, glycosylation, and/or hydroxylation enzymes, are recombinant expression sys-

tems. These systems contain the coding sequences operably linked to promoters, enhancers, and/or termination sequences that operate to effect expression of the coding sequence in compatible host cells. The host cells are modified by transformation with the recombinant DNA expression vectors of the invention to contain these sequences either as extrachromosomal elements or integrated into the chromosome. The invention also provides methods to produce PKS and post-PKS tailoring enzymes as well as polyketides and antibiotics using these modified host cells.

[0073] As used herein, the term expression vector refers to a nucleic acid that can be introduced into a host cell or cell-free transcription and translation medium. An expression vector can be maintained stably or transiently in a cell, whether as part of the chromosomal or other DNA in the cell or in any cellular compartment, such as a replicating vector in the cytoplasm. An expression vector also comprises a gene that serves to produce RNA, which typically is translated into a polypeptide in the cell or cell extract. To drive

production of the RNA, the expression vector typically comprises one or more promoter elements. Furthermore, expression vectors typically contain additional functional elements, such as, for example, a resistance-conferring gene that acts as a selectable marker.

[0074] The various components of an expression vector can vary widely, depending on the intended use of the vector. In particular, the components depend on the host cell(s) in which the vector will be introduced or in which it is intended to function. Components for expression and maintenance of vectors in *E. coli* are widely known and commercially available, as are components for other commonly used organisms, such as yeast cells and *Streptomyces* cells.

[0075] One important component is the promoter, which can be referred to as, or can be included within, a control sequence or control element, which drives expression of the desired gene product in the heterologous host cell. Suitable promoters include those that function in eucaryotic or pro-caryotic host cells. In addition to a promoter, a control element can include, optionally, operator sequences, and other elements, such as ribosome binding sites, depending on the nature of the host. Regulatory sequences that allow for regulation of expression of the heterologous gene relative to the growth of the host cell may also be included. Examples of such regulatory sequences known to those of skill in the art are those that cause the expression of a gene

to be turned on or off in response to a chemical or physical stimulus. Preferred host cells for purposes of selecting vector components include fungal host cells such as yeast and procaryotic, especially *E. coli* and *Streptomyces*, host cells, but single cell cultures of, for example, mammalian cells can also be used. In hosts such as yeasts, plants, or mammalian cells that ordinarily do not produce polyketides, it may be necessary to provide, also typically by recombinant means, suitable holo-ACP synthases to convert the recombinantly produced PKS to functionality. Provision of such enzymes is described, for example, in PCI publication Nos. WO 97/13845 and 98/27203, each of which is incorporated herein by reference. Control systems for expression in yeast, including controls that effect secretion are widely available and can be routinely used. For *E. coli* or other bacterial host cells, promoters such as those derived from sugar metabolizing enzymes, such as galactose, lactose (lac), and maltose, can be used. Additional examples include promoters derived from genes encoding biosynthetic enzymes, and the tryptophan (trp), the beta-lactamase (bla), bacteriophage lambda PL, and T5 promoters. In addition, synthetic promoters, such as the tac promoter (U.S. Pat. No. 4,551,433), can also be used.

[0076] Particularly preferred are control sequences compatible with *Streptomyces* spp. Particularly useful promoters for *Streptomyces* host cells include those from PKS gene clusters that result in the production of polyketides as secondary metabolites, including promoters from aromatic (Type II) PKS gene clusters. Examples of Type II PKS gene cluster promoters are act gene promoters and tcm gene promoters; an example of a Type I PKS gene cluster promoter is the spiramycin PKS gene promoter.

[0077] If a *Streptomyces* or other host ordinarily produces polyketides, it may be desirable to modify the host so as to prevent the production of endogenous polyketides prior to its use to express a recombinant PKS of the invention. Such hosts have been described, for example, in U.S. Pat. No. 5,672,491, incorporated herein by reference. In such hosts, it may not be necessary to provide enzymatic activities for all of the desired post-translational modifications of the enzymes that make up the recombinantly produced PKS, because the host naturally expresses such enzymes. In particular, these hosts generally contain holo-ACP synthases that provide the pantotheinyl residue needed for functionality of the PKS.

[0078] Thus, in one important embodiment, the vectors of the invention are used to transform *Streptomyces* host cells to provide the recombinant *Streptomyces* host cells of the invention. *Streptomyces* is a convenient host for expressing narbonolide or 10-deoxymethynolide or derivatives of those compounds, because narbonolide and 10-deoxymethynolide are naturally produced in certain *Streptomyces* species, and *Streptomyces* generally produce the precursors needed to form the desired polyketide. The present invention also provides the narbonolide PKS gene promoter in recombinant form, located upstream of the picAI gene on cosmid pKOS023-27. This promoter can be used to drive expression of the narbonolide PKS or any other coding sequence of interest in host cells in which the promoter functions, particularly *S. venezuelae* and generally any *Streptomyces* species. As described below, however, promoters other than the promoter of the narbonolide PKS genes will typically be used for heterologous expression.

[0079] For purposes of the invention, any host cell other than *Streptomyces venezuelae* is a heterologous host cell. Thus, *S. narbonensis*, which produces narbomycin but not picromycin is a heterologous host cell of the invention, although other host cells are generally preferred for purposes of heterologous expression. Those of skill in the art will recognize that, if a *Streptomyces* host that produces a picromycin or methymycin precursor is used as the host cell, the recombinant vector need drive expression of only a portion of the genes constituting the picromycin gene cluster. As used herein, the picromycin gene cluster includes the narbonolide PKS, the desosamine biosynthetic and transferase genes, the beta-glucosidase gene, and the picK hydroxylase gene. Thus, such a vector may comprise only a single ORF, with the desired remainder of the polypeptides encoded by the picromycin gene cluster provided by the genes, on the host cell chromosomal DNA.

[0080] The present invention also provides compounds and recombinant DNA vectors useful for disrupting any gene in the picromycin gene cluster (as described above and illustrated in the examples below). Thus, the invention provides a variety of modified host cells (particularly, *S. narbonensis* and *S. venezuelae*) in which one or more of the genes in the picromycin gene cluster have been disrupted. These cells are especially useful when it is desired to replace the disrupted function with a gene product expressed by a recombinant DNA vector. Thus, the invention provides such *Streptomyces* host cells, which are preferred host cells for expressing narbonolide derivatives of the invention. Particularly preferred host cells of this type include those in which the coding sequence for the loading module has been disrupted, those in which one or more of any of the PKS gene ORFs has been disrupted, and/or those in which the picK gene has been disrupted.

[0081] In a preferred embodiment, the expression vectors of the invention are used to construct a heterologous recombinant *Streptomyces* host cell that expresses a recombinant PKS of the invention. As noted above, a heterologous host cell for purposes of the present invention is any host cell other than *S. venezuelae*, and in most cases other than *S. narbonensis* as well. Particularly preferred heterologous host cells are those which lack endogenous functional PKS genes. Illustrative host cells of this type include the modified *Streptomyces coelicolor* CH999 and similarly modified *S. lividans* described in PCT publication No. WO 96/40968.

[0082] The invention provides a wide variety of expression vectors for use in *Streptomyces*. For replicating vectors, the origin of replication can be, for example and without limitation, a low copy number vector, such as SCP2* (see Hopwood et al., *Genetic Manipulation of Streptomyces: A Laboratory manual* (The John Innes Foundation, Norwich, U.K., 1985); Lydiate et al., 1985, *Gene* 35: 223-235; and Kieser and Melton, 1988, *Gene* 65: 83-91, each of which is incorporated herein by reference), SLP1.2 (Thompson et al., 1982, *Gene* 20: 51-62, incorporated herein by reference), and pSG5(ts) (Muth et al., 1989, *Mol. Gen. Genet.* 219: 341-348, and Bierman et al., 1992, *Gene* 116: 43-49, each of which is incorporated herein by reference), or a high copy number vector, such as pJ101 and pJV1 (see Katz et al., 1983, *J. Gen. Microbiol.* 129: 2703-2714; Vara et al., 1989, *J. Bacteriol.* 171: 5782-5781; and Servin-Gonzalez, 1993, *Plasmid* 30: 131-140, each of which is incorporated herein by reference). High copy number vectors are generally, however, not preferred for expression of large genes or multiple genes. For non-replicating and integrating vectors and generally for any vector, it is useful to include at least

an *E. coli* origin of replication, such as from pUC, p1P, p1I, and pBR. For phage based vectors, the phage phiC31 and its derivative KC515 can be employed (see Hopwood et al., supra). Also, plasmid pSET152, plasmid pSAM, plasmids pSE101 and pSE211, all of which integrate site-specifically in the chromosomal DNA of *S. lividans*, can be employed.

[0083] Preferred *Streptomyces* host cell/vector combinations of the invention include *S. coelicolor* CH999 and, *S. lividans* K4-114 host cells, which do not produce actinorhodin, and expression vectors derived from the pRM1 and pRM5 vectors, as described in U.S. Pat. No. 5,830,750 and U.S. patent application Ser. No. 08/828,898, filed 31 Mar. 1997, and Ser. No. 09/181,833, filed 28 Oct. 1998, each of which is incorporated herein by reference.

[0084] As described above, particularly useful control sequences are those that alone or together with suitable regulatory systems activate expression during transition from growth to stationary phase in the vegetative mycelium. The system contained in the illustrative plasmid pRM5, i.e., the actI/actIII promoter pair and the actII-ORF4 activator gene, is particularly preferred. Other useful *Streptomyces* promoters include without limitation those from the ermE gene and the melC1 gene, which act constitutively, and the tipA gene and the merA gene, which can be induced at any growth stage. In addition, the T7 RNA polymerase system has been transferred to *Streptomyces* and can be employed in the vectors and host cells of the invention. In this system, the coding sequence for the T7 RNA polymerase is inserted into a neutral site of the chromosome or in a vector under the control of the inducible merA promoter, and the gene of interest is placed under the control of the T7 promoter. As noted above, one or more activator genes can also be employed to enhance the activity of a promoter. Activator genes in addition to the actII-ORF4 gene described above include dnrI, redD, and ptpA genes (see U.S. patent application Ser. No. 09/181,833, supra).

[0085] Typically, the expression vector will comprise one or more marker genes by which host cells containing the vector can be identified and/or selected. Selectable markers are often preferred for recombinant expression vectors. A variety of markers are known that are useful in selecting for transformed cell lines and generally comprise a gene that confers a selectable phenotype on transformed cells when the cells are grown in an appropriate selective medium. Such markers include, for example, genes that confer antibiotic resistance or sensitivity to the plasmid. Alternatively, several polyketides are naturally colored, and this characteristic can provide a built-in marker for identifying cells. Preferred selectable markers include antibiotic resistance conferring genes. Preferred for use in *Streptomyces* host cells are the ermE (confers resistance to erythromycin and lincomycin), tsr (confers resistance to thiostrepton), aadA (confers resistance to spectinomycin and streptomycin), aacC4 (confers resistance to apramycin, kanamycin, gentamicin, geneticin (G418), and neomycin), hyg (confers resistance to hygromycin), and vph (confers resistance to viomycin) resistance conferring genes.

[0086] To provide a preferred host cell and vector for purposes of the invention, the narbonolide PKS genes were placed on a recombinant expression vector that was transferred to the non-macrolide producing host *Streptomyces lividans* K4-114, as described in Example 3. Transformation of *S. lividans* K4-114 with this expression vector resulted in a strain which produced two compounds in similar yield (5-10 mg/L each). Analysis of extracts by LC/MS followed

by ¹H-NMR spectroscopy of the purified compounds established their identity as narbonolide (FIG. 5, compound 4) and 10-deoxymethynolide (FIG. 5, compound 5), the respective 14 and 12-membered polyketide precursors of narbomycin and YC17.

[0087] To provide a host cell of the invention that produces the narbonolide PKS as well as an additional narbonolide biosynthetic gene and to investigate the possible role of the Pik TEII in picromycin biosynthesis, the picB gene was integrated into the chromosome to provide the host cell of the invention *Streptomyces lividans* K39-18. The picB gene was cloned into the *Streptomyces* genome integrating vector pSET152 (see Bierman et al., 1992, Gene 116:43, incorporated herein by reference) under control of the same promoter (PactI) as the PKS on plasmid pKOS039-86.

[0088] A comparison of strains *Streptomyces lividans* K39-18/pKOS039-86 and KS 114/pKOS039-86 grown under identical conditions indicated that the strain containing TEII produced 47 times more total polyketide. This increased production indicates that the enzyme is functional in this strain and is consistent with the observation that yields fall to below 5% for both picromycin and methymycin when picB is disrupted in *S. venezuelae*. Because the production levels of compound 4 and 5 from K39-18/pKOS03986 increased by the same relative amounts, TEII does not appear to influence the ratio of 12 and 14-membered lactone ring formation. Thus, the invention provides methods of coexpressing the picB gene product or any other type II thioesterase with the narbonolide PKS or any other PKS in heterologous host cells to increase polyketide production.

[0089] In accordance with the methods of the invention, picromycin biosynthetic genes in addition to the genes encoding the PKS and Pik TEII can be introduced into heterologous host cells. In particular, the picK gene, desosamine biosynthetic genes, and the desosaminyl transferase gene can be expressed in the recombinant host cells of the invention to produce any and all of the polyketides in the picromycin biosynthetic pathway (or derivatives thereof). Those of skill will recognize that the present invention enables one to select whether only the 12-membered polyketides, or only the 14-membered polyketides, or both 12- and 14-membered polyketides will be produced. To produce only the 12-membered polyketides, the invention provides expression vectors in which the last module is deleted or the KS domain of that module is deleted or rendered inactive. To produce only the 14-membered polyketides, the invention provides expression vectors in which the coding sequences of extender modules 5 and 6 are fused to provide only a single polypeptide.

[0090] In one important embodiment, the invention provides methods for desosaminylating polyketides or other compounds. In this method, a host cell other than *Streptomyces venezuelae* is transformed with one or more recombinant vectors of the invention comprising the desosamine biosynthetic and desosaminyl transferase genes and control sequences positioned to express those genes. The host cells so transformed can either produce the polyketide to be desosaminylated naturally or can be transformed with expression vectors encoding the PKS that produces the desired polyketide. Alternatively, the polyketide can be supplied to the host cell containing those genes. Upon production of the polyketide and expression of the desosamine biosynthetic and desosaminyl transferase genes, the

desired desosaminylated polyketide is produced. This method is especially useful in the production of polyketides to be used as antibiotics, because the presence of the desosamine residue is known to increase, relative to their undesosaminylated counterparts, the antibiotic activity of many polyketides significantly. The present invention also provides a method for desosaminylating a polyketide by transforming an *S. venezuelae* or *S. narbonensis* host cell with a recombinant vector that encodes a PKS that produces the polyketide and culturing the transformed cell under conditions such that said polyketide is produced and desosaminylated. In this method, use of an *S. venezuelae* or *S. narbonensis* host cell of the invention that does not produce a functional endogenous narbonolide PKS is preferred.

[0091] In a related aspect, the invention provides a method for improving the yield of a desired desosaminylated polyketide in a host cell, which method comprises transforming the host cell with a beta-glucosidase gene. This method is not limited to host cells that have been transformed with expression vectors of the invention encoding the desosamine biosynthetic and desosaminyl transferase genes of the invention but instead can be applied to any host cell that desosaminylates polyketides or other compounds. Moreover, while the beta-glucosidase gene from *Streptomyces venezuelae* provided by the invention is preferred for use in the method, any beta-glucosidase gene may be employed. In another embodiment, the beta-glucosidase treatment is conducted in a cell free extract.

[0092] Thus, the invention provides methods not only for producing narbonolide and 10-deoxymethynolide in heterologous host cells but also for producing narbomycin and YC-17 in heterologous host cells. In addition, the invention provides methods for expressing the picK gene product in heterologous host cells, thus providing a means to produce picromycin, methymycin, and neomethymycin in heterologous host cells. Moreover, because the recombinant expression vectors provided by the invention enable the artisan to provide for desosamine biosynthesis and transfer and/or C10 or C12 hydroxylation in any host cell, the invention provides methods and reagents for producing a very wide variety of glycosylated and/or hydroxylated polyketides. This variety of polyketides provided by the invention can be better appreciated upon consideration of the following section relating to the production of polyketides from heterologous or hybrid PKS enzymes provided by the invention.

[0093] Section V: Hybrid PKS Genes

[0094] The present invention provides recombinant DNA compounds encoding each of the domains of each of the modules of the narbonolide PKS, the proteins involved in desosamine biosynthesis and transfer to narbonolide, and the PicK protein. The availability of these compounds permits their use in recombinant procedures for production of desired portions of the narbonolide PKS fused to or expressed in conjunction with all or a portion of a heterologous PKS. The resulting hybrid PKS can then be expressed in a host cell, optionally with the desosamine biosynthesis and transfer genes and/or the picK hydroxylase gene to produce a desired polyketide.

[0095] Thus, in accordance with the methods of the invention, a portion of the narbonolide PKS coding sequence that encodes a particular activity can be isolated and manipulated, for example, to replace the corresponding region in a different modular PKS. In addition, coding sequences for

individual modules of the PKS can be ligated into suitable expression systems and used to produce the portion of the protein encoded. The resulting protein can be isolated and purified or can may be employed in situ to effect polyketide synthesis. Depending on the host for the recombinant production of the domain, module, protein, or combination of proteins, suitable control sequences such as promoters, termination sequences, enhancers, and the like are ligated to the nucleotide sequence encoding the desired protein in the construction of the expression vector.

[0096] In one important embodiment, the invention thus provides a hybrid PKS and the corresponding recombinant DNA compounds that encode those hybrid PKS enzymes. For purposes of the invention, a hybrid PKS is a recombinant PKS that comprises all or part of one or more extender modules, loading module, and/or thioesterase/cyclase domain of a first PKS and all or part of one or more extender modules, loading module, and/or thioesterase/cyclase domain of a second PKS. In one preferred embodiment, the first PKS is most but not all of the narbonolide PKS, and the second PKS is only a portion or all of a non-narbonolide PKS. An illustrative example of such a hybrid PKS includes a narbonolide PKS in which the natural loading module has been replaced with a loading module of another PKS. Another example of such a hybrid PKS is a narbonolide PKS in which the AT domain of extender module 3 is replaced with an AT domain that binds only malonyl CoA.

[0097] In another preferred embodiment, the first PKS is most but not all of a non-narbonolide PKS, and the second PKS is only a portion or all of the narbonolide PKS. An illustrative example of such a hybrid PKS includes a DEBS PKS in which an AT specific for methylmalonyl CoA is replaced with the AT from the narbonolide PKS specific for malonyl CoA.

[0098] Those of skill in the art will recognize that all or part of either the first or second PKS in a hybrid PKS of the invention need not be isolated from a naturally occurring source. For example, only a small portion of an AT domain determines its specificity. See U.S. provisional patent application Ser. No. 60/091,526, and Lau et al., infra, incorporated herein by reference. The state of the art in DNA synthesis allows the artisan to construct de novo DNA compounds of size sufficient to construct a useful portion of a PKS module or domain. Thus, the desired derivative coding sequences can be synthesized using standard solid phase synthesis methods such as those described by Jaye et al., 1984, *J. Biol. Chem.* 259: 6331, and instruments for automated synthesis are available commercially from, for example, Applied Biosystems, Inc. For purposes of the invention, such synthetic DNA compounds are deemed to be a portion of a PKS.

[0099] With this general background regarding hybrid PKSs of the invention, one can better appreciate the benefit provided by the DNA compounds of the invention that encode the individual domains, modules, and proteins that comprise the narbonolide PKS. As described above, the narbonolide PKS is comprised of a loading module, six extender modules composed of a KS, AT, ACP, and zero, one, two, or three KR, DH, and ER domains, and a thioesterase domain. The DNA compounds of the invention that encode these domains individually or in combination are useful in the construction of the hybrid PKS encoding DNA compounds of the invention.

[0100] The recombinant DNA compounds of the invention that encode the loading module of the narbonolide PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the narbonolide PKS loading module is inserted into a DNA compound that comprises the coding sequence for a heterologous PKS. The resulting construct, in which the coding sequence for the loading module of the heterologous PKS is replaced by that for the coding sequence of the narbonolide PKS loading module provides a novel PKS. Examples include the 6-deoxyerythronolide B, rapamycin, FK506, FK520, rifamycin, and avermectin PKS coding sequences. In another embodiment, a DNA compound comprising a sequence that encodes the narbonolide PKS loading module is inserted into a DNA compound that comprises the coding sequence for the narbonolide PKS or a recombinant narbonolide PKS that produces a narbonolide derivative.

[0101] In another embodiment, a portion of the loading module coding sequence is utilized in conjunction with a heterologous coding sequence. In this embodiment, the invention provides, for example, replacing the propionyl CoA specific AT with an acetyl CoA, butyryl CoA, or other CoA specific AT. In addition, the KS^Q and/or ACP can be replaced by another inactivated KS and/or another ACP. Alternatively, the KS^Q, AT, and ACP of the loading module can be replaced by an AT and ACP of a loading module such as that of DEBS. The resulting heterologous loading module coding sequence can be utilized in conjunction with a coding sequence for a PKS that synthesizes narbonolide, a narbonolide derivative, or another polyketide.

[0102] The recombinant DNA compounds of the invention that encode the first extender module of the narbonolide PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the narbonolide PKS first extender module is inserted into a DNA compound that comprises the coding sequence for a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the first extender module of the narbonolide PKS or the latter is merely added to coding sequences for modules of the heterologous PKS, provides a novel PKS coding sequence. In another embodiment, a DNA compound comprising a sequence that encodes the first extender module of the narbonolide PKS is inserted into a DNA compound that comprises coding sequences for the narbonolide PKS or a recombinant narbonolide PKS that produces a narbonolide derivative.

[0103] In another embodiment, a portion or all of the first extender module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or carboxyglycolyl CoA specific AT; deleting (which includes inactivating) the KR; inserting a DH or a DH and ER; and/or replacing the KR with another KR, a DH and KR, or a DH, KR, and ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous MS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the narbonolide PKS, from a gene for a PKS that

produces a polyketide other than narbonolide, or from chemical synthesis. The resulting heterologous first extender module coding sequence can be utilized in conjunction with a coding sequence for a PKS that synthesizes narbonolide, a narbonolide derivative, or another polyketide.

[0104] In an illustrative embodiment of this aspect of the invention, the invention provides recombinant PKSs and recombinant DNA compounds and vectors that encode such PKSs in which the KS domain of the first extender module has been inactivated. Such constructs are especially useful when placed in translational reading frame with the remaining modules and domains of a narbonolide PKS or narbonolide derivative PKS. The utility of these constructs is that host cells expressing, or cell free extracts containing, the PKS encoded thereby can be fed or supplied with N-acetylcysteamine thioesters of novel precursor molecules to prepare narbonolide derivatives. See U.S. patent application Ser. No. 60/117,384, filed 27 Jan. 1999, and PCT publication Nos. WO 99/03986 and 97/02358, each of which is incorporated herein by reference.

[0105] The recombinant DNA compounds of the invention that encode the second extender module of the narbonolide PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the narbonolide PKS second extender module is inserted into a DNA compound that comprises the coding sequence for a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the second extender module of the narbonolide PKS or the latter is merely added to coding sequences for the modules of the heterologous PKS, provides a novel PKS. In another embodiment, a DNA compound comprising a sequence that encodes the second extender module of the narbonolide PKS is inserted into a DNA compound that comprises the coding sequences for the narbonolide PKS or a recombinant narbonolide PKS that produces a narbonolide derivative.

[0106] In another embodiment, a portion or all of the second extender module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, replacing the malonyl CoA specific AT with a methylmalonyl CoA, ethylmalonyl CoA, or carboxyglycolyl CoA specific AT; deleting (or inactivating) the KR, the DH, or both the DH and KR; replacing the KR or the KR and DH with a KR, a KR and a DH, or a KR, DH, and ER; and/or inserting an ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the narbonolide PKS, from a coding sequence for a PKS that produces a polyketide other than narbonolide, or from chemical synthesis. The resulting heterologous second extender module coding sequence can be utilized in conjunction with a coding sequence from a PKS that synthesizes narbonolide, a narbonolide derivative, or another polyketide.

[0107] The recombinant DNA compounds of the invention that encode the third extender module of the narbonolide PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment,

a DNA compound comprising a sequence that encodes the narbonolide PKS third extender module is inserted into a DNA compound that comprises the coding sequence for a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the third extender module of the narbonolide PKS or the latter is merely added to coding sequences for the modules of the heterologous PKS, provides a novel PKS. In another embodiment, a DNA compound comprising a sequence that encodes the third extender module of the narbonolide PKS is inserted into a DNA compound that comprises coding sequences for the narbonolide PKS or a recombinant narbonolide PKS that produces a narbonolide derivative.

[0108] In another embodiment, a portion or all of the third extender module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or carboxyglycolyl CoA specific AT; deleting the inactive KR; and/or inserting a KR, or a KR and DH, or a KR, DH, and ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the narbonolide PKS, from a gene for a PKS that produces a polyketide other than narbonolide, or from chemical synthesis. The resulting heterologous third extender module coding sequence can be utilized in conjunction with a coding sequence for a PKS that synthesizes narbonolide, a narbonolide derivative, or another polyketide.

[0109] The recombinant DNA compounds of the invention that encode the fourth extender module of the narbonolide PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the narbonolide PKS fourth extender module is inserted into a DNA compound that comprises the coding sequence for a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the fourth extender module of the narbonolide PKS or the latter is merely added to coding sequences for the modules of the heterologous PKS, provides a novel PKS. In another embodiment, a DNA compound comprising a sequence that encodes the fourth extender module of the narbonolide PKS is inserted into a DNA compound that comprises coding sequences for the narbonolide PKS or a recombinant narbonolide PKS that produces a narbonolide derivative.

[0110] In another embodiment, a portion of the fourth extender module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or carboxyglycolyl CoA specific AT; deleting any one, two, or all three of the ER, DH, and KR; and/or replacing any one, two, or all three of the ER, DH, and KR with either a KR, a DH and KR, or a KR, DH, and ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for

another module of the narbonolide PKS, from a coding sequence for a PKS that produces a polyketide other than narbonolide, or from chemical synthesis. The resulting heterologous fourth extender module coding sequence can be utilized in conjunction with a coding sequence for a PKS that synthesizes narbonolide, a narbonolide derivative, or another polyketide.

[0111] The recombinant DNA compounds of the invention that encode the fifth extender module of the narbonolide PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the narbonolide PKS fifth extender module is inserted into a DNA compound that comprises the coding sequence for a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the fifth extender module of the narbonolide PKS or the latter is merely added to coding sequences for the modules of the heterologous PKS, provides a novel PKS. In another embodiment, a DNA compound comprising a sequence that encodes the fifth extender module of the narbonolide PKS is inserted into a DNA compound that comprises the coding sequence for the narbonolide PKS or a recombinant narbonolide PKS that produces a narbonolide derivative.

[0112] In another embodiment, a portion or all of the fifth extender module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or carboxyglycolyl CoA specific AT; deleting (or inactivating) the KR; inserting a DH or a DH and ER; and/or replacing the KR with another KR, a DH and KR, or a DH, KR, and ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the narbonolide PKS, from a coding sequence for a PKS that produces a polyketide other than narbonolide, or from chemical synthesis. The resulting heterologous fifth extender module coding sequence can be utilized in conjunction with a coding sequence for a PKS that synthesizes narbonolide, a narbonolide derivative, or another polyketide.

[0113] The recombinant DNA compounds of the invention that encode the sixth extender module of the narbonolide PKS and the corresponding polypeptides encoded thereby are useful for a variety of applications. In one embodiment, a DNA compound comprising a sequence that encodes the narbonolide PKS sixth extender module is inserted into a DNA compound that comprises the coding sequence for a heterologous PKS. The resulting construct, in which the coding sequence for a module of the heterologous PKS is either replaced by that for the sixth extender module of the narbonolide PKS or the latter is merely added to coding sequences for the modules of the heterologous PKS, provides a novel PKS. In another embodiment, a DNA compound comprising a sequence that encodes the sixth extender module of the narbonolide PKS is inserted into a DNA compound that comprises the coding sequences for the narbonolide PKS or a recombinant narbonolide PKS that produces a narbonolide derivative.

[0114] In another embodiment, a portion or all of the sixth extender module coding sequence is utilized in conjunction with other PKS coding sequences to create a hybrid module. In this embodiment, the invention provides, for example, replacing the methylmalonyl CoA specific AT with a malonyl CoA, ethylmalonyl CoA, or carboxyglycolyl CoA specific AT; and/or inserting a KR, a KR and DH, or a KR, DH, and an ER. In addition, the KS and/or ACP can be replaced with another KS and/or ACP. In each of these replacements or insertions, the heterologous KS, AT, DH, KR, ER, or ACP coding sequence can originate from a coding sequence for another module of the narbonolide PKS, from a coding sequence for a PKS that produces a polyketide other than narbonolide, or from chemical synthesis. The resulting heterologous sixth extender module coding sequence can be utilized in conjunction with a coding sequence for a PKS that synthesizes narbonolide, a narbonolide derivative, or another polyketide.

[0115] The sixth extender module of the narbonolide PKS is followed by a thioesterase domain. This domain is important in the cyclization of the polyketide and its cleavage from the PKS. The present invention provides recombinant DNA compounds that encode hybrid PKS enzymes in which the narbonolide PKS is fused to a heterologous thioesterase or a heterologous PKS is fused to the narbonolide synthase thioesterase. Thus, for example, a thioesterase domain coding sequence from another PKS gene can be inserted at the end of the sixth extender module coding sequence in recombinant DNA compounds of the invention. Recombinant DNA compounds encoding this thioesterase domain are therefore useful in constructing DNA compounds that encode the narbonolide PKS, a PKS that produces a narbonolide derivative, and a PKS that produces a polyketide other than narbonolide or a narbonolide derivative. The following Table lists references describing illustrative PKS genes and corresponding enzymes that can be utilized in the construction of the recombinant hybrid PKSs and the corresponding DNA compounds that encode them of the invention. Also presented are various references describing tailoring enzymes and corresponding genes that can be employed in accordance with the methods of the invention.

[0116] Avermectin

[0117] U.S. Pat. No. 5,252,474 to Merck.

[0118] MacNeil et al., 1993, *Industrial Microorganisms: Basic and Applied Molecular Genetics*, Baltz, Hegeman, & Skatrud, eds. (ASM), pp. 245-256, A Comparison of the Genes Encoding the Polyketide Synthases for Avermectin, Erythromycin, and Nemadectin.

[0119] MacNeil et al., 1992, *Gene* 115: 119-125, Complex Organization of the *Streptomyces avermitilis* genes encoding the avermectin polyketide synthase.

[0120] Candicidin (FR008)

[0121] Hu et al., 1994, *Mol. Microbiol.* 14 163-172.

[0122] Epothilone

[0123] U.S. patent application Ser. No. 60/130,560, filed 22 Apr. 1999, and Ser. No. 60/122,620, filed 3 Mar. 1999.

[0124] Erythromycin

[0125] PCT Pub. No. 93/13663 to Abbott.

[0126] U.S. Pat. No. 5,824,513 to Abbott.

[0127] Donadio et al., 1991, *Science* 252:675-9.

[0128] Cortes et al., 8 Nov. 1990, *Nature* 348:176-8, An unusually large multifunctional polypeptide in the erythromycin producing polyketide synthase of *Saccharopolyspora erythraea*.

[0129] Glycosylation Enzymes

[0130] PCT Pat. App. Pub. No. 97/23630 to Abbott.

[0131] FK506

[0132] Motamedi et al., 1998, The biosynthetic gene cluster for the macrolactone ring of the immunosuppressant FK506, *Eur. J. biochem.* 256: 528-534.

[0133] Motamedi et al., 1997, Structural organization of a multifunctional polyketide synthase involved in the biosynthesis of the macrolide immunosuppressant FK506, *Eur. J. Biochem.* 244: 74-80.

[0134] Methyltransferase

[0135] U.S. Pat. No. 5,264,355, issued 23 Nov. 1993, Methylating enzyme from *Streptomyces* MA6858. 31-O-desmethyl-FK506 methyltransferase.

[0136] Motamedi et al., 1996, Characterization of methyltransferase and hydroxylase genes involved in the biosynthesis of the immunosuppressants FK506 and FK520, *J. Bacteriol.* 178: 5243-5248.

[0137] FK520

[0138] U.S. patent application Ser. No. 60/123,810, filed 11 Mar. 1999.

[0139] Nielsen et al., 1991, *Biochem.* 30:5789-96.

[0140] Lovastatin

[0141] U.S. Pat. No. 5,744,350 to Merck.

[0142] Nemadectin

[0143] MacNeil et al., 1993, *supra*.

[0144] Niddamycin

[0145] Kakavas et al., 1997, Identification and characterization of the niddamycin polyketide synthase genes from *Streptomyces caelestis*, *J. Bacteriol.* 179: 7515-7522.

[0146] Oleandomycin

[0147] Swan et al., 1994, Characterisation of a *Streptomyces antibioticus* gene encoding a type I polyketide synthase which has an unusual coding sequence, *Mol. Gen. Genet.* 242: 358-362.

[0148] Olano et al., 1998, Analysis of a *Streptomyces antibioticus* chromosomal region involved in oleandomycin biosynthesis, which encodes two glycosyltransferases responsible for glycosylation of the riacrolactone ring, *Mol. Gen. Genet.* 259(3): 299-308.

[0149] U.S. patent application Ser. No. 60/120,254, filed 16 Feb. 1999, and Ser. No. 60/106,000, filed 29 Oct. 1998.

[0150] Platenolide

[0151] EP Pat. App. Pub. No. 791,656 to Lilly.

[0152] Pradimicin

[0153] PCI Pat. Pub. No. WO 98/11230 to Bristol-Myers Squibb.

[0154] Rapamycin

[0155] Schwewe et al., August 1995, The biosynthetic gene cluster for the polyketide rapamycin, *Proc. Natl. Acad. Sci. USA* 92:7839-7843.

[0156] Aparicio et al., 1996, Organization of the biosynthetic gene cluster for rapamycin in *Streptomyces hygroscopicus*: analysis of the enzymatic domains in the modular polyketide synthase, *Gene* 169: 9-16.

[0157] Rifamycin

[0158] August et al., 13 Feb. 1998, Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the rif biosynthetic gene cluster of *Amycolatopsis mediterranei* S669, *Chemistry & Biology*, 5(2): 69-79.

[0159] Soraphen

[0160] U.S. Pat. No. 5,716,849 to Novartis.

[0161] Schupp et al., 1995, *J. Bacteriology* 177: 3673-3679. A *Sorangium cellulosum* (Myxobacterium) Gene Cluster for the Biosynthesis of the Macrolide Antibiotic Soraphen A: Cloning, Characterization, and Homology to Polyketide Synthase Genes from Actinomycetes.

[0162] Spiramycin

[0163] U.S. Pat. No. 5,098,837 to Lilly.

[0164] Activator Gene

[0165] U.S. Pat. No. 5,514,544 to Lilly.

[0166] Tylosin

[0167] EP Pub. No. 791,655 to Lilly.

[0168] Kuhstoss et al., 1996, *Gene* 183:231-6., Production of a novel polyketide through the construction of a hybrid polyketide synthase.

[0169] 25. U.S. Pat. No. 5,876,991 to Lilly.

[0170] Tailoring Enzymes

[0171] Merson-Davies and Cundliffe, 1994, *Mol. Microbiol.* 13: 349-355. Analysis of five tylosin biosynthetic genes from the tylBA region of the *Streptomyces fradiae* genome.

[0172] As the above Table illustrates, there are a wide variety of PKS genes that serve as readily available sources of DNA and sequence information for use in constructing the hybrid PKS-encoding DNA compounds of the invention. Methods for constructing hybrid PKS-encoding DNA compounds are described without reference to the narbonolide PKS in U.S. Pat. Nos. 5,672,491 and 5,712,146 and PCT publication No. 98/49315, each of which is incorporated herein by reference.

[0173] In constructing hybrid PKSs of the invention, certain general methods may be helpful. For example, it is often beneficial to retain the framework of the module to be altered to make the hybrid PKS. Thus, if one desires to add DH and ER functionalities to a module, it is often preferred to replace the KR domain of the original module with a KR, DH, and ER domain-containing segment from another module, instead of merely inserting DH and ER domains. One can alter the stereochemical specificity of a module by replacement of the KS domain with a KS domain from a module that specifies a different stereochemistry. See Lau et al., 1999, Dissecting the role of acyltransferase domains of modular polyketide synthases in the choice and stereochemical fate of extender units *Biochemistry* 38(5):1643-1651, incorporated herein by reference. One can alter the specificity of an AT domain by changing only a small segment of the domain. See Lau et al., supra. One can also take advantage of known linker regions in PKS proteins to link modules from two different PKSs to create a hybrid PKS. See Gokhale et al., 16 Apr. 1999, Dissecting and Exploiting Intermodular Communication in Polyketide Synthases, *Science* 284: 482-485, incorporated herein by reference.

[0174] The hybrid PKS-encoding DNA compounds of the invention can be and often are hybrids of more than two PKS genes. Even where only two genes are used, there are often two or more modules in the hybrid gene in which all or part of the module is derived from a second (or third) PKS gene. Thus, as one illustrative example, the invention provides a hybrid narbonolide PKS that contains the naturally occurring loading module and thioesterase domain as well as extender modules one, two, four, and six of the narbonolide PKS and further contains hybrid or heterologous extender modules three and five. Hybrid or heterologous extender modules three and five contain AT domains specific for malonyl CoA and derived from, for example, the rapamycin PKS genes.

[0175] To construct a hybrid PKS or narbonolide derivative PKS of the invention, one can employ a technique, described in PCT Pub. No. 98/27203, which is incorporated herein by reference, in which the large PKS gene cluster is divided into two or more, typically three, segments, and each segment is placed on a separate expression vector. In this manner, each of the segments of the gene can be altered, and various altered segments can be combined in a single host cell to provide a recombinant PKS gene of the invention. This technique makes more efficient the construction of large libraries of recombinant PKS genes, vectors for expressing those genes, and host cells comprising those vectors.

[0176] The invention also provides libraries of PKS genes, PKS proteins, and ultimately, of polyketides, that are constructed by generating modifications in the narbonolide PKS so that the protein complexes produced have altered activities in one or more respects and thus produce polyketides other than the natural product of the PKS. Novel polyketides may thus be prepared, or polyketides in general prepared more readily, using this method. By providing a large number of different genes or gene clusters derived from a naturally occurring PKS gene cluster, each of which has been modified in a different way from the native cluster, an effectively combinatorial library of polyketides can be produced as a result of the multiple variations in these activities. As will be further described below, the metes and bounds of

this embodiment of the invention can be described on both the protein level and the encoding nucleotide sequence level.

[0177] As described above, a modular PKS “derived from” the narbonolide or other naturally occurring PKS includes a modular PKS (or its corresponding encoding gene(s)) that retains the scaffolding of the utilized portion of the naturally occurring gene. Not all modules need be included in the constructs. On the constant scaffold, at least one enzymatic activity is mutated, deleted, replaced, or inserted so as to alter the activity of the resulting PKS relative to the original PKS. Alteration results when these activities are deleted or are replaced by a different version of the activity, or simply mutated in such a way that a polyketide other than the natural product results from these collective activities. This occurs because there has been a resulting alteration of the starter unit and/or extender unit, and/or stereochemistry, and/or chain length or cyclization, and/or reductive or dehydration cycle outcome at a corresponding position in the product polyketide. Where a deleted activity is replaced, the origin of the replacement activity may come from a corresponding activity in a different naturally occurring PKS or from a different region of the narbonolide PKS. Any or all of the narbonolide PKS genes may be included in the derivative or portions of any of these may be included, but the scaffolding of the PKS protein is retained in whatever derivative is constructed. The derivative preferably contains a thioesterase activity from the narbonolide or another PKS.

[0178] In summary, a PKS derived from the narbonolide PKS includes a PKS that contains the scaffolding of all or a portion of the narbonolide PKS. The derived PKS also contains at least two extender modules that are functional, preferably three extender modules, and more preferably four or more extender modules, and most preferably six extender modules. The derived PKS also contains mutations, deletions, insertions, or replacements of one or more of the activities of the functional modules of the narbonolide PKS so that the nature of the resulting polyketide is altered. This definition applies both at the protein and DNA sequence levels. Particular preferred embodiments include those wherein a KS, AT, KR, DH, or ER has been deleted or replaced by a version of the activity from a different PKS or from another location within the same PKS. Also preferred are derivatives where at least one non-condensation cycle enzymatic activity (KR, DH, or ER) has been deleted or added or wherein any of these activities has been mutated so as to change the structure of the polyketide synthesized by the PKS.

[0179] Conversely, also included within the definition of a PKS derived from the narbonolide PKS are functional PKS modules or their encoding genes wherein at least one portion, preferably two portions, of the narbonolide PKS activities have been inserted. Exemplary is the use of the narbonolide AT for extender module 2 which accepts a malonyl CoA extender unit rather than methylmalonyl CoA to replace a methylmalonyl specific AT in a PKS. Other examples include insertion of portions of non-condensation cycle enzymatic activities or other regions of narbonolide synthase activity into a heterologous PKS. Again, the derived from definition applies to the PKS at both the genetic and protein levels.

[0180] Thus, there are at least five degrees of freedom for constructing a hybrid PKS in terms of the polyketide that

will be produced. First, the polyketide chain length is determined by the number of modules in the PKS. Second, the nature of the carbon skeleton of the PKS is determined by the specificities of the acyl transferases that determine the nature of the extender units at each position, e.g., malonyl, methylmalonyl, ethylmalonyl, or other substituted malonyl. Third, the loading module specificity also has an effect on the resulting carbon skeleton of the polyketide. The loading module may use a different starter unit, such as acetyl, butyryl, and the like. As noted above and in the examples below, another method for varying loading module specificity involves inactivating the KS activity in extender module 1 (KS1) and providing alternative substrates, called diketides that are chemically synthesized analogs of extender module 1 diketide products, for extender module 2. This approach was illustrated in PCT publication Nos. 97/02358 and 99/03986, incorporated herein by reference, wherein the KS1 activity was inactivated through mutation. Fourth, the oxidation state at various positions of the polyketide will be determined by the dehydratase and reductase portions of the modules. This will determine the presence and location of ketone and alcohol moieties and C—C double bonds or C—C single bonds in the polyketide. Finally, the stereochemistry of the resulting polyketide is a function of three aspects of the synthase. The first aspect is related to the AT/KS specificity associated with substituted malonyls as extender units, which affects stereochemistry only when the reductive cycle is missing or when it contains only a ketoreductase, as the dehydratase would abolish chirality. Second, the specificity of the ketoreductase may determine the chirality of any beta-OH. Finally, the enoyl-reductase specificity for substituted malonyls as extender units may influence the result when there is a complete KR/DH/ER available.

[0181] Thus, the modular PKS systems, and in particular, the narbonolide PKS system, permit a wide range of polyketides to be synthesized. As compared to the aromatic PKS systems, a wider range of starter units including aliphatic monomers (acetyl, propionyl, butyryl, isovaleryl, etc.), aromatics (aminohydroxybenzoyl), alicyclics (cyclohexanoyl), and heterocyclics (thiazolyl) are found in various macrocyclic polyketides. Recent studies have shown that modular PKSs have relaxed specificity for their starter units (Kao et al., 1994, *Science*, supra). Modular PKSs also exhibit considerable variety with regard to the choice of extender units in each condensation cycle. The degree of beta-ketoreduction following a condensation reaction has also been shown to be altered by genetic manipulation (Donadio et al., 1991, *Science*, supra; Donadio et al., 1993, *Proc. Natl. Acad. Sci. USA* 90: 7119-7123). Likewise, the size of the polyketide product can be varied by designing mutants with the appropriate number of modules (Kao et al., 1994, *J. Am. Chem. Soc.* 116:1612-11613). Lastly, these enzymes are particularly well known for generating an impressive range of asymmetric centers in their products in a highly controlled manner. The polyketides and antibiotics produced by the methods of the invention are typically single stereoisomeric forms. Although the compounds of the invention can occur as mixtures of stereoisomers, it may be beneficial in some instances to generate individual stereoisomers. Thus, the combinatorial potential within modular PKS pathways based on any naturally occurring modular, such as the narbonolide, PKS scaffold is virtually unlimited.

[0182] The combinatorial potential is increased even further when one considers that mutations in DNA encoding a polypeptide can be used to introduce, alter, or delete an activity in the encoded polypeptide. Mutations can be made to the native sequences using conventional techniques. The substrates for mutation can be an entire cluster of genes or only one or two of them; the substrate for mutation may also be portions of one or more of these genes. Techniques for mutation include preparing synthetic oligonucleotides including the mutations and inserting the mutated sequence into the gene encoding a PKS subunit using restriction endonuclease digestion. See, e.g., Kunkel, 1985, *Proc. Natl. Acad. Sci. USA* 82: 448; Geisselsoder et al., 1987, *BioTechniques* 5:786. Alternatively, the mutations can be effected using a mismatched primer (generally 10-20 nucleotides in length) that hybridizes to the native nucleotide sequence, at a temperature below the melting temperature of the mismatched duplex. The primer can be made specific by keeping primer length and base composition within relatively narrow limits and by keeping the mutant base centrally located. See Zoller and Smith, 1983, *Methods Enzymol.* 100:468. Primer extension is effected using DNA polymerase, the product cloned, and clones containing the mutated DNA, derived by segregation of the primer extended strand, selected. Identification can be accomplished using the mutant primer as a hybridization probe. The technique is also applicable for generating multiple point mutations. See, e.g., Dalbie-McFarland et al., 1982, *Proc. Natl. Acad. Sci. USA* 79: 6409. PCR mutagenesis can also be used to effect the desired mutations. Random mutagenesis of selected portions of the nucleotide sequences encoding enzymatic activities can also be accomplished by several different techniques known in the art, e.g., by inserting an oligonucleotide linker randomly into a plasmid, by irradiation with X-rays or ultraviolet light, by incorporating incorrect nucleotides during in vitro DNA synthesis, by error-prone PCR mutagenesis, by preparing synthetic mutants, or by damaging plasmid DNA in vitro with chemicals. Chemical mutagens include, for example, sodium bisulfite, nitrous acid, nitrosoguanidine, hydroxylamine, agents which damage or remove bases thereby preventing normal base-pairing such as hydrazine or formic acid, analogues of nucleotide precursors such as 5-bromouracil, 2-aminopurine, or acridine intercalating agents such as proflavine, acriflavine, quinacrine, and the like. Generally, plasmid DNA or DNA fragments are treated with chemicals, transformed into *E. coli* and propagated as a pool or library of mutant plasmids.

[0183] In constructing a hybrid PKS of the invention, regions encoding enzymatic activity, i.e., regions encoding corresponding activities from different PKS synthases or from different locations in the same PKS, can be recovered, for example, using PCR techniques with appropriate primers. By "corresponding" activity encoding regions is meant those regions encoding the same general type of activity. For example, a KR activity encoded at one location of a gene cluster "corresponds" to a KR encoding activity in another location in the gene cluster or in a different gene cluster. Similarly, a complete reductase cycle could be considered corresponding. For example, KR/DH/ER corresponds to KR alone.

[0184] If replacement of a particular target region in a host PKS is to be made, this replacement can be conducted in vitro using suitable restriction enzymes. The replacement

can also be effected in vivo using recombinant techniques involving homologous sequences framing the replacement gene in a donor plasmid and a receptor region in a recipient plasmid. Such systems, advantageously involving plasmids of differing temperature sensitivities are described, for example, in PCT publication No. WO 96/40968, incorporated herein by reference. The vectors used to perform the various operations to replace the enzymatic activity in the host PKS genes or to support mutations in these regions of the host PKS genes can be chosen to contain control sequences operably linked to the resulting coding sequences in a manner such that expression of the coding sequences can be effected in an appropriate host.

[0185] However, simple cloning vectors may be used as well. If the cloning vectors employed to obtain PKS genes encoding derived PKS lack control sequences for expression operably linked to the encoding nucleotide sequences, the nucleotide sequences are inserted into appropriate expression vectors. This need not be done individually, but a pool of isolated encoding nucleotide sequences can be inserted into expression vectors, the resulting vectors transformed or transfected into host cells, and the resulting cells plated out into individual colonies.

[0186] The various PKS nucleotide sequences can be cloned into one or more recombinant vectors as individual cassettes, with separate control elements, or under the control of, e.g., a single promoter. The PKS subunit encoding regions can include flanking restriction sites to allow for the easy deletion and insertion of other PKS subunit encoding sequences so that hybrid PKSs can be generated. The design of such unique restriction sites is known to those of skill in the art and can be accomplished using the techniques described above, such as site-directed mutagenesis and PCR.

[0187] The expression vectors containing nucleotide sequences encoding a variety of PKS enzymes for the production of different polyketides are then transformed into the appropriate host cells to construct the library. In one straightforward approach, a mixture of such vectors is transformed into the selected host cells and the resulting cells plated into individual colonies and selected to identify successful transformants. Each individual colony has the ability to produce a particular PKS synthase and ultimately a particular polyketide. Typically, there will be duplications in some, most, or all of the colonies; the subset of the transformed colonies that contains a different PKS in each member colony can be considered the library. Alternatively, the expression vectors can be used individually to transform hosts, which transformed hosts are then assembled into a library. A variety of strategies are available to obtain a multiplicity of colonies each containing a PKS gene cluster derived from the naturally occurring host gene cluster so that each colony in the library produces a different PKS and ultimately a different polyketide. The number of different polyketides that are produced by the library is typically at least four, more typically at least ten, and preferably at least 20, and more preferably at least 50, reflecting similar numbers of different altered PKS gene clusters and PKS gene products. The number of members in the library is arbitrarily chosen; however, the degrees of freedom outlined above with respect to the variation of starter, extender units, stereochemistry, oxidation state, and chain length is quite large.

[0188] Methods for introducing the recombinant vectors of the invention into suitable hosts are known to those of skill in the art and typically include the use of CaCl_2 or agents such as other divalent cations, lipofection, DMSO, protoplast transformation, infection, transfection, and electroporation. The polyketide producing colonies can be identified and isolated using known techniques and the produced polyketides further characterized. The polyketides produced by these colonies can be used collectively in a panel to represent a library or may be assessed individually for activity.

[0189] The libraries of the invention can thus be considered at four levels: (1) a multiplicity of colonies each with a different PKS encoding sequence; (2) colonies that contain the proteins that are members of the PKS library produced by the coding sequences; (3) the polyketides produced; and (4) antibiotics or compounds with other desired activities derived from the polyketides. Of course, combination libraries can also be constructed wherein members of a library derived, for example, from the narbonolide PKS can be considered as a part of the same library as those derived from, for example, the rapamycin PKS or DEBS.

[0190] Colonies in the library are induced to produce the relevant synthases and thus to produce the relevant polyketides to obtain a library of polyketides. The polyketides secreted into the media can be screened for binding to desired targets, such as receptors, signaling proteins, and the like. The supernatants per se can be used for screening, or partial or complete purification of the polyketides can first be effected. Typically, such screening methods involve detecting the binding of each member of the library to receptor or other target ligand. Binding can be detected either directly or through a competition assay. Means to screen such libraries for binding are well known in the art. Alternatively, individual polyketide members of the library can be tested against a desired target. In this event, screens wherein the biological response of the target is measured can more readily be included. Antibiotic activity can be verified using typical screening assays such as those set forth in Lehrer et al., 1991, *J. Immunol. Meth.* 137:167-173, incorporated herein by reference, and in the examples below.

[0191] The invention provides methods for the preparation of a large number of polyketides. These polyketides are useful intermediates in formation of compounds with antibiotic or other activity through hydroxylation and glycosylation reactions as described above. In general, the polyketide products of the PKS must be further modified, typically by hydroxylation and glycosylation, to exhibit antibiotic activity. Hydroxylation results in the novel polyketides of the invention that contain hydroxyl groups at C6, which can be accomplished using the hydroxylase encoded by the *erF* gene, and/or C12, which can be accomplished using the hydroxylase encoded by the *picK* or *eryK* gene. The presence of hydroxyl groups at these positions can enhance the antibiotic activity of the resulting compound relative to its unhydroxylated counterpart.

[0192] Glycosylation is important in conferring antibiotic activity to a polyketide as well. Methods for glycosylating the polyketides are generally known in the art; the glycosylation may be effected intracellularly by providing the appropriate glycosylation enzymes or may be effected in vitro using chemical synthetic means as described herein and in PCT publication No. WO 98/49315, incorporated herein by reference. Preferably, glycosylation with desos-

amine is effected in accordance with the methods of the invention in recombinant host cells provided by the invention. In general, the approaches to effecting glycosylation mirror those described above with respect to hydroxylation. The purified enzymes, isolated from native sources or recombinantly produced may be used in vitro. Alternatively and as noted, glycosylation may be effected intracellularly using endogenous or recombinantly produced intracellular glycosylases. In addition, synthetic chemical methods may be employed.

[0193] The antibiotic modular polyketides may contain any of a number of different sugars, although D-desosamine, or a close analog thereof, is most common. Erythromycin, picromycin, narbomycin and methymycin contain desosamine. Erythromycin also contains L-cladinose (34-methyl mycarose). Tylosin contains mycaminose (4-hydroxy desosamine), mycarose and 6-deoxy-D-allose. 2-acetyl-1-bromodesosamine has been used as a donor to glycosylate polyketides by Masamune et al., 1975, *J. Am. Chem. Soc.* 97: 3512-3513. Other, apparently more stable donors include glycosyl fluorides, thioglycosides, and trichloroacetimidates; see Woodward et al., 1981, *J. Am. Chem. Soc.* 103: 3215; Martinet et al., 1997, *J. Am. Chem. Soc.* 119: 3193; Toshima et al., 1995, *J. Am. Chem. Soc.* 117: 3717; Matsuoto et al., 1988, *Tetrahedron Lett.* 29: 3575. Glycosylation can also be effected using the polyketide aglycones as starting materials and using *Saccharopolyspora erythraea* or *Streptomyces venezuelae* to make the conversion, preferably using mutants unable to synthesize macrolides.

[0194] To provide an illustrative hybrid PKS of the invention as well as an expression vector for that hybrid PKS and host cells comprising the vector and producing the hybrid polyketide, a portion of the narbonolide PKS gene was fused to the DEBS genes. This construct also allowed the examination of whether the TE domain of the narbonolide PKS (*pikTE*) could promote formation of 12-membered lactones in the context of a different PKS. A construct was generated, plasmid pKOS039-18, in which the *pikTE* ORF was fused with the DEBS genes in place of the DEBS TE ORF (see FIG. 5). To allow the TE to distinguish between substrates most closely resembling those generated by the narbonolide PKS, the fusion junction was chosen between the AT and ACP to eliminate ketoreductase activity in DEBS extender module 6 (KR6). This results in a hybrid PKS that presents the TE with a β -ketone heptaketide intermediate and a β -(S)-hydroxy hexaketide intermediate to cyclize, as in narbonolide and 10-deoxymethynolide biosynthesis.

[0195] Analysis of this construct indicated the production of the 14-membered ketolide 3,6-dideoxy-3-oxo-erythronolide B (FIG. 5, compound 6). Extracts were analyzed by LC/MS. The identity of compound 6 was verified by comparison to a previously authenticated sample (see PCT publication No. 98/49315, incorporated herein by reference). The predicted 12-membered macrolactone, (8R,9S)-8,9-dihydromethyl-9-hydroxy-10-deoxymethynolide (see Kao et al, 1995, *J. Am. Chem. Soc.* 127, incorporated herein by reference) was not detected. This result, along with others reported herein, suggests that protein interactions between the narbonolide PKS modules play a role in formation of the 12 and 14-membered macrolides.

[0196] The above example illustrates also how engineered PKSs can be improved for production of novel compounds. Compound 6 was originally produced by deletion of the KR6 domain in DEBS to create a 3-ketolide producing PKS (see U.S. patent application Ser. No. 09/073,538, filed 6 May

1998, and PCT publication No. WO 98/49315, each of which is incorporated herein by reference). Although the desired molecule was made, purification of compound 6 from this strain was hampered by the presence of 2-desmethyl ketolides that could not be easily separated. Extracts from *Streptomyces lividans* KS 114/pKOS039-18, however, do not contain the 2-desmethyl compounds, greatly simplifying purification. Thus, the invention provides a useful method of producing such compounds. The ability to combine the narbonolide PKS with DEBS and other modular PKSs provides a significant advantage in the production of macrolide antibiotics.

[0197] Two other hybrid PKSs of the invention were constructed that yield this same compound. These constructs also illustrate the method of the invention in which hybrid PKSs are constructed at the protein, as opposed to the module, level. Thus, the invention provides a method for constructing a hybrid PKS which comprises the coexpression of at least one gene from a first modular PKS gene cluster in a host cell that also expresses at least one gene from a second PKS gene cluster. The invention also provides novel hybrid PKS enzymes prepared in accordance with the method. This method is not limited to hybrid PKS enzymes composed of at least one narbonolide PKS gene, although such constructs are illustrative and preferred. Moreover, the hybrid PKS enzymes are not limited to hybrids composed of unmodified proteins; as illustrated below, at least one of the genes can optionally be a hybrid PKS gene.

[0198] In the first construct, the eryAI and eryAI genes were coexpressed with picAIV and a gene encoding a hybrid extender module 5 composed of the KS and AT domains of extender module 5 of DEBS3 and the KR and ACP domains of extender module 5 of the narbonolide PKS. In the second construct, the picAIV coding sequence was fused to the hybrid extender module 5 coding sequence used in the first construct to yield a single protein. Each of these constructs produced 3-deoxy-3-oxo-6-deoxyerythronolide B. In a third construct, the coding sequence for extender module 5 of DEBS3 was fused to the picAIV coding sequence, but the levels of product produced were below the detection limits of the assay.

[0199] A variant of the first construct hybrid PKS was constructed that contained an inactivated DEBS1 extender module 1 KS domain. When host cells containing the resultant hybrid PKS were supplied the appropriate diketide precursor, the desired 13-desethyl-13-propyl compounds were obtained, as described in the examples below.

[0200] Other illustrative hybrid PKSs of the invention were made by coexpressing the picAI and picAII genes with genes encoding DEBS3 or DEBS3 variants. These constructs illustrate the method of the invention in which a hybrid PKS is produced from coexpression of PKS genes unmodified at the modular or domain level. In the first construct, the enjAIII gene was coexpressed with the picAI and picAII genes, and the hybrid PKS produced 10-desmethyl-10,11-anhydro-6-deoxyerythronolide B in *Streptomyces lividans*. Such a hybrid PKS could also be constructed in accordance with the method of the invention by transformation of *S. venezuelae* with an expression vector that produces the enyAIII gene product, DEBS3. In a preferred embodiment, the *S. venezuelae* host cell has been modified to inactivate the picAIII gene.

[0201] In the second construct, the DEBS3 gene was a variant that had an inactive KR in extender module 5. The hybrid PKS produced 5,6-dideoxy-5-oxo-10-desmethyl-10,11-anhydroerythronolide B in *Streptomyces lividans*.

[0202] In the third construct, the DEBS3 gene was a variant in which the KR domain of extender module 5 was replaced by the DH and KR domains of extender module 4 of the rapamycin PKS. This construct produced 5,6-dideoxy-5-oxo-10-desmethyl-10,11-anhydroerythronolide B and 5,6-dideoxy-4,5-anhydro-10-desmethyl-10,11-anhydroerythronolide B in *Streptomyces lividans*, indicating that the rapamycin DH and KR domains functioned only inefficiently in this construct.

[0203] In the fourth construct, the DEBS3 gene was a variant in which the KR domain of extender module 5 was replaced by the DH, KR, and ER domains of extender module 1 of the rapamycin PKS. This construct produced 5,6-dideoxy-5-oxo-10-desmethyl-10,11-anhydroerythronolide B as well as 5,6-dideoxy-10-desmethyl-10,11-anhydroerythronolide B in *Streptomyces lividans*, indicating that the rapamycin DH, KR, and ER domains functioned only inefficiently in this construct.

[0204] In the fifth construct, the DEBS3 gene was a variant in which the KR domain of extender module 6 was replaced by the DH and KR domains of extender module 4 of the rapamycin PKS. This construct produced 3,6-dideoxy-2,3-anhydro-10-desmethyl-10,11-anhydroerythronolide B in *Streptomyces lividans*.

[0205] In the sixth construct, the DEBS3 gene was a variant in which the AT domain of extender module 6 was replaced by the AT domain of extender module 2 of the rapamycin PKS. This construct produced 2,10-didesmethyl-10,11-anhydro-6-deoxyerythronolide B in *Streptomyces lividans*.

[0206] These hybrid PKSs illustrate the wide variety of polyketides that can be produced by the methods and compounds of the invention. These polyketides are useful as antibiotics and as intermediates in the synthesis of other useful compounds, as described in the following section.

[0207] Section VI: Compounds

[0208] The methods and recombinant DNA compounds of the invention are useful in the production of polyketides. In one important aspect, the invention provides methods for making ketolides, polyketide compounds with significant antibiotic activity. See Griesgraber et al., 1996, *J. Antibiot.* 49: 465-477, incorporated herein by reference. Most if not all of the ketolides prepared to date are synthesized using erythromycin A, a derivative of 6-dEB, as an intermediate. While the invention provides hybrid PKSs that produce a polyketide different in structure from 6-dEB, the invention also provides methods for making intermediates useful in preparing traditional, 6-dEB-derived ketolide compounds.

[0209] Because 6-dEB in part differs from narbonolide in that it comprises a 10-methyl group, the novel hybrid PKS genes of the invention based on the narbonolide PKS provide many novel ketolides that differ from the known ketolides only in that they lack a 10-methyl group. Thus, the invention provides the 10-desmethyl analogues of the ketolides and intermediates and precursor compounds described in, for example, Griesgraber et al., supra; Agouridas et al., 1998, *J. Med. Chem.* 41: 4080-4100, U.S. Pat. Nos. 5,770,579; 5,760,233; 5,750,510; 5,747,467; 5,747,466; 5,656,607; 5,635,485; 5,614,614; 5,556,118; 5,543,

400; 5,527,780; 5,444,051; 5,439,890; 5,439,889; and PCT publication Nos. WO 98/09978 and 98/28316, each of which is incorporated herein by reference. Because the invention also provides hybrid PKS genes that include a methylmalonyl-specific AT domain in extender module 2 of the narbonolide PKS, the invention also provides hybrid PKS that can be used to produce the 10-methyl-containing ketolides known in the art.

[0210] Thus, a hybrid PKS of the invention that produces 10-methyl narbonolide is constructed by substituting the malonyl-specific AT domain of the narbonolide PKS extender module 2 with a methylmalonyl specific AT domain from a heterologous PKS. A hybrid narbonolide PKS in which the AT of extender module 2 was replaced with the AT from DEBS extender module 2 was constructed using boundaries described in PCT publication No. 98/49315, incorporated herein by reference. However, when the hybrid PKS expression vector was introduced into *Streptomyces venezuelae*, detectable quantities of 10-methyl picromycin were not produced. Thus, to construct such a hybrid PKS of the invention, an AT domain from a module other than DEBS extender module 2 is preferred. One could also employ DEBS extender module 2 or another methylmalonyl specific AT but utilize instead different boundaries than those used for the substitution described above. In addition, one can construct such a hybrid PKS by substituting, in addition to the AT domain, additional extender module 2 domains, including the KS, the KR, and the DH, and/or additional extender module 3 domains.

[0211] Although modification of extender module 2 of the narbonolide PKS is required, the extent of hybrid modules engineered need not be limited to module 2 to make 10-methyl narbonolide. For example, substitution of the KS domain of extender module 3 of the narbonolide PKS with a heterologous domain or module can result in more efficient processing of the intermediate generated by the hybrid extender module 2. Likewise, a heterologous TE domain may be more efficient in cyclizing 10-methyl narbonolide.


[0212] Substitution of the entire extender module 2 of the narbonolide PKS with a module encoding the correct enzymatic activities, i.e., a KS, a methylmalonyl specific AT, a KR, a DH, and an ACP, can also be used to create a hybrid PKS of the invention that produces a 10-methyl ketolide. Modules useful for such whole module replacements include extender modules 4 and 10 from the rapamycin PKS, extender modules 1 and 5 from the FK506 PKS, extender module 2 of the tylosin PKS, and extender module 4 of the rifamycin PKS. Thus, the invention provides many different hybrid PKSs that can be constructed starting from the narbonolide PKS that can be used to produce 10-methyl narbonolide. While 10-methyl narbonolide is referred to in describing these hybrid PKSs, those of skill recognize that the invention also therefore provides the corresponding derivatives produced by glycosylation and hydroxylation. For example, if the hybrid PKS is expressed in *Streptomyces narbonensis* or *S. venezuelae*, the compounds produced are 10-methyl narbomycin and picromycin, respectively. Alternatively, the PKS can be expressed in a host cell transformed with the vectors of the invention that encode the desosamine biosynthesis and desosaminyl transferase and picK hydroxylase genes.

[0213] Other important compounds provided by the invention are the 6-hydroxy ketolides. These compounds include

3-deoxy-3-oxo erythronolide B, 6-hydroxy narbonolide, and 6-hydroxy-10-methyl narbonolide. In the examples below, the invention provides a method for utilizing EryF to hydroxylate 3-ketolides that is applicable for the production of any 6-hydroxy-3-ketolide.

[0214] Thus, the hybrid PKS genes of the invention can be expressed in a host cell that contains the desosamine biosynthetic genes and desosaminyl transferase gene as well as the required hydroxylase gene(s), which may be either picK (for the C12 position) or eryK (for the C12 position) and/or eryF (for the C6 position). The resulting compounds have antibiotic activity but can be further modified, as described in the patent publications referenced above, to yield a desired compound with improved or otherwise desired properties. Alternatively, the aglycone compounds can be produced in the recombinant host cell, and the desired glycosylation and hydroxylation steps carried out in vitro or in vivo, in the latter case by supplying the converting cell with the aglycone.

[0215] The compounds of the invention are thus optionally glycosylated forms of the polyketide set forth in formula (2) below which are hydroxylated at either the C6 or the C12 or both. The compounds of formula (2) can be prepared using the loading and the six extender modules of a modular PKS, modified or prepared in hybrid form as herein described. These polyketides have the formula:



(2)

[0216] including the glycosylated and isolated stereoisomeric forms thereof;

[0217] wherein R* is a straight chain, branched or cyclic, saturated or unsaturated substituted or unsubstituted hydrocarbonyl of 1-4C;

[0218] each of R¹-R⁶ is independently H or alkyl (1-4C) wherein any alkyl at R¹ may optionally be substituted;

[0219] each of X¹-X⁵ is independently two H, H and OH, or =O; or

[0220] each of X¹-X⁵ is independently H and the compound of formula (2) contains a double-bond in the ring adjacent to the position of said X at 2-3, 4-5, 6-7, 8-9 and/or 10-11;

[0221] with the proviso that:

[0222] at least two of R¹-R⁶ are alkyl (1-4C).

[0223] Preferred compounds comprising formula 2 are those wherein at least three of R¹-R⁵ are alkyl (1-4C),

preferably methyl or ethyl; more preferably wherein at least four of R¹-R⁵ are alkyl (1-4C), preferably methyl or ethyl. Also preferred are those wherein X² is two H, =O, or H and OH, and/or X³ is H, and/or X¹ is OH and/or X⁵ is OH and/or X⁵ is OH. Also preferred are compounds with variable R* when R¹-R⁵ is methyl, X² is =O, and X¹, X⁴ and X⁵ are OH. The glycosylated forms of the foregoing are also preferred.

[0224] The invention also provides the 12-membered macrolides corresponding to the compounds above but produced from a narbonolide-derived PKS lacking extender modules 5 and 6 of the narbonolide PKS.

[0225] The compounds of the invention can be produced by growing and fermenting the host cells of the invention under conditions known in the art for the production of other polyketides. The compounds of the invention can be isolated from the fermentation broths of these cultured cells and purified by standard procedures. The compounds can be readily formulated to provide the pharmaceutical compositions of the invention. The pharmaceutical compositions of the invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid, or liquid form. This preparation will contain one or more of the compounds of the invention as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral application. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.

[0226] The carriers which can be used include water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, and other carriers suitable for use in manufacturing preparations, in solid, semi-solid, or liquefied form. In addition, auxiliary stabilizing, thickening, and coloring agents and perfumes may be used. For example, the compounds of the invention may be utilized with hydroxypropyl methylcellulose essentially as described in U.S. Pat. No. 4,916,138, incorporated herein by reference, or with a surfactant essentially as described in EPO patent publication No. 428,169, incorporated herein by reference.

[0227] Oral dosage forms may be prepared essentially as described by Hondo et al., 1987, *Transplantation Proceedings XIX*, Supp. 6: 17-22, incorporated herein by reference. Dosage forms for external application may be prepared essentially as described in EPO patent publication No. 423,714, incorporated herein by reference. The active compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the disease process or condition.

[0228] For the treatment of conditions and diseases caused by infection, a compound of the invention may be administered orally, topically, parenterally, by inhalation spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvant, and vehicles. The term parenteral, as used herein, includes subcutaneous injections, and intravenous, intramuscular, and intrasternal injection or infusion techniques.

[0229] Dosage levels of the compounds of the invention are of the order from about 0.01 mg to about 50 mg per kilogram of body weight per day, preferably from about 0.1

mg to about 10 mg per kilogram of body weight per day. The dosage levels are useful in the treatment of the above-indicated conditions (from about 0.7 mg to about 3.5 mg per patient per day, assuming a 70 kg patient). In addition, the compounds of the invention may be administered on an intermittent basis, i.e., at semi-weekly, weekly, semi-monthly, or monthly intervals.

[0230] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for oral administration to humans may contain from 0.5 mg to 5 gm of active agent compounded with an appropriate and convenient amount of carrier material, which may vary from about 5 percent to about 95 percent of the total composition. Dosage unit forms will generally contain from about 0.5 mg to about 500 mg of active ingredient. For external administration, the compounds of the invention may be formulated within the range of, for example, 0.00001% to 60% by weight, preferably from 0.001% to 10% by weight, and most preferably from about 0.005% to 0.8% by weight.

[0231] It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors. These factors include the activity of the specific compound employed; the age, body weight, general health, sex, and diet of the subject; the time and route of administration and the rate of excretion of the drug; whether a drug combination is employed in the treatment; and the severity of the particular disease or condition for which therapy is sought.

[0232] A detailed description of the invention having been provided above, the following examples are given for the purpose of illustrating the invention and shall not be construed as being a limitation on the scope of the invention or claims.

EXAMPLE 1

General Methodology

[0233] Bacterial strains, plasmids, and culture conditions. *Streptomyces coelicolor* CH999 described in WO 95/08548, published 30 Mar. 1995, or *S. lividans* K4-114, described in Ziermann and Betlach, Jan. 99, Recombinant Polyketide Synthesis in *Streptomyces*: Engineering of Improved Host Strains, BioTechniques 26:106-110, incorporated herein by reference, was used as an expression host. DNA manipulations were performed in *Escherichia coli* XL1-Blue, available from Stratagene. *E. coli* MC1061 is also suitable for use as a host for plasmid manipulation. Plasmids were passaged through *E. coli* ET12567 (dam dcm hsdS Cm^r) (MacNeil, 1988, *J. Bacteriol.* 170: 5607, incorporated herein by reference) to generate unmethylated DNA prior to transformation of *S. coelicolor*. *E. coli* strains were grown under standard conditions. *S. coelicolor* strains were grown on R2YE agar plates (Hopwood et al., *Genetic manipulation of Streptomyces. A laboratory manual*. The John Innes Foundation: Norwich, 1985, incorporated herein by reference).

[0234] Many of the expression vectors of the invention illustrated in the examples are derived from plasmid pRM5, described in WO 95/08548, incorporated herein by reference. This plasmid includes a colEI replicon, an appropri-

ately truncated SCP2* *Streptomyces* replicon, two act-promoters to allow for bidirectional cloning, the gene encoding the actII-ORF4 activator which induces transcription from act promoters during the transition from growth phase to stationary phase, and appropriate marker genes. Engineered restriction sites in the plasmid facilitate the combinatorial construction of PKS gene clusters starting from cassettes encoding individual domains of naturally occurring PKSs. When plasmid pRM5 is used for expression of a PKS, all relevant biosynthetic genes can be plasmid-borne and therefore amenable to facile manipulation and mutagenesis in *E. coli*. This plasmid is also suitable for use in *Streptomyces* host cells. *Streptomyces* is genetically and physiologically well-characterized and expresses the ancillary activities required for in vivo production of most polyketides. Plasmid pRM5 utilizes the act promoter for PKS gene expression, so polyketides are produced in a secondary metabolite-like manner, thereby alleviating the toxic effects of synthesizing potentially bioactive compounds in vivo.

[0235] Manipulation of DNA and organisms. Polymerase chain reaction (PCR) was performed using Pfu polymerase (Stratagene; Taq polymerase from Perkin Elmer Cetus can also be used) under conditions recommended by the enzyme manufacturer. Standard in vitro techniques were used for DNA manipulations (Sambrook et al. *Molecular Cloning: A Laboratory Manual* (Current Edition)). *E. coli* was transformed using standard calcium chloride-based methods; a Bio-Rad *E. coli* pulsing apparatus and protocols provided by Bio-Rad could also be used. *S. coelicolor* was transformed by standard procedures (Hopwood et al. *Genetic manipulation of Streptomyces. A laboratory manual*. The John Innes Foundation: Norwich, 1985), and depending on what selectable marker was employed, transformants were selected using 1 mL of a 1.5 mg/mL thiostrepton overlay, 1 mL of a 2 mg/mL apramycin overlay, or both.

EXAMPLE 2

Cloning of the Picromycin Biosynthetic Gene Cluster from *Streptomyces venezuelae*

[0236] Genomic DNA (100 μ g) isolated from *Streptomyces venezuelae* ATCC15439 using standard procedures was partially digested with Sau3AI endonuclease to generate fragments ~40 kbp in length. SuperCosI (Stratagene) DNA cosmid arms were prepared as directed by the manufacturer. A cosmid library was prepared by ligating 2.5 μ g of the digested genomic DNA with 1.5 μ g of cosmid arms in a 20 μ L reaction. One microliter of the ligation mixture was propagated in *E. coli* XL1-Blue MR (Stratagene) using a GigapackIII XL packaging extract kit (Stratagene). The resulting library of ~3000 colonies was plated on a 10x150 mm agar plate and replicated to a nylon membrane.

[0237] The library was initially screened by direct colony hybridization with a DNA probe specific for ketosynthase domain coding sequences of PKS genes. Colonies were alkaline lysed, and the DNA was crosslinked to the membrane using UV irradiation. After overnight incubation with the probe at 42° C., the membrane was washed twice at 25° C. in 2xSSC buffer+0.1% SDS for 15 minutes, followed by two 15 minute washes with 2xSSC buffer at 55° C. Approximately 30 colonies gave positive hybridization signals with the degenerate probe. Several cosmids were selected and divided into two classes based on restriction digestion

patterns. A representative cosmid was selected from each class for further analysis. The representative cosmids were designated pKOS023-26 and pKOS023-27. These cosmids were determined by DNA sequencing to comprise the narbonolide PKS genes, the desosamine biosynthesis and transferase genes, the beta-glucosidase gene and the picK hydroxylase gene.

[0238] These cosmids were deposited with the American Type Culture Collection in accordance with the terms of the Budapest Treaty. Cosmid pKOS023-26 was assigned accession number ATCC 203141, and cosmid pKOS023-27 was assigned accession number ATCC 203142.

[0239] To demonstrate that the narbonolide PKS genes had been cloned and to illustrate how the invention provides methods and reagents for constructing deletion variants of narbonolide PKS genes, a narbonolide PKS gene was deleted from the chromosome of *Streptomyces venezuelae*. This deletion is shown schematically in FIG. 4, parts B and C. A ~2.4 kb EcoRI-KpnI fragment and a ~2.1 kb KpnI-XhoI fragment, which together comprise both ends of the picAI gene (but lack a large portion of the coding sequence), were isolated from cosmid pKOS023-27 and ligated together into the commercially available vector pLitmus 28 (digested with restriction enzymes EcoRI and XhoI) to give plasmid pKOS039-07. The ~4.5 kb HindIII-SpeI fragment from plasmid pKOS039-07 was ligated with the 2.5 kb HindIII-NheI fragment of integrating vector pSET152, available from the NRRL, which contains an *E. coli* origin of replication and an apramycin resistance-conferring gene to create plasmid pKOS039-16. This vector was used to transform *S. venezuelae*, and apramycin-resistant transformants were selected.

[0240] Then, to select for double-crossover mutants, the selected transformants were grown in TSB liquid medium without antibiotics for three transfers and then plated onto non-selective media to provide single colony isolates. The isolated colonies were tested for sensitivity to apramycin, and the apramycin-sensitive colonies were then tested to determine if they produced picromycin. The tests performed included a bioassay and LC/MS analysis of the fermentation media. Colonies determined not to produce picromycin (or methymycin or neomethymycin) were then analyzed using PCR to detect an amplification product diagnostic of the deletion. A colony designated K3903 was identified, providing confirmation that the narbonolide PKS genes had been cloned. Transformation of strain K39-03 with plasmid pKOS039-27 comprising an intact picA gene under the control of the ermE* promoter from plasmid pWHM3 (see Vara et al., 1989, *J. Bact.* 171: 5872-5881, incorporated herein by reference) was able to restore picromycin production.

[0241] To determine that the cosmids also contained the picK hydroxylase gene, each cosmid was probed by Southern hybridization using a labeled DNA fragment amplified by PCR from the *Saccharopolyspora erythraea* C12-hydroxylase gene, eryK. The cosmids were digested with BamHI endonuclease and electrophoresed on a 1% agarose gel, and the resulting fragments were transferred to a nylon membrane. The membrane was incubated with the eryK probe overnight at 42° C., washed twice at 25° C. in 2xSSC buffer with 0.1% SDS for 15 minutes, followed by two 15 minute washes with 2xSSC buffer at 50° C. Cosmid

pKOS023-26 produced an ~3 kb fragment that hybridized with the probe under these conditions. This fragment was subcloned into the PCRscript™ (Stratagene) cloning vector to yield plasmid pKOS023-28 and sequenced. The ~1.2 kb gene designated picK above was thus identified. The picK gene product is homologous to eryK and other known macrolide cytochrome P450 hydroxylases.

[0242] By such methodology, the complete set of picromycin biosynthetic genes were isolated and identified. DNA sequencing of the cloned DNA provided further confirmation that the correct genes had been cloned. In addition, and as described in the following example, the identity of the genes was confirmed by expression of narbomycin in heterologous host cells.

EXAMPLE 3

Heterologous Expression of the Narbonolide PKS and the Picromycin Biosynthetic Gene Cluster

[0243] To provide a preferred host cell and vector for purposes of the invention, the narbonolide PKS was transferred to the non-macrolide producing host *Streptomyces lividans* K4-114 (see Ziermann and Betlach, 1999, *Biotechniques* 26, 106-110, and U.S. patent application Ser. No. 09/181,833, filed 28 Oct. 1998, each of which is incorporated herein by reference). This was accomplished by replacing the three DEBS ORFs on a modified version of pCK7 (see Kao et al., 1994, *Science* 265, 509-512, and U.S. Pat. No. 5,672,491, each of which is incorporated herein by reference) with all four narbonolide PKS ORFs to generate plasmid pKOS039-86 (see FIG. 5). The pCK7 derivative employed, designated pCK7-Kan', differs from pCK7 only in that it contains a kanamycin resistance conferring gene inserted at its HindIII restriction enzyme recognition site. Because the plasmid contains two selectable markers, one can select for both markers and so minimize contamination with cells containing rearranged, undesired vectors.

[0244] Protoplasts were transformed using standard procedures and transformants selected using overlays containing antibiotics. The strains were grown in liquid R5 medium for growth/seed and production cultures at 30° C. Transformed strains produced two compounds in similar yield (~5-10 mg/L each). Polyketides produced in the host cells were analyzed by bioassay against *Bacillus subtilis* and by LC/MS analysis. Analysis of extracts by LC/MS followed by ¹H-NMR spectroscopy of the purified compounds established their identity as narbonolide (FIG. 5, compound 4; see Kaiho et al., 1982, *J. Org. Chem.* 47: 1612-1614, incorporated herein by reference) and 10-deoxymethynolide (FIG. 5, compound 5; see Lambalot et al., 1992, *J. Antibiotics* 45, 1981-1982, incorporated herein by reference), the respective 14 and 12-membered polyketide aglycones of YC17, narbomycin, picromycin, and methymycin.

[0245] The production of narbonolide in *Streptomyces lividans* represents the expression of an entire modular polyketide pathway in a heterologous host. The combined yields of compounds 4 and 5 are similar to those obtained with expression of DEBS from pCK7 (see Kao et al., 1994, *Science* 265: 509-512, incorporated herein by reference). Furthermore, based on the relative ratios (~1:1) of compounds 4 and 5 produced, it is apparent that the narbonolide PKS itself possesses an inherent ability to produce both 12

and 14-membered macrolactones without the requirement of additional activities unique to *S. venezuelae*. Although the existence of a complementary enzyme present in *S. lividans* that provides this function is possible, it would be unusual to find such a specific enzyme in an organism that does not produce any known macrolide.

[0246] To provide a heterologous host cell of the invention that produces the narbonolide PKS and the picB gene, the picB gene was integrated into the chromosome of *Streptomyces lividans* harboring plasmid pKOS039-86 to yield *S. lividans* K39-18/pKOS039-86. To provide the integrating vector utilized, the picB gene was cloned into the *Streptomyces* genome integrating vector pSET152 (see Bierman et al., 1992, *Gene* 116, 43, incorporated herein by reference) under control of the same promoter (Pact1) as the PKS on plasmid pKOS039-86.

[0247] A comparison of strains K39-18/pKOS39-86 and K4-114/pKOS039-86 grown under identical conditions indicated that the strain containing TEII produced 47 times more total polyketide. Each strain was grown in 30 mL of R5 (see Hopwood et al., *Genetic Manipulation of Streptomyces: A Laboratory Manual*; John Innes Foundation: Norwich, UK, 1985, incorporated herein by reference) liquid (with 20 µg/mL thiostrepton) at 30° C. for 9 days. The fermentation broth was analyzed directly by reverse phase HPLC. Absorbance at 235 nm was used to monitor compounds and measure relative abundance. This increased production indicates that the enzyme is functional in this strain. As noted above, because the production levels of compound 4 and 5 from K39-18/pKOS03986 increased by the same relative amounts, TEII does not appear to influence the ratio of 12 and 14-membered lactone ring formation.

[0248] To express the glycosylated counterparts of narbonolide (narbomycin) and 10-deoxymethynolide (YC17) in heterologous host cells, the desosamine biosynthetic genes and desosaminyl transferase gene were transformed into the host cells harboring plasmid pKOS039-86 (and, optionally, the picB gene, which can be integrated into the chromosome as described above).

[0249] Plasmid pKOS039-104, see FIG. 6, comprises the desosamine biosynthetic genes, the beta-glucosidase gene, and the desosaminyl transferase gene. This plasmid was constructed by first inserting a polylinker oligonucleotide, containing a restriction enzyme recognition site for PacI, a Shine-Dalgarno sequence, and restriction enzyme recognition sites for NdeI, BglII, and HindIII, into a pUC19 derivative, called pKOS2447, to yield plasmid pKOS039-98.

[0250] An ~0.3 kb PCR fragment comprising the coding sequence for the N-terminus of the desI gene product and an ~0.12 kb PCR fragment comprising the coding sequence for the C-terminus of the desR gene product were amplified from cosmid pKOS23-26 (ATCC 203141) and inserted together into pLitmus28 treated with restriction enzymes NsiI and EcoRI to produce plasmid pKOS039-101. The ~6 kb SphI-PstI restriction fragment of pKOS23-26 containing the desI, desII, desIII, desIV, and desV genes was inserted into plasmid pUC19 (Stratagene) to yield plasmid pKOS039-102. The ~6 kb SphI-EcoRI restriction fragment from plasmid pKOS039-102 was inserted into pKOS039-101 to produce plasmid pKOS039-103. The ~6 kb BglII-PstI fragment from pKOS23-26 that contains the desR, desVI,

desVII, and desVIII genes was inserted into pKOS39-98 to yield pKOS39-100. The ~6 kb *PacI*-*PstI* restriction fragment of pKOS39-100 and the 6.4 kb *NsiI*-*EcoRI* fragment of pKOS39-103 were cloned into pKOS39-44 to yield pKOS39-104.

[0251] When introduced into *Streptomyces lividans* host cells comprising the recombinant narbonolide PKS of the invention, plasmid pKOS39-104 drives expression of the desosamine biosynthetic genes, the beta-glucosidase gene, and the desosaminyl transferase gene. The glycosylated antibiotic narbomycin was produced in these host cells, and it is believed that YC17 was produced as well. When these host cells are transformed with vectors that drive expression of the picK gene, the antibiotics methymycin, neomethymycin, and picromycin are produced.

[0252] In similar fashion, when plasmid pKOS039-18, which encodes a hybrid PKS of the invention that produces 3-deoxy-3-oxo-6-deoxyerythronolide B was expressed in *Streptomyces lividans* host cells transformed with plasmid pKOS39-104, the 5-desosaminylated analog was produced. Likewise, when plasmid pCK7, which encodes DEBS, which produces 6-deoxyerythronolide B, was expressed in *Streptomyces lividans* host cells transformed with plasmid pKC639-104, the 5-desosaminylated analog was produced. These compounds have antibiotic activity and are useful as intermediates in the synthesis of other antibiotics.

EXAMPLE 4

Expression Vector for Desosaminyl Transferase

[0253] While the invention provides expression vectors comprising all of the genes required for desosamine biosynthesis and transfer to a polyketide, the invention also provides expression vectors that encode any subset of those genes or any single gene. As one illustrative example, the invention provides an expression vector for desosaminyl transferase. This vector is useful to desosaminylate polyketides in host cells that produce NDP-desosamine but lack a desosaminyl transferase gene or express a desosaminyl transferase that does not function as efficiently on the polyketide of interest as does the desosaminyl transferase of *Streptomyces venezuelae*. This expression vector was constructed by first amplifying the desosaminyl transferase coding sequence from pKOS023-27 using the primers:

N3917: 5'-CCCTGCAGCGGCAAGGAAGGACACGACGCCA-3';
and

N3918: 5'-AGGTCTAGAGCTCAGTGCCGGGCGTCGGCCGG-3',

[0254] to give a 1.5 kb product. This product was then treated with restriction enzymes PstI and XbaI and ligated with HindIII and XbaI digested plasmid pKOS039-06 together with the 7.6 kb PstI-HindIII restriction fragment of plasmid pWHM1104 to provide plasmid pKOS039-14. Plasmid pWHM1104, described in Tang et al., 1996, *Molec. Microbiol.* 22(5): 801-813, incorporated herein by reference, encodes the ermE* promoter. Plasmid pKOS039-14 is constructed so that the desosaminyl transferase gene is placed under the control of the ermE* promoter and is suitable for expression of the desosaminyl transferase in *Streptomyces*, *Saccharopolyspora erythraea*, and other host cells in which the ermE* promoter functions.

EXAMPLE 5

Heterologous Expression of the picK Gene Product in *E. coli*

[0255] The picK gene was PCR amplified from plasmid pKOS023-28 using the oligonucleotide primers:

N024-36B (forward):
5'-TTGCATGCATATGCGCCGTACCCAGCAGGGAACGACC;
and

N024-37B (reverse):
5'-TTGAATTCTCAACTAGTACGGCGGCCCGCCTCCCGTCC.

[0256] These primers alter the *Streptomyces* GTG start codon to ATG and introduce a SpeI site at the C-terminal end of the gene, resulting in the substitution of a serine for the terminal glycine amino acid residue. The blunt-ended PCR product was subcloned into the commercially available vector pCRscript at the SrfI site to yield plasmid pKOS023-60. An ~1.3 kb NdeI-XhoI fragment was then inserted into the NdeI/XhoI sites of the T7 expression vector pET22b (Novagen, Madison, Wis.) to generate pKOS023-61. Plasmid pKOS023-61 was digested with restriction enzymes SpeI and EcoRI, and a short linker fragment encoding 6 histidine residues and a stop codon (composed of oligonucleotides 30-85a: 5'-CTAGTATGCATCATCATCATCATCAATTA-3'; and 30-85b: 5'-AATTTTAAATGATGATGATGATGATGCATA-3') was inserted to obtain plasmid pKOS023-68. Both plasmid pKOS023-61 and pKOS023-68 produced active PicK enzyme in recombinant *E. coli* host cells.

[0257] Plasmid pKOS023-61 was transformed into *E. coli* BL21-DE3. Successful transformants were grown in LB-containing carbenicillin (100 µg/ml) at 37° C. to an OD₆₀₀ of 0.6. Isopropyl-beta-D-thiogalactopyranoside (G) was added to a final concentration of 1 mM, and the cells were grown for an additional 3 hours before harvesting. The cells were collected by centrifugation and frozen at -80° C. A control culture of BL21-DE3 containing the vector plasmid pET21c (Invitrogen) was prepared in parallel.

[0258] The frozen BL21-DE3/pKOS023-61 cells were thawed, suspended in 2 μ L of cold cell disruption buffer (5 mM imidazole, 500 mM NaCl, 20 mM Tris/HCl, pH 8.0) and sonicated to facilitate lysis. Cellular debris and supernatant were separated by centrifugation and subjected to SDSPAGE on 10-15% gradient gels, with Coomassie Blue staining, using a Pharmacia Phast Gel Electrophoresis system. The soluble crude extract from BL21-DE3/pKOS023-61 contained a Coomassie stained band of $M_r \sim 46$ kDa, which was absent in the control strain BL21-DE3/pET21c.

[0259] The hydroxylase activity of the picK protein was assayed as follows. The crude supernatant (20 μ L) was added to a reaction mixture (100 μ L total volume) containing 50 mM Tris/HCl (pH 7.5), 20 μ M spinach ferredoxin, 0.025 Unit of spinach ferredoxin:NADP⁺ oxidoreductase, 0.8 Unit of glucose-6-phosphate dehydrogenase, 1.4 mM NADP⁺, 7.6 mM glucose-6 phosphate, and 20 mmol of narbomycin. The narbomycin was purified from a culture of *Streptomyces narbonensis*, and upon LC/MS analysis gave a single peak of [M+H]⁺=510. The reaction was allowed to proceed for 105 minutes at 30° C. Half of the reaction mixture was

loaded onto an HPLC, and the effluent was analyzed by evaporative light scattering (ELSD) and mass spectrometry. The control extract (BL21-DE3/pET21c) was processed identically. The BL21-DE3/pKOS023-61 reaction contained a compound not present in the control having the same retention time, molecular weight and mass fragmentation pattern as picromycin ($[M+H]^+=526$). The conversion of narbomycin to picromycin under these conditions was estimated to be greater than 90% by ELSD peak area.

[0260] The poly-histidine-linked PicK hydroxylase was prepared from pKOS023-68 transformed into *E. coli* BL21 (DE3) and cultured as described above. The cells were harvested and the PicK protein purified as follows. All purification steps were performed at 4° C. *E. coli* cell pellets were suspended in 32 μ L of cold binding buffer (20 mM Tris/HCl, pH 8.0, 5 mM imidazole, 500 mM NaCl) per mL of culture and lysed by sonication. For analysis of *E. coli* cell-free extracts, the cellular debris was removed by low-speed centrifugation, and the supernatant was used directly in assays. For purification of PicK/6-His, the supernatant was loaded (0.5 mL/min.) onto a 5 mL HiTrap Chelating column (Pharmacia, Piscataway, N.J.), equilibrated with binding buffer. The column was washed with 25 μ L of binding buffer and the protein was eluted with a 35 μ L linear gradient (5-500 mM imidazole in binding buffer). Column effluent was monitored at 280 nm and 416 nm. Fractions corresponding to the 416 nm absorbance peak were pooled and dialyzed against storage buffer (45 mM Tris/HCl, pH 7.5, 0.1 mM EDTA, 0.2 mM DTT, 10% glycerol). The purified 46 kDa protein was analyzed by SDS-PAGE using Coomassie blue staining, and enzyme concentration and yield were determined.

[0261] Narbomycin was purified as described above from a culture of *Streptomyces narbonensis* ATCC19790. Reactions for kinetic assays (100 μ L) consisted of 50 mM Tris/HCl (pH 7.5), 100 μ M spinach ferredoxin, 0.025 Unit of spinach ferredoxin:NADP⁺ oxidoreductase, 0.8 U glucose-6-phosphate dehydrogenase, 1.4 mM NADP⁺, 7.6 mM glucose-6-phosphate, 20-500 μ M narbomycin substrate, and 50-500 nM of PicK enzyme. The reaction proceeded at 30° C., and samples were withdrawn for analysis at 5, 10, 15, and 90 minutes.

[0262] Reactions were stopped by heating to 100° C., for 1 minute, and denatured protein was removed by centrifugation. Depletion of narbomycin and formation of picromycin were determined by high performance liquid chromatography (HPLC, Beckman C-18 0.46 \times 15 cm column) coupled to atmospheric pressure chemical ionization (APCI) mass spectroscopic detection (Perkin Elmer/Sciex API 100) and evaporative light scattering detection (Alltech 500 ELSD).

EXAMPLE 6

Expression of the picK Gene Encoding the Hydroxylase in *Streptomyces narbonensis*

[0263] To produce picromycin in *Streptomyces narbonensis*, a host that produces narbomycin but not picromycin, the methods and vectors of the invention were used to express the picK gene in this host.

[0264] The picK gene was amplified from cosmid pKOS023-26 using the primers:

N3903: 5'-TCCTCTAGACGTTTCCGT-3';
and
N3904: 5'-TGAAGCTTGAATTCAACCGGT-3'

[0265] to obtain an ~1.3 kb product. The product was treated with restriction enzymes XbaI and HindIII and ligated with the 7.6 kb XbaI-HindIII restriction fragment of plasmid pWHM1104 to provide plasmid pKOS039-01, placing the picK gene under the control of the ermE* promoter. The resulting plasmid was transformed into purified stocks of *S. narbonensis* by protoplast fusion and electroporation. The transformants were grown in suitable media and shown to convert narbomycin to picromycin at a yield of over 95%.

EXAMPLE 7

Construction of a Hybrid DEBS/Narbonolide PKS

[0266] This example describes the construction of illustrative hybrid PKS expression vectors of the invention. The hybrid PKS contains portions of the narbonolide PKS and portions of rapamycin and/or DEBS PKS. In the first constructs, pKOS039-18 and pKOS039-19 the hybrid PKS comprises the narbonolide PKS extender module 6 ACP and thioesterase domains and the DEBS loading module and extender modules 1-5 as well as the KS and AT domains of DEBS extender module 6 (but not the KR domain of extender module 6). In pKOS039-19, the hybrid PKS is identical except that the KS1 domain is inactivated, i.e., the ketosynthase in extender module 1 is disabled. The inactive DEBS KS1 domain and its construction are described in detail in PCT publication Nos. WO 97/02358 and 99/03986, each of which is incorporated herein by reference. To construct pKOS039-18, the 2.33 kb BamHI-EcoRI fragment of pKOS023-27, which contains the desired sequence, was amplified by PCR and subcloned into plasmid pUC9. The primers used in the PCR were:

N3905: 5'-TTTATGCATCCCGGGTCCCGGCGAG-3';
and
N3906: 5'-TCAGAATTCTGTCGGTCACTTGCCCGC-3'.

[0267] The 1.6 kb PCR product was digested with PstI and EcoRI and cloned into the corresponding sites of plasmid pKOS015-52 (this plasmid contains the relevant portions of the coding sequence for the DEBS extender module 6) and commercially available plasmid pLitmus 28 to provide plasmids pKOS039-12 and pKOS039-13, respectively. The BglIII-EcoRI fragment of plasmid pKOS039-12 was cloned into plasmid pKOS011-77, which contains the functional DEBS gene cluster and into plasmid pJRJ2, which contains the mutated DEBS gene that produces a DEBS PKS in which the KS domain of extender module I has been rendered inactive. Plasmid pJRJ2 is described in PCI publication Nos. 99/03986 and 97/02358, incorporated herein by reference.

[0268] Plasmids pKOS039-18 and pKOS039-19, respectively, were obtained. These two plasmids were transformed into *Streptomyces coelicolor* CH999 by protoplast fusion.

The resulting cells were cultured under conditions such that expression of the PKS occurred. Cells transformed with plasmid pKOS039-18 produced the expected product 3-deoxy-3-oxo-6-deoxyerythronolide B. When cells transformed with plasmid pKOS039-19 were provided (2S,3R)-2-methyl-3-hydroxyhexanoate NACS, 13-desethyl-13-propyl-3-deoxy-3-oxo-6-deoxyerythronolide B was produced.

EXAMPLE 8

6-Hydroxylation of 3,6-dideoxy-3-oxoerythronolide B Using the eryF Hydroxylase

[0269] Certain compounds of the invention can be hydroxylated at the C6 position in a host cell that expresses the eryF gene. These compounds can also be hydroxylated in vitro, as illustrated by this example.

[0270] The 6-hydroxylase encoded by eryF was expressed in *E. coli*, and partially purified. The hydroxylase (100 pmol in 10 μ L) was added to a reaction mixture (100 μ L total volume) containing 50 mM Tris/HCl (pH 7.5), 20 μ M spinach ferredoxin, 0.025 Unit of spinach ferredoxin:NADP⁺ oxidoreductase, 0.8 Unit of glucose-6-phosphate dehydrogenase, 1.4 mM NADP⁺, 7.6 mM glucose-6-phosphate, and 10 nmol 6-deoxyerythronolide B. The reaction was allowed to proceed for 90 minutes at 30° C. Half of the reaction mixture was loaded onto an HPLC, and the effluent was analyzed by mass spectrometry. The production of erythronolide B as evidenced by a new peak eluting earlier in the gradient and showing [M+H]⁺=401. Conversion was estimated at 50% based on relative total ion counts.

[0271] Those of skill in the art will recognize the potential for hemiketal formation in the above compound and compounds of similar structure. To reduce the amount of hemiketal formed, one can use more basic (as opposed to acidic) conditions or employ sterically hindered derivative compounds, such as 5-desosaminylated compounds.

EXAMPLE 9

Measurement of Antibacterial Activity

[0272] Antibacterial activity was determined using either disk diffusion assays with *Bacillus cereus* as the test organism or by measurement of minimum inhibitory concentrations (MIC) in liquid culture against sensitive and resistant strains of *Staphylococcus pneumoniae*.

Example 10

Construction of Desosamine Containing Polyketide Libraries Using a Glycosyltransferase with Broad Substrate Specificity

[0273] Desosamine is an important deoxyaminosugar present on a number of structurally related macrolide antibiotics such as erythromycin and is the only glycoside present on picromycin, methymycin, and the highly potent semisynthetic ketolides. In this example, a set of nine deoxysugar biosynthetic and auxiliary genes from the picromycin/methymycin (pik) cluster was integrated in the chromosome of *Streptomyces lividans* to create a host that synthesizes TDP-D-desosamine and can be used in combination with PKS expression plasmids to generate libraries of desosaminylated polyketides. The versatility of the DesVII

desosaminyltransferase is demonstrated by formation of desosaminylated macrolides from more than twenty different 14-membered lactones. The attachment of desosamine is sufficient to confer antibiotic activity to each of the otherwise inactive aglycones, reinforcing the belief that this sugar plays a critical role in the molecular binding properties of erythromycin and related macrolides. This host and others that can be engineered to produce deoxysugar and polyketide tailoring pathways in accordance with the methods of the invention are valuable tools for expanding the size and diversity of polyketides that can be generated by combinatorial biosynthesis. References cited in this example are indicated by a reference number; the numbered list of references is located at the end of this example. All references cited are incorporated herein by reference.

[0274] Much of the structural diversity and complexity among polyketides can be attributed to the chemistry performed by PKSs (1), and the modular architecture of catalytic domains within PKSs has been exploited by different rational and combinatorial engineering approaches to create polyketide diversity (24). However, structural variability among polyketides can also result from post-PKS biosynthetic steps, including oxidation and/or glycosylation with unique deoxy and amino sugars. Such modifications are often necessary to impart or enhance the specific biological activity of the molecule. For example, erythromycin A contains two deoxysugar moieties, L-cladinose and D-desosamine, that are required for antibacterial activity and the absence of either carbohydrate results in loss of potency. Although some chemical modifications to erythromycin have been discovered that can ameliorate the loss of the cladinose residue (5-7), there has been no substitution found for desosamine. This important deoxyaminosugar is also present in other macrolide antibiotics, such as oleandomycin and megalomicin, and is the only glycoside necessary to confer antibacterial activity to picromycin, methymycin, and the semisynthetic ketolide pharmacophores.

[0275] Polyketide libraries generated by genetic modification of macrolide PKSs in which enzymatic domains and entire protein subunits were removed, added, or exchanged in various combinations have been produced (3, 4, 8). Because these libraries were constructed in heterologous hosts lacking glycosylation pathways, only the corresponding aglycones were produced. The methods and reagents of the present invention can be used to expand the capabilities of the combinatorial biosynthesis strategies described to incorporate post-PKS tailoring steps, in particular the addition of deoxysugar components.

[0276] Some experiments have been performed in which structurally modified macrolactones are subsequently glycosylated in their native hosts (9-13), and also in bioconversion experiments in which a modified aglycone is fed to a PKS blocked mutant strain (14). These experiments indicate that glycosyltransferases are able to accept polyketide substrates with some amount of structural alteration. However, neither of these approaches is well-suited for the production and biological screening of large numbers of compounds, because most polyketide host organisms are difficult to manipulate genetically and the bioconversion of aglycones requires a tedious initial purification step.

[0277] A more practical approach is the heterologous expression of deoxysugar biosynthetic pathways in hosts

that have been developed for library expression. Although the effort to clone entire deoxysugar biosynthetic pathways in a heterologous organism can be a significant initial investment (most deoxysugars require six or more enzymatic steps whose genes are typically scattered within a polyketide gene cluster), these expression vectors, once made, can be easily combined with those containing PKSs to engineer glycosylated libraries rapidly. Olano et al. recently utilized a two-plasmid system to produce L-daunosamine, the deoxyaminosugar of daunorubicin and doxorubicin, in *Streptomyces lividans* (15).

[0278] Here we report the development of a single expression vector for the production of desosaminylated macrolides in *Streptomyces*. Desosamine was selected as the sugar constituent, because it was believed that addition of this single deoxysugar would be sufficient to confer antibacterial activity upon macrolactones to which it was attached. The expression vector was combined with a library of existing PMS expression plasmids to produce several novel glycosylated macrolide compounds in *S. lividans*, providing the first examples in which both polyketide and deoxysugar pathways have been placed in a single heterologous host.

[0279] A. Material and Methods

[0280] (i) Strains, Culture Conditions, and DNA Manipulation

[0281] DNA manipulation was performed in *Escherichia coli* XL1-Blue (Stratagene) using standard protocols (16). *Bacillus subtilis* was grown in LB at 37° C. PCR was performed with Pfu polymerase (Stratagene) under conditions recommended by the manufacturer. *S. lividans* K4-114 (17) was used as the host for expression of engineered PKS and desosamine genes. *S. lividans* strains were maintained on R2YE agar plates (18) with appropriate antibiotic selection. *S. lividans* protoplasts were transformed by the standard procedure (18) and transformants were selected using 1 ml of a 1 mg/ml thiostrepton and/or 1 ml of a 2 mg/ml apramycin overlay on R2YE regeneration plates.

[0282] (ii) Construction of Expression Plasmids


[0283] Expression plasmid pKOS39-104 was constructed as follows. The 6.0 kb Bgl II-Pst I fragment containing the picromycin des VIII, des VII, des VI and des R (partial) genes from cosmid pKOS23-26 (19) was subcloned into the Bgl II-Pst I sites of pKOS39-98, a pUC19 derivative with a redesigned multiple cloning site. The resulting plasmid, pKOS39-100, contains a Pac I site upstream of the Bgl II site which is used in a later cloning step. The 6 kb Sph I-Pst I fragment containing the des I (partial), des II, des III, des IV and des V genes from pKOS23-26 was subcloned into the Sph I-Pst I of pUC19 to make pKOS39-102. The remaining 3'-end of the des R gene and 5'-end of the des I gene were PCR amplified from cosmid pKOS23-26 with the following oligonucleotides (restriction sites shown in *italics*):

desR gene:
forward 5'-AGATGCATTTCTGGGATGCCGCCACGGA;
and
reverse 5'-CGTCTAGACGTCACCAGACGTTGACCGTG;
desI gene:

-continued

forward 5'-TTTCTAGACGGTGGCCGGAGGGAACATC;
and
reverse 5'-CGGAATTCGCGAGCTGCTCGGCGCGCA.

[0284] The two PCR fragments were digested with Nsi I-Xba I and Xba I-EcoR I, respectively, and ligated with Nsi I-EcoR I digested Litmus 28 (New England Biolabs) to obtain pKOS39-101B. The 6 kb Sph I-EcoR I fragment of pKOS39-102 was inserted into pKOS39-101B to make pKOS39-103. The 6.4 kb Nsi I-EcoR I fragment of pKOS39-103 and the 6 kb Pac I-Pst I fragment of pKOS39-100 were then ligated together with the 8.5 kb Pac I-EcoR I fragment of pKOS39-44 (20), yielding the final expression plasmid pKOS39-104. A restriction site and function map of this plasmid is shown below.



[0285] (iii) Production and Analysis of Compounds

[0286] All strains were grown in 5 ml liquid R2YE medium at 30° C. and analyzed following 5 days growth. For bioconversion experiments, aglycones (~10 mg/liter) were fed at the start of fermentation. Fermentation broth was analyzed directly by liquid chromatography/mass spectrometry (LC/MS) and evaporative light scattering detection (ELSD) as previously described (20). An authentic sample of narbomycin prepared from *Streptomyces narbonensis* (19) was used to validate production of this compound. For LC/MS analysis of strains containing PKS expression plasmids the cultures were extracted twice with 5 ml of ethyl acetate/triethylamine (99:1), concentrated to dryness and resuspended in 0.5 ml of acetonitrile.


[0287] (iv) Antibacterial Assays

[0288] Extracts prepared from the culture broths as above were assayed for biological activity against *B. subtilis* using an agar plate diffusion method (see Example 9). Samples (5 µl) from each of the extracts were pipetted to sterile filter disks, dried, and placed on an LB plate spread with 20 µl of an overnight culture of *B. subtilis*. The plates were incubated overnight at 37° C. to visualize zones of growth inhibition.

[0289] B. Results

[0290] (i) Construction and Validation of a Desosamine Expression System

[0291] The picromycin/methymycin (pik) gene cluster from *Streptomyces venezuelae* (21) was chosen as the source of desosamine biosynthetic genes rather than other available clusters (i.e. erythromycin, oleandomycin, or megalomicin) for several reasons. First, all of the genes required for biosynthesis of TDP desosamine from glucose-1-phosphate, a primary metabolite, as well as the desosaminyl transferase are present in the pik cluster whereas one or more of the genes are missing or not yet identified in each of the other clusters. Second, the genes from the pik cluster are comprised in a single contiguous segment of DNA (the des cluster), compared to those in other clusters which are dispersed among other genes, facilitating cloning and plasmid construction. The organization of these genes in the picromycin biosynthetic gene cluster is shown below, followed by the depiction of the biosynthetic pathway.



[0292] Third, the natural substrates for the desosaminyl transferase from the pik gene cluster, narbonolide and 10-deoxymethynolide, are themselves aglycones; in each of the other cases, desosamine is attached subsequent to addition of at least one other sugar. Furthermore, the difference in macrolactone ring sizes between narbonolide and 10-deoxymethynolide (14 and 12 atoms, respectively) suggests that the desosaminyl transferase from this cluster is somewhat forgiving towards its polyketide substrate.

[0293] Seven genes in the des cluster, desI, desII, desIII, desIV, desV, desVI, and desVIII, are presumed to be responsible for the biosynthesis of TDP-D-desosamine (22). Also present is the des VII gene encoding the glycosyltransferase. In addition to catalyzing the transfer of desosamine to both 12- and 14-membered macrolactones, it has been shown that DesVII is able to incorporate non-natural deoxysugar substrates (22, 23). The desR gene encodes a β -glucosidase that removes a glucose residue attached to the C-2' hydroxyl of desosamine (24). It is believed that the glucosylation of desosamine containing macrolides like methy-

mycin, picromycin, and oleandomycin, causes inactivation and provides self-resistance to these compounds which are reactivated by a 13-glucosidase upon export (24, 25). *S. lividans* is known to possess at least two such glucosyltransferases which inactivate erythromycin and picromycin by the same mechanism (26). Therefore, it was important to include this gene for expression in *S. lividans* to produce desosaminylated compounds without the glucose modification.

[0294] The expression system used here was adopted from the multi-vector system developed for separate expression of erythromycin PKS, or 6-deoxyerythronolide B synthase (DEBS), subunits in *Streptomyces* (4, 27; see also U.S. Pat. No. 6,033,883). Plasmid pKOS39-104 contains the des genes cloned in a single orientation under control of the actI promoter and actII-44 activator. Since pKOS39-104 is a derivative of pSET152 (28), it contains the ϕ C31-int-attP loci for chromosomal integration in *Streptomyces* and can be used in conjunction with the pRM5-based PKS expression

plasmid library (3; see also U.S. Pat. No. 5,672,491). *S. lividans* K4114 was transformed with pKOS39-104 and designated K39-22. Confirmation that this strain produced TDP-D-desosamine was performed by feeding aglycones to the strain and looking for the presence of desosaminylated compounds by LC/MS analysis.

[0295] Four aglycones (10 mg/liter each) were fed to liquid fermentations of *S. lividans* K39-22: narbonolide and 10-deoxymethynolide, the natural substrates for DesVII, 3-keto-6-deoxyerythronolide B (dEB), and 6-dEB. Fermentation broth from all four aglycone fed strains displayed antibacterial activity against *B. subtilis* whereas *S. lividans* K39-22 alone produced no detectable activity. LC/MS analysis demonstrated that each of the corresponding desosaminylated compounds narbomycin, 10-deoxymethymycin (YC17), 3-keto-5-O-desosaminyl-6-dEB, and 5-O-desosaminyl-6-dEB were produced. In each case, the parent ion ($M+H^+$) of the expected compound was detected in addition to a characteristic ion at 158 amu produced by the desosamine fragment. Production of narbomycin in the narbono-

lide fed strain was further confirmed by comparison to authentic narbomycin obtained from *S. narbonensis*. LC/MS also revealed that a significant amount (50-90%) of the aglycone remained unconverted in each of the samples.

[0296] These results established that the des expression vector was functional and that the DesVII glycosyltransferase was able to glycosylate non-natural macrolactone substrates. The bioassay results also confirmed that desosamine is sufficient to confer antibacterial activity to these macrolactones. There were no 2'-O-glucosyl derivatives detected, which indicates that the DesR glucosidase included in pKOS39-104 was also operational, although minor glucosylated products were putatively found in subsequent experiments with the strain (see below).

[0297] (ii) Co-Expression of Desosamine and Aglycone Pathways in *S. lividans*.





[0298] Although expression of both a modular polyketide pathway and a deoxysugar pathway together in a heterologous host has not been reported, the bioconversion results suggested that transformation of *S. lividans* K39-22 with plasmids encoding macrolide PKSs would lead to production of desosaminylated compounds. Plasmids encoding the PKSs that, in *S. lividans*, produce the same four aglycones used in the bioconversion studies were therefore transformed into *S. lividans* K39-22. Plasmid pKOS39-86 contains the picromycin/methymycin PKS and produces both narbonolide and 10-deoxymethynolide (20). Plasmid pKAO127 contains DEBS and produces 6-dEB (17). Plasmid pKOS39-18 contains DEBS with a modified terminal module that produces 3-keto dB (20).

[0299] Culture broth from each of the transformed strains displayed activity against *B. subtilis*. LC/MS analysis as above confirmed the presence of each of the expected desosaminylated compounds as well as their aglycone precursors and minor amounts of the corresponding 2'-O-glucosyl derivatives. The total yield of narbomycin and 10-deoxymethymycin in *S. lividans* K39-22/pKOS3986 was approximately 1 mg/liter each and represents about a 20% conversion of the total aglycone produced. Thus, although both PKS and deoxysugar pathways function as expected, complete glycosylation of even the natural substrates for DesVII did not occur under these conditions. *S. lividans* K39-22 contains a copy of the ermE macrolide resistance gene, and no obvious growth defects were observed with production of the biologically active compounds. These results suggest that a limiting amount of TDP-desosamine is being produced by the strain under these conditions.


[0300] (iii) Production and Biological Screening of a Glycosylated Macrolide Library

[0301] Over 50 PKS expression plasmids have been constructed and tested in using DEBS and other macrolide PKS genes (3, 8, 20). These PKSs produce a variety of 14-membered macrolactones in which single or multiple carbon centers have been altered. Each plasmid contains the same pRM5-based vector as above, providing a convenient opportunity to expand and diversify any existing aglycone library by routine transformation of *S. lividans* K39-22. Because a C-5 hydroxyl would be necessary for glycosylation, a subset of 19 additional plasmids encoding PKSs that produce compounds containing this functional group was selected and tested. The desired desosaminylated polyketides would theoretically possess antibiotic activity, and the transformed strains can therefore be readily analyzed in a simple bioassay for production of glycosylated macrolides.

[0302] All of the strains transformed and tested displayed antimicrobial activity against *B. subtilis*. The presumed structures of the desosamine containing compounds, based on the structures of the aglycones produced by the PKS on each plasmid, are shown below.




-continued




KOS11-62


-continued




KOS16-47





KOS11-62




KOS15-22



KOS11-64


KOS15-106
KOS15-109

KOS11-66




KOS15-106

-continued




KOS11-82


-continued




KOS15-42




KOS11-83




KOS39-20




KOS15-116




KOS15-46



KOS15-87



KOS15-125



[0303] Culture extracts from six of these strains (those containing plasmids pKOS15-22, pKOS15-106, pKOS39-20, pKOS1142, pKOS15-30, and pKOS2415) were examined by LC/MS and, in each case, the expected parent ion was found along with the 158 amu desosamine fragment. Two compounds were detected in the strain containing pKOS15-106 with molecular weights corresponding to 3-hydroxy and 3-keto derivatives. This is consistent with both aglycones being produced by plasmid pKOS15-109 in *S. lividans*. Two compounds were also detected in the strain with pKOS112, the predicted molecule, 5-O-desosaminyl-10-desmethyl-6-dEB, and a putative dehydrated derivative at carbons C-10 and C-11. Both aglycones were also produced when the plasmid was originally analyzed in *S. lividans* K4-114 (3), although only the former was reported at that time. As with the first set of plasmids tested, small amounts of 2'-O-glucosylated derivatives could also be detected in some of the culture extracts. The yields of the desosamine containing compounds were too low to determine absolute titers (<1 mg/L) and, therefore, the relative antibacterial activity of the compounds could not be determined from these assays.

[0304] C. Discussion

[0305] This example demonstrates that a minimal set of seven genes (desI, II, III, IV, V, VI, VIII) is sufficient for biosynthesis of TDP-desosamine from glucose-1-phosphate in *S. lividans*. The apparent low abundance of TDP-desosamine in the engineered host could be due either to the availability of glucose-1-phosphate in this host or to poor expression of the sugar biosynthesis and/or transferase genes. Alternatively, it is interesting to note that narbonolide and 10-deoxymethynolide are present in the natural picromycin/methymycin producing organism, *S. venezuelae*, and could therefore reflect that one or more of the enzymes from the des cluster is relatively inefficient. One can increase the amount of TDP-desosamine either by increasing expression levels of these genes and/or by complementing one or more of the enzymes in the pathway with homologs from other clusters such as erythromycin or oleandomycin.

[0306] Expression of the minimal desosamine biosynthesis genes together with the DesVII desosaminyltransferase in *S. lividans* has enabled the production of more than 20 glycosylated macrolides with detectable antibacterial activity. The structures of the macrolides that were glycosylated highlight both the remarkable substrate tolerance of the DesVII glycosyltransferase as well as the ability of desosamine to impart biological activity to structurally diverse macrolactones. In addition to their antibacterial properties the desosamine containing compounds presented here may possess additional biological properties that are associated with erythromycin and other macrolides, including motilin antagonism and anti-inflammatory activities. Furthermore, the demonstration by others that DesVII and other glycosyltransferases can also tolerate modifications of the sugar substituent (22, 23, 29) opens the door to manipulation of both polyketide and deoxysugar pathways for the production of 'unnatural' natural product libraries.

REFERENCES

- [0307] 1. O'Hagan, D. (1991) *The polyketide metabolites* (Ellis Horwood, Chichester, UK).
- [0308] 2. Hutchinson, C. R. (1998) *Curr. Opin. Microbiol.* 1, 319-329.
- [0309] 3. McDaniel, R., Thamchaipenet, A., Gustafsson, C., Fu, H., Betlach, M., Betlach, M. & Ashley, G. (1999) *Proc. Natl. Acad. Sci. USA* 96, 1846-1851.
- [0310] 4. Xue, Q., Ashley, G., Hutchinson, C. R. & Santi, D. V. (1999) *Proc. Natl. Acad. Sci. USA* 96, 11740-11745.
- [0311] 5. Asaka, T., Misawa, Y., Kashimura, M., Morimoto, S. & Hatayama, K. (1997) U.S. Pat. No. 5,631,354.
- [0312] 6. Elliot, R. L., Or, Y. S., Pireh, D. & Chu, D. T. (1998) U.S. Pat. No. 5,747,466.
- [0313] 7. Agouridas, C., Denis, A., Auger, J. -M., Benedetti, Y., Bonnefoy, A., Bretin, F., Chantot, J. -F., Dussarat, A., Fromentin, C., D'Ambrieres, S. G., et al. (1998) *J. Med. Chem.* 41, 4080-4100.
- [0314] 8. Tang, L., Fu, H. & McDaniel, R. (2000) *Chem. & Biol.* 7, 77-84.

- [0315] 9. Donadio, S., Staver, M. J., McAlpine, J. B., Swanson, S. J. & Katz, L. (1991) *Science* 252, 675-679.
- [0316] 10. Donadio, S., McAlpine, J. B., Sheldon, P. J., Jackson, M. & Katz, L. (1993) *Proc. Natl. Acad. Sci. USA* 90, 7119-7123.
- [0317] 11. Ruan, X. R., Pereda, A., Stassi, D. L., Zeidner, D., Summers, R. G., Jackson, M., Shivakumar, A., Kakavas, S., Staver, M. J., Donadio, S., et al. (1997) *J. Bacteriol.* 179, 641-6425.
- [0318] 12. Stassi, D. L., Kakavas, S. J., Reynolds, K. A., Gunawardana, G., Swanson, S., Zeidner, D., Jackson, M., Liu, H., Buko, A. & Katz, L. (1998) *Proc. Natl. Acad. Sci. USA* 95, 7305-7309.
- [0319] 13. Marsden, A. F. A., Wilkinson, B., Cortés, J., Dunster, N. J., Staunton, J. & Leadlay, P. F. (1998) *Science* 279, 199-202.
- [0320] 14. Jacobsen, J. R., Hutchinson, C. R., Cane, D. E. & Khosla, C. (1997) *Science* 277, 367-369.
- [0321] 15. Olano, C., Lomovskaya, N., Fonstein, L., Roll, J. T. & Hutchinson, C. R. (1999) *Chem. & Biol.* 6, 845-855.
- [0322] 16. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Plainview, N.Y.).
- [0323] 17. Ziermann, R. & Betlach, M. C. (1999) *Bio-techniques* 26, 106-110.
- [0324] 18. Hopwood, D. A., Bibb, M. J., Chater, K. F., Kieser, T., Bruton, C. J., Kieser, H. M., Lydiate, D. J., Smith, C. P., Ward, J. M. & Schrempf, H. (1985) *Genetic Manipulation of Streptomyces: A Laboratory Manual* (The John Innes Foundation, Norwich, UK).
- [0325] 19. Betlach, M. C., Kealey, J. T., Betlach, M. C., Ashley, G. A. & McDaniel, R. (1998) *Biochemistry* 37, 14937-14942.
- [0326] 20. Tang, L., Fu, H., Betlach, M. C. & McDaniel, R. (1999) *Chem. & Biol.* 6, 553-558.
- [0327] 21. Xue, Y., Zhao, L., Liu, H. -w. & Sherman, D. H. (1998) *Proc. Natl. Acad. Sci. USA* 95, 12111-12116.
- [0328] 22. Zhao, L., Sherman, D. H. & Liu, H. -w. (1998) *J. Am. Chem. Soc.* 120, 10256-10257.
- [0329] 23. Zhao, L., Ahlert, J., Xue, Y., Thorson, J. S., Sherman, D. H. & Liu, H. -w. (1999) *J. Am. Chem. Soc.* 121, 9881-9882.
- [0330] 24. Zhao, L., Sherman, D. H. & Liu, H. -w. (1998) *J. Am. Chem. Soc.* 120, 9374-9375.
- [0331] 25. Quiros, L. M., Aguirrezabalaga, I., Olano, C., Mendez, C. & Salas, J. A. (1998) *Mol. Microbiol.* 28, 1177-1185.
- [0332] 26. Jenkins, G. & Cundliffe, E. (1991) *Gene* 108, 55-62.
- [0333] 27. Ziermann, R. & Betlach, M. (2000) *J. Ind. Microbiol. Biotech.* 24, 4650.
- [0334] 28. Bierman, M., Logan, R., O'Brien, K., Seno, E. T., Nagaraja, R. & Schoner, B. E. (1992) *Gene* 116, 47-49.
- [0335] 29. Gaisser, S., Reather, J., Wirtz, G., Kellenberger, L., Staunton, J. & Leadlay, P. F. (2000) *Mol. Microbiol.* 36, 391-401.
- [0336] The invention having now been described by way of written description and example, those of skill in the art will recognize that the invention can be practiced in a variety of embodiments and that the foregoing description and examples are for purposes of illustration and not limitation of the following claims.

 SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 39

<210> SEQ ID NO 1

<211> LENGTH: 4551

<212> TYPE: PRT

<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 1

Met Ser Thr Val Ser Lys Ser Glu Ser Glu Glu Phe Val Ser Val Ser
1 5 10 15

Asn Asp Ala Gly Ser Ala His Gly Thr Ala Glu Pro Val Ala Val Val
20 25 30

Gly Ile Ser Cys Arg Val Pro Gly Ala Arg Asp Pro Arg Glu Phe Trp
35 40 45

Glu Leu Leu Ala Ala Gly Gly Gln Ala Val Thr Asp Val Pro Ala Asp
50 55 60

Arg Trp Asn Ala Gly Asp Phe Tyr Asp Pro Asp Arg Ser Ala Pro Gly
65 70 75 80

Arg Ser Asn Ser Arg Trp Gly Gly Phe Ile Glu Asp Val Asp Arg Phe
85 90 95

-continued

Asp	Ala	Ala	Phe	Phe	Gly	Ile	Ser	Pro	Arg	Glu	Ala	Ala	Glu	Met	Asp	100	105	110
Pro	Gln	Gln	Arg	Leu	Ala	Leu	Glu	Leu	Gly	Trp	Glu	Ala	Leu	Glu	Arg	115	120	125
Ala	Gly	Ile	Asp	Pro	Ser	Ser	Leu	Thr	Gly	Thr	Arg	Thr	Gly	Val	Phe	130	135	140
Ala	Gly	Ala	Ile	Trp	Asp	Asp	Tyr	Ala	Thr	Leu	Lys	His	Arg	Gln	Gly	145	150	155
Gly	Ala	Ala	Ile	Thr	Pro	His	Thr	Val	Thr	Gly	Leu	His	Arg	Gly	Ile	165	170	175
Ile	Ala	Asn	Arg	Leu	Ser	Tyr	Thr	Leu	Gly	Leu	Arg	Gly	Pro	Ser	Met	180	185	190
Val	Val	Asp	Ser	Gly	Gln	Ser	Ser	Leu	Val	Ala	Val	His	Leu	Ala		195	200	205
Cys	Glu	Ser	Leu	Arg	Arg	Gly	Glu	Ser	Glu	Leu	Ala	Leu	Ala	Gly	Gly	210	215	220
Val	Ser	Leu	Asn	Leu	Val	Pro	Asp	Ser	Ile	Ile	Gly	Ala	Ser	Lys	Phe	225	230	235
Gly	Gly	Leu	Ser	Pro	Asp	Gly	Arg	Ala	Tyr	Thr	Phe	Asp	Ala	Arg	Ala	245	250	255
Asn	Gly	Tyr	Val	Arg	Gly	Glu	Gly	Gly	Gly	Phe	Val	Val	Leu	Lys	Arg	260	265	270
Leu	Ser	Arg	Ala	Val	Ala	Asp	Gly	Asp	Pro	Val	Leu	Ala	Val	Ile	Arg	275	280	285
Gly	Ser	Ala	Val	Asn	Asn	Gly	Gly	Ala	Ala	Gln	Gly	Met	Thr	Thr	Pro	290	295	300
Asp	Ala	Gln	Ala	Gln	Glu	Ala	Val	Leu	Arg	Glu	Ala	His	Glu	Arg	Ala	305	310	315
Gly	Thr	Ala	Pro	Ala	Asp	Val	Arg	Tyr	Val	Glu	Leu	His	Gly	Thr	Gly	325	330	335
Thr	Pro	Val	Gly	Asp	Pro	Ile	Glu	Ala	Ala	Ala	Leu	Gly	Ala	Ala	Leu	340	345	350
Gly	Thr	Gly	Arg	Pro	Ala	Gly	Gln	Pro	Leu	Leu	Val	Gly	Ser	Val	Lys	355	360	365
Thr	Asn	Ile	Gly	His	Leu	Glu	Gly	Ala	Ala	Gly	Ile	Ala	Gly	Leu	Ile	370	375	380
Lys	Ala	Val	Leu	Ala	Val	Arg	Gly	Arg	Ala	Leu	Pro	Ala	Ser	Leu	Asn	385	390	395
Tyr	Glu	Thr	Pro	Asn	Pro	Ala	Ile	Pro	Phe	Glu	Glu	Leu	Asn	Leu	Arg	405	410	415
Val	Asn	Thr	Glu	Tyr	Leu	Pro	Trp	Glu	Pro	Glu	His	Asp	Gly	Gln	Arg	420	425	430
Met	Val	Val	Gly	Val	Ser	Ser	Phe	Gly	Met	Gly	Gly	Thr	Asn	Ala	His	435	440	445
Val	Val	Leu	Glu	Glu	Ala	Pro	Gly	Val	Val	Glu	Gly	Ala	Ser	Val	Val	450	455	460
Glu	Ser	Thr	Val	Gly	Gly	Ser	Ala	Val	Gly	Gly	Gly	Val	Val	Pro	Trp	465	470	475
Val	Val	Ser	Ala	Lys	Ser	Ala	Ala	Ala	Leu	Asp	Ala	Gln	Ile	Glu	Arg	485	490	495

Leu	Ala	Ala	Phe	Ala	Ser	Arg	Asp	Arg	Thr	Asp	Gly	Val	Asp	Ala	Gly
			500				505						510		
Ala	Val	Asp	Ala	Gly	Ala	Val	Asp	Ala	Gly	Ala	Val	Ala	Arg	Val	Leu
			515				520						525		
Ala	Gly	Gly	Arg	Ala	Gln	Phe	Glu	His	Arg	Ala	Val	Val	Val	Gly	Ser
			530				535						540		
Gly	Pro	Asp	Asp	Leu	Ala	Ala	Ala	Leu	Ala	Ala	Pro	Glu	Gly	Leu	Val
			545				550						555		
Arg	Gly	Val	Ala	Ser	Gly	Val	Gly	Arg	Val	Ala	Phe	Val	Phe	Pro	Gly
			565				570						575		
Gln	Gly	Thr	Gln	Trp	Ala	Gly	Met	Gly	Ala	Glu	Leu	Leu	Asp	Ser	Ser
			580				585						590		
Ala	Val	Phe	Ala	Ala	Ala	Met	Ala	Glu	Cys	Glu	Ala	Ala	Leu	Ser	Pro
			595				600						605		
Tyr	Val	Asp	Trp	Ser	Leu	Glu	Ala	Val	Val	Arg	Gln	Ala	Pro	Gly	Ala
			610				615						620		
Pro	Thr	Leu	Glu	Arg	Val	Asp	Val	Val	Gln	Pro	Val	Thr	Phe	Ala	Val
			625				630						635		
Met	Val	Ser	Leu	Ala	Arg	Val	Trp	Gln	His	His	Gly	Val	Thr	Pro	Gln
			645				650						655		
Ala	Val	Val	Gly	His	Ser	Gln	Gly	Glu	Ile	Ala	Ala	Ala	Tyr	Val	Ala
			660				665						670		
Gly	Ala	Leu	Ser	Leu	Asp	Asp	Ala	Ala	Arg	Val	Val	Thr	Leu	Arg	Ser
			675				680						685		
Lys	Ser	Ile	Ala	Ala	His	Leu	Ala	Gly	Lys	Gly	Gly	Met	Leu	Ser	Leu
			690				695						700		
Ala	Leu	Ser	Glu	Asp	Ala	Val	Leu	Glu	Arg	Leu	Ala	Gly	Phe	Asp	Gly
			705				710						715		
Leu	Ser	Val	Ala	Ala	Val	Asn	Gly	Pro	Thr	Ala	Thr	Val	Val	Ser	Gly
			725				730						735		
Asp	Pro	Val	Gln	Ile	Glu	Glu	Leu	Ala	Arg	Ala	Cys	Glu	Ala	Asp	Gly
			740				745						750		
Val	Arg	Ala	Arg	Val	Ile	Pro	Val	Asp	Tyr	Ala	Ser	His	Ser	Arg	Gln
			755				760						765		
Val	Glu	Ile	Ile	Glu	Ser	Glu	Leu	Ala	Glu	Val	Leu	Ala	Gly	Leu	Ser
			770				775						780		
Pro	Gln	Ala	Pro	Arg	Val	Pro	Phe	Phe	Ser	Thr	Leu	Glu	Gly	Ala	Trp
			785				790						795		
Ile	Thr	Glu	Pro	Val	Leu	Asp	Gly	Gly	Tyr	Trp	Tyr	Arg	Asn	Leu	Arg
			805				810						815		
His	Arg	Val	Gly	Phe	Ala	Pro	Ala	Val	Glu	Thr	Leu	Ala	Thr	Asp	Glu
			820				825						830		
Gly	Phe	Thr	His	Phe	Val	Glu	Val	Ser	Ala	His	Pro	Val	Leu	Thr	Met
			835				840						845		
Ala	Leu	Pro	Gly	Thr	Val	Thr	Gly	Leu	Ala	Thr	Leu	Arg	Arg	Asp	Asn
			850				855						860		
Gly	Gly	Gln	Asp	Arg	Leu	Val	Ala	Ser	Leu	Ala	Glu	Ala	Trp	Ala	Asn
			865				870						875		
Gly	Leu	Ala	Val	Asp	Trp	Ser	Pro	Leu	Leu	Pro	Ser	Ala	Thr	Gly	His
			885				890						895		
His	Ser	Asp	Leu	Pro	Thr	Tyr	Ala	Phe	Gln	Thr	Glu				

-continued

900					905					910						
Gly	Glu	Ile	Glu	Ala	Leu	Ala	Pro	Ala	Gly	Glu	Pro	Ala	Val	Gln	Pro	
915					920					925						
Ala	Val	Leu	Arg	Thr	Glu	Ala	Ala	Glu	Pro	Ala	Glu	Leu	Asp	Arg	Asp	
930					935					940						
Glu	Gln	Leu	Arg	Val	Ile	Leu	Asp	Lys	Val	Arg	Ala	Gln	Thr	Ala	Gln	
945					950					955					960	
Val	Leu	Gly	Tyr	Ala	Thr	Gly	Gly	Gln	Ile	Glu	Val	Asp	Arg	Thr	Phe	
965					970					975						
Arg	Glu	Ala	Gly	Cys	Thr	Ser	Leu	Thr	Gly	Val	Asp	Leu	Arg	Asn	Arg	
980					985					990						
Ile	Asn	Ala	Ala	Phe	Gly	Val	Arg	Met	Ala	Pro	Ser	Met	Ile	Phe	Asp	
995					1000					1005						
Phe	Pro	Thr	Pro	Glu	Ala	Leu	Ala	Glu	Gln	Leu	Leu	Leu	Val	Val	His	
1010					1015					1020						
Gly	Glu	Ala	Ala	Ala	Asn	Pro	Ala	Gly	Ala	Glu	Pro	Ala	Pro	Val	Ala	
1025					1030					1035					1040	
Ala	Ala	Gly	Ala	Val	Asp	Glu	Pro	Val	Ala	Ile	Val	Gly	Met	Ala	Cys	
1045					1050					1055						
Arg	Leu	Pro	Gly	Gly	Val	Ala	Ser	Pro	Glu	Asp	Leu	Trp	Arg	Leu	Val	
1060					1065					1070						
Ala	Gly	Gly	Gly	Asp	Ala	Ile	Ser	Glu	Phe	Pro	Gln	Asp	Arg	Gly	Trp	
1075					1080					1085						
Asp	Val	Glu	Gly	Leu	Tyr	His	Pro	Asp	Pro	Glu	His	Pro	Gly	Thr	Ser	
1090					1095					1100						
Tyr	Val	Arg	Gln	Gly	Gly	Phe	Ile	Glu	Asn	Val	Ala	Gly	Phe	Asp	Ala	
1105					1110					1115					1120	
Ala	Phe	Phe	Gly	Ile	Ser	Pro	Arg	Glu	Ala	Leu	Ala	Met	Asp	Pro	Gln	
1125					1130					1135						
Gln	Arg	Leu	Leu	Leu	Glu	Thr	Ser	Trp	Glu	Ala	Val	Glu	Asp	Ala	Gly	
1140					1145					1150						
Ile	Asp	Pro	Thr	Ser	Leu	Arg	Gly	Arg	Gln	Val	Gly	Val	Phe	Thr	Gly	
1155					1160					1165						
Ala	Met	Thr	His	Glu	Tyr	Gly	Pro	Ser	Leu	Arg	Asp	Gly	Gly	Glu	Gly	
1170					1175					1180						
Leu	Asp	Gly	Tyr	Leu	Leu	Thr	Gly	Asn	Thr	Ala	Ser	Val	Met	Ser	Gly	
1185					1190					1195					1200	
Arg	Val	Ser	Tyr	Thr	Leu	Gly	Leu	Glu	Gly	Pro	Ala	Leu	Thr	Val	Asp	
1205					1210					1215						
Thr	Ala	Cys	Ser	Ser	Ser	Leu	Val	Ala	Leu	His	Leu	Ala	Val	Gln	Ala	
1220					1225					1230						
Leu	Arg	Lys	Gly	Glu	Val	Asp	Met	Ala	Leu	Ala	Gly	Gly	Val	Ala	Val	
1235					1240					1245						
Met	Pro	Thr	Pro	Gly	Met	Phe	Val	Glu	Phe	Ser	Arg	Gln	Arg	Gly	Leu	
1250					1255					1260						
Ala	Gly	Asp	Gly	Arg	Ser	Lys	Ala	Phe	Ala	Ala	Ser	Ala	Asp	Gly	Thr	
1265					1270					1275					1280	
Ser	Trp	Ser	Glu	Gly	Val	Gly	Val	Leu	Leu	Val	Glu	Arg	Leu	Ser	Asp	
1285					1290					1295						
Ala	Arg	Arg	Asn	Gly	His	Gln	Val	Leu	Ala	Val	Val	Arg	Gly	Ser	Ala	
1300					1305					1310						

-continued

Val Asn Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro Asn Gly Pro	1315	1320	1325
Ser Gln Gln Arg Val Ile Arg Arg Ala Leu Ala Asp Ala Arg Leu Thr	1330	1335	1340
Thr Ser Asp Val Asp Val Val Glu Ala His Gly Thr Gly Thr Arg Leu	1345	1350	1355 1360
Gly Asp Pro Ile Glu Ala Gln Ala Leu Ile Ala Thr Tyr Gly Gln Gly	1365	1370	1375
Arg Asp Asp Glu Gln Pro Leu Arg Leu Gly Ser Leu Lys Ser Asn Ile	1380	1385	1390
Gly His Thr Gln Ala Ala Ala Gly Val Ser Gly Val Ile Lys Met Val	1395	1400	1405
Gln Ala Met Arg His Gly Leu Leu Pro Lys Thr Leu His Val Asp Glu	1410	1415	1420
Pro Ser Asp Gln Ile Asp Trp Ser Ala Gly Ala Val Glu Leu Leu Thr	1425	1430	1435 1440
Glu Ala Val Asp Trp Pro Glu Lys Gln Asp Gly Gly Leu Arg Arg Ala	1445	1450	1455
Ala Val Ser Ser Phe Gly Ile Ser Gly Thr Asn Ala His Val Val Leu	1460	1465	1470
Glu Glu Ala Pro Val Val Val Glu Gly Ala Ser Val Val Glu Pro Ser	1475	1480	1485
Val Gly Gly Ser Ala Val Gly Gly Gly Val Thr Pro Trp Val Val Ser	1490	1495	1500
Ala Lys Ser Ala Ala Ala Leu Asp Ala Gln Ile Glu Arg Leu Ala Ala	1505	1510	1515 1520
Phe Ala Ser Arg Asp Arg Thr Asp Asp Ala Asp Ala Gly Ala Val Asp	1525	1530	1535
Ala Gly Ala Val Ala His Val Leu Ala Asp Gly Arg Ala Gln Phe Glu	1540	1545	1550
His Arg Ala Val Ala Leu Gly Ala Gly Ala Asp Asp Leu Val Gln Ala	1555	1560	1565
Leu Ala Asp Pro Asp Gly Leu Ile Arg Gly Thr Ala Ser Gly Val Gly	1570	1575	1580
Arg Val Ala Phe Val Phe Pro Gly Gln Gly Thr Gln Trp Ala Gly Met	1585	1590	1595 1600
Gly Ala Glu Leu Leu Asp Ser Ser Ala Val Phe Ala Ala Met Ala	1605	1610	1615
Glu Cys Glu Ala Ala Leu Ser Pro Tyr Val Asp Trp Ser Leu Glu Ala	1620	1625	1630
Val Val Arg Gln Ala Pro Gly Ala Pro Thr Leu Glu Arg Val Asp Val	1635	1640	1645
Val Gln Pro Val Thr Phe Ala Val Met Val Ser Leu Ala Arg Val Trp	1650	1655	1660
Gln His His Gly Val Thr Pro Gln Ala Val Val Gly His Ser Gln Gly	1665	1670	1675 1680
Glu Ile Ala Ala Ala Tyr Val Ala Gly Ala Leu Pro Leu Asp Asp Ala	1685	1690	1695
Ala Arg Val Val Thr Leu Arg Ser Lys Ser Ile Ala Ala His Leu Ala	1700	1705	1710

-continued

Gly Lys Gly Gly Met Leu Ser Leu Ala Leu Asn Glu Asp Ala Val Leu	1715	1720	1725
Glu Arg Leu Ser Asp Phe Asp Gly Leu Ser Val Ala Ala Val Asn Gly	1730	1735	1740
Pro Thr Ala Thr Val Val Ser Gly Asp Pro Val Gln Ile Glu Glu Leu	1745	1750	1755
Ala Gln Ala Cys Lys Ala Asp Gly Phe Arg Ala Arg Ile Ile Pro Val	1765	1770	1775
Asp Tyr Ala Ser His Ser Arg Gln Val Glu Ile Ile Glu Ser Glu Leu	1780	1785	1790
Ala Gln Val Leu Ala Gly Leu Ser Pro Gln Ala Pro Arg Val Pro Phe	1795	1800	1805
Phe Ser Thr Leu Glu Gly Thr Trp Ile Thr Glu Pro Val Leu Asp Gly	1810	1815	1820
Thr Tyr Trp Tyr Arg Asn Leu Arg His Arg Val Gly Phe Ala Pro Ala	1825	1830	1835
Ile Glu Thr Leu Ala Val Asp Glu Gly Phe Thr His Phe Val Glu Val	1845	1850	1855
Ser Ala His Pro Val Leu Thr Met Thr Leu Pro Glu Thr Val Thr Gly	1860	1865	1870
Leu Gly Thr Leu Arg Arg Glu Gln Gly Gly Gln Glu Arg Leu Val Thr	1875	1880	1885
Ser Leu Ala Glu Ala Trp Val Asn Gly Leu Pro Val Ala Trp Thr Ser	1890	1895	1900
Leu Leu Pro Ala Thr Ala Ser Arg Pro Gly Leu Pro Thr Tyr Ala Phe	1905	1910	1915
Gln Ala Glu Arg Tyr Trp Leu Glu Asn Thr Pro Ala Ala Leu Ala Thr	1925	1930	1935
Gly Asp Asp Trp Arg Tyr Arg Ile Asp Trp Lys Arg Leu Pro Ala Ala	1940	1945	1950
Glu Gly Ser Glu Arg Thr Gly Leu Ser Gly Arg Trp Leu Ala Val Thr	1955	1960	1965
Pro Glu Asp His Ser Ala Gln Ala Ala Ala Val Leu Thr Ala Leu Val	1970	1975	1980
Asp Ala Gly Ala Lys Val Glu Val Leu Thr Ala Gly Ala Asp Asp Asp	1985	1990	1995
Arg Glu Ala Leu Ala Ala Arg Leu Thr Ala Leu Thr Thr Gly Asp Gly	2005	2010	2015
Phe Thr Gly Val Val Ser Leu Leu Asp Gly Leu Val Pro Gln Val Ala	2020	2025	2030
Trp Val Gln Ala Leu Gly Asp Ala Gly Ile Lys Ala Pro Leu Trp Ser	2035	2040	2045
Val Thr Gln Gly Ala Val Ser Val Gly Arg Leu Asp Thr Pro Ala Asp	2050	2055	2060
Pro Asp Arg Ala Met Leu Trp Gly Leu Gly Arg Val Val Ala Leu Glu	2065	2070	2075
His Pro Glu Arg Trp Ala Gly Leu Val Asp Leu Pro Ala Gln Pro Asp	2085	2090	2095
Ala Ala Ala Leu Ala His Leu Val Thr Ala Leu Ser Gly Ala Thr Gly	2100	2105	2110
Glu Asp Gln Ile Ala Ile Arg Thr Thr Gly Leu His Ala Arg Arg Leu			

-continued

2115	2120	2125
Ala Arg Ala Pro Leu His Gly Arg Arg Pro Thr Arg Asp Trp Gln Pro 2130	2135	2140
His Gly Thr Val Leu Ile Thr Gly Gly Thr Gly Ala Leu Gly Ser His 2145	2150	2155 2160
Ala Ala Arg Trp Met Ala His His Gly Ala Glu His Leu Leu Leu Val 2165	2170	2175
Ser Arg Ser Gly Glu Gln Ala Pro Gly Ala Thr Gln Leu Thr Ala Glu 2180	2185	2190
Leu Thr Ala Ser Gly Ala Arg Val Thr Ile Ala Ala Cys Asp Val Ala 2195	2200	2205
Asp Pro His Ala Met Arg Thr Leu Leu Asp Ala Ile Pro Ala Glu Thr 2210	2215	2220
Pro Leu Thr Ala Val Val His Thr Ala Gly Ala Leu Asp Asp Gly Ile 2225	2230	2235 2240
Val Asp Thr Leu Thr Ala Glu Gln Val Arg Arg Ala His Arg Ala Lys 2245	2250	2255
Ala Val Gly Ala Ser Val Leu Asp Glu Leu Thr Arg Asp Leu Asp Leu 2260	2265	2270
Asp Ala Phe Val Leu Phe Ser Ser Val Ser Ser Thr Leu Gly Ile Pro 2275	2280	2285
Gly Gln Gly Asn Tyr Ala Pro His Asn Ala Tyr Leu Asp Ala Leu Ala 2290	2295	2300
Ala Arg Arg Arg Ala Thr Gly Arg Ser Ala Val Ser Val Ala Trp Gly 2305	2310	2315 2320
Pro Trp Asp Gly Gly Gly Met Ala Ala Gly Asp Gly Val Ala Glu Arg 2325	2330	2335
Leu Arg Asn His Gly Val Pro Gly Met Asp Pro Glu Leu Ala Leu Ala 2340	2345	2350
Ala Leu Glu Ser Ala Leu Gly Arg Asp Glu Thr Ala Ile Thr Val Ala 2355	2360	2365
Asp Ile Asp Trp Asp Arg Phe Tyr Leu Ala Tyr Ser Ser Gly Arg Pro 2370	2375	2380
Gln Pro Leu Val Glu Glu Leu Pro Glu Val Arg Arg Ile Ile Asp Ala 2385	2390	2395 2400
Arg Asp Ser Ala Thr Ser Gly Gln Gly Gly Ser Ser Ala Gln Gly Ala 2405	2410	2415
Asn Pro Leu Ala Glu Arg Leu Ala Ala Ala Ala Pro Gly Glu Arg Thr 2420	2425	2430
Glu Ile Leu Leu Gly Leu Val Arg Ala Gln Ala Ala Ala Val Leu Arg 2435	2440	2445
Met Arg Ser Pro Glu Asp Val Ala Ala Asp Arg Ala Phe Lys Asp Ile 2450	2455	2460
Gly Phe Asp Ser Leu Ala Gly Val Glu Leu Arg Asn Arg Leu Thr Arg 2465	2470	2475 2480
Ala Thr Gly Leu Gln Leu Pro Ala Thr Leu Val Phe Asp His Pro Thr 2485	2490	2495
Pro Leu Ala Leu Val Ser Leu Leu Arg Ser Glu Phe Leu Gly Asp Glu 2500	2505	2510
Glu Thr Ala Asp Ala Arg Arg Ser Ala Ala Leu Pro Ala Thr Val Gly 2515	2520	2525

-continued

Ala Gly Ala Gly Ala Gly	Ala Gly Thr Asp	Ala Asp Asp Asp	Pro Ile
2530	2535	2540	
Ala Ile Val Ala Met Ser Cys Arg Tyr Pro	Gly Asp Ile Arg Ser	Pro	
2545	2550	2555	2560
Glu Asp Leu Trp Arg Met Leu Ser Glu Gly Gly Glu Gly Ile Thr Pro			
	2565	2570	2575
Phe Pro Thr Asp Arg Gly Trp Asp Leu Asp Gly Leu Tyr Asp Ala Asp			
	2580	2585	2590
Pro Asp Ala Leu Gly Arg Ala Tyr Val Arg Glu Gly Gly Phe Leu His			
	2595	2600	2605
Asp Ala Ala Glu Phe Asp Ala Glu Phe Phe Gly Val Ser Pro Arg Glu			
	2610	2615	2620
Ala Leu Ala Met Asp Pro Gln Gln Arg Met Leu Leu Thr Thr Ser Trp			
	2625	2630	2635
Glu Ala Phe Glu Arg Ala Gly Ile Glu Pro Ala Ser Leu Arg Gly Ser			
	2645	2650	2655
Ser Thr Gly Val Phe Ile Gly Leu Ser Tyr Gln Asp Tyr Ala Ala Arg			
	2660	2665	2670
Val Pro Asn Ala Pro Arg Gly Val Glu Gly Tyr Leu Leu Thr Gly Ser			
	2675	2680	2685
Thr Pro Ser Val Ala Ser Gly Arg Ile Ala Tyr Thr Phe Gly Leu Glu			
	2690	2695	2700
Gly Pro Ala Thr Thr Val Asp Thr Ala Cys Ser Ser Ser Leu Thr Ala			
	2705	2710	2715
Leu His Leu Ala Val Arg Ala Leu Arg Ser Gly Glu Cys Thr Met Ala			
	2725	2730	2735
Leu Ala Gly Gly Val Ala Met Met Ala Thr Pro His Met Phe Val Glu			
	2740	2745	2750
Phe Ser Arg Gln Arg Ala Leu Ala Pro Asp Gly Arg Ser Lys Ala Phe			
	2755	2760	2765
Ser Ala Asp Ala Asp Gly Phe Gly Ala Ala Glu Gly Val Gly Leu Leu			
	2770	2775	2780
Leu Val Glu Arg Leu Ser Asp Ala Arg Arg Asn Gly His Pro Val Leu			
	2785	2790	2795
Ala Val Val Arg Gly Thr Ala Val Asn Gln Asp Gly Ala Ser Asn Gly			
	2805	2810	2815
Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln Arg Val Ile Arg Gln Ala			
	2820	2825	2830
Leu Ala Asp Ala Arg Leu Ala Pro Gly Asp Ile Asp Ala Val Glu Thr			
	2835	2840	2845
His Gly Thr Gly Thr Ser Leu Gly Asp Pro Ile Glu Ala Gln Gly Leu			
	2850	2855	2860
Gln Ala Thr Tyr Gly Lys Glu Arg Pro Ala Glu Arg Pro Leu Ala Ile			
	2865	2870	2875
Gly Ser Val Lys Ser Asn Ile Gly His Thr Gln Ala Ala Ala Gly Ala			
	2885	2890	2895
Ala Gly Ile Ile Lys Met Val Leu Ala Met Arg His Gly Thr Leu Pro			
	2900	2905	2910
Lys Thr Leu His Ala Asp Glu Pro Ser Pro His Val Asp Trp Ala Asn			
	2915	2920	2925

-continued

Ser Gly Leu Ala Leu Val Thr Glu Pro Ile Asp Trp Pro Ala Gly Thr		
2930	2935	2940
Gly Pro Arg Arg Ala Ala Val Ser Ser Phe Gly Ile Ser Gly Thr Asn		
2945	2950	2955 2960
Ala His Val Val Leu Glu Gln Ala Pro Asp Ala Ala Gly Glu Val Leu		
	2965	2970 2975
Gly Ala Asp Glu Val Pro Glu Val Ser Glu Thr Val Ala Met Ala Gly		
	2980	2985 2990
Thr Ala Gly Thr Ser Glu Val Ala Glu Gly Ser Glu Ala Ser Glu Ala		
	2995	3000 3005
Pro Ala Ala Pro Gly Ser Arg Glu Ala Ser Leu Pro Gly His Leu Pro		
	3010	3015 3020
Trp Val Leu Ser Ala Lys Asp Glu Gln Ser Leu Arg Gly Gln Ala Ala		
3025	3030	3035 3040
Ala Leu His Ala Trp Leu Ser Glu Pro Ala Ala Asp Leu Ser Asp Ala		
	3045	3050 3055
Asp Gly Pro Ala Arg Leu Arg Asp Val Gly Tyr Thr Leu Ala Thr Ser		
	3060	3065 3070
Arg Thr Ala Phe Ala His Arg Ala Ala Val Thr Ala Ala Asp Arg Asp		
	3075	3080 3085
Gly Phe Leu Asp Gly Leu Ala Thr Leu Ala Gln Gly Gly Thr Ser Ala		
3090	3095	3100
His Val His Leu Asp Thr Ala Arg Asp Gly Thr Thr Ala Phe Leu Phe		
3105	3110	3115 3120
Thr Gly Gln Gly Ser Gln Arg Pro Gly Ala Gly Arg Glu Leu Tyr Asp		
	3125	3130 3135
Arg His Pro Val Phe Ala Arg Ala Leu Asp Glu Ile Cys Ala His Leu		
	3140	3145 3150
Asp Gly His Leu Glu Leu Pro Leu Leu Asp Val Met Phe Ala Ala Glu		
	3155	3160 3165
Gly Ser Ala Glu Ala Ala Leu Leu Asp Glu Thr Arg Tyr Thr Gln Cys		
3170	3175	3180
Ala Leu Phe Ala Leu Glu Val Ala Leu Phe Arg Leu Val Glu Ser Trp		
3185	3190	3195 3200
Gly Met Arg Pro Ala Ala Leu Leu Gly His Ser Val Gly Glu Ile Ala		
	3205	3210 3215
Ala Ala His Val Ala Gly Val Phe Ser Leu Ala Asp Ala Ala Arg Leu		
	3220	3225 3230
Val Ala Ala Arg Gly Arg Leu Met Gln Glu Leu Pro Ala Gly Gly Ala		
	3235	3240 3245
Met Leu Ala Val Gln Ala Ala Glu Asp Glu Ile Arg Val Trp Leu Glu		
3250	3255	3260
Thr Glu Glu Arg Tyr Ala Gly Arg Leu Asp Val Ala Ala Val Asn Gly		
3265	3270	3275 3280
Pro Glu Ala Ala Val Leu Ser Gly Asp Ala Asp Ala Ala Arg Glu Ala		
	3285	3290 3295
Glu Ala Tyr Trp Ser Gly Leu Gly Arg Arg Thr Arg Ala Leu Arg Val		
	3300	3305 3310
Ser His Ala Phe His Ser Ala His Met Asp Gly Met Leu Asp Gly Phe		
3315	3320	3325
Arg Ala Val Leu Glu Thr Val Glu Phe Arg Arg Pro Ser Leu Thr Val		

-continued

3330	3335	3340
Val Ser Asn Val Thr Gly Leu Ala Ala Gly Pro Asp Asp Leu Cys Asp 3345 3350 3355 3360		
Pro Glu Tyr Trp Val Arg His Val Arg Gly Thr Val Arg Phe Leu Asp 3365 3370 3375		
Gly Val Arg Val Leu Arg Asp Leu Gly Val Arg Thr Cys Leu Glu Leu 3380 3385 3390		
Gly Pro Asp Gly Val Leu Thr Ala Met Ala Ala Asp Gly Leu Ala Asp 3395 3400 3405		
Thr Pro Ala Asp Ser Ala Ala Gly Ser Pro Val Gly Ser Pro Ala Gly 3410 3415 3420		
Ser Pro Ala Asp Ser Ala Ala Gly Ala Leu Arg Pro Arg Pro Leu Leu 3425 3430 3435 3440		
Val Ala Leu Leu Arg Arg Lys Arg Ser Glu Thr Glu Thr Val Ala Asp 3445 3450 3455		
Ala Leu Gly Arg Ala His Ala His Gly Thr Gly Pro Asp Trp His Ala 3460 3465 3470		
Trp Phe Ala Gly Ser Gly Ala His Arg Val Asp Leu Pro Thr Tyr Ser 3475 3480 3485		
Phe Arg Arg Asp Arg Tyr Trp Leu Asp Ala Pro Ala Ala Asp Thr Ala 3490 3495 3500		
Val Asp Thr Ala Gly Leu Gly Leu Gly Thr Ala Asp His Pro Leu Leu 3505 3510 3515 3520		
Gly Ala Val Val Ser Leu Pro Asp Arg Asp Gly Leu Leu Leu Thr Gly 3525 3530 3535		
Arg Leu Ser Leu Arg Thr His Pro Trp Leu Ala Asp His Ala Val Leu 3540 3545 3550		
Gly Ser Val Leu Leu Pro Gly Ala Ala Met Val Glu Leu Ala Ala His 3555 3560 3565		
Ala Ala Glu Ser Ala Gly Leu Arg Asp Val Arg Glu Leu Thr Leu Leu 3570 3575 3580		
Glu Pro Leu Val Leu Pro Glu His Gly Gly Val Glu Leu Arg Val Thr 3585 3590 3595 3600		
Val Gly Ala Pro Ala Gly Glu Pro Gly Gly Glu Ser Ala Gly Asp Gly 3605 3610 3615		
Ala Arg Pro Val Ser Leu His Ser Arg Leu Ala Asp Ala Pro Ala Gly 3620 3625 3630		
Thr Ala Trp Ser Cys His Ala Thr Gly Leu Leu Ala Thr Asp Arg Pro 3635 3640 3645		
Glu Leu Pro Val Ala Pro Asp Arg Ala Ala Met Trp Pro Pro Gln Gly 3650 3655 3660		
Ala Glu Glu Val Pro Leu Asp Gly Leu Tyr Glu Arg Leu Asp Gly Asn 3665 3670 3675 3680		
Gly Leu Ala Phe Gly Pro Leu Phe Gln Gly Leu Asn Ala Val Trp Arg 3685 3690 3695		
Tyr Glu Gly Glu Val Phe Ala Asp Ile Ala Leu Pro Ala Thr Thr Asn 3700 3705 3710		
Ala Thr Ala Pro Ala Thr Ala Asn Gly Gly Gly Ser Ala Ala Ala Ala 3715 3720 3725		
Pro Tyr Gly Ile His Pro Ala Leu Leu Asp Ala Ser Leu His Ala Ile 3730 3735 3740		

-continued

Ala Val Gly Gly Leu Val Asp Glu Pro Glu Leu Val Arg Val Pro Phe
3745 3750 3755 3760

His Trp Ser Gly Val Thr Val His Ala Ala Gly Ala Ala Ala Arg
3765 3770 3775

Val Arg Leu Ala Ser Ala Gly Thr Asp Ala Val Ser Leu Ser Leu Thr
3780 3785 3790

Asp Gly Glu Gly Arg Pro Leu Val Ser Val Glu Arg Leu Thr Leu Arg
3795 3800 3805

Pro Val Thr Ala Asp Gln Ala Ala Ala Ser Arg Val Gly Gly Leu Met
3810 3815 3820

His Arg Val Ala Trp Arg Pro Tyr Ala Leu Ala Ser Ser Gly Glu Gln
3825 3830 3835 3840

Asp Pro His Ala Thr Ser Tyr Gly Pro Thr Ala Val Leu Gly Lys Asp
3845 3850 3855

Glu Leu Lys Val Ala Ala Ala Leu Glu Ser Ala Gly Val Glu Val Gly
3860 3865 3870

Leu Tyr Pro Asp Leu Ala Ala Leu Ser Gln Asp Val Ala Ala Gly Ala
3875 3880 3885

Pro Ala Pro Arg Thr Val Leu Ala Pro Leu Pro Ala Gly Pro Ala Asp
3890 3895 3900

Gly Gly Ala Glu Gly Val Arg Gly Thr Val Ala Arg Thr Leu Glu Leu
3905 3910 3915 3920

Leu Gln Ala Trp Leu Ala Asp Glu His Leu Ala Gly Thr Arg Leu Leu
3925 3930 3935

Leu Val Thr Arg Gly Ala Val Arg Asp Pro Glu Gly Ser Gly Ala Asp
3940 3945 3950

Asp Gly Gly Glu Asp Leu Ser His Ala Ala Ala Trp Gly Leu Val Arg
3955 3960 3965

Thr Ala Gln Thr Glu Asn Pro Gly Arg Phe Gly Leu Leu Asp Leu Ala
3970 3975 3980

Asp Asp Ala Ser Ser Tyr Arg Thr Leu Pro Ser Val Leu Ser Asp Ala
3985 3990 3995 4000

Gly Leu Arg Asp Glu Pro Gln Leu Ala Leu His Asp Gly Thr Ile Arg
4005 4010 4015

Leu Ala Arg Leu Ala Ser Val Arg Pro Glu Thr Gly Thr Ala Ala Pro
4020 4025 4030

Ala Leu Ala Pro Glu Gly Thr Val Leu Leu Thr Gly Gly Thr Gly Gly
4035 4040 4045

Leu Gly Gly Leu Val Ala Arg His Val Val Gly Glu Trp Gly Val Arg
4050 4055 4060

Arg Leu Leu Leu Val Ser Arg Arg Gly Thr Asp Ala Pro Gly Ala Asp
4065 4070 4075 4080

Glu Leu Val His Glu Leu Glu Ala Leu Gly Ala Asp Val Ser Val Ala
4085 4090 4095

Ala Cys Asp Val Ala Asp Arg Glu Ala Leu Thr Ala Val Leu Asp Ala
4100 4105 4110

Ile Pro Ala Glu His Pro Leu Thr Ala Val Val His Thr Ala Gly Val
4115 4120 4125

Leu Ser Asp Gly Thr Leu Pro Ser Met Thr Thr Glu Asp Val Glu His
4130 4135 4140

-continued

Val Leu Arg Pro Lys	Val Asp Ala Ala Phe	Leu Leu Asp Glu Leu Thr
4145	4150	4155 4160
Ser Thr Pro Ala Tyr	Asp Leu Ala Ala Phe	Val Met Phe Ser Ser Ala
4165	4170	4175
Ala Ala Val Phe Gly Gly	Ala Gly Gln Gly Ala Tyr	Ala Ala Ala Asn
4180	4185	4190
Ala Thr Leu Asp Ala Leu	Ala Trp Arg Arg Arg	Ala Ala Gly Leu Pro
4195	4200	4205
Ala Leu Ser Leu Gly Trp	Gly Leu Trp Ala Glu	Thr Ser Gly Met Thr
4210	4215	4220
Gly Glu Leu Gly Gln	Ala Asp Leu Arg Arg	Met Ser Arg Ala Gly Ile
4225	4230	4235 4240
Gly Gly Ile Ser Asp	Ala Glu Gly Ile	Ala Leu Leu Asp Ala Ala Leu
4245	4250	4255
Arg Asp Asp Arg His	Pro Val Leu Leu Pro	Leu Arg Leu Asp Ala Ala
4260	4265	4270
Gly Leu Arg Asp Ala	Ala Gly Asn Asp Pro	Ala Gly Ile Pro Ala Leu
4275	4280	4285
Phe Arg Asp Val Val	Gly Ala Arg Thr Val	Arg Ala Arg Pro Ser Ala
4290	4295	4300
Ala Ser Ala Ser Thr	Thr Ala Gly Thr Ala	Gly Thr Pro Gly Thr Ala
4305	4310	4315 4320
Asp Gly Ala Ala Glu	Thr Ala Ala Val Thr	Leu Ala Asp Arg Ala Ala
4325	4330	4335
Thr Val Asp Gly Pro	Ala Arg Gln Arg	Leu Leu Leu Glu Phe Val Val
4340	4345	4350
Gly Glu Val Ala Glu	Val Leu Gly His Ala	Arg Gly His Arg Ile Asp
4355	4360	4365
Ala Glu Arg Gly Phe	Leu Asp Leu Gly Phe	Asp Ser Leu Thr Ala Val
4370	4375	4380
Glu Leu Arg Asn Arg	Leu Asn Ser Ala Gly	Gly Leu Ala Leu Pro Ala
4385	4390	4395 4400
Thr Leu Val Phe Asp	His Pro Ser Pro	Ala Ala Leu Ala Ser His Leu
4405	4410	4415
Asp Ala Glu Leu Pro	Arg Gly Ala Ser Asp	Gln Asp Gly Ala Gly Asn
4420	4425	4430
Arg Asn Gly Asn Glu	Asn Gly Thr Thr	Ala Ser Arg Ser Thr Ala Glu
4435	4440	4445
Thr Asp Ala Leu Leu	Ala Gln Leu Thr Arg	Leu Glu Gly Ala Leu Val
4450	4455	4460
Leu Thr Gly Leu Ser	Asp Ala Pro Gly Ser	Glu Glu Val Leu Glu His
4465	4470	4475 4480
Leu Arg Ser Leu Arg	Ser Met Val Thr	Gly Glu Thr Gly Thr Gly Thr
4485	4490	4495
Ala Ser Gly Ala Pro	Asp Gly Ala Gly Ser	Gly Ala Glu Asp Arg Pro
4500	4505	4510
Trp Ala Ala Gly Asp	Gly Ala Gly Gly Gly	Ser Glu Asp Gly Ala Gly
4515	4520	4525
Val Pro Asp Phe Met	Asn Ala Ser Ala Glu	Glu Leu Phe Gly Leu Leu
4530	4535	4540
Asp Gln Asp Pro Ser	Thr Asp	

-continued

4545 4550

<210> SEQ ID NO 2
 <211> LENGTH: 3739
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 2

Val Ser Thr Val Asn Glu Glu Lys Tyr Leu Asp Tyr Leu Arg Arg Ala
 1 5 10 15

Thr Ala Asp Leu His Glu Ala Arg Gly Arg Leu Arg Glu Leu Glu Ala
 20 25 30

Lys Ala Gly Glu Pro Val Ala Ile Val Gly Met Ala Cys Arg Leu Pro
 35 40 45

Gly Gly Val Ala Ser Pro Glu Asp Leu Trp Arg Leu Val Ala Gly Gly
 50 55 60

Glu Asp Ala Ile Ser Glu Phe Pro Gln Asp Arg Gly Trp Asp Val Glu
 65 70 75 80

Gly Leu Tyr Asp Pro Asn Pro Glu Ala Thr Gly Lys Ser Tyr Ala Arg
 85 90 95

Glu Ala Gly Phe Leu Tyr Glu Ala Gly Glu Phe Asp Ala Asp Phe Phe
 100 105 110

Gly Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu
 115 120 125

Leu Leu Glu Ala Ser Trp Glu Ala Phe Glu His Ala Gly Ile Pro Ala
 130 135 140

Ala Thr Ala Arg Gly Thr Ser Val Gly Val Phe Thr Gly Val Met Tyr
 145 150 155 160

His Asp Tyr Ala Thr Arg Leu Thr Asp Val Pro Glu Gly Ile Glu Gly
 165 170 175

Tyr Leu Gly Thr Gly Asn Ser Gly Ser Val Ala Ser Gly Arg Val Ala
 180 185 190

Tyr Thr Leu Gly Leu Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys
 195 200 205

Ser Ser Ser Leu Val Ala Leu His Leu Ala Val Gln Ala Leu Arg Lys
 210 215 220

Gly Glu Val Asp Met Ala Leu Ala Gly Gly Val Thr Val Met Ser Thr
 225 230 235 240

Pro Ser Thr Phe Val Glu Phe Ser Arg Gln Arg Gly Leu Ala Pro Asp
 245 250 255

Gly Arg Ser Lys Ser Phe Ser Ser Thr Ala Asp Gly Thr Ser Trp Ser
 260 265 270

Glu Gly Val Gly Val Leu Leu Val Glu Arg Leu Ser Asp Ala Arg Arg
 275 280 285

Lys Gly His Arg Ile Leu Ala Val Val Arg Gly Thr Ala Val Asn Gln
 290 295 300

Asp Gly Ala Ser Ser Gly Leu Thr Ala Pro Asn Gly Pro Ser Gln Gln
 305 310 315 320

Arg Val Ile Arg Arg Ala Leu Ala Asp Ala Arg Leu Thr Thr Ser Asp
 325 330 335

Val Asp Val Val Glu Ala His Gly Thr Gly Thr Arg Leu Gly Asp Pro
 340 345 350

-continued

Ile	Glu	Ala	Gln	Ala	Val	Ile	Ala	Thr	Tyr	Gly	Gln	Gly	Arg	Asp	Gly
		355					360					365			
Glu	Gln	Pro	Leu	Arg	Leu	Gly	Ser	Leu	Lys	Ser	Asn	Ile	Gly	His	Thr
		370				375					380				
Gln	Ala	Ala	Ala	Gly	Val	Ser	Gly	Val	Ile	Lys	Met	Val	Gln	Ala	Met
385					390					395					400
Arg	His	Gly	Val	Leu	Pro	Lys	Thr	Leu	His	Val	Glu	Lys	Pro	Thr	Asp
			405						410					415	
Gln	Val	Asp	Trp	Ser	Ala	Gly	Ala	Val	Glu	Leu	Leu	Thr	Glu	Ala	Met
		420						425					430		
Asp	Trp	Pro	Asp	Lys	Gly	Asp	Gly	Gly	Leu	Arg	Arg	Ala	Ala	Val	Ser
		435				440						445			
Ser	Phe	Gly	Val	Ser	Gly	Thr	Asn	Ala	His	Val	Val	Leu	Glu	Glu	Ala
	450				455						460				
Pro	Ala	Ala	Glu	Glu	Thr	Pro	Ala	Ser	Glu	Ala	Thr	Pro	Ala	Val	Glu
465					470					475					480
Pro	Ser	Val	Gly	Ala	Gly	Leu	Val	Pro	Trp	Leu	Val	Ser	Ala	Lys	Thr
			485					490						495	
Pro	Ala	Ala	Leu	Asp	Ala	Gln	Ile	Gly	Arg	Leu	Ala	Ala	Phe	Ala	Ser
			500					505					510		
Gln	Gly	Arg	Thr	Asp	Ala	Ala	Asp	Pro	Gly	Ala	Val	Ala	Arg	Val	Leu
		515					520					525			
Ala	Gly	Gly	Arg	Ala	Glu	Phe	Glu	His	Arg	Ala	Val	Val	Leu	Gly	Thr
	530				535						540				
Gly	Gln	Asp	Asp	Phe	Ala	Gln	Ala	Leu	Thr	Ala	Pro	Glu	Gly	Leu	Ile
545				550						555					560
Arg	Gly	Thr	Pro	Ser	Asp	Val	Gly	Arg	Val	Ala	Phe	Val	Phe	Pro	Gly
			565					570						575	
Gln	Gly	Thr	Gln	Trp	Ala	Gly	Met	Gly	Ala	Glu	Leu	Leu	Asp	Val	Ser
		580					585						590		
Lys	Glu	Phe	Ala	Ala	Ala	Met	Ala	Glu	Cys	Glu	Ser	Ala	Leu	Ser	Arg
	595					600						605			
Tyr	Val	Asp	Trp	Ser	Leu	Glu	Ala	Val	Val	Arg	Gln	Ala	Pro	Gly	Ala
	610				615						620				
Pro	Thr	Leu	Glu	Arg	Val	Asp	Val	Val	Gln	Pro	Val	Thr	Phe	Ala	Val
625					630					635					640
Met	Val	Ser	Leu	Ala	Lys	Val	Trp	Gln	His	His	Gly	Val	Thr	Pro	Gln
			645						650					655	
Ala	Val	Val	Gly	His	Ser	Gln	Gly	Glu	Ile	Ala	Ala	Ala	Tyr	Val	Ala
			660				665						670		
Gly	Ala	Leu	Thr	Leu	Asp	Asp	Ala	Ala	Arg	Val	Val	Thr	Leu	Arg	Ser
	675					680						685			
Lys	Ser	Ile	Ala	Ala	His	Leu	Ala	Gly	Lys	Gly	Gly	Met	Ile	Ser	Leu
	690					695					700				
Ala	Leu	Ser	Glu	Glu	Ala	Thr	Arg	Gln	Arg	Ile	Glu	Asn	Leu	His	Gly
705					710					715					720
Leu	Ser	Ile	Ala	Ala	Val	Asn	Gly	Pro	Thr	Ala	Thr	Val	Val	Ser	Gly
			725						730					735	
Asp	Pro	Thr	Gln	Ile	Gln	Glu	Leu	Ala	Gln	Ala	Cys	Glu	Ala	Asp	Gly
		740						745					750		
Val	Arg	Ala	Arg	Ile	Ile	Pro	Val	Asp	Tyr	Ala	Ser	His	Ser	Ala	His

-continued

755					760					765					
Val	Glu	Thr	Ile	Glu	Ser	Glu	Leu	Ala	Glu	Val	Leu	Ala	Gly	Leu	Ser
770						775					780				
Pro	Arg	Thr	Pro	Glu	Val	Pro	Phe	Phe	Ser	Thr	Leu	Glu	Gly	Ala	Trp
785					790					795					800
Ile	Thr	Glu	Pro	Val	Leu	Asp	Gly	Thr	Tyr	Trp	Tyr	Arg	Asn	Leu	Arg
				805					810					815	
His	Arg	Val	Gly	Phe	Ala	Pro	Ala	Val	Glu	Thr	Leu	Ala	Thr	Asp	Glu
			820					825					830		
Gly	Phe	Thr	His	Phe	Ile	Glu	Val	Ser	Ala	His	Pro	Val	Leu	Thr	Met
	835						840					845			
Thr	Leu	Pro	Glu	Thr	Val	Thr	Gly	Leu	Gly	Thr	Leu	Arg	Arg	Glu	Gln
	850					855					860				
Gly	Gly	Gln	Glu	Arg	Leu	Val	Thr	Ser	Leu	Ala	Glu	Ala	Trp	Thr	Asn
865					870					875					880
Gly	Leu	Thr	Ile	Asp	Trp	Ala	Pro	Val	Leu	Pro	Thr	Ala	Thr	Gly	His
				885					890					895	
His	Pro	Glu	Leu	Pro	Thr	Tyr	Ala	Phe	Gln	Arg	Arg	His	Tyr	Trp	Leu
			900				905						910		
His	Asp	Ser	Pro	Ala	Val	Gln	Gly	Ser	Val	Gln	Asp	Ser	Trp	Arg	Tyr
		915					920				925				
Arg	Ile	Asp	Trp	Lys	Arg	Leu	Ala	Val	Ala	Asp	Ala	Ser	Glu	Arg	Ala
	930					935					940				
Gly	Leu	Ser	Gly	Arg	Trp	Leu	Val	Val	Val	Pro	Glu	Asp	Arg	Ser	Ala
945					950					955					960
Glu	Ala	Ala	Pro	Val	Leu	Ala	Ala	Leu	Ser	Gly	Ala	Gly	Ala	Asp	Pro
				965					970					975	
Val	Gln	Leu	Asp	Val	Ser	Pro	Leu	Gly	Asp	Arg	Gln	Arg	Leu	Ala	Ala
			980					985					990		
Thr	Leu	Gly	Glu	Ala	Leu	Ala	Ala	Ala	Gly	Gly	Ala	Val	Asp	Gly	Val
	995						1000					1005			
Leu	Ser	Leu	Leu	Ala	Trp	Asp	Glu	Ser	Ala	His	Pro	Gly	His	Pro	Ala
1010						1015					1020				
Pro	Phe	Thr	Arg	Gly	Thr	Gly	Ala	Thr	Leu	Thr	Leu	Val	Gln	Ala	Leu
1025					1030					1035					1040
Glu	Asp	Ala	Gly	Val	Ala	Ala	Pro	Leu	Trp	Cys	Val	Thr	His	Gly	Ala
				1045					1050					1055	
Val	Ser	Val	Gly	Arg	Ala	Asp	His	Val	Thr	Ser	Pro	Ala	Gln	Ala	Met
			1060				1065						1070		
Val	Trp	Gly	Met	Gly	Arg	Val	Ala	Ala	Leu	Glu	His	Pro	Glu	Arg	Trp
	1075					1080						1085			
Gly	Gly	Leu	Ile	Asp	Leu	Pro	Ser	Asp	Ala	Asp	Arg	Ala	Ala	Leu	Asp
1090					1095						1100				
Arg	Met	Thr	Thr	Val	Leu	Ala	Gly	Gly	Thr	Gly	Glu	Asp	Gln	Val	Ala
1105					1110					1115					1120
Val	Arg	Ala	Ser	Gly	Leu	Leu	Ala	Arg	Arg	Leu	Val	Arg	Ala	Ser	Leu
				1125					1130					1135	
Pro	Ala	His	Gly	Thr	Ala	Ser	Pro	Trp	Trp	Gln	Ala	Asp	Gly	Thr	Val
			1140					1145					1150		
Leu	Val	Thr	Gly	Ala	Glu	Glu	Pro	Ala	Ala	Ala	Glu	Ala	Ala	Arg	Arg
	1155						1160					1165			

-continued

Leu Ala Arg Asp Gly Ala Gly His Leu Leu Leu His Thr Thr Pro Ser		
1170	1175	1180
Gly Ser Glu Gly Ala Glu Gly Thr Ser Gly Ala Ala Glu Asp Ser Gly		
1185	1190	1195 1200
Leu Ala Gly Leu Val Ala Glu Leu Ala Asp Leu Gly Ala Thr Ala Thr		
1205	1210	1215
Val Val Thr Cys Asp Leu Thr Asp Ala Glu Ala Ala Ala Arg Leu Leu		
1220	1225	1230
Ala Gly Val Ser Asp Ala His Pro Leu Ser Ala Val Leu His Leu Pro		
1235	1240	1245
Pro Thr Val Asp Ser Glu Pro Leu Ala Ala Thr Asp Ala Asp Ala Leu		
1250	1255	1260
Ala Arg Val Val Thr Ala Lys Ala Thr Ala Ala Leu His Leu Asp Arg		
1265	1270	1275 1280
Leu Leu Arg Glu Ala Ala Ala Ala Gly Gly Arg Pro Pro Val Leu Val		
1285	1290	1295
Leu Phe Ser Ser Val Ala Ala Ile Trp Gly Gly Ala Gly Gln Gly Ala		
1300	1305	1310
Tyr Ala Ala Gly Thr Ala Phe Leu Asp Ala Leu Ala Gly Gln His Arg		
1315	1320	1325
Ala Asp Gly Pro Thr Val Thr Ser Val Ala Trp Ser Pro Trp Glu Gly		
1330	1335	1340
Ser Arg Val Thr Glu Gly Ala Thr Gly Glu Arg Leu Arg Arg Leu Gly		
1345	1350	1355 1360
Leu Arg Pro Leu Ala Pro Ala Thr Ala Leu Thr Ala Leu Asp Thr Ala		
1365	1370	1375
Leu Gly His Gly Asp Thr Ala Val Thr Ile Ala Asp Val Asp Trp Ser		
1380	1385	1390
Ser Phe Ala Pro Gly Phe Thr Thr Ala Arg Pro Gly Thr Leu Leu Ala		
1395	1400	1405
Asp Leu Pro Glu Ala Arg Arg Ala Leu Asp Glu Gln Gln Ser Thr Thr		
1410	1415	1420
Ala Ala Asp Asp Thr Val Leu Ser Arg Glu Leu Gly Ala Leu Thr Gly		
1425	1430	1435 1440
Ala Glu Gln Gln Arg Arg Met Gln Glu Leu Val Arg Glu His Leu Ala		
1445	1450	1455
Val Val Leu Asn His Pro Ser Pro Glu Ala Val Asp Thr Gly Arg Ala		
1460	1465	1470
Phe Arg Asp Leu Gly Phe Asp Ser Leu Thr Ala Val Glu Leu Arg Asn		
1475	1480	1485
Arg Leu Lys Asn Ala Thr Gly Leu Ala Leu Pro Ala Thr Leu Val Phe		
1490	1495	1500
Asp Tyr Pro Thr Pro Arg Thr Leu Ala Glu Phe Leu Leu Ala Glu Ile		
1505	1510	1515 1520
Leu Gly Glu Gln Ala Gly Ala Gly Glu Gln Leu Pro Val Asp Gly Gly		
1525	1530	1535
Val Asp Asp Glu Pro Val Ala Ile Val Gly Met Ala Cys Arg Leu Pro		
1540	1545	1550
Gly Gly Val Ala Ser Pro Glu Asp Leu Trp Arg Leu Val Ala Gly Gly		
1555	1560	1565

-continued

Glu	Asp	Ala	Ile	Ser	Gly	Phe	Pro	Gln	Asp	Arg	Gly	Trp	Asp	Val	Glu
1570						1575					1580				
Gly	Leu	Tyr	Asp	Pro	Asp	Pro	Asp	Ala	Ser	Gly	Arg	Thr	Tyr	Cys	Arg
1585					1590					1595					1600
Ala	Gly	Gly	Phe	Leu	Asp	Glu	Ala	Gly	Glu	Phe	Asp	Ala	Asp	Phe	Phe
				1605					1610					1615	
Gly	Ile	Ser	Pro	Arg	Glu	Ala	Leu	Ala	Met	Asp	Pro	Gln	Gln	Arg	Leu
			1620					1625					1630		
Leu	Leu	Glu	Thr	Ser	Trp	Glu	Ala	Val	Glu	Asp	Ala	Gly	Ile	Asp	Pro
		1635					1640					1645			
Thr	Ser	Leu	Gln	Gly	Gln	Gln	Val	Gly	Val	Phe	Ala	Gly	Thr	Asn	Gly
	1650				1655					1660					
Pro	His	Tyr	Glu	Pro	Leu	Leu	Arg	Asn	Thr	Ala	Glu	Asp	Leu	Glu	Gly
1665					1670					1675					1680
Tyr	Val	Gly	Thr	Gly	Asn	Ala	Ala	Ser	Ile	Met	Ser	Gly	Arg	Val	Ser
				1685					1690					1695	
Tyr	Thr	Leu	Gly	Leu	Glu	Gly	Pro	Ala	Val	Thr	Val	Asp	Thr	Ala	Cys
		1700						1705					1710		
Ser	Ser	Ser	Leu	Val	Ala	Leu	His	Leu	Ala	Val	Gln	Ala	Leu	Arg	Lys
		1715					1720					1725			
Gly	Glu	Cys	Gly	Leu	Ala	Leu	Ala	Gly	Gly	Val	Thr	Val	Met	Ser	Thr
	1730					1735					1740				
Pro	Thr	Thr	Phe	Val	Glu	Phe	Ser	Arg	Gln	Arg	Gly	Leu	Ala	Glu	Asp
1745					1750					1755					1760
Gly	Arg	Ser	Lys	Ala	Phe	Ala	Ala	Ser	Ala	Asp	Gly	Phe	Gly	Pro	Ala
				1765					1770					1775	
Glu	Gly	Val	Gly	Met	Leu	Leu	Val	Glu	Arg	Leu	Ser	Asp	Ala	Arg	Arg
		1780						1785					1790		
Asn	Gly	His	Arg	Val	Leu	Ala	Val	Val	Arg	Gly	Ser	Ala	Val	Asn	Gln
		1795					1800						1805		
Asp	Gly	Ala	Ser	Asn	Gly	Leu	Thr	Ala	Pro	Asn	Gly	Pro	Ser	Gln	Gln
	1810					1815					1820				
Arg	Val	Ile	Arg	Arg	Ala	Leu	Ala	Asp	Ala	Arg	Leu	Thr	Thr	Ala	Asp
1825					1830					1835					1840
Val	Asp	Val	Val	Glu	Ala	His	Gly	Thr	Gly	Thr	Arg	Leu	Gly	Asp	Pro
				1845					1850					1855	
Ile	Glu	Ala	Gln	Ala	Leu	Ile	Ala	Thr	Tyr	Gly	Gln	Gly	Arg	Asp	Thr
		1860						1865					1870		
Glu	Gln	Pro	Leu	Arg	Leu	Gly	Ser	Leu	Lys	Ser	Asn	Ile	Gly	His	Thr
		1875					1880					1885			
Gln	Ala	Ala	Ala	Gly	Val	Ser	Gly	Ile	Ile	Lys	Met	Val	Gln	Ala	Met
	1890						1895				1900				
Arg	His	Gly	Val	Leu	Pro	Lys	Thr	Leu	His	Val	Asp	Arg	Pro	Ser	Asp
1905					1910					1915					1920
Gln	Ile	Asp	Trp	Ser	Ala	Gly	Thr	Val	Glu	Leu	Leu	Thr	Glu	Ala	Met
				1925					1930					1935	
Asp	Trp	Pro	Arg	Lys	Gln	Glu	Gly	Gly	Leu	Arg	Arg	Ala	Ala	Val	Ser
		1940						1945					1950		
Ser	Phe	Gly	Ile	Ser	Gly	Thr	Asn	Ala	His	Ile	Val	Leu	Glu	Glu	Ala
	1955						1960					1965			
Pro	Val	Asp	Glu	Asp	Ala	Pro	Ala	Asp	Glu	Pro	Ser	Val	Gly	Gly	Val

-continued

1970					1975					1980					
Val	Pro	Trp	Leu	Val	Ser	Ala	Lys	Thr	Pro	Ala	Ala	Leu	Asp	Ala	Gln
1985					1990					1995					2000
Ile	Gly	Arg	Leu	Ala	Ala	Phe	Ala	Ser	Gln	Gly	Arg	Thr	Asp	Ala	Ala
				2005					2010					2015	
Asp	Pro	Gly	Ala	Val	Ala	Arg	Val	Leu	Ala	Gly	Gly	Arg	Ala	Gln	Phe
			2020					2025					2030		
Glu	His	Arg	Ala	Val	Ala	Leu	Gly	Thr	Gly	Gln	Asp	Asp	Leu	Ala	Ala
		2035					2040					2045			
Ala	Leu	Ala	Ala	Pro	Glu	Gly	Leu	Val	Arg	Gly	Val	Ala	Ser	Gly	Val
	2050					2055					2060				
Gly	Arg	Val	Ala	Phe	Val	Phe	Pro	Gly	Gln	Gly	Thr	Gln	Trp	Ala	Gly
2065					2070					2075					2080
Met	Gly	Ala	Glu	Leu	Leu	Asp	Val	Ser	Lys	Glu	Phe	Ala	Ala	Ala	Met
				2085					2090						2095
Ala	Glu	Cys	Glu	Ala	Ala	Leu	Ala	Pro	Tyr	Val	Asp	Trp	Ser	Leu	Glu
			2100					2105					2110		
Ala	Val	Val	Arg	Gln	Ala	Pro	Gly	Ala	Pro	Thr	Leu	Glu	Arg	Val	Asp
		2115					2120					2125			
Val	Val	Gln	Pro	Val	Thr	Phe	Ala	Val	Met	Val	Ser	Leu	Ala	Lys	Val
	2130					2135					2140				
Trp	Gln	His	His	Gly	Val	Thr	Pro	Gln	Ala	Val	Val	Gly	His	Ser	Gln
2145					2150					2155					2160
Gly	Glu	Ile	Ala	Ala	Ala	Tyr	Val	Ala	Gly	Ala	Leu	Ser	Leu	Asp	Asp
			2165						2170					2175	
Ala	Ala	Arg	Val	Val	Thr	Leu	Arg	Ser	Lys	Ser	Ile	Gly	Ala	His	Leu
			2180					2185					2190		
Ala	Gly	Gln	Gly	Gly	Met	Leu	Ser	Leu	Ala	Leu	Ser	Glu	Ala	Ala	Val
		2195					2200					2205			
Val	Glu	Arg	Leu	Ala	Gly	Phe	Asp	Gly	Leu	Ser	Val	Ala	Ala	Val	Asn
	2210					2215					2220				
Gly	Pro	Thr	Ala	Thr	Val	Val	Ser	Gly	Asp	Pro	Thr	Gln	Ile	Gln	Glu
2225					2230					2235					2240
Leu	Ala	Gln	Ala	Cys	Glu	Ala	Asp	Gly	Val	Arg	Ala	Arg	Ile	Ile	Pro
			2245						2250					2255	
Val	Asp	Tyr	Ala	Ser	His	Ser	Ala	His	Val	Glu	Thr	Ile	Glu	Ser	Glu
			2260					2265					2270		
Leu	Ala	Asp	Val	Leu	Ala	Gly	Leu	Ser	Pro	Gln	Thr	Pro	Gln	Val	Pro
		2275					2280					2285			
Phe	Phe	Ser	Thr	Leu	Glu	Gly	Ala	Trp	Ile	Thr	Glu	Pro	Ala	Leu	Asp
	2290					2295					2300				
Gly	Gly	Tyr	Trp	Tyr	Arg	Asn	Leu	Arg	His	Arg	Val	Gly	Phe	Ala	Pro
2305					2310					2315					2320
Ala	Val	Glu	Thr	Leu	Ala	Thr	Asp	Glu	Gly	Phe	Thr	His	Phe	Val	Glu
			2325						2330				2335		
Val	Ser	Ala	His	Pro	Val	Leu	Thr	Met	Ala	Leu	Pro	Glu	Thr	Val	Thr
			2340					2345					2350		
Gly	Leu	Gly	Thr	Leu	Arg	Arg	Asp	Asn	Gly	Gly	Gln	His	Arg	Leu	Thr
	2355						2360					2365			
Thr	Ser	Leu	Ala	Glu	Ala	Trp	Ala	Asn	Gly	Leu	Thr	Val	Asp	Trp	Ala
	2370					2375					2380				

-continued

Ser	Leu	Leu	Pro	Thr	Thr	Thr	Thr	His	Pro	Asp	Leu	Pro	Thr	Tyr	Ala	2385	2390	2395	2400
Phe	Gln	Thr	Glu	Arg	Tyr	Trp	Pro	Gln	Pro	Asp	Leu	Ser	Ala	Ala	Gly	2405	2410	2415	
Asp	Ile	Thr	Ser	Ala	Gly	Leu	Gly	Ala	Ala	Glu	His	Pro	Leu	Leu	Gly	2420	2425	2430	
Ala	Ala	Val	Ala	Leu	Ala	Asp	Ser	Asp	Gly	Cys	Leu	Leu	Thr	Gly	Ser	2435	2440	2445	
Leu	Ser	Leu	Arg	Thr	His	Pro	Trp	Leu	Ala	Asp	His	Ala	Val	Ala	Gly	2450	2455	2460	
Thr	Val	Leu	Leu	Pro	Gly	Thr	Ala	Phe	Val	Glu	Leu	Ala	Phe	Arg	Ala	2465	2470	2475	2480
Gly	Asp	Gln	Val	Gly	Cys	Asp	Leu	Val	Glu	Glu	Leu	Thr	Leu	Asp	Ala	2485	2490	2495	
Pro	Leu	Val	Leu	Pro	Arg	Arg	Gly	Ala	Val	Arg	Val	Gln	Leu	Ser	Val	2500	2505	2510	
Gly	Ala	Ser	Asp	Glu	Ser	Gly	Arg	Arg	Thr	Phe	Gly	Leu	Tyr	Ala	His	2515	2520	2525	
Pro	Glu	Asp	Ala	Pro	Gly	Glu	Ala	Glu	Trp	Thr	Arg	His	Ala	Thr	Gly	2530	2535	2540	
Val	Leu	Ala	Ala	Arg	Ala	Asp	Arg	Thr	Ala	Pro	Val	Ala	Asp	Pro	Glu	2545	2550	2555	2560
Ala	Trp	Pro	Pro	Pro	Gly	Ala	Glu	Pro	Val	Asp	Val	Asp	Gly	Leu	Tyr	2565	2570	2575	
Glu	Arg	Phe	Ala	Ala	Asn	Gly	Tyr	Gly	Tyr	Gly	Pro	Leu	Phe	Gln	Gly	2580	2585	2590	
Val	Arg	Gly	Val	Trp	Arg	Arg	Gly	Asp	Glu	Val	Phe	Ala	Asp	Val	Ala	2595	2600	2605	
Leu	Pro	Ala	Glu	Val	Ala	Gly	Ala	Glu	Gly	Ala	Arg	Phe	Gly	Leu	His	2610	2615	2620	
Pro	Ala	Leu	Leu	Asp	Ala	Ala	Val	Gln	Ala	Ala	Gly	Ala	Gly	Gly	Ala	2625	2630	2635	2640
Phe	Gly	Ala	Gly	Thr	Arg	Leu	Pro	Phe	Ala	Trp	Ser	Gly	Ile	Ser	Leu	2645	2650	2655	
Tyr	Ala	Val	Gly	Ala	Thr	Ala	Leu	Arg	Val	Arg	Leu	Ala	Pro	Ala	Gly	2660	2665	2670	
Pro	Asp	Thr	Val	Ser	Val	Ser	Ala	Ala	Asp	Ser	Ser	Gly	Gln	Pro	Val	2675	2680	2685	
Phe	Ala	Ala	Asp	Ser	Leu	Thr	Val	Leu	Pro	Val	Asp	Pro	Ala	Gln	Leu	2690	2695	2700	
Ala	Ala	Phe	Ser	Asp	Pro	Thr	Leu	Asp	Ala	Leu	His	Leu	Leu	Glu	Trp	2705	2710	2715	2720
Thr	Ala	Trp	Asp	Gly	Ala	Ala	Gln	Ala	Leu	Pro	Gly	Ala	Val	Val	Leu	2725	2730	2735	
Gly	Gly	Asp	Ala	Asp	Gly	Leu	Ala	Ala	Ala	Leu	Arg	Ala	Gly	Gly	Thr	2740	2745	2750	
Glu	Val	Leu	Ser	Phe	Pro	Asp	Leu	Thr	Asp	Leu	Val	Glu	Ala	Val	Asp	2755	2760	2765	
Arg	Gly	Glu	Thr	Pro	Ala	Pro	Ala	Thr	Val	Leu	Val	Ala	Cys	Pro	Ala	2770	2775	2780	

-continued

Ala Gly Pro Gly Gly Pro Glu His Val Arg Glu Ala Leu His Gly Ser	2785	2790	2795	2800
Leu Ala Leu Met Gln Ala Trp Leu Ala Asp Glu Arg Phe Thr Asp Gly		2805	2810	2815
Arg Leu Val Leu Val Thr Arg Asp Ala Val Ala Ala Arg Ser Gly Asp		2820	2825	2830
Gly Leu Arg Ser Thr Gly Gln Ala Ala Val Trp Gly Leu Gly Arg Ser		2835	2840	2845
Ala Gln Thr Glu Ser Pro Gly Arg Phe Val Leu Leu Asp Leu Ala Gly		2850	2855	2860
Glu Ala Arg Thr Ala Gly Asp Ala Thr Ala Gly Asp Gly Leu Thr Thr		2865	2870	2875
Gly Asp Ala Thr Val Gly Gly Thr Ser Gly Asp Ala Ala Leu Gly Ser		2885	2890	2895
Ala Leu Ala Thr Ala Leu Gly Ser Gly Glu Pro Gln Leu Ala Leu Arg		2900	2905	2910
Asp Gly Ala Leu Leu Val Pro Arg Leu Ala Arg Ala Ala Ala Pro Ala		2915	2920	2925
Ala Ala Asp Gly Leu Ala Ala Ala Asp Gly Leu Ala Ala Leu Pro Leu		2930	2935	2940
Pro Ala Ala Pro Ala Leu Trp Arg Leu Glu Pro Gly Thr Asp Gly Ser		2945	2950	2955
Leu Glu Ser Leu Thr Ala Ala Pro Gly Asp Ala Glu Thr Leu Ala Pro		2965	2970	2975
Glu Pro Leu Gly Pro Gly Gln Val Arg Ile Ala Ile Arg Ala Thr Gly		2980	2985	2990
Leu Asn Phe Arg Asp Val Leu Ile Ala Leu Gly Met Tyr Pro Asp Pro		2995	3000	3005
Ala Leu Met Gly Thr Glu Gly Ala Gly Val Val Thr Ala Thr Gly Pro		3010	3015	3020
Gly Val Thr His Leu Ala Pro Gly Asp Arg Val Met Gly Leu Leu Ser		3025	3030	3035
Gly Ala Tyr Ala Pro Val Val Val Ala Asp Ala Arg Thr Val Ala Arg		3045	3050	3055
Met Pro Glu Gly Trp Thr Phe Ala Gln Gly Ala Ser Val Pro Val Val		3060	3065	3070
Phe Leu Thr Ala Val Tyr Ala Leu Arg Asp Leu Ala Asp Val Lys Pro		3075	3080	3085
Gly Glu Arg Leu Leu Val His Ser Ala Ala Gly Gly Val Gly Met Ala		3090	3095	3100
Ala Val Gln Leu Ala Arg His Trp Gly Val Glu Val His Gly Thr Ala		3105	3110	3115
Ser His Gly Lys Trp Asp Ala Leu Arg Ala Leu Gly Leu Asp Asp Ala		3125	3130	3135
His Ile Ala Ser Ser Arg Thr Leu Asp Phe Glu Ser Ala Phe Arg Ala		3140	3145	3150
Ala Ser Gly Gly Ala Gly Met Asp Val Val Leu Asn Ser Leu Ala Arg		3155	3160	3165
Glu Phe Val Asp Ala Ser Leu Arg Leu Leu Gly Pro Gly Gly Arg Phe		3170	3175	3180
Val Glu Met Gly Lys Thr Asp Val Arg Asp Ala Glu Arg Val Ala Ala				

-continued

3185	3190	3195	3200
Asp His Pro Gly Val Gly Tyr Arg Ala Phe Asp Leu Gly Glu Ala Gly	3205	3210	3215
Pro Glu Arg Ile Gly Glu Met Leu Ala Glu Val Ile Ala Leu Phe Glu	3220	3225	3230
Asp Gly Val Leu Arg His Leu Pro Val Thr Thr Trp Asp Val Arg Arg	3235	3240	3245
Ala Arg Asp Ala Phe Arg His Val Ser Gln Ala Arg His Thr Gly Lys	3250	3255	3260
Val Val Leu Thr Met Pro Ser Gly Leu Asp Pro Glu Gly Thr Val Leu	3265	3270	3275
Leu Thr Gly Gly Thr Gly Ala Leu Gly Gly Ile Val Ala Arg His Val	3285	3290	3295
Val Gly Glu Trp Gly Val Arg Arg Leu Leu Leu Val Ser Arg Arg Gly	3300	3305	3310
Thr Asp Ala Pro Gly Ala Gly Glu Leu Val His Glu Leu Glu Ala Leu	3315	3320	3325
Gly Ala Asp Val Ser Val Ala Ala Cys Asp Val Ala Asp Arg Glu Ala	3330	3335	3340
Leu Thr Ala Val Leu Asp Ser Ile Pro Ala Glu His Pro Leu Thr Ala	3345	3350	3355
Val Val His Thr Ala Gly Val Leu Ser Asp Gly Thr Leu Pro Ser Met	3365	3370	3375
Thr Ala Glu Asp Val Glu His Val Leu Arg Pro Lys Val Asp Ala Ala	3380	3385	3390
Phe Leu Leu Asp Glu Leu Thr Ser Thr Pro Gly Tyr Asp Leu Ala Ala	3395	3400	3405
Phe Val Met Phe Ser Ser Ala Ala Ala Val Phe Gly Gly Ala Gly Gln	3410	3415	3420
Gly Ala Tyr Ala Ala Ala Asn Ala Thr Leu Asp Ala Leu Ala Trp Arg	3425	3430	3435
Arg Arg Thr Ala Gly Leu Pro Ala Leu Ser Leu Gly Trp Gly Leu Trp	3445	3450	3455
Ala Glu Thr Ser Gly Met Thr Gly Gly Leu Ser Asp Thr Asp Arg Ser	3460	3465	3470
Arg Leu Ala Arg Ser Gly Ala Thr Pro Met Asp Ser Glu Leu Thr Leu	3475	3480	3485
Ser Leu Leu Asp Ala Ala Met Arg Arg Asp Asp Pro Ala Leu Val Pro	3490	3495	3500
Ile Ala Leu Asp Val Ala Ala Leu Arg Ala Gln Gln Arg Asp Gly Met	3505	3510	3515
Leu Ala Pro Leu Leu Ser Gly Leu Thr Arg Gly Ser Arg Val Gly Gly	3525	3530	3535
Ala Pro Val Asn Gln Arg Arg Ala Ala Ala Gly Gly Ala Gly Glu Ala	3540	3545	3550
Asp Thr Asp Leu Gly Gly Arg Leu Ala Ala Met Thr Pro Asp Asp Arg	3555	3560	3565
Val Ala His Leu Arg Asp Leu Val Arg Thr His Val Ala Thr Val Leu	3570	3575	3580
Gly His Gly Thr Pro Ser Arg Val Asp Leu Glu Arg Ala Phe Arg Asp	3585	3590	3595
			3600

-continued

Thr Gly Phe Asp Ser Leu Thr Ala Val Glu Leu Arg Asn Arg Leu Asn
3605 3610 3615

Ala Ala Thr Gly Leu Arg Leu Pro Ala Thr Leu Val Phe Asp His Pro
3620 3625 3630

Thr Pro Gly Glu Leu Ala Gly His Leu Leu Asp Glu Leu Ala Thr Ala
3635 3640 3645

Ala Gly Gly Ser Trp Ala Glu Gly Thr Gly Ser Gly Asp Thr Ala Ser
3650 3655 3660

Ala Thr Asp Arg Gln Thr Thr Ala Ala Leu Ala Glu Leu Asp Arg Leu
3665 3670 3675 3680

Glu Gly Val Leu Ala Ser Leu Ala Pro Ala Ala Gly Gly Arg Pro Glu
3685 3690 3695

Leu Ala Ala Arg Leu Arg Ala Leu Ala Ala Ala Leu Gly Asp Asp Gly
3700 3705 3710

Asp Asp Ala Thr Asp Leu Asp Glu Ala Ser Asp Asp Asp Leu Phe Ser
3715 3720 3725

Phe Ile Asp Lys Glu Leu Gly Asp Ser Asp Phe
3730 3735

<210> SEQ ID NO 3
<211> LENGTH: 1562
<212> TYPE: PRT
<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 3

Met Ala Asn Asn Glu Asp Lys Leu Arg Asp Tyr Leu Lys Arg Val Thr
1 5 10 15

Ala Glu Leu Gln Gln Asn Thr Arg Arg Leu Arg Glu Ile Glu Gly Arg
20 25 30

Thr His Glu Pro Val Ala Ile Val Gly Met Ala Cys Arg Leu Pro Gly
35 40 45

Gly Val Ala Ser Pro Glu Asp Leu Trp Gln Leu Val Ala Gly Asp Gly
50 55 60

Asp Ala Ile Ser Glu Phe Pro Gln Asp Arg Gly Trp Asp Val Glu Gly
65 70 75 80

Leu Tyr Asp Pro Asp Pro Asp Ala Ser Gly Arg Thr Tyr Cys Arg Ser
85 90 95

Gly Gly Phe Leu His Asp Ala Gly Glu Phe Asp Ala Asp Phe Phe Gly
100 105 110

Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Leu Ser
115 120 125

Leu Thr Thr Ala Trp Glu Ala Ile Glu Ser Ala Gly Ile Asp Pro Thr
130 135 140

Ala Leu Lys Gly Ser Gly Leu Gly Val Phe Val Gly Gly Trp His Thr
145 150 155 160

Gly Tyr Thr Ser Gly Gln Thr Thr Ala Val Gln Ser Pro Glu Leu Glu
165 170 175

Gly His Leu Val Ser Gly Ala Ala Leu Gly Phe Leu Ser Gly Arg Ile
180 185 190

Ala Tyr Val Leu Gly Thr Asp Gly Pro Ala Leu Thr Val Asp Thr Ala
195 200 205

Cys Ser Ser Ser Leu Val Ala Leu His Leu Ala Val Gln Ala Leu Arg

-continued

210	215	220
Lys Gly Glu Cys Asp Met Ala Leu Ala Gly Gly Val Thr Val Met Pro 225 230 235 240		
Asn Ala Asp Leu Phe Val Gln Phe Ser Arg Gln Arg Gly Leu Ala Ala 245 250 255		
Asp Gly Arg Ser Lys Ala Phe Ala Thr Ser Ala Asp Gly Phe Gly Pro 260 265 270		
Ala Glu Gly Ala Gly Val Leu Leu Val Glu Arg Leu Ser Asp Ala Arg 275 280 285		
Arg Asn Gly His Arg Ile Leu Ala Val Val Arg Gly Ser Ala Val Asn 290 295 300		
Gln Asp Gly Ala Ser Asn Gly Leu Thr Ala Pro His Gly Pro Ser Gln 305 310 315 320		
Gln Arg Val Ile Arg Arg Ala Leu Ala Asp Ala Arg Leu Ala Pro Gly 325 330 335		
Asp Val Asp Val Val Glu Ala His Gly Thr Gly Thr Arg Leu Gly Asp 340 345 350		
Pro Ile Glu Ala Gln Ala Leu Ile Ala Thr Tyr Gly Gln Glu Lys Ser 355 360 365		
Ser Glu Gln Pro Leu Arg Leu Gly Ala Leu Lys Ser Asn Ile Gly His 370 375 380		
Thr Gln Ala Ala Ala Gly Val Ala Gly Val Ile Lys Met Val Gln Ala 385 390 395 400		
Met Arg His Gly Leu Leu Pro Lys Thr Leu His Val Asp Glu Pro Ser 405 410 415		
Asp Gln Ile Asp Trp Ser Ala Gly Thr Val Glu Leu Leu Thr Glu Ala 420 425 430		
Val Asp Trp Pro Glu Lys Gln Asp Gly Gly Leu Arg Arg Ala Ala Val 435 440 445		
Ser Ser Phe Gly Ile Ser Gly Thr Asn Ala His Val Val Leu Glu Glu 450 455 460		
Ala Pro Ala Val Glu Asp Ser Pro Ala Val Glu Pro Pro Ala Gly Gly 465 470 475 480		
Gly Val Val Pro Trp Pro Val Ser Ala Lys Thr Pro Ala Ala Leu Asp 485 490 495		
Ala Gln Ile Gly Gln Leu Ala Ala Tyr Ala Asp Gly Arg Thr Asp Val 500 505 510		
Asp Pro Ala Val Ala Ala Arg Ala Leu Val Asp Ser Arg Thr Ala Met 515 520 525		
Glu His Arg Ala Val Ala Val Gly Asp Ser Arg Glu Ala Leu Arg Asp 530 535 540		
Ala Leu Arg Met Pro Glu Gly Leu Val Arg Gly Thr Ser Ser Asp Val 545 550 555 560		
Gly Arg Val Ala Phe Val Phe Pro Gly Gln Gly Thr Gln Trp Ala Gly 565 570 575		
Met Gly Ala Glu Leu Leu Asp Ser Ser Pro Glu Phe Ala Ala Ser Met 580 585 590		
Ala Glu Cys Glu Thr Ala Leu Ser Arg Tyr Val Asp Trp Ser Leu Glu 595 600 605		
Ala Val Val Arg Gln Glu Pro Gly Ala Pro Thr Leu Asp Arg Val Asp 610 615 620		

-continued

Val	Val	Gln	Pro	Val	Thr	Phe	Ala	Val	Met	Val	Ser	Leu	Ala	Lys	Val
625					630					635					640
Trp	Gln	His	His	Gly	Ile	Thr	Pro	Gln	Ala	Val	Val	Gly	His	Ser	Gln
				645					650						655
Gly	Glu	Ile	Ala	Ala	Ala	Tyr	Val	Ala	Gly	Ala	Leu	Thr	Leu	Asp	Asp
			660					665						670	
Ala	Ala	Arg	Val	Val	Thr	Leu	Arg	Ser	Lys	Ser	Ile	Ala	Ala	His	Leu
		675					680						685		
Ala	Gly	Lys	Gly	Gly	Met	Ile	Ser	Leu	Ala	Leu	Asp	Glu	Ala	Ala	Val
	690					695					700				
Leu	Lys	Arg	Leu	Ser	Asp	Phe	Asp	Gly	Leu	Ser	Val	Ala	Ala	Val	Asn
705					710					715					720
Gly	Pro	Thr	Ala	Thr	Val	Val	Ser	Gly	Asp	Pro	Thr	Gln	Ile	Glu	Glu
				725					730					735	
Leu	Ala	Arg	Thr	Cys	Glu	Ala	Asp	Gly	Val	Arg	Ala	Arg	Ile	Ile	Pro
			740					745					750		
Val	Asp	Tyr	Ala	Ser	His	Ser	Arg	Gln	Val	Glu	Ile	Ile	Glu	Lys	Glu
		755					760					765			
Leu	Ala	Glu	Val	Leu	Ala	Gly	Leu	Ala	Pro	Gln	Ala	Pro	His	Val	Pro
	770					775					780				
Phe	Phe	Ser	Thr	Leu	Glu	Gly	Thr	Trp	Ile	Thr	Glu	Pro	Val	Leu	Asp
785					790					795					800
Gly	Thr	Tyr	Trp	Tyr	Arg	Asn	Leu	Arg	His	Arg	Val	Gly	Phe	Ala	Pro
				805					810					815	
Ala	Val	Glu	Thr	Leu	Ala	Val	Asp	Gly	Phe	Thr	His	Phe	Ile	Glu	Val
				820				825					830		
Ser	Ala	His	Pro	Val	Leu	Thr	Met	Thr	Leu	Pro	Glu	Thr	Val	Thr	Gly
		835					840					845			
Leu	Gly	Thr	Leu	Arg	Arg	Glu	Gln	Gly	Gly	Gln	Glu	Arg	Leu	Val	Thr
	850					855					860				
Ser	Leu	Ala	Glu	Ala	Trp	Ala	Asn	Gly	Leu	Thr	Ile	Asp	Trp	Ala	Pro
865					870					875					880
Ile	Leu	Pro	Thr	Ala	Thr	Gly	His	His	Pro	Glu	Leu	Pro	Thr	Tyr	Ala
				885					890					895	
Phe	Gln	Thr	Glu	Arg	Phe	Trp	Leu	Gln	Ser	Ser	Ala	Pro	Thr	Ser	Ala
			900					905						910	
Ala	Asp	Asp	Trp	Arg	Tyr	Arg	Val	Glu	Trp	Lys	Pro	Leu	Thr	Ala	Ser
		915					920					925			
Gly	Gln	Ala	Asp	Leu	Ser	Gly	Arg	Trp	Ile	Val	Ala	Val	Gly	Ser	Glu
	930					935					940				
Pro	Glu	Ala	Glu	Leu	Leu	Gly	Ala	Leu	Lys	Ala	Ala	Gly	Ala	Glu	Val
945					950					955					960
Asp	Val	Leu	Glu	Ala	Gly	Ala	Asp	Asp	Asp	Arg	Glu	Ala	Leu	Ala	Ala
				965					970					975	
Arg	Leu	Thr	Ala	Leu	Thr	Thr	Gly	Asp	Gly	Phe	Thr	Gly	Val	Val	Ser
			980					985					990		
Leu	Leu	Asp	Asp	Leu	Val	Pro	Gln	Val	Ala	Trp	Val	Gln	Ala	Leu	Gly
		995					1000					1005			
Asp	Ala	Gly	Ile	Lys	Ala	Pro	Leu	Trp	Ser	Val	Thr	Gln	Gly	Ala	Val
	1010					1015						1020			

-continued

Ser Val Gly Arg Leu Asp Thr Pro Ala Asp Pro Asp Arg Ala Met Leu		
1025	1030	1035 1040
Trp Gly Leu Gly Arg Val Val Ala Leu Glu His Pro Glu Arg Trp Ala		
	1045	1050 1055
Gly Leu Val Asp Leu Pro Ala Gln Pro Asp Ala Ala Ala Leu Ala His		
	1060	1065 1070
Leu Val Thr Ala Leu Ser Gly Ala Thr Gly Glu Asp Gln Ile Ala Ile		
	1075	1080 1085
Arg Thr Thr Gly Leu His Ala Arg Arg Leu Ala Arg Ala Pro Leu His		
	1090	1095 1100
Gly Arg Arg Pro Thr Arg Asp Trp Gln Pro His Gly Thr Val Leu Ile		
	1105	1110 1115 1120
Thr Gly Gly Thr Gly Ala Leu Gly Ser His Ala Ala Arg Trp Met Ala		
	1125	1130 1135
His His Gly Ala Glu His Leu Leu Leu Val Ser Arg Ser Gly Glu Gln		
	1140	1145 1150
Ala Pro Gly Ala Thr Gln Leu Thr Ala Glu Leu Thr Ala Ser Gly Ala		
	1155	1160 1165
Arg Val Thr Ile Ala Ala Cys Asp Val Ala Asp Pro His Ala Met Arg		
	1170	1175 1180
Thr Leu Leu Asp Ala Ile Pro Ala Glu Thr Pro Leu Thr Ala Val Val		
	1185	1190 1195 1200
His Thr Ala Gly Ala Pro Gly Gly Asp Pro Leu Asp Val Thr Gly Pro		
	1205	1210 1215
Glu Asp Ile Ala Arg Ile Leu Gly Ala Lys Thr Ser Gly Ala Glu Val		
	1220	1225 1230
Leu Asp Asp Leu Leu Arg Gly Thr Pro Leu Asp Ala Phe Val Leu Tyr		
	1235	1240 1245
Ser Ser Asn Ala Gly Val Trp Gly Ser Gly Ser Gln Gly Val Tyr Ala		
	1250	1255 1260
Ala Ala Asn Ala His Leu Asp Ala Leu Ala Ala Arg Arg Arg Ala Arg		
	1265	1270 1275 1280
Gly Glu Thr Ala Thr Ser Val Ala Trp Gly Leu Trp Ala Gly Asp Gly		
	1285	1290 1295
Met Gly Arg Gly Ala Asp Asp Ala Tyr Trp Gln Arg Arg Gly Ile Arg		
	1300	1305 1310
Pro Met Ser Pro Asp Arg Ala Leu Asp Glu Leu Ala Lys Ala Leu Ser		
	1315	1320 1325
His Asp Glu Thr Phe Val Ala Val Ala Asp Val Asp Trp Glu Arg Phe		
	1330	1335 1340
Ala Pro Ala Phe Thr Val Ser Arg Pro Ser Leu Leu Leu Asp Gly Val		
	1345	1350 1355 1360
Pro Glu Ala Arg Gln Ala Leu Ala Ala Pro Val Gly Ala Pro Ala Pro		
	1365	1370 1375
Gly Asp Ala Ala Val Ala Pro Thr Gly Gln Ser Ser Ala Leu Ala Ala		
	1380	1385 1390
Ile Thr Ala Leu Pro Glu Pro Glu Arg Arg Pro Ala Leu Leu Thr Leu		
	1395	1400 1405
Val Arg Thr His Ala Ala Ala Val Leu Gly His Ser Ser Pro Asp Arg		
	1410	1415 1420
Val Ala Pro Gly Arg Ala Phe Thr Glu Leu Gly Phe Asp Ser Leu Thr		

-continued

1425	1430	1435	1440
Ala Val Gln Leu Arg Asn Gln Leu Ser Thr Val Val Gly Asn Arg Leu	1445	1450	1455
Pro Ala Thr Thr Val Phe Asp His Pro Thr Pro Ala Ala Leu Ala Ala	1460	1465	1470
His Leu His Glu Ala Tyr Leu Ala Pro Ala Glu Pro Ala Pro Thr Asp	1475	1480	1485
Trp Glu Gly Arg Val Arg Arg Ala Leu Ala Glu Leu Pro Leu Asp Arg	1490	1495	1500
Leu Arg Asp Ala Gly Val Leu Asp Thr Val Leu Arg Leu Thr Gly Ile	1505	1510	1515
Glu Pro Glu Pro Gly Ser Gly Gly Ser Asp Gly Gly Ala Ala Asp Pro	1525	1530	1535
Gly Ala Glu Pro Glu Ala Ser Ile Asp Asp Leu Asp Ala Glu Ala Leu	1540	1545	1550
Ile Arg Met Ala Leu Gly Pro Arg Asn Thr	1555	1560	

<210> SEQ ID NO 4
 <211> LENGTH: 1346
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 4

Met Thr Ser Ser Asn Glu Gln Leu Val Asp Ala Leu Arg Ala Ser Leu	1	5	10	15
Lys Glu Asn Glu Glu Leu Arg Lys Glu Ser Arg Arg Arg Ala Asp Arg	20	25	30	
Arg Gln Glu Pro Met Ala Ile Val Gly Met Ser Cys Arg Phe Ala Gly	35	40	45	
Gly Ile Arg Ser Pro Glu Asp Leu Trp Asp Ala Val Ala Ala Gly Lys	50	55	60	
Asp Leu Val Ser Glu Val Pro Glu Glu Arg Gly Trp Asp Ile Asp Ser	65	70	75	80
Leu Tyr Asp Pro Val Pro Gly Arg Lys Gly Thr Thr Tyr Val Arg Asn	85	90	95	
Ala Ala Phe Leu Asp Asp Ala Ala Gly Phe Asp Ala Ala Phe Phe Gly	100	105	110	
Ile Ser Pro Arg Glu Ala Leu Ala Met Asp Pro Gln Gln Arg Gln Leu	115	120	125	
Leu Glu Ala Ser Trp Glu Val Phe Glu Arg Ala Gly Ile Asp Pro Ala	130	135	140	
Ser Val Arg Gly Thr Asp Val Gly Val Tyr Val Gly Cys Gly Tyr Gln	145	150	155	160
Asp Tyr Ala Pro Asp Ile Arg Val Ala Pro Glu Gly Thr Gly Gly Tyr	165	170	175	
Val Val Thr Gly Asn Ser Ser Ala Val Ala Ser Gly Arg Ile Ala Tyr	180	185	190	
Ser Leu Gly Leu Glu Gly Pro Ala Val Thr Val Asp Thr Ala Cys Ser	195	200	205	
Ser Ser Leu Val Ala Leu His Leu Ala Leu Lys Gly Leu Arg Asn Gly	210	215	220	

-continued

Asp	Cys	Ser	Thr	Ala	Leu	Val	Gly	Gly	Val	Ala	Val	Leu	Ala	Thr	Pro
225					230					235					240
Gly	Ala	Phe	Ile	Glu	Phe	Ser	Ser	Gln	Gln	Ala	Met	Ala	Ala	Asp	Gly
				245					250					255	
Arg	Thr	Lys	Gly	Phe	Ala	Ser	Ala	Ala	Asp	Gly	Leu	Ala	Trp	Gly	Glu
			260					265					270		
Gly	Val	Ala	Val	Leu	Leu	Leu	Glu	Arg	Leu	Ser	Asp	Ala	Arg	Arg	Lys
		275					280					285			
Gly	His	Arg	Val	Leu	Ala	Val	Val	Arg	Gly	Ser	Ala	Ile	Asn	Gln	Asp
	290					295					300				
Gly	Ala	Ser	Asn	Gly	Leu	Thr	Ala	Pro	His	Gly	Pro	Ser	Gln	Gln	Arg
305					310					315					320
Leu	Ile	Arg	Gln	Ala	Leu	Ala	Asp	Ala	Arg	Leu	Thr	Ser	Ser	Asp	Val
				325					330					335	
Asp	Val	Val	Glu	Gly	His	Gly	Thr	Gly	Thr	Arg	Leu	Gly	Asp	Pro	Ile
			340					345					350		
Glu	Ala	Gln	Ala	Leu	Leu	Ala	Thr	Tyr	Gly	Gln	Gly	Arg	Ala	Pro	Gly
		355					360					365			
Gln	Pro	Leu	Arg	Leu	Gly	Thr	Leu	Lys	Ser	Asn	Ile	Gly	His	Thr	Gln
	370					375					380				
Ala	Ala	Ser	Gly	Val	Ala	Gly	Val	Ile	Lys	Met	Val	Gln	Ala	Leu	Arg
385					390					395					400
His	Gly	Val	Leu	Pro	Lys	Thr	Leu	His	Val	Asp	Glu	Pro	Thr	Asp	Gln
			405					410						415	
Val	Asp	Trp	Ser	Ala	Gly	Ser	Val	Glu	Leu	Leu	Thr	Glu	Ala	Val	Asp
		420					425					430			
Trp	Pro	Glu	Arg	Pro	Gly	Arg	Leu	Arg	Arg	Ala	Gly	Val	Ser	Ala	Phe
		435				440						445			
Gly	Val	Gly	Gly	Thr	Asn	Ala	His	Val	Val	Leu	Glu	Glu	Ala	Pro	Ala
	450				455						460				
Val	Glu	Glu	Ser	Pro	Ala	Val	Glu	Pro	Pro	Ala	Gly	Gly	Gly	Val	Val
465					470					475					480
Pro	Trp	Pro	Val	Ser	Ala	Lys	Thr	Ser	Ala	Ala	Leu	Asp	Ala	Gln	Ile
			485					490						495	
Gly	Gln	Leu	Ala	Ala	Tyr	Ala	Glu	Asp	Arg	Thr	Asp	Val	Asp	Pro	Ala
		500						505					510		
Val	Ala	Ala	Arg	Ala	Leu	Val	Asp	Ser	Arg	Thr	Ala	Met	Glu	His	Arg
		515				520						525			
Ala	Val	Ala	Val	Gly	Asp	Ser	Arg	Glu	Ala	Leu	Arg	Asp	Ala	Leu	Arg
	530				535						540				
Met	Pro	Glu	Gly	Leu	Val	Arg	Gly	Thr	Val	Thr	Asp	Pro	Gly	Arg	Val
545				550						555					560
Ala	Phe	Val	Phe	Pro	Gly	Gln	Gly	Thr	Gln	Trp	Ala	Gly	Met	Gly	Ala
			565					570						575	
Glu	Leu	Leu	Asp	Ser	Ser	Pro	Glu	Phe	Ala	Ala	Ala	Met	Ala	Glu	Cys
			580					585					590		
Glu	Thr	Ala	Leu	Ser	Pro	Tyr	Val	Asp	Trp	Ser	Leu	Glu	Ala	Val	Val
		595					600					605			
Arg	Gln	Ala	Pro	Ser	Ala	Pro	Thr	Leu	Asp	Arg	Val	Asp	Val	Val	Gln
	610					615					620				
Pro	Val	Thr	Phe	Ala	Val	Met	Val	Ser	Leu	Ala	Lys	Val	Trp	Gln	His

-continued

625	630	635	640
His Gly Ile Thr Pro	Glu Ala Val Ile Gly	His Ser Gln Gly Glu Ile	
	645	650	655
Ala Ala Ala Tyr Val	Ala Gly Ala Leu Thr	Leu Asp Asp Ala Ala Arg	
	660	665	670
Val Val Thr Leu Arg Ser	Lys Ser Ile Ala Ala His	Leu Ala Gly Lys	
	675	680	685
Gly Gly Met Ile Ser	Leu Ala Leu Ser Glu Glu	Ala Thr Arg Gln Arg	
	690	695	700
Ile Glu Asn Leu His Gly	Leu Ser Ile Ala Ala Val	Asn Gly Pro Thr	
	705	710	715
Ala Thr Val Val Ser	Gly Asp Pro Thr Gln Ile	Gln Glu Leu Ala Gln	
	725	730	735
Ala Cys Glu Ala Asp	Gly Ile Arg Ala Arg Ile	Ile Pro Val Asp Tyr	
	740	745	750
Ala Ser His Ser Ala His	Val Glu Thr Ile Glu Asn	Glu Leu Ala Asp	
	755	760	765
Val Leu Ala Gly Leu Ser	Pro Gln Thr Pro Gln Val	Pro Phe Phe Ser	
	770	775	780
Thr Leu Glu Gly Thr Trp	Ile Thr Glu Pro Ala Leu	Asp Gly Gly Tyr	
	785	790	795
Trp Tyr Arg Asn Leu Arg	His Arg Val Gly Phe Ala	Pro Ala Val Glu	
	805	810	815
Thr Leu Ala Thr Asp	Glu Gly Phe Thr His Phe	Ile Glu Val Ser Ala	
	820	825	830
His Pro Val Leu Thr Met	Thr Leu Pro Asp Lys Val	Thr Gly Leu Ala	
	835	840	845
Thr Leu Arg Arg Glu Asp	Gly Gly Gln His Arg Leu	Thr Thr Ser Leu	
	850	855	860
Ala Glu Ala Trp Ala Asn	Gly Leu Ala Leu Asp Trp	Ala Ser Leu Leu	
	865	870	875
Pro Ala Thr Gly Ala Leu	Ser Pro Ala Val Pro Asp	Leu Pro Thr Tyr	
	885	890	895
Ala Phe Gln His Arg Ser	Tyr Trp Ile Ser Pro Ala	Gly Pro Gly Glu	
	900	905	910
Ala Pro Ala His Thr Ala	Ser Gly Arg Glu Ala Val	Ala Glu Thr Gly	
	915	920	925
Leu Ala Trp Gly Pro Gly	Ala Glu Asp Leu Asp Glu	Glu Gly Arg Arg	
	930	935	940
Ser Ala Val Leu Ala Met	Val Met Arg Gln Ala Ala	Ser Val Leu Arg	
	945	950	955
Cys Asp Ser Pro Glu Glu	Val Pro Val Asp Arg Pro	Leu Arg Glu Ile	
	965	970	975
Gly Phe Asp Ser Leu Thr	Ala Val Asp Phe Arg Asn	Arg Val Asn Arg	
	980	985	990
Leu Thr Gly Leu Gln Leu	Pro Pro Thr Val Val Phe	Glu His Pro Thr	
	995	1000	1005
Pro Val Ala Leu Ala Glu	Arg Ile Ser Asp Glu Leu	Ala Glu Arg Asn	
	1010	1015	1020
Trp Ala Val Ala Glu Pro	Ser Asp His Glu Gln Ala	Glu Glu Glu Lys	
	1025	1030	1035
			1040

-continued

Ala Ala Ala Pro Ala Gly Ala Arg Ser Gly Ala Asp Thr Gly Ala Gly
1045 1050 1055

Ala Gly Met Phe Arg Ala Leu Phe Arg Gln Ala Val Glu Asp Asp Arg
1060 1065 1070

Tyr Gly Glu Phe Leu Asp Val Leu Ala Glu Ala Ser Ala Phe Arg Pro
1075 1080 1085

Gln Phe Ala Ser Pro Glu Ala Cys Ser Glu Arg Leu Asp Pro Val Leu
1090 1095 1100

Leu Ala Gly Gly Pro Thr Asp Arg Ala Glu Gly Arg Ala Val Leu Val
1105 1110 1115 1120

Gly Cys Thr Gly Thr Ala Ala Asn Gly Gly Pro His Glu Phe Leu Arg
1125 1130 1135

Leu Ser Thr Ser Phe Gln Glu Glu Arg Asp Phe Leu Ala Val Pro Leu
1140 1145 1150

Pro Gly Tyr Gly Thr Gly Thr Gly Thr Ala Leu Leu Pro Ala
1155 1160 1165

Asp Leu Asp Thr Ala Leu Asp Ala Gln Ala Arg Ala Ile Leu Arg Ala
1170 1175 1180

Ala Gly Asp Ala Pro Val Leu Leu Gly His Ser Gly Gly Ala Leu
1185 1190 1195 1200

Leu Ala His Glu Leu Ala Phe Arg Leu Glu Arg Ala His Gly Ala Pro
1205 1210 1215

Pro Ala Gly Ile Val Leu Val Asp Pro Tyr Pro Pro Gly His Gln Glu
1220 1225 1230

Pro Ile Glu Val Trp Ser Arg Gln Leu Gly Glu Gly Leu Phe Ala Gly
1235 1240 1245

Glu Leu Glu Pro Met Ser Asp Ala Arg Leu Leu Ala Met Gly Arg Tyr
1250 1255 1260

Ala Arg Phe Leu Ala Gly Pro Arg Pro Gly Arg Ser Ser Ala Pro Val
1265 1270 1275 1280

Leu Leu Val Arg Ala Ser Glu Pro Leu Gly Asp Trp Gln Glu Glu Arg
1285 1290 1295

Gly Asp Trp Arg Ala His Trp Asp Leu Pro His Thr Val Ala Asp Val
1300 1305 1310

Pro Gly Asp His Phe Thr Met Met Arg Asp His Ala Pro Ala Val Ala
1315 1320 1325

Glu Ala Val Leu Ser Trp Leu Asp Ala Ile Glu Gly Ile Glu Gly Ala
1330 1335 1340

Gly Lys
1345

<210> SEQ ID NO 5
<211> LENGTH: 281
<212> TYPE: PRT
<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 5

Val Thr Asp Arg Pro Leu Asn Val Asp Ser Gly Leu Trp Ile Arg Arg
1 5 10 15

Phe His Pro Ala Pro Asn Ser Ala Val Arg Leu Val Cys Leu Pro His
20 25 30

Ala Gly Gly Ser Ala Ser Tyr Phe Phe Arg Phe Ser Glu Glu Leu His

-continued

35	40	45
Pro Ser Val Glu Ala Leu Ser Val Gln Tyr Pro Gly Arg Gln Asp Arg		
50	55	60
Arg Ala Glu Pro Cys Leu Glu Ser Val Glu Glu Leu Ala Glu His Val		
65	70	75 80
Val Ala Ala Thr Glu Pro Trp Trp Gln Glu Gly Arg Leu Ala Phe Phe		
	85	90 95
Gly His Ser Leu Gly Ala Ser Val Ala Phe Glu Thr Ala Arg Ile Leu		
	100	105 110
Glu Gln Arg His Gly Val Arg Pro Glu Gly Leu Tyr Val Ser Gly Arg		
	115	120 125
Arg Ala Pro Ser Leu Ala Pro Asp Arg Leu Val His Gln Leu Asp Asp		
	130	135 140
Arg Ala Phe Leu Ala Glu Ile Arg Arg Leu Ser Gly Thr Asp Glu Arg		
	145	150 155 160
Phe Leu Gln Asp Asp Glu Leu Leu Arg Leu Val Leu Pro Ala Leu Arg		
	165	170 175
Ser Asp Tyr Lys Ala Ala Glu Thr Tyr Leu His Arg Pro Ser Ala Lys		
	180	185 190
Leu Thr Cys Pro Val Met Ala Leu Ala Gly Asp Arg Asp Pro Lys Ala		
	195	200 205
Pro Leu Asn Glu Val Ala Glu Trp Arg Arg His Thr Ser Gly Pro Phe		
	210	215 220
Cys Leu Arg Ala Tyr Ser Gly Gly His Phe Tyr Leu Asn Asp Gln Trp		
	225	230 235 240
His Glu Ile Cys Asn Asp Ile Ser Asp His Leu Leu Val Thr Arg Gly		
	245	250 255
Ala Pro Asp Ala Arg Val Val Gln Pro Pro Thr Ser Leu Ile Glu Gly		
	260	265 270
Ala Ala Lys Arg Trp Gln Asn Pro Arg		
	275	280

<210> SEQ ID NO 6
 <211> LENGTH: 379
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae
 <220> FEATURE:
 <221> NAME/KEY: 251
 <222> LOCATION: unsure
 <223> OTHER INFORMATION: unsure of amino acid at this position
 <400> SEQUENCE: 6

Val Ser Ser Arg Ala Glu Thr Pro Arg Val Pro Phe Leu Asp Leu Lys		
1	5	10 15
Ala Ala Tyr Glu Glu Leu Arg Ala Glu Thr Asp Ala Ala Ile Ala Arg		
	20	25 30
Val Leu Asp Ser Gly Arg Tyr Leu Leu Gly Pro Glu Leu Glu Gly Phe		
	35	40 45
Glu Ala Glu Phe Ala Ala Tyr Cys Glu Thr Asp His Ala Val Gly Val		
	50	55 60
Asn Ser Gly Met Asp Ala Leu Gln Leu Ala Leu Arg Gly Leu Gly Ile		
	65	70 75 80
Gly Pro Gly Asp Glu Val Ile Val Pro Ser His Thr Tyr Ile Ala Ser		
	85	90 95

-continued

Trp Leu Ala Val Ser Ala Thr Gly Ala Thr Pro Val Pro Val Glu Pro
 100 105 110
 His Glu Asp His Pro Thr Leu Asp Pro Leu Leu Val Glu Lys Ala Ile
 115 120 125
 Thr Pro Arg Thr Arg Ala Leu Leu Pro Val His Leu Tyr Gly His Pro
 130 135 140
 Ala Asp Met Asp Ala Leu Arg Glu Leu Ala Asp Arg His Gly Leu His
 145 150 155 160
 Ile Val Glu Asp Ala Ala Gln Ala His Gly Ala Arg Tyr Arg Gly Arg
 165 170 175
 Arg Ile Gly Ala Gly Ser Ser Val Ala Ala Phe Ser Phe Tyr Pro Gly
 180 185 190
 Lys Asn Leu Gly Cys Phe Gly Asp Gly Gly Ala Val Val Thr Gly Asp
 195 200 205
 Pro Glu Leu Ala Glu Arg Leu Arg Met Leu Arg Asn Tyr Gly Ser Arg
 210 215 220
 Gln Lys Tyr Ser His Glu Thr Lys Gly Thr Asn Ser Arg Leu Asp Glu
 225 230 235 240
 Met Gln Ala Ala Val Leu Arg Ile Arg Leu Xaa His Leu Asp Ser Trp
 245 250 255
 Asn Gly Arg Arg Ser Ala Leu Ala Ala Glu Tyr Leu Ser Gly Leu Ala
 260 265 270
 Gly Leu Pro Gly Ile Gly Leu Pro Val Thr Ala Pro Asp Thr Asp Pro
 275 280 285
 Val Trp His Leu Phe Thr Val Arg Thr Glu Arg Arg Asp Glu Leu Arg
 290 295 300
 Ser His Leu Asp Ala Arg Gly Ile Asp Thr Leu Thr His Tyr Pro Val
 305 310 315 320
 Pro Val His Leu Ser Pro Ala Tyr Ala Gly Glu Ala Pro Pro Glu Gly
 325 330 335
 Ser Leu Pro Arg Ala Glu Ser Phe Ala Arg Gln Val Leu Ser Leu Pro
 340 345 350
 Ile Gly Pro His Leu Glu Arg Pro Gln Ala Leu Arg Val Ile Asp Ala
 355 360 365
 Val Arg Glu Trp Ala Glu Arg Val Asp Gln Ala
 370 375

<210> SEQ ID NO 7
 <211> LENGTH: 382
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae
 <400> SEQUENCE: 7

Val Ala Asp Arg Glu Leu Gly Thr His Leu Leu Glu Thr Arg Gly Ile
 1 5 10 15
 His Trp Ile His Ala Ala Asn Gly Asp Pro Tyr Ala Thr Val Leu Arg
 20 25 30
 Gly Gln Ala Asp Asp Pro Tyr Pro Ala Tyr Glu Arg Val Arg Ala Arg
 35 40 45
 Gly Ala Leu Ser Phe Ser Pro Thr Gly Ser Trp Val Thr Ala Asp His
 50 55 60
 Ala Leu Ala Ala Ser Ile Leu Cys Ser Thr Asp Phe Gly Val Ser Gly

-continued

65	70	75	80
Ala Asp Gly Val Pro	Val Pro Gln Gln	Val Leu Ser Tyr Gly	Glu Gly
	85	90	95
Cys Pro Leu Glu Arg	Glu Gln Val Leu	Pro Ala Ala Gly Asp	Val Pro
	100	105	110
Glu Gly Gly Gln Arg	Ala Val Val Glu Gly	Ile His Arg Glu Thr	Leu
	115	120	125
Glu Gly Leu Ala Pro	Asp Pro Ser Ala Ser	Tyr Ala Phe Glu Leu	Leu
	130	135	140
Gly Gly Phe Val Arg	Pro Ala Val Thr Ala	Ala Ala Ala Val Leu	
	145	150	155
Gly Val Pro Ala Asp	Arg Arg Ala Asp	Phe Ala Asp Leu Leu	Glu Arg
	165	170	175
Leu Arg Pro Leu Ser	Asp Ser Leu Leu Ala	Pro Gln Ser Leu Arg	Thr
	180	185	190
Val Arg Ala Ala Asp	Gly Ala Leu Ala Glu Leu	Thr Ala Leu Leu Ala	
	195	200	205
Asp Ser Asp Asp Ser	Pro Gly Ala Leu Leu	Ser Ala Leu Gly Val Thr	
	210	215	220
Ala Ala Val Gln Leu Thr	Gly Asn Ala Val Leu	Ala Leu Leu Ala His	
	225	230	235
Pro Glu Gln Trp Arg	Glu Leu Cys Asp Arg	Pro Gly Leu Ala Ala Ala	
	245	250	255
Ala Val Glu Glu Thr	Leu Arg Tyr Asp Pro	Pro Val Gln Leu Asp Ala	
	260	265	270
Arg Val Val Arg Gly	Glu Thr Glu Leu Ala Gly	Arg Arg Leu Pro Ala	
	275	280	285
Gly Ala His Val Val	Val Leu Thr Ala Ala Thr	Gly Arg Asp Pro Glu	
	290	295	300
Val Phe Thr Asp Pro	Glu Arg Phe Asp Leu	Ala Arg Pro Asp Ala Ala	
	305	310	315
Ala His Leu Ala Leu	His Pro Ala Gly Pro	Tyr Gly Pro Val Ala Ser	
	325	330	335
Leu Val Arg Leu Gln	Ala Glu Val Ala Leu	Arg Thr Leu Ala Gly Arg	
	340	345	350
Phe Pro Gly Leu Arg	Gln Ala Gly Asp Val	Leu Arg Pro Arg Arg Ala	
	355	360	365
Pro Val Gly Arg Gly	Pro Leu Ser Val Pro	Val Ser Ser Ser	
	370	375	380

<210> SEQ ID NO 8

<211> LENGTH: 426

<212> TYPE: PRT

<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 8

Met Arg Val Leu Leu Thr	Ser Phe Ala His His	Thr His Tyr Tyr Gly
1	5	10
Leu Val Pro Leu Ala Trp	Ala Leu Leu Ala Ala	Gly His Glu Val Arg
20	25	30
Val Ala Ser Gln Pro	Ala Leu Thr Asp	Thr Ile Thr Gly Ser
35	40	45

-continued

Ala	Ala	Val	Pro	Val	Gly	Thr	Asp	His	Leu	Ile	His	Glu	Tyr	Arg	Val
50						55					60				
Arg	Met	Ala	Gly	Glu	Pro	Arg	Pro	Asn	His	Pro	Ala	Ile	Ala	Phe	Asp
65					70					75					80
Glu	Ala	Arg	Pro	Glu	Pro	Leu	Asp	Trp	Asp	His	Ala	Leu	Gly	Ile	Glu
				85					90					95	
Ala	Ile	Leu	Ala	Pro	Tyr	Phe	Tyr	Leu	Leu	Ala	Asn	Asn	Asp	Ser	Met
			100					105					110		
Val	Asp	Asp	Leu	Val	Asp	Phe	Ala	Arg	Ser	Trp	Gln	Pro	Asp	Leu	Val
	115						120					125			
Leu	Trp	Glu	Pro	Thr	Thr	Tyr	Ala	Gly	Ala	Val	Ala	Ala	Gln	Val	Thr
	130					135					140				
Gly	Ala	Ala	His	Ala	Arg	Val	Leu	Trp	Gly	Pro	Asp	Val	Met	Gly	Ser
145					150					155					160
Ala	Arg	Arg	Lys	Phe	Val	Ala	Leu	Arg	Asp	Arg	Gln	Pro	Pro	Glu	His
			165						170					175	
Arg	Glu	Asp	Pro	Thr	Ala	Glu	Trp	Leu	Thr	Trp	Thr	Leu	Asp	Arg	Tyr
		180						185					190		
Gly	Ala	Ser	Phe	Glu	Glu	Glu	Leu	Leu	Thr	Gly	Gln	Phe	Thr	Ile	Asp
	195						200					205			
Pro	Thr	Pro	Pro	Ser	Leu	Arg	Leu	Asp	Thr	Gly	Leu	Pro	Thr	Val	Gly
	210					215					220				
Met	Arg	Tyr	Val	Pro	Tyr	Asn	Gly	Thr	Ser	Val	Val	Pro	Asp	Trp	Leu
225					230					235					240
Ser	Glu	Pro	Pro	Ala	Arg	Pro	Arg	Val	Cys	Leu	Thr	Leu	Gly	Val	Ser
				245					250					255	
Ala	Arg	Glu	Val	Leu	Gly	Gly	Asp	Gly	Val	Ser	Gln	Gly	Asp	Ile	Leu
		260					265						270		
Glu	Ala	Leu	Ala	Asp	Leu	Asp	Ile	Glu	Leu	Val	Ala	Thr	Leu	Asp	Ala
	275					280						285			
Ser	Gln	Arg	Ala	Glu	Ile	Arg	Asn	Tyr	Pro	Lys	His	Thr	Arg	Phe	Thr
	290					295					300				
Asp	Phe	Val	Pro	Met	His	Ala	Leu	Leu	Pro	Ser	Cys	Ser	Ala	Ile	Ile
305					310					315					320
His	His	Gly	Gly	Ala	Gly	Thr	Tyr	Ala	Thr	Ala	Val	Ile	Asn	Ala	Val
				325					330					335	
Pro	Gln	Val	Met	Leu	Ala	Glu	Leu	Trp	Asp	Ala	Pro	Val	Lys	Ala	Arg
		340						345					350		
Ala	Val	Ala	Glu	Gln	Gly	Ala	Gly	Phe	Phe	Leu	Pro	Pro	Ala	Glu	Leu
	355					360						365			
Thr	Pro	Gln	Ala	Val	Arg	Asp	Ala	Val	Val	Arg	Ile	Leu	Asp	Asp	Pro
	370					375					380				
Ser	Val	Ala	Thr	Ala	Ala	His	Arg	Leu	Arg	Glu	Glu	Thr	Phe	Gly	Asp
385					390					395					400
Pro	Thr	Pro	Ala	Gly	Ile	Val	Pro	Glu	Leu	Glu	Arg	Leu	Ala	Ala	Gln
			405					410						415	
His	Arg	Arg	Pro	Pro	Ala	Asp	Ala	Arg	His						
		420					425								

<210> SEQ ID NO 9

<211> LENGTH: 331

<212> TYPE: PRT

-continued

```

<213> ORGANISM: Streptomyces venezuelae
<220> FEATURE:
<221> NAME/KEY: 272
<222> LOCATION: unsure
<223> OTHER INFORMATION: unsure of amino acid at this position

<400> SEQUENCE: 9

Val Lys Ser Ala Leu Ser Asp Leu Ala Phe Phe Gly Gly Pro Ala Ala
 1             5             10            15

Phe Asp Gln Pro Leu Leu Val Gly Arg Pro Asn Arg Ile Asp Arg Ala
          20             25            30

Arg Leu Tyr Glu Arg Leu Asp Arg Ala Leu Asp Ser Gln Trp Leu Ser
          35             40            45

Asn Gly Gly Pro Leu Val Arg Glu Phe Glu Glu Arg Val Ala Gly Leu
          50             55            60

Ala Gly Val Arg His Ala Val Ala Thr Cys Asn Ala Thr Ala Gly Leu
          65             70            75            80

Gln Leu Leu Ala His Ala Ala Gly Leu Thr Gly Glu Val Ile Met Pro
          85             90            95

Ser Met Thr Phe Ala Ala Thr Pro His Ala Leu Arg Trp Ile Gly Leu
          100            105           110

Thr Pro Val Phe Ala Asp Ile Asp Pro Asp Thr Gly Asn Leu Asp Pro
          115           120           125

Asp Gln Val Ala Ala Ala Val Thr Pro Arg Thr Ser Ala Val Val Gly
          130           135           140

Val His Leu Trp Gly Arg Pro Cys Ala Ala Asp Gln Leu Arg Lys Val
          145           150           155           160

Ala Asp Glu His Gly Leu Arg Leu Tyr Phe Asp Ala Ala His Ala Leu
          165           170           175

Gly Cys Ala Val Asp Gly Arg Pro Ala Gly Ser Leu Gly Asp Ala Glu
          180           185           190

Val Phe Ser Phe His Ala Thr Lys Ala Val Asn Ala Phe Glu Gly Gly
          195           200           205

Ala Val Val Thr Asp Asp Ala Asp Leu Ala Ala Arg Ile Arg Ala Leu
          210           215           220

His Asn Phe Gly Phe Asp Leu Pro Gly Gly Ser Pro Ala Gly Gly Thr
          225           230           235           240

Asn Ala Lys Met Ser Glu Ala Ala Ala Ala Met Gly Leu Thr Ser Leu
          245           250           255

Asp Ala Phe Pro Glu Val Ile Asp Arg Asn Arg Arg Asn His Ala Xaa
          260           265           270

Tyr Arg Glu His Leu Ala Asp Leu Pro Gly Val Leu Val Ala Asp His
          275           280           285

Asp Arg His Gly Leu Asn Asn His Gln Tyr Val Ile Val Glu Ile Asp
          290           295           300

Glu Ala Thr Thr Gly Ile His Arg Asp Leu Val Met Glu Val Leu Lys
          305           310           315           320

Ala Glu Gly Val His Thr Arg Ala Tyr Phe Ser
          325           330

<210> SEQ ID NO 10
<211> LENGTH: 485
<212> TYPE: PRT
<213> ORGANISM: Streptomyces venezuelae

```

-continued

<400> SEQUENCE: 10

```

Met Thr Ala Pro Ala Leu Ser Ala Thr Ala Pro Ala Glu Arg Cys Ala
 1           5           10           15
His Pro Gly Ala Asp Leu Gly Ala Ala Val His Ala Val Gly Gln Thr
          20           25           30
Leu Ala Ala Gly Gly Leu Val Pro Pro Asp Glu Ala Gly Thr Thr Ala
          35           40           45
Arg His Leu Val Arg Leu Ala Val Arg Tyr Gly Asn Ser Pro Phe Thr
          50           55           60
Pro Leu Glu Glu Ala Arg His Asp Leu Gly Val Asp Arg Asp Ala Phe
          65           70           75           80
Arg Arg Leu Leu Ala Leu Phe Gly Gln Val Pro Glu Leu Arg Thr Ala
          85           90           95
Val Glu Thr Gly Pro Ala Gly Ala Tyr Trp Lys Asn Thr Leu Leu Pro
          100          105          110
Leu Glu Gln Arg Gly Val Phe Asp Ala Ala Leu Ala Arg Lys Pro Val
          115          120          125
Phe Pro Tyr Ser Val Gly Leu Tyr Pro Gly Pro Thr Cys Met Phe Arg
          130          135          140
Cys His Phe Cys Val Arg Val Thr Gly Ala Arg Tyr Asp Pro Ser Ala
          145          150          155          160
Leu Asp Ala Gly Asn Ala Met Phe Arg Ser Val Ile Asp Glu Ile Pro
          165          170          175
Ala Gly Asn Pro Ser Ala Met Tyr Phe Ser Gly Gly Leu Glu Pro Leu
          180          185          190
Thr Asn Pro Gly Leu Gly Ser Leu Ala Ala His Ala Thr Asp His Gly
          195          200          205
Leu Arg Pro Thr Val Tyr Thr Asn Ser Phe Ala Leu Thr Glu Arg Thr
          210          215          220
Leu Glu Arg Gln Pro Gly Leu Trp Gly Leu His Ala Ile Arg Thr Ser
          225          230          235          240
Leu Tyr Gly Leu Asn Asp Glu Glu Tyr Glu Gln Thr Thr Gly Lys Lys
          245          250          255
Ala Ala Phe Arg Arg Val Arg Glu Asn Leu Arg Arg Phe Gln Gln Leu
          260          265          270
Arg Ala Glu Arg Glu Ser Pro Ile Asn Leu Gly Phe Ala Tyr Ile Val
          275          280          285
Leu Pro Gly Arg Ala Ser Arg Leu Leu Asp Leu Val Asp Phe Ile Ala
          290          295          300
Asp Leu Asn Asp Ala Gly Gln Gly Arg Thr Ile Asp Phe Val Asn Ile
          305          310          315          320
Arg Glu Asp Tyr Ser Gly Arg Asp Asp Gly Lys Leu Pro Gln Glu Glu
          325          330          335
Arg Ala Glu Leu Gln Glu Ala Leu Asn Ala Phe Glu Glu Arg Val Arg
          340          345          350
Glu Arg Thr Pro Gly Leu His Ile Asp Tyr Gly Tyr Ala Leu Asn Ser
          355          360          365
Leu Arg Thr Gly Ala Asp Ala Glu Leu Leu Arg Ile Lys Pro Ala Thr
          370          375          380
Met Arg Pro Thr Ala His Pro Gln Val Ala Val Gln Val Asp Leu Leu

```

-continued

385	390	395	400
Gly Asp Val Tyr	Leu Tyr Arg Glu Ala Gly Phe Pro Asp Leu Asp Gly		
	405	410	415
Ala Thr Arg Tyr	Ile Ala Gly Arg Val Thr Pro Asp Thr Ser Leu Thr		
	420	425	430
Glu Val Val Arg Asp Phe Val Glu Arg Gly Gly Glu Val Ala Ala Val			
	435	440	445
Asp Gly Asp Glu Tyr Phe Met Asp Gly Phe Asp Gln Val Val Thr Ala			
	450	455	460
Arg Leu Asn Gln Leu Glu Arg Asp Ala Ala Asp Gly Trp Glu Glu Ala			
	465	470	475
Arg Gly Phe Leu Arg			
	485		

<210> SEQ ID NO 11
 <211> LENGTH: 237
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 11

Val Tyr Glu Val Asp His Ala Asp Val Tyr Asp Leu Phe Tyr Leu Gly			
1	5	10	15
Arg Gly Lys Asp Tyr Ala Ala Glu Ala Ser Asp Ile Ala Asp Leu Val			
	20	25	30
Arg Ser Arg Thr Pro Glu Ala Ser Ser Leu Leu Asp Val Ala Cys Gly			
	35	40	45
Thr Gly Thr His Leu Glu His Phe Thr Lys Glu Phe Gly Asp Thr Ala			
	50	55	60
Gly Leu Glu Leu Ser Glu Asp Met Leu Thr His Ala Arg Lys Arg Leu			
	65	70	75
Pro Asp Ala Thr Leu His Gln Gly Asp Met Arg Asp Phe Arg Leu Gly			
	85	90	95
Arg Lys Phe Ser Ala Val Val Ser Met Phe Ser Ser Val Gly Tyr Leu			
	100	105	110
Lys Thr Thr Glu Glu Leu Gly Ala Ala Val Ala Ser Phe Ala Glu His			
	115	120	125
Leu Glu Pro Gly Gly Val Val Val Val Glu Pro Trp Trp Phe Pro Glu			
	130	135	140
Thr Phe Ala Asp Gly Trp Val Ser Ala Asp Val Val Arg Arg Asp Gly			
	145	150	155
Arg Thr Val Ala Arg Val Ser His Ser Val Arg Glu Gly Asn Ala Thr			
	165	170	175
Arg Met Glu Val His Phe Thr Val Ala Asp Pro Gly Lys Gly Val Arg			
	180	185	190
His Phe Ser Asp Val His Leu Ile Thr Leu Phe His Gln Ala Glu Tyr			
	195	200	205
Glu Ala Ala Phe Thr Ala Ala Gly Leu Arg Val Glu Tyr Leu Glu Gly			
	210	215	220
Gly Pro Ser Gly Arg Gly Leu Phe Val Gly Val Pro Ala			
	225	230	235

<210> SEQ ID NO 12
 <211> LENGTH: 769

-continued

<212> TYPE: PRT

<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 12

Met Thr Leu Asp Glu Lys Ile Ser Phe Val His Trp Ala Leu Asp Pro
1 5 10 15
Asp Arg Gln Asn Val Gly Tyr Leu Pro Gly Val Pro Arg Leu Gly Ile
20 25 30
Pro Glu Leu Arg Ala Ala Asp Gly Pro Asn Gly Ile Arg Leu Val Gly
35 40 45
Gln Thr Ala Thr Ala Leu Pro Ala Pro Val Ala Leu Ala Ser Thr Phe
50 55 60
Asp Asp Thr Met Ala Asp Ser Tyr Gly Lys Val Met Gly Arg Asp Gly
65 70 75 80
Arg Ala Leu Asn Gln Asp Met Val Leu Gly Pro Met Met Asn Asn Ile
85 90 95
Arg Val Pro His Gly Gly Arg Asn Tyr Glu Thr Phe Ser Glu Asp Pro
100 105 110
Leu Val Ser Ser Arg Thr Ala Val Ala Gln Ile Lys Gly Ile Gln Gly
115 120 125
Ala Gly Leu Met Thr Thr Ala Lys His Phe Ala Ala Asn Asn Gln Glu
130 135 140
Asn Asn Arg Phe Ser Val Asn Ala Asn Val Asp Glu Gln Thr Leu Arg
145 150 155 160
Glu Ile Glu Phe Pro Ala Phe Glu Ala Ser Ser Lys Ala Gly Ala Gly
165 170 175
Ser Phe Met Cys Ala Tyr Asn Gly Leu Asn Gly Lys Pro Ser Cys Gly
180 185 190
Asn Asp Glu Leu Leu Asn Asn Val Leu Arg Thr Gln Trp Gly Phe Gln
195 200 205
Gly Trp Val Met Ser Asp Trp Leu Ala Thr Pro Gly Thr Asp Ala Ile
210 215 220
Thr Lys Gly Leu Asp Gln Glu Met Gly Val Glu Leu Pro Gly Asp Val
225 230 235 240
Pro Lys Gly Glu Pro Ser Pro Pro Ala Lys Phe Phe Gly Glu Ala Leu
245 250 255
Lys Thr Ala Val Leu Asn Gly Thr Val Pro Glu Ala Ala Val Thr Arg
260 265 270
Ser Ala Glu Arg Ile Val Gly Gln Met Glu Lys Phe Gly Leu Leu Leu
275 280 285
Ala Thr Pro Ala Pro Arg Pro Glu Arg Asp Lys Ala Gly Ala Gln Ala
290 295 300
Val Ser Arg Lys Val Ala Glu Asn Gly Ala Val Leu Leu Arg Asn Glu
305 310 315 320
Gly Gln Ala Leu Pro Leu Ala Gly Asp Ala Gly Lys Ser Ile Ala Val
325 330 335
Ile Gly Pro Thr Ala Val Asp Pro Lys Val Thr Gly Leu Gly Ser Ala
340 345 350
His Val Val Pro Asp Ser Ala Ala Ala Pro Leu Asp Thr Ile Lys Ala
355 360 365
Arg Ala Gly Ala Gly Ala Thr Val Thr Tyr Glu Thr Gly Glu Glu Thr
370 375 380

-continued

Phe Gly Thr Gln Ile	Pro Ala Gly Asn Leu Ser	Pro Ala Phe Asn Gln
385	390	395 400
Gly His Gln Leu Glu	Pro Gly Lys Ala Gly Ala Leu Tyr Asp Gly Thr	
	405	410 415
Leu Thr Val Pro Ala Asp Gly Glu Tyr Arg Ile Ala Val Arg Ala Thr		
	420	425 430
Gly Gly Tyr Ala Thr Val Gln Leu Gly Ser His Thr Ile Glu Ala Gly		
	435	440 445
Gln Val Tyr Gly Lys Val Ser Ser Pro Leu Leu Lys Leu Thr Lys Gly		
	450	455 460
Thr His Lys Leu Thr Ile Ser Gly Phe Ala Met Ser Ala Thr Pro Leu		
	465	470 475 480
Ser Leu Glu Leu Gly Trp Val Thr Pro Ala Ala Asp Ala Thr Ile		
	485	490 495
Ala Lys Ala Val Glu Ser Ala Arg Lys Ala Arg Thr Ala Val Val Phe		
	500	505 510
Ala Tyr Asp Asp Gly Thr Glu Gly Val Asp Arg Pro Asn Leu Ser Leu		
	515	520 525
Pro Gly Thr Gln Asp Lys Leu Ile Ser Ala Val Ala Asp Ala Asn Pro		
	530	535 540
Asn Thr Ile Val Val Leu Asn Thr Gly Ser Ser Val Leu Met Pro Trp		
	545	550 555 560
Leu Ser Lys Thr Arg Ala Val Leu Asp Met Trp Tyr Pro Gly Gln Ala		
	565	570 575
Gly Ala Glu Ala Thr Ala Ala Leu Leu Tyr Gly Asp Val Asn Pro Ser		
	580	585 590
Gly Lys Leu Thr Gln Ser Phe Pro Ala Ala Glu Asn Gln His Ala Val		
	595	600 605
Ala Gly Asp Pro Thr Ser Tyr Pro Gly Val Asp Asn Gln Gln Thr Tyr		
	610	615 620
Arg Glu Gly Ile His Val Gly Tyr Arg Trp Phe Asp Lys Glu Asn Val		
	625	630 635 640
Lys Pro Leu Phe Pro Phe Gly His Gly Leu Ser Tyr Thr Ser Phe Thr		
	645	650 655
Gln Ser Ala Pro Thr Val Val Arg Thr Ser Thr Gly Gly Leu Lys Val		
	660	665 670
Thr Val Thr Val Arg Asn Ser Gly Lys Arg Ala Gly Gln Glu Val Val		
	675	680 685
Gln Ala Tyr Leu Gly Ala Ser Pro Asn Val Thr Ala Pro Gln Ala Lys		
	690	695 700
Lys Lys Leu Val Gly Tyr Thr Lys Val Ser Leu Ala Ala Gly Glu Ala		
	705	710 715 720
Lys Thr Val Thr Val Asn Val Asp Arg Arg Gln Leu Gln Phe Trp Asp		
	725	730 735
Ala Ala Thr Asp Asn Trp Lys Thr Gly Thr Gly Asn Arg Leu Leu Gln		
	740	745 750
Thr Gly Ser Ser Ala Asp Leu Arg Gly Ser Ala Thr Val Asn Val		
	755	760 765
Trp		

-continued

<210> SEQ ID NO 13
<211> LENGTH: 928
<212> TYPE: PRT
<213> ORGANISM: Streptomyces venezuelae
<220> FEATURE:
<221> NAME/KEY: 694
<222> LOCATION: unsure
<223> OTHER INFORMATION: unsure of amino acid at this position

<400> SEQUENCE: 13

Met Asn Leu Val Glu Arg Asp Gly Glu Ile Ala His Leu Arg Ala Val
1 5 10 15

Leu Asp Ala Ser Ala Ala Gly Asp Gly Thr Leu Leu Leu Val Ser Gly
20 25 30

Pro Ala Gly Ser Gly Lys Thr Glu Leu Leu Arg Ser Leu Arg Arg Leu
35 40 45

Ala Ala Glu Arg Glu Thr Pro Val Trp Ser Val Arg Ala Leu Pro Gly
50 55 60

Asp Arg Asp Ile Pro Leu Gly Val Leu Cys Gln Leu Leu Arg Ser Ala
65 70 75 80

Glu Gln His Gly Ala Asp Thr Ser Ala Val Arg Asp Leu Leu Asp Ala
85 90 95

Ala Ser Arg Arg Ala Gly Thr Ser Pro Pro Pro Thr Arg Arg Ser
100 105 110

Ala Ser Thr Arg His Thr Ala Cys Thr Thr Gly Cys Ser Pro Ser Pro
115 120 125

Ala Gly Thr Pro Phe Leu Val Ala Val Asp Asp Leu Thr His Ala Asp
130 135 140

Thr Ala Ser Leu Arg Phe Leu Leu Tyr Cys Ala Ala His His Asp Gln
145 150 155 160

Gly Gly Ile Gly Phe Val Met Thr Glu Arg Ala Ser Gln Arg Ala Gly
165 170 175

Tyr Arg Val Phe Arg Ala Glu Leu Leu Arg Gln Pro His Cys Arg Asn
180 185 190

Met Trp Leu Ser Gly Leu Pro Pro Ser Gly Val Arg Gln Leu Leu Ala
195 200 205

His Tyr Tyr Gly Pro Glu Ala Ala Glu Arg Arg Ala Pro Ala Tyr His
210 215 220

Ala Thr Thr Gly Gly Asn Pro Leu Leu Leu Arg Ala Leu Thr Gln Asp
225 230 235 240

Arg Gln Ala Ser His Thr Thr Leu Gly Ala Ala Gly Gly Asp Glu Pro
245 250 255

Val His Gly Asp Ala Phe Ala Gln Ala Val Leu Asp Cys Leu His Arg
260 265 270

Ser Ala Glu Gly Thr Leu Glu Thr Ala Arg Trp Leu Ala Val Leu Glu
275 280 285

Gln Ser Asp Pro Leu Leu Val Glu Arg Leu Thr Gly Thr Thr Ala Ala
290 295 300

Ala Val Glu Arg His Ile Gln Glu Leu Ala Ala Ile Gly Leu Leu Asp
305 310 315 320

Glu Asp Gly Thr Leu Gly Gln Pro Ala Ile Arg Glu Ala Ala Leu Gln
325 330 335

Asp Leu Pro Ala Gly Glu Arg Thr Glu Leu His Arg Arg Ala Ala Glu
340 345 350

-continued

Gln	Leu	His	Arg	Asp	Gly	Ala	Asp	Glu	Asp	Thr	Val	Ala	Arg	His	Leu
	355						360					365			
Leu	Val	Gly	Gly	Ala	Pro	Asp	Ala	Pro	Trp	Ala	Leu	Pro	Leu	Leu	Glu
	370					375					380				
Arg	Gly	Ala	Gln	Gln	Ala	Leu	Phe	Asp	Asp	Arg	Leu	Asp	Asp	Ala	Phe
385					390					395					400
Arg	Ile	Leu	Glu	Phe	Ala	Val	Arg	Ser	Ser	Thr	Asp	Asn	Thr	Gln	Leu
			405						410					415	
Ala	Arg	Leu	Ala	Pro	His	Leu	Val	Ala	Ala	Ser	Trp	Arg	Met	Asn	Pro
		420						425					430		
His	Met	Thr	Thr	Arg	Ala	Leu	Ala	Leu	Phe	Asp	Arg	Leu	Leu	Ser	Gly
	435					440						445			
Glu	Leu	Pro	Pro	Ser	His	Pro	Val	Met	Ala	Leu	Ile	Arg	Cys	Leu	Val
	450					455					460				
Trp	Tyr	Gly	Arg	Leu	Pro	Glu	Ala	Ala	Asp	Ala	Leu	Ser	Arg	Leu	Arg
465					470					475					480
Pro	Ser	Ser	Asp	Asn	Asp	Ala	Leu	Glu	Leu	Ser	Leu	Thr	Arg	Met	Trp
			485						490					495	
Leu	Ala	Ala	Leu	Cys	Pro	Pro	Leu	Leu	Glu	Ser	Leu	Pro	Ala	Thr	Pro
		500						505					510		
Glu	Pro	Glu	Arg	Gly	Pro	Val	Pro	Val	Arg	Leu	Ala	Pro	Arg	Thr	Thr
	515						520					525			
Ala	Leu	Gln	Ala	Gln	Ala	Gly	Val	Phe	Gln	Arg	Gly	Pro	Asp	Asn	Ala
	530					535					540				
Ser	Val	Ala	Gln	Ala	Glu	Gln	Ile	Leu	Gln	Gly	Cys	Arg	Leu	Ser	Glu
545					550					555					560
Glu	Thr	Tyr	Glu	Ala	Leu	Glu	Thr	Ala	Leu	Leu	Val	Leu	Val	His	Ala
			565					570						575	
Asp	Arg	Leu	Asp	Arg	Ala	Leu	Phe	Trp	Ser	Asp	Ala	Leu	Leu	Ala	Glu
		580						585					590		
Ala	Val	Glu	Arg	Arg	Ser	Leu	Gly	Trp	Glu	Ala	Val	Phe	Ala	Ala	Thr
	595						600					605			
Arg	Ala	Met	Ile	Ala	Ile	Arg	Cys	Gly	Asp	Leu	Pro	Thr	Ala	Arg	Glu
	610					615					620				
Arg	Ala	Glu	Leu	Ala	Leu	Ser	His	Ala	Ala	Pro	Glu	Ser	Trp	Gly	Leu
625					630					635					640
Ala	Val	Gly	Met	Pro	Leu	Ser	Ala	Leu	Leu	Leu	Ala	Cys	Thr	Glu	Ala
			645						650					655	
Gly	Glu	Tyr	Glu	Gln	Ala	Glu	Arg	Val	Leu	Arg	Gln	Pro	Val	Pro	Asp
		660						665					670		
Ala	Met	Phe	Asp	Ser	Arg	His	Gly	Met	Glu	Tyr	Met	His	Ala	Arg	Gly
	675						680					685			
Arg	Tyr	Trp	Leu	Ala	Xaa	Gly	Arg	Leu	His	Ala	Ala	Leu	Gly	Glu	Phe
	690					695					700				
Met	Leu	Cys	Gly	Glu	Ile	Leu	Gly	Ser	Trp	Asn	Leu	Asp	Gln	Pro	Ser
705					710					715					720
Ile	Val	Pro	Trp	Arg	Thr	Ser	Ala	Ala	Glu	Val	Tyr	Leu	Arg	Leu	Gly
				725					730					735	
Asn	Arg	Gln	Lys	Ala	Arg	Ala	Leu	Ala	Glu	Ala	Gln	Leu	Ala	Leu	Val
		740						745					750		

-continued

Arg	Pro	Gly	Arg	Ser	Arg	Thr	Arg	Gly	Leu	Thr	Leu	Arg	Val	Leu	Ala
		755						760					765		
Ala	Ala	Val	Asp	Gly	Gln	Gln	Ala	Glu	Arg	Leu	His	Ala	Glu	Ala	Val
		770					775					780			
Asp	Met	Leu	His	Asp	Ser	Gly	Asp	Arg	Leu	Glu	His	Ala	Arg	Ala	Leu
		785				790				795					800
Ala	Gly	Met	Ser	Arg	His	Gln	Gln	Ala	Gln	Gly	Asp	Asn	Tyr	Arg	Ala
				805						810					815
Arg	Met	Thr	Ala	Arg	Leu	Ala	Gly	Asp	Met	Ala	Trp	Ala	Cys	Gly	Ala
			820					825						830	
Tyr	Pro	Leu	Ala	Glu	Glu	Ile	Val	Pro	Gly	Arg	Gly	Gly	Arg	Arg	Ala
		835					840					845			
Lys	Ala	Val	Ser	Thr	Glu	Leu	Glu	Leu	Pro	Gly	Gly	Pro	Asp	Val	Gly
		850					855				860				
Leu	Leu	Ser	Glu	Ala	Glu	Arg	Arg	Val	Ala	Ala	Leu	Ala	Ala	Arg	Gly
		865				870				875					880
Leu	Thr	Asn	Arg	Gln	Ile	Ala	Arg	Arg	Leu	Cys	Val	Thr	Ala	Ser	Thr
				885					890						895
Val	Glu	Gln	His	Leu	Thr	Arg	Val	Tyr	Arg	Lys	Leu	Asn	Val	Thr	Arg
				900				905						910	
Arg	Ala	Asp	Leu	Pro	Ile	Ser	Leu	Ala	Gln	Asp	Lys	Ser	Val	Thr	Ala
		915					920					925			

<210> SEQ ID NO 14

<211> LENGTH: 292

<212> TYPE: PRT

<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 14

Met	Lys	Gly	Ile	Val	Leu	Ala	Gly	Gly	Ser	Gly	Thr	Arg	Leu	His	Pro
1				5					10					15	
Ala	Thr	Ser	Val	Ile	Ser	Lys	Gln	Ile	Leu	Pro	Val	Tyr	Asn	Lys	Pro
			20					25						30	
Met	Ile	Tyr	Tyr	Pro	Leu	Ser	Val	Leu	Met	Leu	Gly	Gly	Ile	Arg	Glu
		35					40					45			
Ile	Gln	Ile	Ile	Ser	Thr	Pro	Gln	His	Ile	Glu	Leu	Phe	Gln	Ser	Leu
		50				55					60				
Leu	Gly	Asn	Gly	Arg	His	Leu	Gly	Ile	Glu	Leu	Asp	Tyr	Ala	Val	Gln
		65			70					75					80
Lys	Glu	Pro	Ala	Gly	Ile	Ala	Asp	Ala	Leu	Leu	Val	Gly	Ala	Glu	His
				85					90					95	
Ile	Gly	Asp	Asp	Thr	Cys	Ala	Leu	Ile	Leu	Gly	Asp	Asn	Ile	Phe	His
		100						105					110		
Gly	Pro	Gly	Leu	Tyr	Thr	Leu	Leu	Arg	Asp	Ser	Ile	Ala	Arg	Leu	Asp
		115					120					125			
Gly	Cys	Val	Leu	Phe	Gly	Tyr	Pro	Val	Lys	Asp	Pro	Glu	Arg	Tyr	Gly
		130				135					140				
Val	Ala	Glu	Val	Asp	Ala	Thr	Gly	Arg	Leu	Thr	Asp	Leu	Val	Glu	Lys
		145			150					155					160
Pro	Val	Lys	Pro	Arg	Ser	Asn	Leu	Ala	Val	Thr	Gly	Leu	Tyr	Leu	Tyr
				165				170						175	
Asp	Asn	Asp	Val	Val	Asp	Ile	Ala	Lys	Asn	Ile	Arg	Pro	Ser	Pro	Arg
			180					185						190	

-continued

Gly Glu Leu Glu Ile Thr Asp Val Asn Arg Val Tyr Leu Glu Arg Gly
 195 200 205
 Arg Ala Glu Leu Val Asn Leu Gly Arg Gly Phe Ala Trp Leu Asp Thr
 210 215 220
 Gly Thr His Asp Ser Leu Leu Arg Ala Ala Gln Tyr Val Gln Val Leu
 225 230 235 240
 Glu Glu Arg Gln Gly Val Trp Ile Ala Gly Leu Glu Glu Ile Ala Phe
 245 250 255
 Arg Met Gly Phe Ile Asp Ala Glu Ala Cys His Gly Leu Gly Glu Gly
 260 265 270
 Leu Ser Arg Thr Glu Tyr Gly Ser Tyr Leu Met Glu Ile Ala Gly Arg
 275 280 285
 Glu Gly Ala Pro
 290

<210> SEQ ID NO 15
 <211> LENGTH: 337
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 15

Val Arg Leu Leu Val Thr Gly Gly Ala Gly Phe Ile Gly Ser His Phe
 1 5 10 15
 Val Arg Gln Leu Leu Ala Gly Ala Tyr Pro Asp Val Pro Ala Asp Glu
 20 25 30
 Val Ile Val Leu Asp Ser Leu Thr Tyr Ala Gly Asn Arg Ala Asn Leu
 35 40 45
 Ala Pro Val Asp Ala Asp Pro Arg Leu Arg Phe Val His Gly Asp Ile
 50 55 60
 Arg Asp Ala Gly Leu Leu Ala Arg Glu Leu Arg Gly Val Asp Ala Ile
 65 70 75 80
 Val His Phe Ala Ala Glu Ser His Val Asp Arg Ser Ile Ala Gly Ala
 85 90 95
 Ser Val Phe Thr Glu Thr Asn Val Gln Gly Thr Gln Thr Leu Leu Gln
 100 105 110
 Cys Ala Val Asp Ala Gly Val Gly Arg Val Val His Val Ser Thr Asp
 115 120 125
 Glu Val Tyr Gly Ser Ile Asp Ser Gly Ser Trp Thr Glu Ser Ser Pro
 130 135 140
 Leu Glu Pro Asn Ser Pro Tyr Ala Ala Ser Lys Ala Gly Ser Asp Leu
 145 150 155 160
 Val Ala Arg Ala Tyr His Arg Thr Tyr Gly Leu Asp Val Arg Ile Thr
 165 170 175
 Arg Cys Cys Asn Asn Tyr Gly Pro Tyr Gln His Pro Glu Lys Leu Ile
 180 185 190
 Pro Leu Phe Val Thr Asn Leu Leu Asp Gly Gly Thr Leu Pro Leu Tyr
 195 200 205
 Gly Asp Gly Ala Asn Val Arg Glu Trp Val His Thr Asp Asp His Cys
 210 215 220
 Arg Gly Ile Ala Leu Val Leu Ala Gly Gly Arg Ala Gly Glu Ile Tyr
 225 230 235 240
 His Ile Gly Gly Gly Leu Glu Leu Thr Asn Arg Glu Leu Thr Gly Ile

-continued

245										250										255									
Leu	Leu	Asp	Ser	Leu	Gly	Ala	Asp	Trp	Ser	Ser	Val	Arg	Lys	Val	Ala														
			260						265					270															
Asp	Arg	Lys	Gly	His	Asp	Leu	Arg	Tyr	Ser	Leu	Asp	Gly	Gly	Lys	Ile														
		275						280					285																
Glu	Arg	Glu	Leu	Gly	Tyr	Arg	Pro	Gln	Val	Ser	Phe	Ala	Asp	Gly	Leu														
		290				295						300																	
Ala	Arg	Thr	Val	Arg	Trp	Tyr	Arg	Glu	Asn	Arg	Gly	Trp	Trp	Glu	Pro														
305					310					315					320														
Leu	Lys	Ala	Thr	Ala	Pro	Gln	Leu	Pro	Ala	Thr	Ala	Val	Glu	Val	Ser														
				325					330						335														

Ala

<210> SEQ ID NO 16
 <211> LENGTH: 332
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 16

Ile	Gly	Tyr	Asp	Ser	Ser	Lys	Lys	Gly	Phe	Asp	Gly	Ala	Ser	Cys	Gly				
1				5					10					15					
Val	Ser	Val	Ser	Ile	Gly	Ser	Gln	Ser	Pro	Asp	Ile	Ala	Gln	Gly	Val				
			20					25					30						
Asp	Thr	Ala	Tyr	Glu	Lys	Arg	Val	Glu	Gly	Ala	Ser	Gln	Arg	Asp	Glu				
		35				40						45							
Gly	Asp	Glu	Leu	Asp	Lys	Gln	Gly	Ala	Gly	Asp	Gln	Gly	Leu	Met	Phe				
	50				55					60									
Gly	Tyr	Ala	Ser	Asp	Glu	Thr	Pro	Glu	Leu	Met	Pro	Leu	Pro	Ile	His				
	65			70				75						80					
Leu	Ala	His	Arg	Leu	Ser	Arg	Arg	Leu	Thr	Glu	Val	Arg	Lys	Asn	Gly				
			85					90						95					
Thr	Ile	Pro	Tyr	Leu	Arg	Pro	Asp	Gly	Lys	Thr	Gln	Val	Thr	Ile	Glu				
		100					105						110						
Tyr	Asp	Gly	Asp	Arg	Ala	Val	Arg	Leu	Asp	Thr	Val	Val	Val	Ser	Ser				
		115					120					125							
Gln	His	Ala	Ser	Asp	Ile	Asp	Leu	Glu	Ser	Leu	Leu	Ala	Pro	Asp	Val				
	130				135						140								
Arg	Lys	Phe	Val	Val	Glu	His	Val	Leu	Ala	Gln	Leu	Val	Glu	Asp	Gly				
	145				150				155					160					
Ile	Lys	Leu	Asp	Thr	Asp	Gly	Tyr	Arg	Leu	Leu	Val	Asn	Pro	Thr	Gly				
		165					170						175						
Arg	Phe	Glu	Ile	Gly	Gly	Pro	Met	Gly	Asp	Ala	Gly	Leu	Thr	Gly	Arg				
		180					185					190							
Lys	Ile	Ile	Ile	Asp	Thr	Tyr	Gly	Gly	Met	Ala	Arg	His	Gly	Gly	Gly				
		195				200					205								
Ala	Phe	Ser	Gly	Lys	Asp	Pro	Ser	Lys	Val	Asp	Arg	Ser	Ala	Ala	Tyr				
	210				215					220									
Ala	Met	Arg	Trp	Val	Ala	Lys	Asn	Val	Val	Ala	Ala	Gly	Leu	Ala	Ser				
	225				230					235				240					
Arg	Cys	Glu	Val	Gln	Val	Ala	Tyr	Ala	Ile	Gly	Lys	Ala	Glu	Pro	Val				
		245						250					255						

Gly Leu Phe Val Glu Thr Phe Gly Thr His Lys Ile Glu Thr Glu Lys

-continued

260	265	270
Ile Glu Asn Ala Ile Gly Glu Val Phe Asp Leu Arg Pro Ala Ala Ile		
275	280	285
Ile Arg Asp Leu Asp Leu Leu Arg Pro Ile Tyr Ser Gln Thr Ala Ala		
290	295	300
Tyr Gly His Phe Gly Arg Glu Leu Pro Asp Phe Thr Trp Glu Arg Thr		
305	310	315
320		
Asp Arg Val Asp Ala Leu Lys Lys Ala Ala Gly Leu		
325	330	

<210> SEQ ID NO 17
 <211> LENGTH: 230
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 17

Met Arg Ile Ala Val Thr Gly Ser Ile Ala Thr Asp His Leu Met Thr		
1	5	10
Phe Pro Gly Arg Phe Ala Glu Gln Ile Leu Pro Asp Gln Leu Ala His		
20	25	30
Val Ser Leu Ser Phe Leu Val Asp Thr Leu Asp Ile Arg His Gly Gly		
35	40	45
Val Ala Ala Asn Ile Ala Tyr Gly Leu Gly Leu Leu Gly Arg Arg Pro		
50	55	60
Val Leu Val Gly Ala Val Gly Lys Asp Phe Asp Gly Tyr Gly Gln Leu		
65	70	75
80		
Leu Arg Ala Ala Gly Val Asp Thr Asp Ser Val Arg Val Ser Asp Arg		
85	90	95
Gln His Thr Ala Arg Phe Met Cys Thr Thr Asp Glu Asp Gly Asn Gln		
100	105	110
Leu Ala Ser Phe Tyr Ala Gly Ala Met Ala Glu Ala Arg Asp Ile Asp		
115	120	125
Leu Gly Glu Thr Ala Gly Arg Pro Gly Gly Ile Asp Leu Val Leu Val		
130	135	140
Gly Ala Asp Asp Pro Glu Ala Met Val Arg His Thr Arg Val Cys Arg		
145	150	155
160		
Glu Leu Gly Leu Arg Arg Ala Ala Asp Pro Ser Gln Gln Leu Ala Arg		
165	170	175
Leu Glu Gly Asp Ser Val Arg Glu Leu Val Asp Gly Ala Glu Leu Leu		
180	185	190
Phe Thr Asn Ala Tyr Glu Arg Ala Leu Leu Leu Ser Lys Thr Gly Trp		
195	200	205
Thr Glu Gln Glu Val Leu Ala Arg Val Gly Thr Trp Ile Thr Thr Leu		
210	215	220
Gly Ala Lys Gly Cys Arg		
225	230	

<210> SEQ ID NO 18
 <211> LENGTH: 416
 <212> TYPE: PRT
 <213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 18

Val Arg Arg Thr Gln Gln Gly Thr Thr Ala Ser Pro Pro Val Leu Asp

-continued

1	5	10	15
Leu Gly Ala	Leu Gly Gln Asp Phe	Ala Ala Asp Pro Tyr	Pro Thr Tyr
	20	25	30
Ala Arg Leu	Arg Ala Glu Gly Pro	Ala His Arg Val Arg	Thr Pro Glu
	35	40	45
Gly Asp Glu	Val Trp Leu Val Val	Gly Tyr Asp Arg	Ala Arg Ala Val
	50	55	60
Leu Ala Asp	Pro Arg Phe Ser Lys	Asp Trp Arg Asn	Ser Thr Thr Pro
	65	70	75
Leu Thr Glu	Ala Glu Ala Ala	Leu Asn His Asn	Met Leu Glu Ser Asp
	85	90	95
Pro Pro Arg	His Thr Arg Leu Arg	Lys Leu Val Ala	Arg Glu Phe Thr
	100	105	110
Met Arg Arg	Val Glu Leu Leu Arg	Pro Arg Val Gln	Glu Ile Val Asp
	115	120	125
Gly Leu Val	Asp Ala Met Leu Ala	Ala Pro Asp Gly	Arg Ala Asp Leu
	130	135	140
Met Glu Ser	Leu Ala Trp Pro Leu	Pro Ile Thr Val	Ile Ser Glu Leu
	145	150	155
Leu Gly Val	Pro Glu Pro Asp Arg	Ala Ala Phe Arg	Val Trp Thr Asp
	165	170	175
Ala Phe Val	Phe Pro Asp Asp Pro	Ala Gln Ala Gln	Thr Ala Met Ala
	180	185	190
Glu Met Ser	Gly Tyr Leu Ser Arg	Leu Ile Asp Ser	Lys Arg Gly Gln
	195	200	205
Asp Gly Glu	Asp Leu Leu Ser Ala	Leu Val Arg Thr	Ser Asp Glu Asp
	210	215	220
Gly Ser Arg	Leu Thr Ser Glu Glu	Leu Leu Gly Met	Ala His Ile Leu
	225	230	235
Leu Val Ala	Gly His Glu Thr Thr	Val Asn Leu Ile	Ala Asn Gly Met
	245	250	255
Tyr Ala Leu	Leu Ser His Pro Asp	Gln Leu Ala Ala	Leu Arg Ala Asp
	260	265	270
Met Thr Leu	Leu Asp Gly Ala Val	Glu Glu Met Leu	Arg Tyr Glu Gly
	275	280	285
Pro Val Glu	Ser Ala Thr Tyr Arg	Phe Pro Val Glu	Pro Val Asp Leu
	290	295	300
Asp Gly Thr	Val Ile Pro Ala Gly	Asp Thr Val Leu	Val Val Leu Ala
	305	310	315
Asp Ala His	Arg Thr Pro Glu Arg	Phe Pro Asp Pro	His Arg Phe Asp
	325	330	335
Ile Arg Arg	Asp Thr Ala Gly His	Leu Ala Phe Gly	His Gly Ile His
	340	345	350
Phe Cys Ile	Gly Ala Pro Leu Ala	Arg Leu Glu Ala	Arg Ile Ala Val
	355	360	365
Arg Ala Leu	Leu Glu Arg Cys Pro	Asp Leu Ala Leu	Asp Val Ser Pro
	370	375	380
Gly Glu Leu	Val Trp Tyr Pro Asn	Pro Met Ile Arg	Gly Leu Lys Ala
	385	390	395
Leu Pro Ile	Arg Trp Arg Arg Gly	Arg Glu Ala Gly	Arg Arg Thr Gly
	405	410	415

-continued

<210> SEQ ID NO 19

<211> LENGTH: 38506

<212> TYPE: DNA

<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 19

```
gatcatgcgg agcactcctt ctctcgtgct cctaccggtg atgtgcgcgc cgaattgatt    60
cgtggagaga tgtcgacagt gtccaagagt gagtccgagg aattcgtgtc cgtgtcgaac    120
gacgccgggt ccgcgcacgg cacagcggaa cccgtcgcgg tcgtcggcat ctctcgccgg    180
gtgcccgggc cccgggaccc gagagagttc tgggaactcc tggcggcagg cggccaggcc    240
gtcaccgacg tccccgcgga ccgctggaac gccggcgact tctacgaccc ggaccgctcc    300
gcccccgggc gtcgaaacag ccggtggggc gggttcatcg aggacgtcga ccggttcgac    360
gccgccttct tcggcatctc gccccgcgag gccgcggaga tggaccgcga gcagcggctc    420
gccctggagc tgggctggga ggcctggag cgcgcggga tcgaccgtc ctcgctcacc    480
ggcaccgcga ccggcgtctt cgcggcgccc atctgggacg actacgccac cctgaagcac    540
cgccaggggc gcgcgcgat caccgcgac accgtcaccg gcctccaccg cggcatcacc    600
gcgaaccgac tctcgtacac gctcgggctc cgcggcccca gcatggctgt cgactccggc    660
cagtctctgt cgctcgtcgc cgtccacctc gcgtgcgaga gcctgcggcg cggcgagtcc    720
gagctcgccc tcgccggcgg cgtctcgctc aacctggtgc cggacagcat catcggggcg    780
agcaagtctg gcggcctctc ccccgacggc cgcgcctaca ccttcgacgc gcgcgccaac    840
ggctacgtac gcggcgaggg cggcggttct gtcgtcctga agcgcctctc ccgggcccgtc    900
gccgacggcg acccggtgct cgcctgatac cggggcagcg ccgtcaacaa cggcggcgcc    960
gcccagggca tgacgacccc cgacgcgcag gcgcaggagg ccgtgctccg cgaggcccac    1020
gagcggggcg ggaccgcgcc ggccgacgtg cgggtacgtc agctgcacgg caccggcacc    1080
cccgtggggc acccgatcga ggccgctcgc ctcgggcgcc ccctcggcac cggccgcccg    1140
gccggacagc cgctcctggt cggctcggtc aagacgaaca tcggccacct ggaggcgcg    1200
gccggcatcg ccggcctcat caaggccgtc ctggcgggtc gcggtcgcgc gctgcccgcc    1260
agcctgaact acgagacccc gaaccggcg atcccgttcg aggaactgaa cctccgggtg    1320
aacacggagt acctgccgtg ggagccggag cacgacgggc agcggatggt cgtcggcgtg    1380
tctcgttcg gcatggggcg cacgaacgcg catgtcgtgc tcgaagaggc cccggggggt    1440
gtcgagggtg cttcggctgt ggagtcgacg gtcggcgggc cggcggtcgg cggcgggtg    1500
gtgccgtggg tgggtgcggc gaagtccgct gccgcgctgg acgcgcagat cgagcggctt    1560
gccgcgttcg cctcgcggga tcgtacggat ggtgtcgcag cgggcgctgt cgatgcgggt    1620
gctgtcgatg cgggtgctgt cgctcgcgta ctggccggcg ggcgtgctca gttcagcac    1680
cgggcgctcg tcgtcggcag cgggcgggac gatctggcgg cagcgtggc cgcgcctgag    1740
ggtctggtcc gggcggtgac ttccggtgtc gggcgagtgg cgttcgtgtt ccccgggcag    1800
ggcagcgagt gggccggcat ggggtccgaa ctgctggact cttccgcggt gttcgcggcg    1860
gccatggccg aatgcgaggc cgcactctcc ccgtacgtcg actggtcgct ggaggccgtc    1920
gtacggcagg cccccggtgc gcccacgctg gagcgggtcg atgtcgtgca gcctgtgacg    1980
ttcgccgtca tggctcgtct ggctcgcgtg tggcagcacc acgggggtgac gcccaggcg    2040
```


-continued

gtcgtcggcc actcgcaggc cgagatcgcc gcccggtacg tcccggtgc cctgagcctg	2100
gacgacgccc ctctgtgtcgt gaccctgcgc agcaagtcca tcccgcccca cctcgcgggc	2160
aaggcgggca tgcgtgccct cgcgctgagc gaggacgccc tccctggagcg actggccggg	2220
ttcgacgggc tgtccgtcgc cgtctgtaac gggcccaccg ccaccgtggt ctccggtgac	2280
cccgtagaca tcgaagagct tgctcgggcg tgtgaggccg atgggggtccg tgcgcgggtc	2340
attcccgtcg actacgcgtc ccacagccgg caggtcgaga tcatcgagag cgagctcgcc	2400
gaggctcctcg cggggtcag cccgaggct cgcgcgtgc cgttcttctc gacactcgaa	2460
gggcctgga tcaccgagcc cgtgctcgac ggcggctact ggtaccgcaa cctgcgccat	2520
cgtgtgggct tcgcccgcgc cgtcgagacc ctggccaccg acgagggtt caccacttc	2580
gtcgaggtea gcgcccacc cgtcctcacc atggccctcc cgggaccgt caccggtctg	2640
gcgacctgc gtcgcgacaa cggcggtcag gaccgcctcg tcgcctccct cgcgaagca	2700
tgggccaacg gactcgcggt cgactggagc ccgctcctcc cctccgcgac cggccaccac	2760
tcgacctcc ccacctacgc gttccagacc gagcgccact ggctgggcca gatcgaggcg	2820
ctgcccccg cggcgagacc ggcggtgag cccgccgtcc tcgcacgga ggcggccgag	2880
ccggcgagc tcgaccggga cgagcagctg cgcgtgatcc tggacaaggc ccggcgagc	2940
acggcccagg tgctggggta cgcgacagc gggcagatcg aggtcgaccg gaccttccgt	3000
gaggccggtt gcacctccct gaccggcgtg gacctgcga accggatcaa cgcgccttc	3060
ggcgtagga tggcgccgtc catgatcttc gacttccca ccccgaggc tctcgaggag	3120
cagctgctcc tcgtcgtgca cggggaggcg cgcgcgaacc cggccggtgc ggagccggt	3180
ccggtggcg cggccggtgc cgtcgacgag ccggtggcga tcgtcgccat ggcctgccgc	3240
ctgcccgggtg gggtcgcctc gccggaggac ctgtggcggc tgggtggccg cggcggggac	3300
gcgatctcg agttcccga ggaccgcgc tgggacgtgg aggggtgta ccccccgat	3360
cccagacacc ccggcacgtc gtacgtccgc caggcggtt tcatcgagaa cgtcgccggc	3420
ttcgacgagg ccttcttcg gatctcgcc cgcgaggccc tcgccatgga ccgcagcag	3480
cggctcctcc tcgaaacctc ctgggaggcc gtcgaggacg ccgggatcga cccgacctcc	3540
ctgccccgac ggcaggctcg cgtcttact gggcgatga cccacagta cggccgagc	3600
ctgccccgac ggcgggaagg cctcgacggc tacctgctga ccggcaaac ggcagcgtg	3660
atgtcgggc gcgtctcgta cacactcgcc cttgaggcc ccgccctgac ggtggacacg	3720
gcctgctcgt cgtcgtggt cgcctgcac ctgccgtgc aggccctgc caaggcgag	3780
gtcgacatgg cgtcgcggc cggcgtggcc gtgatgccc cggccgggat gttcgtcgag	3840
ttcagccgc agcgcggtc ggcggggac ggcgggtcga aggcgttcgc cgcgtcggc	3900
gacggacca gctggctcga gggcgtcgc gtcctcctc tcgagccct gtcggacgcc	3960
cgcgcaacg gacaccaggt cctcgcggtc gtccgcggca gcgcgtgaa ccaggacggc	4020
gcgagcaac gcctcacggc tcggaacgg ccctcgagc agcgctcat ccggcgcgcg	4080
ctggcgagc cccggctgac gacctcgac gtggacgtc tcgaggcaca cggcacggc	4140
acgcgactcg gcgaccgat cgaggcgag gccctgatc ccacctacg ccagggccgt	4200
gacgacgaac agccgctgc cctcgggtc ttgaagtcca acatcgggca caccagggc	4260
gcggccggcg tctccggtg catcaagatg gtccaggcga tgcgccacg actgctgcc	4320

-continued

aagacgctgc acgtcgacga gccctcggac cagatcgact ggtcggctgg cgccgtggaa	4380
ctctcaccgc aggcgcgcga ctggccggag aagcaggacg gcgggctgcg ccgggcccgc	4440
gtctcctcct tcgggatcag cggcaccaat gcgcattgtg tgctcgaaga gggcccgggtg	4500
gttgctgagg gtgcttcggt cgtcgagccg tcggttgccg ggtcggcggt cgccggcggt	4560
gtgacgcctt ggggtgtgtc ggccgaagtcc gctgccgcgc tcgacgcgca gatcgagcgg	4620
cttgccgcct tcgcctcgcg ggatcgtagc gatgacgcgc acgccggtgc tgctgacgcg	4680
ggcgtgtgcg ctacagctact ggctgacggg cgtgctcagt tcgagcaccg ggccgtcgcg	4740
ctcggcgccg ggggggacga cctcgtacag gcgctggccg atccggacgg gctgatacgc	4800
ggaacggctt ccggtgtcgc gcgagtggcg ttcgtgttcc ccggtcaggg cagcagtggt	4860
gctggcatgg gtgccgaact gctggactct tccgcggtgt tcgcgcgccg catggccgag	4920
tgtgaggccg cgtctgtccc gtacgtcgac tggctcgtgg aggcctcgt acggcaggcc	4980
cccggtcgcg ccacgctgga gcgggtcgat gtcgtgcagc ctgtgacgtt cgccgtcatg	5040
gtctcgtcgg ctgcgctgtg gcagcaccac ggtgtgacgc ccagggcggt cgtcgccac	5100
tcgcaggggc agatcgccgc cgcgtacgtc gccggagccc tgcccctgga cgacgccgc	5160
cgcgtcgtca ccctgcgcag caagtccatc gccgccacc tcgccggcaa gggcgccatg	5220
ctgtccctcg cgtgaacga ggacgccgc ctggagcgac tgagtactt cgacgggctg	5280
tccgtcgcgc ccgtcaacgg gccaccgcc actgtcgtgt cgggtgaccc cgtacagatc	5340
gaagagcttg ctacggcgtg caaggcgac ggattccgcg cgcggatcat tcccgtcgac	5400
tacgctccc acagccggca ggtcgagatc atcgagagcg agctcgccca ggtcctcgcc	5460
ggtctcagcc cgcaggcccc gcgctgccc ttcttctcga cgtcgaagg cacctggatc	5520
accgagcccc tcctcgacgg caccactagg taccgcaacc tccgtcaccg cgtcgcttc	5580
gcccccgcca tcgagaccct ggccgtcgac gagggcttca cgcacttcgt cgaggtcagc	5640
gcccccccg tcctcaccat gaccctcccc gagaccgta ccggcctcgg caccctccgt	5700
cgcgaacagg gagggccaaga gcgtctgtgc acctcgctcg ccgaggcgtg ggtcaacggg	5760
cttccggtgg catggacttc gctcctgccc gccacggcct ccgccccgg tctgcccacc	5820
tacgccttcc aggcgcagcg ctactggctc gagaacactc ccgccgcctt ggccaccggc	5880
gacgactggc gctaccgcat cgactggaag cgcctcccgg ccgcccaggg gtccgagcgc	5940
accggcctgt ccggccgctg gctcgccgtc acgcccggag accactccgc gcaggccgcc	6000
gccgtgtcga ccgcgctggt cgacgccggg gcgaaggctg aggtgtgtgac ggccggggcg	6060
gacgacgacc gtgaggccct cgcgcccg ctcaccgcac tgacgacgg tgacggcttc	6120
accggcgtgg tctcgtcct cgacggactc gtaccgcagg tcgcctgggt ccaggcgctc	6180
ggcgacgccg gaatcaaggc gcccctgtgg tccgtcacc agggcgcggt ctccgtcgga	6240
cgtctcgaca ccccgccga ccccgaccgg gccatgctct ggggcctcgg ccgcgtcgtc	6300
gccccttgag accccgaacg ctgggcccgc ctcgtcgacc tccccgcca gcccgatgcc	6360
gccgccctcg cccacctcgt caccgcactc tccggcgcca ccggcgagga ccagatcgcc	6420
atccgcacca ccggactcca cgcgccgc ctcgcccg caccctcca ccgacgtcgg	6480
ccccccgcg actggcagcc ccacggcacc gtcctcatca ccggcggaac ccgagccctc	6540
ggcagccacg ccgcacgctg gatggcccac cagggagccg aacacctcct cctcgtcagc	6600

-continued

cgagcgggc	aacaagcccc	cggagccacc	caactcaccg	ccgaactcac	cgcatcgggc	6660
gccccgcgca	ccatcgccgc	ctgcgacgtc	gccgaccccc	acgccatgcg	cacctcctc	6720
gacgccatcc	ccgccgagac	gccccctacc	gccgtcgtcc	acaccgccgg	cgcgctcgac	6780
gacggcatcg	tggacacgct	gaccgccgag	caggtccggc	gggcccaccg	tgcgaaggcc	6840
gtcggcgccct	cgggtgctga	cgagctgacc	cgggacctcg	acctcgacgc	gttcgtgctc	6900
ttctcgtccg	tgtcgagcac	tctgggcatc	cccggtcagg	gcaactacgc	cccgcacaaac	6960
gcctacctcg	acgccctcgc	ggctcgccgc	cgggccaccg	gccggtccgc	cgtctcggtg	7020
gcctggggac	cgtgggacgg	tggcgccatg	gccgccggtg	acggcggtgg	cgagcggctg	7080
cgcaaccacg	gcgtgccccg	catggaccgc	gaactcgccc	tggccgcact	ggagtccgcg	7140
ctcggccggg	acgagaccgc	gatcaccgtc	gcggacatcg	actgggaccg	cttctacctc	7200
gcgtactcct	ccggtcgccc	gcagccccctc	gtcgaggagc	tgcccagagt	gcggcgcatc	7260
atcgacgcac	gggacagcgc	cacgtccgga	caggcgggga	gctccgcca	ggcgccaaac	7320
ccctggcccg	agcggctggc	cgcgcggct	cccggcgagc	gtacggagat	cctcctcggg	7380
ctcgtacggg	cgcagccgc	cgcctgctc	cggatgcgtt	cgcggagga	cgtcgccgcc	7440
gaccgcgcct	tcaaggacat	cggcttcgac	tcgctcgccg	gtgtcgagct	gcgcaacagg	7500
ctgaccgggg	cgaccgggct	ccagctgccc	gcgacgctcg	tcttcgacca	ccgacgcgcg	7560
ctggccctcg	tgtcgtgct	ccgcagcgag	ttcctcggtg	acgaggagac	ggcggaacgc	7620
cggcggtccg	cggcgctgcc	cgcgactgtc	ggtgccggtg	ccggcgccgg	cgcgggcacc	7680
gatgccgacg	acgatccgat	cgcgatcgtc	gcgatgagct	gccgctaccc	cggtgacatc	7740
cgcagcccg	aggacctgtg	gcggatgctg	tccgaggggc	gcgaggccat	cacgccgttc	7800
cccaccgacc	gcggctggga	cctcgacggc	ctgtacgacg	ccgaccggga	cgcgctcggc	7860
agggcgtagc	tccgcgaggg	cgggttcctg	cacgacgcgg	ccgagttcga	cgcggagttc	7920
ttcggcgtct	cgcgcgcga	ggcgctggcc	atggaccgc	agcagcggat	gctcctgacg	7980
acgtcctggg	aggccttcga	gcgggccggc	atcgagccgg	catcgctgcg	cggcagcagc	8040
accggtgtct	tcatcgccct	ctcctaccag	gactacgcgg	cccgcgtccc	gaacgccccg	8100
cgtggcgctg	agggttacct	gctgaccggc	agcacgccga	gcgtcgctc	ggcccgatc	8160
gcgtacacct	tcggtctcga	agggcccgcg	acgaccgtcg	acaccgcctg	ctcgtcgtcg	8220
ctgaccggcc	tgcacctggc	ggtgcggggc	ctgcgcagcg	gcgagtgcac	gatggcgctc	8280
gccggtggcg	tggcgatgat	ggcgaccccg	cacatgttcg	tggagtccag	ccgtcagcgg	8340
gcgctcgccc	cggacggccg	cagcaaggcc	ttctcggcgg	acgccgacgg	gttcggcgcc	8400
gcggaggggc	tcggcctgct	gctcgtggag	cggctctcgg	acgcgcggcg	caacggtcac	8460
ccggtgctcg	ccgtggtccg	cggtaaccgc	gtcaaccagg	acggcgccag	caacgggctg	8520
accgcgcccc	acggaccctc	gcagcagcgg	gtgatccggc	aggcgctcgc	cgaacggccg	8580
ctggcaccgc	gcgacatcga	cgcctcgcag	acgcacggca	cgggaacctc	gctgggcgac	8640
cccatcgagg	cccaggccct	ccaggccacg	tacggcaagg	agcgccccgc	ggaacggccg	8700
ctcgccatcg	gtccctgtaa	gtccaacatc	ggacacaccc	aggccgcggc	cggtgccggc	8760
ggcatcatca	agatggtcct	cgcgatgcgc	cacggcacc	tgcgaagac	cctccacgcc	8820
gacgagccga	gcccgcacgt	cgactggggc	aacagcggcc	tggccctcgt	caccgagccg	8880

—continued

atcgactggc cggccggcac cggtcgcgc cgcgccgccg tctcctcctt cggcatcagc	8940
gggacgaacg cgcacgtcgt gctggagcag gcgccggatg ctgctggtga ggtgcttggg	9000
gccgatgagg tgcttgaggt gtctgagacg gtagcgatgg ctgggacggc tgggacctcc	9060
gaggtcgctg agggctctga ggcctccgag gcccccgcg ccccggcag cctgaggcg	9120
tccctccccg ggcacctgcc ctgggtgctg tccgccaaagg acgagcagtc gctgcgcggc	9180
caggccgcgc ccctgcacgc gtggctgtcc gagcccgccg ccgacctgtc ggacgcggac	9240
ggaccggccc gcctgcggga cgtcgggtac acgctcgcca cgagccgtac cgccttcgcg	9300
caccgcgcgc cctgaccgc cgcgcaccgc gacgggttcc tggacgggct ggccacgctg	9360
gcccaggcg gcacctcggc ccacgtccac ctggacaccg cccgggacgg caccaccgcg	9420
ttctcttca cggccaggg cagtcagcgc cccggcgccg gccgtgagct gtacgaccgg	9480
caccctgtct tcgccgggc gctcgacgag atctgcgccc acctcgacgg tcacctcgaa	9540
ctgccccgc tcgacgtgat gtctgcggcc gagggcagcg cggaggccgc gctgctcgac	9600
gagacgcggt acacgcagtg cgcgtgttc gccctggagg tcgcgctctt cgggctcgtc	9660
gagagctggg gcatgcggcc ggccgcactg ctcggtcact cggtcggcga gatcgccgc	9720
gcgcacgtcg ccggtgtgtt ctgcctgcgc gacgcgcgcc gcctggtcgc cgcgcgcggc	9780
cggctcatgc aggagctgcc cgcgggtggc gcgatgctcg ccgtccaggc cgcggaggac	9840
gagatccgcg tgtggctgga gacggaggag cggtagcgcg gacgtctgga cgtcgccgc	9900
gtcaacggcc ccgagccgc cgtcctgtcc ggcgacgcg acgcggcgcg ggaggcggag	9960
gcgtactggt ccgggctcgg ccgcaggacc cgcgcgctgc gggtcagcca cgccttcac	10020
tccgcgcaca tggacggcat gctcgacggg ttccgcgcgc tctggagac ggtggagtct	10080
cggcgccct ccctgacct ggtctcgaa gtcaccggcc tggccgcgcg cccggacgac	10140
ctgtgcgacc ccgagtaact ggtccggcac gtccgcgcca ccgtccgctt cctcgacggc	10200
gtcgtgtcc tcgcgcacct cggcgtgcgg acctgcctgg agctgggccc cgacggggtc	10260
ctcaccgcca tggcggcga cggcctcgcg gacaccccg cggattcgc tgccggtcc	10320
cccgtcggct ctcccgccg ctctccgcgc gactccgcgc cggcgcgct cggccccgcg	10380
ccgctgctcg tggcgctgct gcgcgcgaag cggtcggaga ccgagacct cgcggacgcc	10440
ctcggcaggg cgcacgcccc cggcaccgga cccgactggc acgcctggtt cgcgggtcc	10500
ggggcgacc gcgtggacct gcccacgtac tccttcggc gcgaccgcta ctggctggac	10560
gccccggcg ccgacaccgc ggtggacacc gccggcctcg gtctcgccac cgcgaccac	10620
ccgctgctcg gcgcggtgt cagccttcgc gaccgggacg gcctgctgct caccggccgc	10680
ctctccctgc gcacccacc gtggctcgcg gaccacgcgc tcctggggag cgtcctgctc	10740
ccccggccgc cgatggtcga actcgccgc cagctgcgc agtccgcgcg tctgctgac	10800
gtgcgggagc tgacctcct tgaacgcgt gtactgccc agcacggtg cgtcgagctg	10860
cgcgtgacgc tcggggcgcc ggccggagag cccggtggcg agtcggccgc ggacggcgca	10920
cggcccgctt ccctccactc gcggctcgc gacgcgcgc ccggtaccgc ctggctcctg	10980
cacgcgaccg gtctgctggc caccgaccgc cccgagcttc ccgtcgccgc cgaccgtgcg	11040
gccatgtggc cgcgcaggg cgcgcaggag gtgcgcctcg acggtctcta cgagcggctc	11100
gacgggaacg gcctcgctt cggtcgcgtg ttccaggggc tgaacgcggt gtggcggtag	11160

-continued

gaggggtgagg	tcttcgccga	catcgcgctc	cccgccacca	cgaatgcgac	cgcgcccgcg	11220
accgcgaacg	gcggcgagg	tgccggcgcg	gccccctacg	gcattccacc	cgccctgctc	11280
gacgcttcgc	tgcacgccat	cgcggtcggc	ggtctcgtcg	acgagcccga	gctcgtccgc	11340
gtcccccttc	actggagcgg	tgtcacccgtg	cacgcggccg	gtgccgcggc	ggccccgggtc	11400
cgtctcgcct	ccgcggggac	ggacgccgtc	tcgctgtccc	tgacggacgg	cgagggacgc	11460
ccgctgggtc	ccgtggaacg	gctcacgctg	cgcccggtca	ccgccgatca	ggcggcgggc	11520
agccgcgtcg	gcggggtgat	gcaccgggtg	gcctggcgtc	cgtacgccct	cgctcgtcc	11580
ggcgaacagg	acccgcacgc	cacttcgtac	gggccgaccg	ccgtcctcgg	caaggacgag	11640
ctgaaggctg	ccgccgcct	ggagtccgcg	ggcgtcgaag	tcgggctcta	ccccgacctg	11700
gccgcgctgt	cccaggacgt	ggcgcccggc	gccccggcgc	cccgtaccgt	ccttgcgccg	11760
ctgccccggg	gtccccccga	cggcgggcgc	gaggggttac	ggggcacggt	ggccccgacg	11820
ctggagctgc	tccaggcctg	gctggccgac	gagcacctcg	cgggcacccg	cctgctcctg	11880
gtcacccgcg	gtgcggtgcg	ggaccccgag	gggtccggcg	ccgacgatgg	cggcgaggac	11940
ctgtcgcacg	cggccgcctg	gggtctcgtg	cggaccgcgc	agaccgagaa	ccccggccgc	12000
ttcggccttc	tcgacctggc	cgacgacgcc	tcgtcgtacc	ggaccctgcc	gtcgggtgctc	12060
tccgacgcgg	gcctgcgcga	cgaaccgcag	ctcgcctcgc	acgacggcac	catcagggtg	12120
gccccctcgg	cctccgtccg	gcccagagacc	ggcaccgcgc	caccggcgct	cgccccggag	12180
ggcacgggtc	tgtgacccg	cggcacccgc	ggcctggggc	gactggtcgc	ccggcacgtg	12240
gtgggcgagt	ggggcgtagc	acgcctgctg	ctggtgagcc	ggcggggcac	ggacgccccg	12300
gggcgcgacg	agctcgtgca	cgagctggag	gccctgggag	ccgacgtctc	ggtggcccg	12360
tgcgacgtcg	ccgaccgcga	agccctcacc	gccgtactcg	acgccatccc	cgcgaacac	12420
ccgctcacgg	cggctcgtcca	cacggcaggc	gtcctctcgg	acggcaccct	cccgtccatg	12480
acgacggagg	acgtggaaca	cgtactgcgg	cccaaggctg	acgccgcgtt	cctcctcgac	12540
gaactcacct	cgacgcccgc	atacgacctg	gcagcggttc	tcatgttctc	ctccgcgcgc	12600
gccgtcttcg	gtggcgcggg	gcaggcgccc	tacgccgcgg	ccaacgccac	cctcgacgcc	12660
ctgcctggc	gcccgcgggc	agccggactc	cccgcctct	ccctcggtcg	ggcctctg	12720
gccgagacca	gcggcatgac	cggcgagctc	ggccaggcgg	acctgcgccg	gatgagccgc	12780
gcgggcatcg	gcgggatcag	cgacgccgag	ggcatcgcg	tcctcgacgc	cgccctccgc	12840
gacgaccgcc	acccggtcct	gctgcccctg	cggctcgacg	ccgccgggct	gcgggacgcg	12900
gccgggaacg	acccggccgg	aatcccgcg	ctcttcgggg	acgtcgtcgg	cggcaggacc	12960
gtccggggcc	ggcgtccgc	ggcctccgcc	tcgacgacag	ccgggacggc	cggcacgccg	13020
gggacggcgg	acggcgcggc	ggaaaacggc	gcggtcacgc	tcgccgaccg	ggcgcgccac	13080
gtggacgggc	ccgcacggca	gcgcctgctg	ctcgagtctg	tcgtcggcga	ggtcgcgaa	13140
gtactcggcc	acgcccgcg	tcaccggatc	gacgccgaac	ggggcttcc	cgacctcggc	13200
ttcgactccc	tgaccgccgt	cgaactccgc	aaccggctca	actccgcggg	tgccctcgcc	13260
ctcccgcgca	ccctggtctt	cgaccaccca	agcccgggcg	cactcgcctc	ccacctggac	13320
gccgagctgc	cgcgcggcgc	ctcggaccag	gacggagccg	ggaaccggaa	cgggaacgag	13380
aacgggacga	cggcgctccc	gagcacccgc	gagacggacg	cgtgctggc	acaactgacc	13440

-continued

cgcctggaag ggccttgggt gctgacgggc ctctcggacg cccccgggag cgaagaagtc	13500
ctggagcacc tgcggtcctt gcgctcgatg gtcacgggag agaccgggac cgggaccgcg	13560
tccggagccc cggacggcgc cgggtccggc gccgaggacc ggccctgggc ggccggggac	13620
ggagccgggg gcgggagtga ggacggcgcg ggagtgcgg acttcatgaa cgctcgggcc	13680
gaggaactct tcggcctcct cgaccaggac ccagcacgg actgatccct gccgcacggt	13740
cgctcccgcc ccggacccc gtcccgggca cctcgactcg aatcacttca tgcgcgcctc	13800
gggcgcctcc aggaactcaa ggggacagcg tgtccacggt gaacgaagag aagtacctcg	13860
actacctgcg tcgtgccacg gcggacctcc acgagggccc tggccgcctc cgcgagctgg	13920
aggcgaaggg gggcgagccg gtggcgatcg tcggcatggc ctgccgcctg ccggcgggcg	13980
tcgcctcgcc cgaaggacct tggcggtggg tggccggcgg cgaaggacgc atctcggagt	14040
tccccaggga ccggggttgg gacgtggagg gctgtacga ccgaacccg gaggccacgg	14100
gcaagagtta cgcgcgcgag gccggattcc tgtacgaggg gggcgagtgc gacgccgact	14160
tcttcgggat ctgcgcgcgc gaggccctcg ccatggaccc gcagcagcgt ctctccttgg	14220
aggcctcctg ggaggcgttc gagcacggcg ggatcccgcc gccacccgcg cgcggcacct	14280
cggtcggcgt ctccaccggc gtgatgtacc acgactacgc caccgtctc accgatgtcc	14340
cggagggcat cgaaggctac ctgggcaccg gcaactccgg cagtgtcgcc tcgggcccgcg	14400
tcgctgtcac gcttgccctg gaggggccgg ccgtcacggt cgacaccgcc tgcctcgtct	14460
cgctggtcgc cctgcacctc gccgtgcagg ccctgcgcaa gggcgaggtc gacatggcgc	14520
tcgcggcgcg cgtgacggtc atgtcgacgc ccagcacctt cgtcgagtgc agccgtcagc	14580
gcgggctggc gccggacggc cggtcgaagt ccttctcgtc gacggccgac ggcaccagct	14640
ggtcgagagg cgtcggcgtc ctctcgtcg agcgctgtc cgacgcgcgt cgcaaggggc	14700
atcggtacct cgcctgtgtc cggggcaccc ccgtcaacca ggacggcgcc agcagcggcc	14760
tcacggctcc gaacgggccc tcgcagcagc ggcgtatccg acgtgccctg gcggacgccc	14820
ggctcacgac ctccgacgtg gacgtcgtcg agggccacgg cacgggtacg cgactcggcg	14880
accgatcga ggcgcaggcc gtcatcgcca cgtacgggca gggccgtgac ggcgaacagc	14940
cgtcgcctc cgggtcgttg aagtccaaca tcggacacac ccaggccgcc gccggtgtct	15000
ccggcgtgat caagatggtc caggcgatgc gccacggcgt cctgccgaag acgctccacg	15060
tggagaagcc gacggaccag gtggactggt ccgcggggcg ggtcgagctg ctaccggagg	15120
ccatggactg gccggacaag ggcgacggcg gactgcgcag ggcgcggtc tcctccttcg	15180
gcgtcagcgg gacgaacgcg cacgtcgtgc tcgaagaggc cccggcggcc gaggagaccc	15240
ctgcctccga ggcgacccc gccgtcgagc cgtcggctcg cgcgggctg gtgccgtggc	15300
tgggtgcggc gaagactccg gccgcgctgg accgccagat cggacgcctc gccgcgttcg	15360
cctcgcaggc ccgtacggac gccgcgcatc cgggcgcggg cgtcgcgta ctggccggcg	15420
ggcgcgccga gttcgcgac cgggcgctg tgctcggcac cggacaggac gatttcgcgc	15480
aggcgtgac cgtccggaa ggactgatac gcggcacgcc ctcgagctg ggcgggtgg	15540
cgttcgtgtt ccccggtcag ggcacgcagt gggccgggat gggcgccgaa ctctcgcagc	15600
tgtcgaagga gttcgcggcg gccatggccg agtcgcgag cgcgctctcc cgtatgtcg	15660
actggtcgtt ggaggccgtc gtccggcagg cgcggggcgc gccacgcctg gagcgggtcg	15720

-continued

acgtcgtcca	gcccgtgacc	ttcgtgtca	tggtttcgct	ggcgaaggtc	tggcagcacc	15780
acggcggtgac	gcccgcaggcc	gtcgtcggcc	actcgcaggg	cgagatcgcc	gccgcgtacg	15840
tcgccggtgc	cctcaccctc	gacgacggcg	cccgcgtcgt	caccctgcgc	agcaagtcca	15900
tcgccgcccc	cctcgccggc	aaggcgcgca	tgatctccct	cgccctcagc	gaggaagcca	15960
cccggcagcg	catcgagaac	ctccacggac	tgtcgatcgc	cgccgtcaac	ggccccaccg	16020
ccaccgtggt	ttcggggcgac	cccacccaga	tccaagagct	cgctcaggcg	tgtgaggccg	16080
acggggtccg	cgcacggatc	atccccgtcg	actacgcctc	ccacagcgcc	cacgtcgaga	16140
ccatcgagag	cgaactcgcc	gaggctcctcg	ccgggctcag	cccgcggaca	cctgagggtgc	16200
cgttcttctc	gacactcgaa	ggcgctcgga	tcaccgagcc	ggtgctcgac	ggcacctact	16260
ggtaccgcaa	cctccgccac	cgcgtcggct	tcgcccccg	cgtcgagacc	ctcgccaccg	16320
acgaaggctt	caccacttc	atcgaggta	gcgcccaccc	cgtcctcacc	atgaccctcc	16380
ccgagaccgt	caccggcctc	ggcacccctc	gccgcgaaca	gggaggccag	gagcgtcttg	16440
tcacctcact	cgcgaagcc	tggaccaacg	gcctcaccat	cgactgggcg	cccgtcctcc	16500
ccaccgcaac	cggccaccac	cccagctcc	ccacctacgc	cttccagcgc	cgtcactact	16560
ggctccacga	ctcccccgcc	gtccagggt	ccgtgcagga	ctcctggcgc	taccgcatcg	16620
actggaagcg	cctcgcggtc	gccgacgcgt	ccgagcgcgc	cgggctgtcc	ggcgctggc	16680
tcgtcgtcgt	ccccgaggac	cgttcggccg	aggccgcccc	ggtgctcgcc	gcgctgtccg	16740
gcgccggcgc	cgaccccgta	cagctggacg	tgtccccgct	ggcgacccgg	cagcggtcgc	16800
ccgcgacgct	gggcgaggcc	ctggcgggcg	ccggtggagc	cgtcgacggc	gtcctctcgc	16860
tgctcgcgtg	ggacgagagc	gcgcaccccg	gccaccccg	ccccttcacc	cggggcaccg	16920
gcgccaccct	caccctgggt	caggcgctgg	aggacgcggg	cgtcgccgcc	ccgctgtggt	16980
gcgtgaccca	cggcgcggtg	tccgtcggcc	gggcccagca	cgtcacctcc	cccgcccagg	17040
ccatggtgtg	gggcatgggc	cgggtcggcg	ccctggagca	ccccgagcgg	tggggcgggc	17100
tgatcgacct	gccctcggac	gccgaccggg	cggccctgga	ccgcatgacc	acggtcctcg	17160
ccggcggtac	gggtgaggac	caggctgcgg	tacgcgcctc	cgggctgtc	gcccgccgcc	17220
tcgtccgcgc	ctccctcccg	gcgcacggca	cggcttcgcc	gtggtggcag	gccgacggca	17280
cgggtgctcgt	caccggtgcc	gaggagcctg	cggccgcgca	ggccgcacgc	cggctggccc	17340
gcgacggcgc	cggacacctc	ctcctccaca	ccacccctc	cggcagcgaa	ggcgccgaag	17400
gcacctccgg	tgccgcggag	gactccggcc	tcgcccggct	cgtcgccgaa	ctcgcggaac	17460
tgggcgcgac	ggccaccgtc	gtgacctgcg	acctcacgga	cgcggaggcg	gccgcccggc	17520
tgctcgcggg	cgtctcggac	gcgcacccgc	tcagcgccgt	cctccacctg	ccgccaccg	17580
tcgactccga	gccgctcgcc	gcgacggagc	cggacgcgct	cgcccggtgc	gtgaccgcga	17640
aggccaccgc	cgcgctccac	ctggaccgcc	tcctgcggga	ggccgcggct	gccggaggcc	17700
gtccgcccgt	cctggctcct	ttctcctcgg	tcgcccgcgt	ctggggcggc	gccggtcagg	17760
gcggtacgc	cgcgggtacg	gccttcctcg	acgcctcgc	cggtcagcac	cggggcgacg	17820
gccccaccgt	gacctcgggt	gcctggagcc	cctgggaggg	cagccgcgtc	accgaggggt	17880
cgaaccggga	gcggctgcgc	cgcctcggcc	tgcgcccct	cgcgcccgcg	acggcgctca	17940
ccgcctgga	caccgcgctc	ggccacggcg	acaccgccgt	cacgatcgcc	gacgtcgact	18000

-continued

```

ggtcgagctt cgccccgcg ttcaccacgg cccggccggg caccctcctc gccgatctgc 18060
ccgaggcgcg ccgcgcgctc gacgagcagc agtcgacgac ggccgcccgc gacaccgtcc 18120
tgagccgcga gctcgggtgcg ctcaccggcg ccgaacagca gcgccgtatg caggagtgtg 18180
tccgcgagca cctcgccgtg gtccctcaacc acccctcccc cgaggccgtc gacacggggc 18240
gggccttccg tgacctcgga ttcgactcgc tgacggcggt cgagctccgc aaccgcctca 18300
agaacgccac cggcctggcc ctcccggcca ctctggtctt cgactaccgc acccccggga 18360
cgctggcgga gttcctcctc gcggagatcc tgggcgagca ggccgggtgc gccgagcagc 18420
ttccgggtga cgggggggtc gacgacgagc ccgtcgcgat cgtcggcatg gcgtgccgcc 18480
tgccggggcg tgtcgccctc ccggaggacc tgtggcggtt ggtggccggc gccgaggacg 18540
cgatctcccg ctccccgcag gaccgcggct gggacgtgga gggcgtgtac gaccgggacc 18600
cggacgcgtc cgggcggagc tactgccgtg ccggtggctt cctcgacgag gcgggcgagt 18660
tcgacgccga ctctctcggt atctcgccgc gcgaggccct cgccatggac ccgcagcagc 18720
ggctcctcct ggagacctcc tgggaggccg tcgaggacgc cgggatcgac ccgacctccc 18780
ttcaggggca gcaggtcggc gtgttcgcgg gcaccaacgg ccccccactac gagccgctgc 18840
tccgcaacac cgcgaggat cttgagggtt acgtcgggac gggcaacgcc gccagcatca 18900
tgtcggggcg tgtctcgtac accctcggcc tggagggccc ggccgtcacg gtcgacaccg 18960
cctgctcctc ctgcgtggtc gccctgcacc tcgccgtgca ggccctgcgc aagggcgaat 19020
gcggactggc gctcgcgggc ggtgtgacgg tcatgtcgac gccacgacg ttcgtggagt 19080
tcagccggca gcgcgggctc gcggaggacg gccggtcgaa ggcgttcgcc gcgtcggcgg 19140
acggcttcgg cccggcgagc ggcgtcggca tgctcctcgt cgagcgcctg tcggacgccc 19200
gccgcaacgg acacctgtgt ctggcggtcg tgcgcggcag ccggttcaac caggacggcg 19260
cgagcaacgg cctgaccgcc ccgaacgggc cctcgagca gcgcgtcatc cggcgcgcgc 19320
tcgcggacgc ccgactgacg accgcgacg tggacgtcgt cgaggccac gccacgggca 19380
cgcgactcgg cgaccgata gaggcacagg ccctcatcgc caccacggc caggggcgcg 19440
acaccgaaca gccgtgcgc ctggggctgt tgaagtcaa catcgacac acccaggccg 19500
ccgcgggtgt ctccggcacc atcaagatgg tcacggcgat gcgccacggc gtcctgccga 19560
agacgctcca cgtggaccgg ccgtcggacc agatcgactg gtcggcgggc acggtcgagc 19620
tgctcaccga ggccatggac tggccgagga agcaggaggg cgggctgcgc cgcgcggccg 19680
tctcctcctt cggcatcagc ggcacgaacg cgcacatcgt gtcgaagaa gcccggctc 19740
acgaggacgc cccggcggac gagccgtcgg tcggcggtgt ggtgccgtgg ctctgttccg 19800
cgaagactcc ggccgcgctg gacgcccaga tcggacgcct cgcgcgcttc gcctcgcagg 19860
gccgtacgga cgcgcgcgat ccgggcgcgg tcgctcgcgt actggccggc gggcgtgcgc 19920
agttcgagca ccgggcgcgt gcgctcggca ccggacagga cgacctggcg gccgcactgg 19980
ccgcgcctga gggctcgtgc cggggtgtgg cctccggtgt gggtcgagtg gcgttcgtgt 20040
tcccgggaca gggcacgcag tgggcgggga tgggtgccga actcctcgac gtgtcgaagg 20100
agttcgcggc ggccatggcc gagtcgaggg ccgcgctcgc tccgtacgtg gactggtcgc 20160
tgaggccctg cgtccgacag gcccgcggcg cgcacacgct ggagcgggtc gatgtcgtcc 20220
agcccgtagc gttcgcgcgt atggtctcgc tggcgaaggc ctggcagcac cacggggtga 20280

```


—continued

ccccgaagc	cgctgctggc	cactcgcagg	gcgagatcgc	cgccgcgtac	gtcgccgggtg	20340
ccctgagcct	ggacgacgcc	gctcgtgtcg	tgaccctgcg	cagcaagtcc	atcggcgccc	20400
acctcgcggg	ccaggcgggc	atgctgtccc	tcgcgctgag	cgaggcgggc	gttgtggagc	20460
gactggccgg	gttcgacggg	ctgtccgtcg	ccgccgtcaa	cgggcctacc	gccaccgtgg	20520
tttcggggca	cccgaccag	atccaagagc	tcgctcaggc	gtgtgaggcc	gacgggggtcc	20580
gcgcacggat	catccccgtc	gactacgcct	cccacagcgc	ccacgtcgag	accatcgaga	20640
gcgaactcgc	cgacgtcctg	gcgggggtgt	ccccccagac	accccaggtc	cccttcttct	20700
ccaccctcga	agggcgcttg	atcacccaac	ccgccctcga	cggcggctac	tggtaccgca	20760
acctccgcca	tcgtgtgggc	ttcgccccgg	ccgtcgaaac	cctggccacc	gacgaaggct	20820
tcaccactt	cgtcgaggtc	agcgcccacc	ccgtcctcac	catggccctg	cccagagccg	20880
tcaccggcct	cggcaccctc	cgccgtgaca	acggcggaca	gcaccgcctc	accacctccc	20940
tcgccgaggc	ctggggccaa	ggcctcaccg	tcgactgggc	ctctctctct	cccaccacga	21000
ccaccacccc	cgatctgccc	acctacgcct	tccagaccga	gcgctactgg	ccgcagcccg	21060
acctctccgc	cgccggtgac	atcacctccg	ccggtctcgg	ggcgccgag	caccgcgtgc	21120
tcggcgcggc	cgtggcgctc	gcggactccg	acggctgcct	gctcacgggg	agcctctccc	21180
tcctgacgca	cccctggctg	gcggaccacg	cggtgcccg	caccgtgctg	ctgccgggaa	21240
cgcgcttcgt	ggagctggcg	ttccgagccg	gggaccaggt	cggttgcgat	ctggtcgagg	21300
agctcaccct	cgacgcgcgc	ctcgtgctgc	cccgtcgtgg	cgcggtccgt	gtgcagctgt	21360
ccgtcgcggc	gagcgacgag	tcggggcgctc	gtaccttcgg	gctctacgcg	caccgggagg	21420
acgcgccggg	cgaggcgagg	tggaacgggc	acgccaccgg	tgtgctggcc	gcccgctgcg	21480
accgcaccgc	ccccgtcgcc	gaccgggagg	cctggccgcc	gccgggcgcc	gagccggtgg	21540
acgtggacgg	tctgtacgag	cgcttcgcgg	cgaacggcta	cggctacggc	cccctcttcc	21600
agggcgctcc	tggtgtctgg	cggcgtggcg	acgaggtgtt	cgccgacgtg	gccctgccgg	21660
ccgaggtcgc	cggtgccgag	ggcgcgcggt	tcggccttca	cccggcgctg	ctcgacgccg	21720
ccgtgcaggc	ggccggtgcg	ggcggggcgt	tcggcgcggg	cacgcggctg	ccgttcgcct	21780
ggagcgggat	ctccctgtac	gcggtcggcg	ccaccgccct	ccgcgtgcgg	ctggcccccg	21840
ccggcccggg	cacgggtgtcc	gtgagcgccg	ccgactcctc	cgggcagccg	gtgttcgccc	21900
cggactccct	cacggtgctg	cccgtcgacc	ccgcgcagct	ggcggccttc	agcgacccga	21960
ctctggacgc	gctgcacctg	ctggagtggg	ccgcctggga	cggtgccgcg	caggccctgc	22020
ccggcgcggt	cgtgctgggc	ggcgacggcg	acggtctcgc	cgcggcgctg	cgcgccgggtg	22080
gcaccgaggt	cctgtccttc	ccggacctta	cggacctggt	ggaggccgctc	gaccggggcg	22140
agaccccggc	cccgcgaccc	gtcctgggtg	cctgccccgc	cgccggcccc	ggtgggcccgg	22200
agcatgtccg	cgaggccctg	cacgggtcgc	tcgcgctgat	gcaggccctg	ctggccgacg	22260
agcggttcac	cgatggggcg	ctggtgctcg	tgaccgcga	cgcggtcgcc	gcccgttccg	22320
gcgacggcct	gcggtccacg	ggacaggccg	ccgtctgggg	cctcggcggg	tcgcgcgaga	22380
cggagagccc	ggcccggttc	gtcctgctcg	acctcgccgg	ggaagcccg	acggccgggg	22440
acgccaccgc	cggggacggc	ctgacgacgg	gggacgccac	cgtcggcggc	acctctggag	22500
acgcgccctt	cggcagcgcc	ctcgcgaccg	ccctcggtct	ggcgagccg	cagctcgccc	22560

-continued

tccgggacgg	ggcgctcctc	gtaccccgcc	tggcgcgggc	cgcgcgcgcc	gccgcggccg	22620
acggcctcgc	cgcggccgac	ggcctcgccg	ctctgccgct	gccgcgcgct	cgggccctct	22680
ggcgtctgga	gcccggtagc	gacggcagcc	tggagagcct	cacggcgggc	cccggcgacg	22740
ccgagaccct	cgcgccggag	cgcctcgccc	cgggacaggt	ccgcatcgcg	atccgggcca	22800
ccggtctcaa	cttcgcgcac	gtcctgatcg	ccctcggcat	gtaccccgat	cgggcgctga	22860
tgggcaccga	gggagccggc	gtggtcaccg	cgaccggccc	cggcgtcacg	cacctcgccc	22920
ccggcgaccg	ggtcatgggc	ctgctctccg	gcgcgtacgc	cccggtcgtc	gtggcggaag	22980
cgcggaccgt	cgcgcggatg	cccgaagggg	ggacgttcgc	ccaggcgccc	tccgtgcccg	23040
tgggtgtcct	gacggccgct	tacgcctcgc	gcgacctggc	ggacgtcaag	cccggcgagc	23100
gcctcctggt	ccactccgcc	gccggtggcg	tgggcatggc	cgcggtgcag	ctcgcccggc	23160
actggggcgt	ggaggtccac	ggcacggcga	gtcacgggaa	gtgggacgcc	ctgcgcgcgc	23220
tcggcctgga	cgacgcgcac	atcgccctct	cccgcaccct	ggacttcgag	tccgcgttcc	23280
gtgccgcttc	cggcgggggc	ggcatggacg	tcgtactgaa	ctcgctcgcc	cgcgagttcg	23340
tcgacgcctc	gtgcgcctcg	ctcggggccg	gcggccggtt	cgtggagatg	gggaagaccg	23400
acgtccgcga	cgcggagcgg	gtcgcgcggc	accaccccg	tgtcggctac	cgcgccttcg	23460
acctggggca	ggccggggcg	gagcggatcg	gcgagatgct	cgcgaggtc	atcgccctct	23520
tcgaggacgg	ggtgctccgg	cacctgcccc	tcacgacctg	ggacgtgcgc	cggggcccg	23580
acgccttcgg	gcacgtcagc	caggcccgcc	acacgggcaa	ggtcgtcctc	acgatgccgt	23640
cgggcctcga	cccggagggt	acggtcctgc	tgaccggcgg	caccggtgcg	ctggggggca	23700
tcgtggcccc	gcacgtggtg	ggcgagtggg	gcgtacgacg	cctgctgctc	gtgagccggc	23760
ggggcacgga	cgcgccgggc	gccggcgagc	tcgtgcacga	gctggaggcc	ctgggagccg	23820
acgtctcggt	ggccgcgtgc	gacgtcgccg	accgcgaagc	cctcacccgc	gtactcgact	23880
cgatccccgc	cgaacacccg	ctcacccgg	tcgtccacac	ggcaggcgctc	ctctccgacg	23940
gcacctctcc	ctcgatgaca	gcggaggatg	tggaacacgt	actgcgtccc	aaggctcgacg	24000
ccgcgttctc	cctcgacgaa	ctcacctcga	cgcgccgcta	cgacctggca	gcgttcgtca	24060
tgttctcctc	cgcgcgcgcc	gtcttcgggt	gcgcggggca	gggcgcctac	gccgcgcgca	24120
acgccaccct	cgcgcgcctc	gcctggcgcc	gccggacagc	cggactcccc	gccctctccc	24180
tcggctgggg	cctctggggc	gagaccagcg	gcatgaccgg	cggactcagc	gacaccgacc	24240
gctcgcggct	ggcccgcttc	ggggcgacgc	ccatggacag	cgagctgacc	ctgtccctcc	24300
tggacgcggc	catgcgccgc	gacgacccgg	cgcctcgtccc	gatcgccctg	gacgtcgccg	24360
cgtcgcgcgc	ccagcagcgc	gacggcatgc	tggcgccgct	gctcagcggg	ctcacccgcg	24420
gatcgccggg	cggcggcgcg	ccggtcaacc	agcgcagggc	agccgcggga	ggcgcgggcg	24480
aggcggaac	ggacctcggc	gggcggctcg	ccgcgatgac	accggacgac	cgggtcgcg	24540
acctgcggga	cctcgtccgt	acgcacgtgg	cgaccgtcct	gggacacggc	accccgagcc	24600
gggtggacct	ggagcggggc	ttcccgagca	ccggtttcga	ctcgtcacc	gccgtcgaa	24660
tccgcaaccg	tctcaacgcc	gcgacggggc	tgcggctgcc	ggccacgctg	gtcttcgacc	24720
acccaccccc	gggggagctc	gccgggcacc	tgctcgacga	actcgccacg	gccgcggcg	24780
ggtcctgggc	ggaaggcacc	gggtccggag	acacggcctc	ggcgaccgat	cggcagacca	24840

-continued

cgggcgccct	cgccgaactc	gaccggctgg	aaggcgtgct	cgctccctc	gcgcccgcg	24900
cgggcgccg	tccggagctc	gcccgcggc	tcagggcgct	ggccgcggc	ctgggggacg	24960
acggcgacga	cgccaccgac	ctggacgagg	cgtccgacga	cgacctcttc	tccttcacgc	25020
acaaggagct	gggcgactcc	gacttctgac	ctgcccgcga	ccaccggcac	caccggcacc	25080
accagccccc	ctcacacacg	gaacacggaa	cggacaggcg	agaacgggag	ccatggcgaa	25140
caacgaagac	aagctccgcg	actacctcaa	gcgcgtcacc	gccgagctgc	agcagaacac	25200
caggcgctct	cgcgagatcg	agggacgcac	gcacgagccg	gtggcgatcg	tgggcatggc	25260
ctgcgcctg	ccgggcggtg	tcgcctcgcc	cgaggacctg	tggcagctgg	tggccgggga	25320
cggggacgcg	atctcggagt	tcccgcagg	ccgcggctgg	gacgtggagg	ggctgtacga	25380
ccccgacccg	gacgcgtccg	gcaggacgta	ctgccggctc	ggcggattcc	tgacgacgc	25440
cggcgagttc	gacgcgact	tcttcgggat	ctgcgcgcg	gaggccctcg	ccatggaccc	25500
gcagcagcga	ctgtccctca	ccaccgcgtg	ggaggcgatc	gagagcgcgg	gcacgcaccc	25560
gacggccctg	aagggcagcg	gcctcggcgt	cttcgtcggc	ggctggcaca	ccggctacac	25620
ctcggggcag	accaccgcgg	tgcactcgcc	cgagctggag	ggccacctgg	tcagcggcgc	25680
ggcgctgggc	ttcctgtccg	gccgtatcgc	gtacgtcctc	ggtacggacg	gaccggccct	25740
gaccgtggac	acggcctgct	cgtcctcgct	ggtcgccctg	cacctcgccg	tgcaaggccct	25800
ccgcaaggcg	gagtgcgaca	tggccctcgc	cgggtggtgc	acggctcatgc	ccaacgcgga	25860
cctgttcgtg	cagttcagcc	ggcagcgcgg	gctggccgcg	gacggccggt	cgaaggcggt	25920
cggccacctg	gcggacggct	tcggcccccgc	ggagggcgcc	ggagtcctgc	tggtgagcgc	25980
cctgtcggac	gcccgcgcga	acggacaccg	gacccctcg	gtcgtccgcg	gcagcgcggc	26040
caaccaggac	ggcgccagca	acggcctcac	ggctccgcac	gggccctccc	agcagcgcgt	26100
catccgacgg	gcccctggcg	acgcccggtc	gcgcgcgggt	gacgtggacg	tcgtcgaggc	26160
gcacggcacg	ggcagcggc	tcggcgaccc	gacgagggc	caggccctca	tcgccacctc	26220
cggccaggag	aagagcagcg	aacagccgct	gaggctgggc	gcgttgaagt	cgaacatcgc	26280
gcacacgcag	gcgcggccg	gtgtcgcagg	tgtcatcaag	atggtccagg	cgatgcgcca	26340
cggactgctg	ccgaagacgc	tgcactcgca	cgagccctcg	gaccagatcg	actggtcggc	26400
gggcacggtg	gaactcctca	ccgaggccgt	cgactggccg	gagaagcagg	acggcgggct	26460
gcgcgcgcg	gctgtctcct	ccttcggcat	cagcgggacg	aacgcgcacg	tcgtcctgga	26520
ggaggccccc	gcggtcgagg	actccccgcg	cgtcgagccg	ccggccggtg	gcggtgtggt	26580
gccgtggccg	gtgtccgcga	agactccggc	cgcgctggac	gcccagatcg	ggcagctcgc	26640
cgcgtacgcg	gacggctgta	cggacgtgga	tccggcggtg	gccgcccgcg	cctggtcga	26700
cagccgtacg	gcgatggagc	accgcgcggc	cgcggtcggc	gacagccggg	aggcaactgc	26760
ggacgcctcg	cggatgccgg	aaggactggt	acgcggcacg	tcctcgagcg	tgggcggggt	26820
ggcgcttcgt	ttccccggcc	agggcacgca	gtgggcgggc	atgggcggcg	aactccttga	26880
cagctcaccg	gagttcgtg	cctcgatggc	cgaatgcgag	accgcgctct	cccgtacgt	26940
cgactggtct	cttgaagccg	tcgtccgaca	ggaacccggc	gcacccacgc	tcgaccgcgt	27000
cgaactcgtc	cagcccggtg	ccttcgctgt	catggtctcg	ctggcggaag	tctggcagca	27060
ccacggcatc	accccccagg	ccgtcgtcgg	ccactcgcag	ggcgagatcg	ccgcgcgcta	27120

-continued

cgtcgccggt	gcactcacc	tcgacgacgc	cgcccgcgtc	gtcaccctgc	gcagcaagtc	27180
catcgccgcc	cacctcgccg	gcaagggcg	catgatctcc	ctcgccctcg	acgaggcggc	27240
cgctctgaag	cgactgagcg	acttcgacgg	actctccgtc	gccgccgtca	acggccccac	27300
cgccaccgtc	gtctccggcg	acccgaccca	gatcgaggaa	ctcgcccgca	cctgcgaggc	27360
cgacggcgtc	cgtgcgggga	tcattcccggt	cgactacgcc	tcccacagcc	ggcagggtcga	27420
gatcatcgag	aaggagctgg	ccgaggtcct	cgccggactc	gccccgcagg	ctccgcacgt	27480
gccgttcttc	tccacctcg	aaggcacctg	gatcacggag	ccggtgctcg	acggcaccta	27540
ctggtaccgc	aacctcgccc	atcgcggtgg	cttcgcccc	gccgtggaga	ccttggcgggt	27600
tgacggcttc	accacttca	tcgaggtcag	cgccacccc	gtcctcacca	tgacctccc	27660
cgagaccgtc	accggcctcg	gcacctccg	ccgcgaacag	ggaggccagg	agcgtctggt	27720
cacctactc	ggcgaagcct	gggccaacgg	cctcaccatc	gactgggcgc	ccatcctccc	27780
caccgcaacc	ggccaccacc	ccgagctccc	cacctacgcc	ttccagaccg	agcgcttctg	27840
gctgcagagc	tccgcgcccc	ccagcgccgc	cgacgactgg	cgttaccgcg	tcgagtggaa	27900
gccgctgacg	gcctccggcc	aggcggaacct	gtccggggcg	tggatcgctg	ccgtcgggag	27960
cgagccagaa	gccgagctgc	tgggcgcgct	gaaggccgcg	ggagcgagg	tcgacgtact	28020
ggaagccggg	gcggacgacg	accgtgaggc	cctcgccgcc	cggctcaccg	cactgacgac	28080
cggcgacggc	ttcaccggcg	tggctctcgt	cctcgacgac	ctcgtgccac	aggtcgccctg	28140
ggtgcaggca	ctcggcgacg	ccggaatcaa	ggcgcccctg	tggctccgtca	cccagggcgc	28200
ggtctccgtc	ggacgtctcg	acacccccgc	cgacccccgac	cgggccatgc	tctggggcct	28260
cggcgcgctc	gtcgcccttg	agcaccgccga	acgtggggcc	ggcctcgctg	acctccccgc	28320
ccagcccgat	gccgcgcgcc	tcgcccacct	cgtcacggca	ctctccggcg	ccaccggcga	28380
ggaccagatc	gccatccgca	ccaccggact	ccacgcccgc	cgcctcgccc	gcgcaccct	28440
ccacggacgt	cgcccacc	gcgactggca	gccccacggc	accgtcctca	tcaccggcgg	28500
caccggagcc	ctcggcagcc	acgcgcacg	ctggatggcc	caccacggag	ccgaacacct	28560
cctcctcgtc	agccgcagcg	gcgaacaagc	ccccggagcc	acccaactca	ccgccgaact	28620
caccgcacgc	ggcgcccgcg	tcaccatcgc	cgcctgcgac	gtcgccgacc	cccacgccat	28680
gcgcaccctc	ctcgacgcca	tcccgcgcga	gacgcccctc	accgccgtcg	tccacaccgc	28740
cggcgacacc	ggcggcgac	cgttggaagt	caccggcccg	gaggacatcg	cccgcatcct	28800
gggcgcgaag	acgagcggcg	ccgaggtcct	cgacgacctg	ctccgcggca	ctcogctgga	28860
cgccttcgtc	ctctactcct	cgaacgcggg	ggtctggggc	agcggcagcc	agggcgtcta	28920
cgcggcgccc	aacgcccacc	tcgacgcgct	cgcgcgccgg	cgcgcgccc	ggggcgagac	28980
ggcgacctcg	gtcgctggg	gcctctggg	cggcgacggc	atggggccgg	gcgcgcagca	29040
cgcgtactgg	cagcgtcgcg	gcattccgtc	gatgagcccc	gaccgcgccc	tggacgaaact	29100
ggccaaggcc	ctgagccacg	acgagacctt	cgtcgccgtg	gccgatgtcg	actgggagcg	29160
gttcgcgccc	gcgttcacgg	tgtcccgctc	cagccttctg	ctcgacggcg	tcccgagggc	29220
ccggcaggcg	ctcgccgcac	ccgtcgggtc	cccggctccc	ggcgacgccg	ccgtggcgcc	29280
gacggggcag	tcgtcgcgcg	tggcccgcat	caccgcgctc	cccgagcccc	agcgccggcc	29340
ggcgctcctc	accctcgtcc	gtacccacgc	ggcgggcgta	ctcggccatt	cctcccccca	29400

-continued

ccgggtggcc	cccgccgtg	ccttcaccga	gctcggcttc	gactcgtga	cgcccggtga	29460
gtcccgcaac	cagctctcca	cggtgggtcg	caacaggctc	cccgccacca	cggtcttcga	29520
ccacccgacg	cccgccgcac	tcgcccgcga	cctccacgag	gcgtacctcg	caccggccga	29580
gccggccccc	acggactggg	aggggcgggt	gcgccgggcc	ctggccgaac	tgcccctcga	29640
ccggctcggg	gacgcggggg	tcctcgacac	cgctctgcgc	ctcaccggca	tcgagcccca	29700
gccgggttcc	ggcggttcgg	acggcggcgc	cgccgaccct	ggtgcggagc	cggaggcgtc	29760
gacgcagcac	ctggacgcg	aggccctgat	ccggatggct	ctcggccccc	gtaaacctg	29820
acccgaccgc	ggtctgcccc	cacgcgccgc	accccgccga	tcccgccac	caccgcgcc	29880
cacacgccc	caaccccatc	cacgagcgg	agaccacacc	cagatgacga	gttccaacga	29940
acagttgggt	gacgtctctg	gcgcctctct	caaggagaac	gaagaactcc	ggaagagag	30000
ccgtcgccgg	gccgaccgtc	ggcaggagcc	catggcgatc	gtcggcatga	gctgccggtt	30060
cgcgggcgga	atccggtccc	ccgaggacct	ctgggacgcc	gtcgcccgcg	gcaaggacct	30120
ggtctccgag	gtaccggagg	agcgcggctg	ggacatcgac	tccctctacg	acccggtgcc	30180
cgggcgcaag	ggcacgacgt	acgtccgcaa	gcgcgcgttc	ctcgacgacg	ccgccggatt	30240
cgacgcggcc	ttcttcggga	tctcgcccg	cgaggccctc	gcatggacc	cgacgacgcg	30300
gcagtcctc	gaagcctcct	gggaggtctt	cgagcgggcc	ggcatcgacc	ccgcgtcgg	30360
cccgccgacc	gacgtcggcg	tgtacgtggg	ctgtggctac	caggactacg	cgccggacat	30420
ccgggtcgcc	cccgaaggca	ccggcgggta	cgctcgtcac	ggcaactcct	ccgccgtggc	30480
ctccggcgcc	atcgctact	ccctcgccct	ggagggaccc	gccgtgaccg	tggacacggc	30540
gtgtctctct	tcgtctctcg	ccctgcacct	cgccctgaag	ggcctgcgga	acggcgactg	30600
ctcgacggca	ctcgtggcg	gcgtggccgt	cctcgcgacg	ccggcgcgct	tcctcgagtt	30660
cagcagccag	caggccatgg	ccgcgcagcg	ccggaccaag	ggcttcgcct	cggcgccgga	30720
cgccctcgcc	tggggcgagg	gcgtcgccgt	actcctcctc	gaacggctct	ccgacgcgcg	30780
gcgcaagggc	caccgggtcc	tggccgtcgt	gcgcggcagc	gcatcaacc	aggacggcgc	30840
gagcaacggc	ctcacggctc	cgcacgggcc	ctcccagcag	cgctgatcc	gccaggccct	30900
ggcgacgcg	cggtcaccgt	cgagcgacgt	ggacgtcgtg	gagggccacg	gcacggggac	30960
ccgtctcgcc	gacccgatcg	aggcgacggc	gctgctcgcc	acgtacgggc	aggggcgcgc	31020
cccgggcgag	ccgctcgccg	tggggacgct	gaagtcgaac	atcgggcaca	cgacggccgc	31080
ttcgggtgtc	gccgggtgtc	tcaagatggt	gcaggcgctg	cgccacgggg	tgctgccgaa	31140
gaccctgcac	gtggacgagc	cgacggacca	ggtcgactgg	tcggccggtt	cggtcgagct	31200
gtccacggag	gccgtggact	ggccggagcg	gccgggcggg	ctccgcgggg	cgggcgtctc	31260
cggttcggc	gtgggcggga	cgaacgcgca	cgctcgtcctg	gaggaggccc	cggcggtcga	31320
ggagtccct	gccgtcgagc	cgccggccgg	tggcggcgtg	gtgccgtggc	cgggtgtccg	31380
gaagacctcg	gccgcactgg	acgccagat	cgggcagctc	gcccatatcg	cgaagaccg	31440
cacggacgtg	gatccggcg	tggccgccc	cgccctggtc	gacagccgta	cggcgatgga	31500
gcaccgcgcg	gtcgcggtcg	gcgacagccg	ggaggcactg	cgggacgccc	tcgggatgcc	31560
ggaaggactg	gtacggggca	cggtcaccga	tccgggcggg	gtggcggttcg	tcttcccccg	31620
ccagggcacg	cagtgggccc	gcatgggcgc	cgaactcctc	gacagctcac	ccgaattcgc	31680

-continued

cgccgccatg gccgaatgcg agaccgcact ctccccgtac gtcgactggg ctctcgaagc	31740
cgctgctccga caggctccca gcgcaccgac actcgaccgc gtcgacgtcg tccagcccgt	31800
caccttcgcc gtcattggtct ccctcgccaa ggtctggcag caccacggca tccccccga	31860
ggccgtcatc ggccactccc agggcgagat cgccgccgcg tacgtcgccg gtgccctcac	31920
ctcgacgac gccgctctg tctgtaccct cgcgagcaag tccatcgccg cccacctcgc	31980
cggcaagggc ggcatgatct ccctcgccct cagcgaggaa gccaccggc agcgcatcga	32040
gaacctccac ggactgtcga tcgccgccgt caacgggcct accgccaccg tggtttcggg	32100
cgacccacc cagatccaag aacttctca ggcgtgtgag gccgacggca tccgcgcacg	32160
gatcatccc gtcgactacg cctccacag cgccacgtc gagaccatcg agaacgaact	32220
cgccgacgtc ctggcggggt tgtccccca gacccccag gtcccttct tctccacct	32280
cgaaggcacc tggatcacgg aaccgcctt cgacggcggc tactgggtacc gcaacctccg	32340
ccatcgtgtg ggcttcgccc cggccgtcga gacctcgcc accgacgaag gcttcacca	32400
cttcacgag gtcagcgccc acccgtcct caccatgacc ctccccgaca aggtcacggg	32460
cctggccacc ctccgacgag aggacggcg acagcaccgc ctcaccacct ccttgccga	32520
ggcctgggccc aacggcctcg ccctcgactg ggcctccctc ctgcccga cgggcgccct	32580
cagccccgcc gtccccgacc tcccgcgta cgccttcag caccgctcgt actggatcag	32640
ccccgcgggt cccggcgagg cgcccgca caccgcttc gggcgcgagg cgtcgccga	32700
gacggggctc gcgtggggcc cgggtgccga ggacctcgac gaggagggcc ggcgcagcgc	32760
cgtactcgcg atggtgatgc ggcaggcgcc ctccgtgctc cgggtcgact cgcccgaaga	32820
ggtcccgctc gaccgcccgc tgcgggagat cggcttcgac tcgctgaccg cgtcgactt	32880
ccgcaaccgc gtcaaccggc tgaccggtct ccagctgccg cccaccgtcg tgttcgagca	32940
cccgcgccc gtcgcgctcg ccgagcgcat cagcgacgag ctggccgagc ggaactgggc	33000
cgtcgccgag ccgtcggtac acgagcaggc ggaggaggag aaggccgccg ctccggcggg	33060
ggcccgctcc gggcccgaca ccggcgccgg cgccgggatg ttccgcgcc tgttcggca	33120
ggccgtggag gacgaccggt acggcgagtt cctcgacgtc ctgccgaag cctcccggtt	33180
ccgcccgag ttccgctcgc ccgaggcctg ctccggagcg ctcgaccggg tctgtctcgc	33240
cggcggtccg acggaccggg cggaaggccg tgcggttctc gtcggctgca ccggcaccgc	33300
ggcgaacggc ggcccgcacg agttcctcgc gctcagcacc tcttccagg aggagcgga	33360
cttctcgcg gtacctctcc ccggtacgg caccggtagc ggcaccggca cgccctcct	33420
cccgccgat ctcgacaccg cgctcgacgc ccaggcccg gcgacctcc gggccgccgg	33480
ggacgcccc gtcgtcctgc tcgggcactc cggcgcgccc ctgctcgcgc acgagctggc	33540
cttcgcctg gagcgggcgc acggcgccc gccggccggg atcgtccttg tcgacctta	33600
tccgcgggg catcaggagc ccacgaggt gtggagcagg cagctggcg agggcctgtt	33660
cgcggcgag ctggagccga tgtccgatgc gcgctgctg gccatgggccc ggtacgcgcg	33720
gttctcgcg gggccgcgc cgggcgagc cagcgcccc gtgcttcttg tccgtgcctc	33780
cgaaccgctg ggcgactggc aggaggagcg gggcgactgg cgtgcccact gggaccttc	33840
gcacacgctc gcggagctgc cggcgacca cttcacgatg atcggggacc acgcgcggc	33900
cgtcgccgag gccgtcctct cctggctcga cgccatcgag ggcacgagg gggcgggcaa	33960

-continued

gtgaccgaca gacctctgaa cgtggacagc ggactgtgga tccggcgctt ccaccccgcg	34020
ccgaacagcg cgggtgcgct ggtctgcctg ccgcacgccc gcggctccgc cagctacttc	34080
ttccgcttct cggaggagct gcacccctcc gtcgaggccc tgtcggtgca gtatccgggc	34140
cgccaggacc ggcggtccga gccgtgtctg gagagcgtcg aggagctcgc cgagcatgtg	34200
gtcgcggcca ccgaacctg gtggcaggag ggccggctgg ccttcttcgg gcacagcctc	34260
ggcgcctccg tcgccttcga gacggcccgc atcctggaac agcggcacgg ggtacggccc	34320
gagggcctgt acgtctccgg tcggcgcgcc ccgtcgctgg cgccggaccg gctcgtccac	34380
cagctggacg accgggctt cctggccgag atccggcggc tcacgggcac cgacgagcgg	34440
ttcctccagg acgacgagct gctgcggctg gtgtgcccgc cgctgcgcag cgactacaag	34500
gcggcggaga cgtacctga ccggccgtcc gccaaagctca cctgcccggt gatggccctg	34560
gccggcgacc gtgacccgaa ggccgcgctg aacgaggtgg ccgagtggcg tcggcacacc	34620
agcgggcccgt tctgcctccg ggcgtactcc ggccggccact tctacctcaa cgaccagtgg	34680
cacgagatct gcaacgacat ctccgaccac ctgctcgtca cccgcggcgc gcccgatgcc	34740
cgcgtcgtgc agccccgcac cagccttata gaaggagcgg cgaagagatg gcagaaccca	34800
cggtgaccga cgacctgacg ggggcccctca cgcagccccc gctgggcccgc accgtccgcg	34860
cggtggccga ccgtgaactc ggcacccacc tcctggagac ccgcggcatc cactggatcc	34920
acgcccgcaa ccgggacccg tacgccaccg tgctgcgcgg ccaggcggac gacccgtatc	34980
ccgcgtacga gcgggtgcgt gcccgcgcg cgctctcctt cagcccgcac ggcagctggg	35040
tcaccgccga tcacgccctg gcggcgagca tcctctgctc gacggacttc ggggtctccg	35100
gcgcgcagcg cgtcccgggt ccgcagcagg tcctctcgta cggggagggc tgtccgctgg	35160
agcgcgagca ggtgctgccg gcggccgggt acgtgccgga gggcgggcag cgtgccgtgg	35220
tcgaggggat ccaccgggag acgctggagg gtctcgcgcc ggacccgtcg gcgtcgtacg	35280
ccttcgagct gctggggcgt ttcgtccgcc cggcggtgac ggccgctgcc gccgcctgctc	35340
tgggtgttcc cgcggaccgg cgcgcggact tcgcggatct gctggagcgg ctccggcccgc	35400
tgtccgacag cctgtggcc ccgcagtccc tgcggacggt acgggcggcg gacggcgcgc	35460
tggccgagct caccggcgtg ctgcgcgatt cggacgactc ccccggggcc ctgctgtcgg	35520
cgtcgggggt caccgcagcc gtccagctca ccgggaacgc ggtgctcgcg ctccctcgcg	35580
atcccgagca gtggcgggag ctgtgcgacc ggcccgggct cgcggcggcc gcggtgagg	35640
agacctccg ctacgaccg ccggtgcagc tcgacgcccg ggtggtccgc ggggagacgg	35700
agctggcggg ccggcggtg ccggccgggg cgcattgtcgt cgtcctgacc gccgcgaccg	35760
gccgggaccc ggaggtcttc acggacccgg agcgtctcga cctcgcgcgc cccgacgcgc	35820
ccgcgcacct cgcgtgcac ccgcgcggtc cgtacggccc ggtggcgctc ctggtccggc	35880
ttcaggcgga ggtcgcgctg ccgacctgg ccgggcgttt ccccgggctg cggcaggcgg	35940
gggacgtgct ccgccccgc cgcgcgcctg tcggccgcgg gccgctgagc gtcccgttca	36000
gcagctcctg agacaccggg gcccgggtcc gcccgggccc ccttcggacg gacgggacgg	36060
ctcggaccac ggggacggct cagacgtcc cgtgtgtccc cgtccggctc ccgtccgccc	36120
catcccgcct ctccaccggc aaggaaggac acgacgcat gcgcgtcctg ctgacctcgt	36180
tcgcacatca cagcactac tacggcctgg tgcccctggc ctgggcgctg ctgcgcgcgc	36240

-continued

```

ggcacgaggt gcgggtcgcc agccagcccg cgctcacgga caccatcacc gggtcggggc 36300
tcgcgcgggt gccggtcggc accgaccacc tcattccacga gtaccgggtg cggatggcgg 36360
gcgagccgcg ccgaacccat ccggcgatcg ccttcgacga gggccgtccc gagccgctgg 36420
actgggacca cgcctcggc atcgaggcga tcctcgcccc gtacttctat ctgctcgcca 36480
acaacgactc gatggtcgac gacctcgtcg acttcgcccc gtcttgccag ccggacctgg 36540
tgctgtggga gccgacgacc tacgcgggcg ccgtcgccgc ccaggtcacc ggtgccgcgc 36600
acgccgggt cctgtggggg ccgacgtga tgggcagcgc ccgccgaag tcgtcgcgcc 36660
tgccggaccg gcagccgccc gagcaccgcg aggacccac cgcgagtggt ctgacgtgga 36720
cgctcgaccg gtacggcgcc tccttcgaag aggagctgct caccggccag ttcacgatcg 36780
acccgacccc gccgagccgt cgcctcgaca cgggcctgcc gaccgtcggg atgcgttatg 36840
ttccgtacaa cggcagctcg gtcgtgccgg actggctgag tgagccgccc gcgcggcccc 36900
gggtctgcct gaccctcggc gtctcgcgcc gtgaggtcct cggcggcgac ggcgtctcgc 36960
agggcgacat cctggaggcg ctgcgcgacc tcgacatcga gctcgtcgcc acgctcgacg 37020
cgagtcagcg cgcgagatc cgcaactacc cgaagcacac ccggttcacg gacttcgtgc 37080
cgatgcacgc gtcctgccg agctgctcgg cgatcatcca ccacggcggg gcgggcacct 37140
acgcgaccgc cgtgatcaac gcggtgccgc aggtcatgct cgccgagctg tgggacgcgc 37200
cggtaaggcg gcgggcccgc gccgagcagg gggcggggtt cttcctgccg ccggccgagc 37260
tcacgcgcga ggccgtgcgg gacgcgcgct tccgcaccct cgacgacccc tcggtcgcca 37320
ccgccgcgca ccgggtcgcc gaggagacct tcggcgaccc caccgccggc gggatcgtec 37380
ccgagctgga gcggctcgcc gcgcagcacc gcccccgcc ggcgacgcc cggcaactgag 37440
ccgcacccct cgcgccaggc ctacccctg tatctcgcc gggggacgcc ccgggccac 37500
cctccgaaag accgaaagca ggagcaccgt gtacgaagtc gaccacgccg acgtctacga 37560
cctcttttac ctgggtcgcg gcaaggacta cgccgcgag gcctccgaca tcgccgacct 37620
gggtcgctcc cgtacccccg aggcctcctc gctcctggac gtggcctgcg gtacgggcac 37680
gcactgggag caattcacca aggagttcgg cgacaccgcc ggcctggagc tgtccgagga 37740
catgctcacc cagcccgca agcggctgcc cgacgccag ctccaccagg gcgacatgcg 37800
ggacttcggc ctggccgga agttctccgc cgtggtcagc atgttcagct ccgtcggcta 37860
cctgaagacg accgaggaac tcggcgcgcc cgtcgccctg ttcgggagc acctggagcc 37920
cggtgccgct gtcgtcgtcg agccgtggtg gttcccgag accttcgccg acggctgggt 37980
cagcgccgac gtcgtccgcc gtgacgggcg caccgtggcc cgtgtctcgc actcggtgcg 38040
ggaggggaac gcgacgcgca tggaggtcca cttaccctg gccgaccgg gcaaggcgct 38100
gcggcacttc tccgagctcc atctcatcac cctgttcac caggccgagt acgaggccgc 38160
gttcacggcc gccgggctgc gcgtcgagta cctggagggc gggccgtcgg gccgtggcct 38220
cttcgtcgcc gtcccccgt gagcaccgcc caagaccccc cggggcggga cgtccgggt 38280
gcaccaagca aagagagaga aacgaaccgt gacaggtgag accgaatac cgcgtgtccg 38340
ccggcgccgc accacgcccc gggccttcac cctggccgct gtcggcacc tgctggcggg 38400
caccacgtg gcggccgccc ctcccggcgc cgccgacag gccaatgttc agtacagag 38460
ccgggcggcg gagctcgtcg ccagatgac gtcgacgag aagatc 38506

```

-continued

<210> SEQ ID NO 20
<211> LENGTH: 2401
<212> TYPE: DNA
<213> ORGANISM: *Streptomyces venezuelae*
<220> FEATURE:
<221> NAME/KEY: 1540
<222> LOCATION: unsure
<223> OTHER INFORMATION: unsure of nucleotide at this position

<400> SEQUENCE: 20

cgtggcggcc gccgctcccg gcgccgccga cacggccaat gttcagtaca cgagccgggc 60
ggcggagctc gtcgcccaga tgacgtcga cgagaagatc agcttcgtcc actgggcgct 120
ggaccccgac cggcagaacg tcggctacct tcccggcggtg ccgctgtctg gcatcccgga 180
gtgctgtgcc gccgacggcc cgaacggcat ccgcctggtg gggcagaccg ccaccgcgct 240
gcccgcgcgc gtcgccttgg ccagcacctt cgacgacacc atggccgaca gctacggcaa 300
ggcatatggc cgcgacggtc gcgcgtcaa ccaggacatg gtcttgggccc cgatgatgaa 360
caacatccgg gtgcgcacg gcggccggaa ctacgagacc ttcagcgagg accccctggt 420
ctctcgcgc accgcggtcg ccagatcaa gggcatccag ggtgcgggtc tgatgaccac 480
ggccaagcac ttcgcggcca acaaccagga gaacaaccgc ttctccgtga acgccaatgt 540
cgacgagcag acgctccgcg agatcgagtt ccggcgcttc gaggcgctct ccaaggcccg 600
cgcgggctcc ttcattgtgt cctacaacgg cctcaacggg aagccgtctc gcggcaacga 660
cgagctcttc aacaacgtgc tgcgcacgca gtggggcttc cagggtctgg tgatgtccga 720
ctggctcgcc accccgggca ccgacgccat caccaagggc ctcgaccagg agatgggcgt 780
cgagctcccc ggcgacgtcc cgaagggcga gccctcgccg ccggccaagt tcttcggcga 840
ggcgctgaag acggccgtcc tgaacggcac ggtccccgag gcggccgtga cgcggtcggc 900
ggagcggatc gtcggccaga tggagaagt cggtctgtc ctgcacctc cggcgccgcg 960
gcccgagcgc gacaaggcgg gtgcccaggc ggtgtcccgc aaggctcgcc agaacggcgc 1020
ggtgtctctg cgcaacgagg gccaggccct gccgtcgcg ggtgacgccg gcaagagcat 1080
cgcggtcatc ggcccgcagg ccgtcgacct caaggtcacc ggcctgggca gcgccacgt 1140
cgtcccggac tcggcgcgcg cgccactcga caccatcaag gccgcgcgg gtgcgggtgc 1200
gacggtgacg tacgagacgg gtgaggagac cttcgggacg cagatcccg cggggaacct 1260
cagcccggcg ttcaaccagg gccaccagct cgagccgggc aaggcgggg cgctgtacga 1320
cggcagcgtg accgtgccc cgcagggcga gtaccgcac gcggtccgtg ccaccggtg 1380
ttacgccacg gtgcagctcg gcagccacac catcgaggcc ggtcaggtct acggcaagg 1440
gagcagcccc ctctcaagc tgaccaaggg cagcacaag ctacgatct cgggtctcgc 1500
gatgagtgcc accccgtct ccctggagct gggctgggtg acgccggcg cgccgcacgc 1560
gacgatcgcg aaggccgtgg agtcggcgcg gaaggcccg acggcggtcg tcttcgccta 1620
cgacgacggc accgagggcg tcgaccgtcc gaacctgtcg ctgccgggta cgcaggacaa 1680
gtgatctcgt gctgtcgcgg acgccaaccc gaacacgac gtggtctcga acaccggttc 1740
gtcgggtgctg atgccgtggc tgtccaagac ccgcgcggtc ctggacatgt ggtaccggg 1800
ccaggcgggc gccgaggcca ccgcgcgct gctctacgt gacgtcaacc cgagcggcaa 1860
gtcacgcag agcttcccg ccgccgagaa ccagcacgcg gtcgccggcg acccgaccag 1920

-continued

```

ctacccgggc gtcgacaacc agcagacgta ccgcgagggc atccacgtcg ggtaccgctg 1980
gttcgacaag gagaacgtca agccgctgtt cccgttcggg caccgcctgt cgtacacctc 2040
gttcacgcag agcgcctcga ccgtcgtgcg tacgtccacg ggtggtctga aggtcacggg 2100
cacgggtccg aacagcggga agcgcgcggg ccaggaggtc gtccaggcgt acctcgggtc 2160
cagccccaac gtgacggctc cgcaggcgaa gaagaagctc gtgggctaca cgaaggcttc 2220
gctcgccgcg ggcgaggcga agacggtgac ggtgaacgct gaccgccgtc agctgcagtt 2280
ctgggatgcc gccacggaca actggaagac gggaacgggc aaccgcctcc tgcagaccgg 2340
ttcgtcctcc gccgacctgc ggggcagcgc caccgtcaac gtctggtgac gtgacgccgt 2400
g 2401

```

```

<210> SEQ ID NO 21
<211> LENGTH: 5970
<212> TYPE: DNA
<213> ORGANISM: Streptomyces venezuelae
<220> FEATURE:
<221> NAME/KEY: 4139 and 4819
<222> LOCATION: unsure
<223> OTHER INFORMATION: unsure of nucleotides at these positions
<400> SEQUENCE: 21

```

```

ggcgagaagt aggcgcgggt gtgcacgcct tcggccttca ggacctccat gacgaggtcg 60
cgggtgatgc cgggtgtggc ctcgtcgatc tcgacgatca cgtactggtg gttgttgagg 120
ccgtggcggg cgtggtcggc gacgaggacg ccggggagggt ccgcgaggtg ctcgcggtag 180
scggcgtggt tgcgcgggtt ccggtcgatg acctcgggaa acgcgtcgag ggaggtgagg 240
cccatggcgg cgggggcctc gctcatcttg gcgttggtcc cgccggcggg gctgccgccg 300
ggcaggtcga agccgaagtt gtggaggcgc cggatccggg cggcgaggtc ggcgtcgctc 360
gtgacgacgg cgcgcctc gaaggcgttg acggccttgg tggcgtggaa gctgaagacc 420
tcggcgtcgc cgaggctgcc ggcggggcgg ccgtcgaccg cgcagccgag ggcgtgcgcg 480
gcgtcgaagt acagccgcag gccgtgctcg tcggcgacct tccgcagctg gtcggcggcg 540
cagggggcgg cccagagggt gacgcgcagc acggccgagg tgcggggtgt gaccgcggcg 600
gccacctggt ccgggtcgag gttgcgggtg tccgggtcga tgtcggcgaa gaccggggtg 660
aggccgatcc agcgcagtgc gtgcggggtg gcggcgaaac tcatcgacgg catgatcact 720
tcgccggtga ggccggcggc gtgcgcgagg agctggagcc cggccgtggc gttgcaggtg 780
gccacggcat gccggacccc ggcgagcccg gcgacgcgct cctcgaaact gcggacgagc 840
gggcccgcgt tggacagcca ctggctgtcg agggcccggg cgagccgctc gtacagcctg 900
gcgcggtcga tgcggttggg ccgccccacg aggagcggct ggtcgaaagc ggcggggccg 960
ccgaagaatg cgaggctcga taaggcgctt ttcacggatg ttccctccgg gccaccgtca 1020
cgaaatgatt cgccgatccg ggaatccga acgaggtcgc cgcgctccac cgtgacgtac 1080
gacgagatgg tcgattgtgg tggctgattt cggggggact ctaatccgcg cggaacggga 1140
ccgacaagag cagcctatgc gctctcgatg tgcttcggat cacatccgcc tccgggggtat 1200
tccatcggcg gccccaatgt gatgatcctt gacaggatcc gggaatcagc cgagccgccg 1260
ggagggccgg ggcgcgctcc gcggaagagt acgtgtgaga agtcccgttc ctcttcccgt 1320
ttccgttccg cttccggccc ggtctggagt tctccgtcgc ccgtacccag cagggaaacga 1380

```

-continued

ccgcttctcc	cccggtaactc	gacctcgggg	ccctggggca	ggatttcgcg	gccgatccgt	1440
atccgacgta	cgcgagactg	cgtgccgagg	gtccggccca	ccgggtgcgc	acccccgagg	1500
gggacgaggt	gtggctggtc	gtcggctacg	accgggcgcg	ggcggtcctc	gccgatcccc	1560
ggttcagcaa	ggactggcgc	aactccacga	ctcccctgac	cgaggccgag	gccgcgctca	1620
accacaacat	gctggagtcc	gaccgcgcgc	ggcacacccg	gctgcgaag	ctggaggccc	1680
gtgagttcac	catgcgccgg	gtcaggttgc	tgccggcccg	ggcccaggag	atcgtcgacg	1740
ggctcgtgga	cgccatgctg	gcggcgcccg	acggccgcgc	cgatctgatg	gagtccttgg	1800
cctggccgct	gccgatcacc	gtgatctccg	aactcctcgg	cgtgcccgag	ccggaccgcg	1860
ccgccttccg	cgtctggacc	gacgccttcg	tcttcccggg	cgatcccgcc	caggcccaga	1920
ccgccatggc	cgagatgagc	ggctatctct	cccggctcat	cgaactccaag	cgcgggcagg	1980
acggcgaggga	cctgctcagc	gcgctcgtgc	ggaccagcga	cgaggacggc	tcccggctga	2040
cctccgagga	gctgctcggg	atggcccaca	tcctgctcgt	cgcggggcac	gagaccacgg	2100
tcaatctgat	cgccaacggc	atgtacgcgc	tgctctcgca	ccccgaccag	ctggccgccc	2160
tgccggccga	catgacgctc	ttggacggcg	cggtggagga	gatgttgccg	tacgagggcc	2220
cggtggaatc	cgcgacctac	cgttcccggg	tcgagcccggt	cgaactggac	ggcacgggtca	2280
tcccggccgg	tgacacggtc	ctcgtcgtcc	tggccgacgc	ccaccgcacc	cccagacgct	2340
tcccggaccc	gcaccgcttc	gacatccgcc	gggacaccgc	cggccatctc	gccttcggcc	2400
acggcatcca	cttctgcate	ggcgcgccct	tggcccgggt	ggaggcccg	atcgccgtcc	2460
gcgcccttct	cgaacgctgc	ccggacctcg	ccctggacgt	ctccccggc	gaactcgtgt	2520
ggtatccgaa	cccgatgac	cgcgggctca	agggcctgcc	gatccgctgg	cgcgaggagc	2580
gggaggcggg	ccgccgtacc	ggttgaaccc	gcacgtcacc	cattacgact	ccttgctacg	2640
gaagccccgg	atcggtcccc	cctcgccgta	acaagacctg	gttagagtga	tggaggacga	2700
cgaagggttc	ggcgcgccga	cgagggggga	cttccgcgat	gaatctgggt	gaacgcgacg	2760
gggagatagc	ccatctcagg	gccgttcttg	acgcatccgc	cgcagggtgac	gggacgctct	2820
tactcgtctc	cggaccggcc	ggcagcggga	agacggagct	gctcgggtcg	ctccgcgggc	2880
tggccgcgga	gcgggagacc	cccgctcggg	cggtccgggc	gctgccgggt	gaccgcgaca	2940
tccccttggg	cgtcctctgc	cagttactcc	gcagcgcgga	acaacacggg	gccgacacct	3000
ccgccgtccg	cgaactgctg	gacgcgcgct	cgcggcgggc	cggaaacctca	cctccccgcg	3060
cgaacgcgcg	ctccgcgtcg	acgagacaca	cgcctgcac	gactggctgc	tctccgtctc	3120
ccgcgcggac	cccgttcctc	gtcgcgctcg	acgacctgac	ccacgcggac	accgcgtccc	3180
tgaggttccct	cctgtactgc	gccgcccacc	acgaccaggg	cggcatcggc	ttcgtcatga	3240
ccgagcgggc	ctcgcagcgc	gccggatacc	gggtgttcgg	cgcgagctg	ctccgccagc	3300
cgcactgccg	caacatgtgg	ctctccgggc	ttccccccag	cggggtacgc	cagttactcg	3360
cccactacta	cggccccgag	gccgcgcgac	ggcgggcccc	cgcgtaccac	gcgacgaccg	3420
gcgggaaccc	gctgctcctg	cgggcgctga	cccaggaccg	gcaggcctcc	cacaccaccc	3480
tcggcgcggc	cggcggcgac	gagcccgctc	acggcgacgc	cttcgcccag	gccgtcctcg	3540
actgcctgca	ccgcagcgcc	gagggcacac	tggagaccgc	ccgctggctc	gcggtcctcg	3600
aacagtcgga	cccgtcctcg	gtggagcggc	tcacgggaac	gaccgcgcgc	gccgtcgagc	3660

-continued

gccacatcca	ggagctcgcc	gccatcgccc	tcctggacga	ggacggcacc	ctgggacagc	3720
cccgatccg	cgaggccgcc	ctccaggacc	tgccggccgg	cgagcgcacc	gaactgcacc	3780
ggcgcccg	ggagcagctg	caccgggacg	gcgcgcacga	ggacaccgtg	gcccgccacc	3840
tgctggtcgg	cgcgccccc	gacgctccct	ggcgctgcc	cctgctcgaa	cggggcgcgc	3900
agcaggccct	gttcgacgac	cgactcgacg	acgccttcgg	gacccctgag	ttcgccgtgc	3960
ggtcgagcac	cgacaacacc	cagctggccc	gcctcgcccc	acacctggtc	gcggcctcct	4020
ggcggatgaa	cccgacatg	acgaccggg	ccctcgccact	cttcgaccgg	ctcctgagcg	4080
gtgaactgcc	gcccagccac	ccggtcatgg	ccctgatccg	ctgcctcgtc	tggtacggnc	4140
ggctgcccga	ggccgcgcac	gcgctgtccc	ggctgcggcc	cagctccgac	aacgatgcct	4200
tgagagctgtc	gtcaccgccg	atgtggctcg	cgcgctgtg	cccgcgcctc	ctggagtccc	4260
tgccggccac	gcccggagccg	gagcggggtc	ccgtccccgt	acggctcgcg	cccgggacga	4320
ccgcgctcca	ggcccaggcc	ggcgtcttcc	agcggggccc	ggacaacgcc	tcggtcgcgc	4380
agcccgaaaca	gatcctgcag	ggctgcccgc	tgctcgagga	gacgtacgag	gccctggaga	4440
cgccctcttt	ggtcctcgtc	cacgcgcacc	ggctcgaccg	ggcgctgttc	tggtcggacg	4500
ccctgctcgc	cgaggccgtg	gagcgggcgt	cgctcggtcg	ggaggcggtc	ttcgccgcga	4560
cccgggcgat	gatcgcgatc	cgctcgcgcg	acctcccgc	ggcgcgggag	cgggccgagc	4620
tgcgctcttc	ccacgcggcg	ccggagagct	ggggcctcgc	cgtgggcatg	cccctctccg	4680
cgctgctgct	cgctgcacg	gaggcggcg	agtacgaaca	ggcggagcgg	gtcctgcggc	4740
agccggtgcc	ggacgcgatg	ttcgactcgc	ggcacggcat	ggagtacatg	cacgcccggg	4800
gccgctactg	gctggcganc	ggccggctgc	acgcggcgct	ggcgaggttc	atgctctcg	4860
gggagatcct	gggcagctgg	aacctcgacc	agccctcgat	cgtgccctgg	cggacctccg	4920
ccgcgaggt	gtacctgcgg	ctcggaacc	gccagaaggc	cagggcgctg	gccgagggcc	4980
agctcgccct	ggtcgggccc	ggcgctccc	gcaccggggg	tctcaccctg	cggtctctgg	5040
cgcgcgcggt	ggacggccag	cagggcgagc	ggctgcacgc	cgaggcggtc	gacatgctgc	5100
acgacagcgg	cgaccggctc	gaacacgccc	gcgcgctcgc	cgggatgagc	cgccaccagc	5160
agggccaggg	ggacaactac	cgggcgagga	tgacggcgcg	gctcgccggc	gacatggcgt	5220
gggcctgcgg	cgctacccc	ctggccgagg	agatcggtcc	gggcgcgggc	ggccgcgggg	5280
cgaaggcggt	gagcacggag	ctggaactgc	cgggcggccc	ggacgtcggc	ctgctctcgg	5340
agggcgaacg	ccgggtggcg	gccctggcag	cccgaggatt	gacgaaccgc	cagatagcgc	5400
gccggctctg	cgtcaccgcg	agcacggctg	aacagcacct	gacgcgcgtc	taccgcaaac	5460
tgaactgtac	ccgccgagca	gacctcccga	tcagcctcgc	ccaggacaag	tccgtcacgg	5520
cctgagccac	ccccggtgtc	cccgctcgac	gacccgcgcg	acggggccacc	gggcccgcgg	5580
ggacacgcgg	gtgcgacacg	ggggcgcgcc	aggtgccatg	gggacctccg	tgaccgcccg	5640
aggcgcccga	ggcgcccggt	gcggcaccgg	gagacgccag	gaccgcgggg	accaccggag	5700
acgcagggga	ccgctgggga	caccggggacc	tcagggaccg	ccgggaccgc	ccgagttgca	5760
ccccggtcgc	ccggggacac	cagacgcgg	ggaccaccgg	aggggtgccc	gtgtggcccc	5820
ggcgccgggg	gtgtccttca	tcgggtgggc	ttcatcgcca	ggaggaagcg	accgtgagac	5880
ccgtcgtgcc	gtcggcgac	agccgcctgt	acgggcgtcg	gactccctgg	cggctcccga	5940

-continued

cccgtcgtac gggctcgcgg gacccgggtgc

5970

<210> SEQ ID NO 22

<211> LENGTH: 3292

<212> TYPE: DNA

<213> ORGANISM: Streptomyces venezuelae

<220> FEATURE:

<221> NAME/KEY: 2875

<222> LOCATION: unsure

<223> OTHER INFORMATION: unsure of nucleotide at this position

<400> SEQUENCE: 22

accccccaaa ggggtggtga cactccccct ggcagcccc tagcgcctcc ctaactcgcc 60
acgccgaccg ttatcaccgg cgcctgtgtg ctagtcttcg agaatgaagg gaatagtcct 120
ggccggcggg agcggaaact ggctgcattc ggcgacctcg gtcatttcga agcagattct 180
tccggtctac aacaaaccga tgatctacta tccgctgtcg gttctcatgc tcggcgggtat 240
tcgcgagatt caaatcatct cgacccccca gcacatcgaa ctcttcaggc cgcttctcgg 300
aaacggcagg cacctgggaa tagaactcga ctatgcggtc cagaaagagc ccgcaggaat 360
cgcgagacga cttctcgtcg gagccgagca catcggcgac gacacctgcg ccttgatcct 420
ggcgacaaac atcttccacg ggcccggcct ctacacgctc ctgcgggaca gcacgcgcg 480
cctcgacggc tgcgtgctct tcggctaccc ggtcaaggac cccgagcggg acggcgtcgc 540
cgaggtggac ggcaggggac ggctgaccga cctcgtcgag aagcccgta agccgcgctc 600
caacctcgcc gtcaccggcc tctacctcta cgacaacgac gtcgtcgaca tcgccaagaa 660
catccggccc tcgcccgcg ggcgagctga gatcaccgac gtcaaccgcg tctacctgga 720
gcggggccgg gccgaactcg tcaacctggg ccgcggcttc gcctggctgg acaccggcac 780
ccacgactcg ctctcgcggg ccgcccagta cgtccaggtc ctggaggagc ggcagggcgt 840
ctggatcgcg ggcttgagg agatcgctt ccgcatgggc ttcatcgacg ccgaggcctg 900
tcacggcctg ggagaaggcc tctcccgac cgagtacggc agctatctga tggagatcgc 960
cgcccgcgag ggagccccgt gagggcacct cgcggccgac gcgttccac gaccgacagc 1020
gccaccgaca gtgcgaccca caccgagacc cgcaccgcca ccgacagtgc gaccacacc 1080
gcgacctaca gcgcgaccga aaggaagacg gcagtgcggc ttctggtgac cggaggtgcg 1140
ggcttcatcg gctcgcaact cgtgcggcag ctctcgccg gggcgtaacc cgacgtgccc 1200
gccgatgagg tgatcgctct ggacagcctc acctacgagg gcaaccgagc caacctcgcc 1260
ccggtggagc cggaccgcgg actgcgcttc gtccacggcg acatccgaga cgcggcctc 1320
ctcgcccggg aactgcgcgg cgtggacgcc atcgtccact tcgcggccga gagccacgtg 1380
gaccgctcca tcgcggggcg gtccgtgttc accgagacca acgtgcaggg cagcgagacg 1440
ctgtccagt gcgcgctga cgcggcgctc ggccgggtcg tgcacgtctc caccgacgag 1500
gtgtacgggt cgatcgactc cggctcctgg accgagagca gcccgctgga gcccactcg 1560
ccctacgagg cgtccaaggc cggctccgac ctctgtgccc gcgcctacca ccggacgtac 1620
ggcctcgacg tacggatcac ccgctgctgc aacaactacg ggccgtacca gacccccgag 1680
aagctcatcc ccctcttcgt gacgaacctc ctcgacggcg ggacgctccc gctgtacggc 1740
gacggcgaga acgtccgga gtgggtgcac accgacgacc actgccgggg catcgcgctc 1800
gtctcgcggg gcggccgggg cggcgagatc taccacatcg gcggcgccct ggagctgacc 1860

-continued

```

aaccgcgaac tcaccggcat cctcctggac tcgctcggcg ccgactggtc ctcggtcccg 1920
aaggctcgccg accgcaaggg ccacgacctg cgctactccc tcgacggcgg caagatcgag 1980
cgcgagctcg gctaccgccc gcaggctctc ttcgcggacg gcctcgcgcg gaccgtccgc 2040
tggtaccggg agaaccgcgg ctggtgggag ccgctcaagg cgaccgcccc gcagctgccc 2100
gccaccgcgg tggaggtgtc cgcgtgagca gccgcgcga gacccccgcg gtcccccttc 2160
tcgacctcaa ggccgcctac gaggagctcc gcgcggagac cgacgcgcgc atcgcccgcg 2220
tcctcgactc ggggcgctac ctccctcgac ccgaactcga aggattcgag gcggagtctg 2280
ccgcgtactg cgagacggac cagccgctcg gcgtgaacag cgggatggac gccctccagc 2340
tcgccctccg cggcctcggc atcggaaccg gggacgaggt gatcgctccc tcgcacacgt 2400
acatcgccag ctggctcgcg gtgtccgcca ccggcgcgac ccccgctccc gtcgagccgc 2460
acgaggacca cccaccctg gacccgctgc tcgtcgagaa ggcgatcacc ccccgacccc 2520
gggcgctcct ccccgctcac ctctacgggc accccgcgca catggacgcc ctccgcgagc 2580
tcgcggaccg gcacggcctg cacatcgctg aggacgcgcg gcaggccac ggcgcccgct 2640
accggggcgg gcggatcggc gccgggtcgt cggtgccgcg gttcagcttc taccgggca 2700
agaacctcgg ctgcttcggc gacggcggcg ccgtcgtcac cggcgacccc gagctcgccg 2760
aacggctccg gatgtccgc aactacggct cgcggcagaa gtacagccac gagacgaag 2820
gcaccaactc ccgcctggac gagatgcagg ccgccgtgct gcggatccgg ctcgncacc 2880
tggaagctg gaacggccgc aggtcggcgc tggccgcgga gtacctctc gggctcgccg 2940
gactgcccg catcgccctg ccggtgaccg cgcgcgacac cgacccggtc tggcacctct 3000
tcaccgtgcg caccgagcgc cgcgacgagc tgcgcagcca cctcgacgcc cgcggcatcg 3060
acacctcac gcactaccg gtaccctgc acctctcgcc cgcctacgcg ggcgaggcac 3120
cgccggaag ctgcctccg cgggcccaga gcttcgcgcg gcaggctctc agcctgccga 3180
tcggcccga cctggagcgc ccgcaggcgc tgcgggtgat cgacgccgtg cgcgaatggg 3240
ccgagcgggt cgaccaggcc tagtcagggt gtccggtaga ccagcaggc cg 3292

```

<210> SEQ ID NO 23

<211> LENGTH: 1693

<212> TYPE: DNA

<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 23

```

atgcggcacc ccttgccgc gagcgtggtg atccaggtgc cgaccgggc gagcacctcc 60
tgctcggctc agcccgctct gctgagcagc agcgcgcgct cgtaggcggt cgtgaacagc 120
agctcggctc cgtcgacgag ctcccggacg ctgtcgccct ccagccgggc gagctgctgc 180
gaggggtccg cggcccggc gagggccagc tcgcggcaga cccgcgtgtg ccgcaccatc 240
gcctcggggt cgtccgcgc gacgaggacg aggtcgatcc cgcggggcgg gccggccgtc 300
tcgccagggt cgatgtcgcg cgcctcggcc atcgcgcccg cgtagaacga ggcgagctga 360
ttgcgctcct cgtcgggtgt gcacatgaag cgggcgggtg gctgacggtc cgacaccgcg 420
acggagtcgg tgtcgacgcc cgcggcgcgg agcagctgcc cgtaccggtc gaagtccctg 480
ccgacggcgc cgacgaggac ggggcggcga ccgagcaggc cgaggccgta cgcgatgttg 540
gcggcgacgc cgcctgccc gatgtccagg gtgtcgacga ggaacgacag ggacacgtgg 600

```

-continued

```

gcgagctggt ccggcaggat ctgctcggcg aagcggcccg ggaaggtcat caggtggtcg 660
gtggcgatcg acccggtgac ggctatacgc atgtcagagc cccgcggcct tcttcagggc 720
gtccacgcgg tcggtgcgct ccaggtgaa gtccggcagc tcgcggccga agtggccgta 780
ggcggcggtc tgggagtaga tcgggcggag caggtcgagg tcgcggatga tcgcggcccg 840
gcggagggtcg aagacctcgc cgatggcggt ctcgatcttc tcggtctcga tcttgtgggt 900
gccgaaggtc tcgacgaaga ggccgacggg ctcggccttg ccgacgcgt acgcgacctg 960
gacctcgca cgcgaggcga gaccggcggc gacgacgttc ttcgccccc agcgcatcgc 1020
gtacgcggcg gagcggtcga ccttcgacgg gtccttgccg gagaaggcgc cgcaccgtg 1080
gcgggcatg ccgccgtagg tgcgatgat gatcttcgg ccggtgaggc cgcgctcgcc 1140
catcgggccc ccgatctcga agcgaccggt cgggttcacg agcaggcggg agccgtcggg 1200
gtcgagcttg atgccgtcct cgacgagctg cgcaagcacg tgctcgacga cgaacttcg 1260
cacgtcgggg gcgagcagcg actccaggtc gatgtccgag gcgtgctgcg aggagacgac 1320
gacctgtcgc agacggaccg ccctgtcgcc gtcgtactcg atggtgacct gggctctgcc 1380
gtcgggacgc aggtacggga tgggtccggt cttgcggacc tcggtcaggc ggcgcgagag 1440
acggtgcgcg aggtggatcg gcagcggcat cagctcgggc gtctcgtccg aggcatagcc 1500
gaacatcagg ccctggtcac cggcgcccgt cttgtcgagc tcgtccccct cgtcccgtg 1560
ggaggacccc tcgacccgct tctcgtacgc ggtgtcgaca ccctgggcga tgtccgggga 1620
ctgcgacccc atggacaccg acacgccga ggaggcggc tcgaagccct tcttcgagga 1680
gtcgtacccc atc 1693

```

<210> SEQ ID NO 24

<211> LENGTH: 1565

<212> TYPE: DNA

<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 24

```

ccccgctcgc ggccccccag acatccacgc ccacgattgg acgtcccca tgaccgccc 60
cgccctctcc gccaccgccc cggccgaacg ctgcgcgcac cccggagccg atctgggggc 120
ggcggtccac gccgtcggcc agaccctcgc cgcggcggc ctcgtgcgc ccgacgaggc 180
cggaacgacc gcccgccacc tcgtccggct cgcgtgcgc tacggcaaca gccccctcac 240
cccgctggag gaggcccgcc acgacctggg cgtcgaccgg gacgccttc ggcgcctcct 300
cgccctgttc gggcagggtc cggagctccg caccgcggtc gagaccggcc ccgccggggc 360
gtactggaag aacacctcgc tcccgtcga acagcgcggc gtcttcgacg cggcgctcgc 420
caggaagccc gtattcccg acagcgtcgg cctctacccc ggcccgaact gcatgttcg 480
ctgcacttc tcgctccgtg tgaccggcgc ccgctacgac ccgtccgccc tcgacgccg 540
caacgccatg ttccggtcgg tcacgcagca gatacccgcg ggcaaccct cggcgatgta 600
cttctccggc ggcttgagc cgctcacc aa cccggcctc gggagcctgg ccgcgcacgc 660
cacgaccac ggctgcggc ccaccgtcta caggaactcc ttcgcgtca ccgagcgac 720
cctggagcgc cagcccggcc tctggggcct gcacgccatc cgcacctcgc tctacggcct 780
caacgacgag gactacgagc agaccaccgg caagaaggcc gccttcggcc gcgtccgga 840
gaacctgcgc cgctccagc agctgcgcgc cagcgcgag tcgccgatca acctcggctt 900

```

-continued

cgctacatc gtgctcccg gccgtgcctc ccgctgctc gacctggtcg acttcatcgc 960
cgacctcaac gacgccgggc agggcaggac gatcgacttc gtcaacattc gcgaggacta 1020
cagcggccgt gacgacggca agctgccga ggaggagcgg gccgagctcc aggaggccct 1080
caacgccttc gaggagcggg tccgcgagcg cccccccgga ctccacatcg actacggcta 1140
cgccctgaac agcctgcgca ccggggccga cgccgaactg ctgcggatca agccccccac 1200
catgcggccc accgcgcacc cgcaggtcgc ggtgcaggtc gatctcctcg gcgacgtgta 1260
cctgtaccgc gaggccggct tccccgacct ggacggcgcg acccgctaca tcgcgggccg 1320
cgtgaccccc gacacctccc tcaccgaggt cgtcagggac ttcgtcagc gcggcggcga 1380
ggtggcggcc gtcgacggcg acgagtactt catggacggc ttcgatcagg tcgtcaccgc 1440
ccgcctgaac cagctggagc gcgacgcgcg ggacggctgg gaggagggcc gcggcttcct 1500
gcgctgacct gcacccgccc cgatcccccc gatccccccc ccacgatccc cccacctgag 1560
ggccc 1565

<210> SEQ ID NO 25
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 25

ccctgcagcg gcaaggaagg acacgacgcc a 31

<210> SEQ ID NO 26
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 26

aggtctagag ctcaagtgcg ggcgtcggcc gg 32

<210> SEQ ID NO 27
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer (forward)

<400> SEQUENCE: 27

ttgcatgcat atgcgccgta cccagcaggg aacgacc 37

<210> SEQ ID NO 28
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer (reverse)

<400> SEQUENCE: 28

ttgaattctc aactagtacg gcggcccgcc tcccgtcc 38

<210> SEQ ID NO 29
<211> LENGTH: 29

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotides 30-85a

<400> SEQUENCE: 29

ctagtatgca tcatcatcat catcattaa

29

<210> SEQ ID NO 30
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Oligonucleotides 30-85b

<400> SEQUENCE: 30

aattttaatg atgatgatga tgatgcata

29

<210> SEQ ID NO 31
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 31

tcctctagac gtttcggt

18

<210> SEQ ID NO 32
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 32

tgaagcttga attcaaccgg t

21

<210> SEQ ID NO 33
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 33

tttatgcac cgcgggtcc cggcgag

27

<210> SEQ ID NO 34
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 34

tcagaattct gtcggtcact tgcccgc

27

<210> SEQ ID NO 35
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer (forward)

27

-continued

```

<400> SEQUENCE: 35
agatgcattt ctgggatgcc gccacgga                28

<210> SEQ ID NO 36
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer (reverse)

<400> SEQUENCE: 36
cgtctagacg tcaccagacg ttgaccgtg                29

<210> SEQ ID NO 37
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer (forward)

<400> SEQUENCE: 37
tttctagacg gtggcccgga gggaacatc                29

<210> SEQ ID NO 38
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer (reverse)

<400> SEQUENCE: 38
cggaattccg cagctggtcg gcggcgca                28

<210> SEQ ID NO 39
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Streptomyces venezuelae

<400> SEQUENCE: 39
Thr Val Asp Ala Cys Ser Ser Ser Leu
1          5

```

1. An isolated recombinant DNA compound that comprises a coding sequence for a domain of a narbonolide PKS.

2. The isolated recombinant DNA compound of claim 1, wherein said domain is selected from the group consisting of a thioesterase domain, a KSQ domain, an AT domain, a KS domain, an ACP domain, a KR domain, a DH domain, and an ER domain.

3. The isolated recombinant DNA compound of claim 2 that comprises the coding sequence for a loading module, thioesterase domain, and all six extender modules of the narbonolide PKS.

4. An isolated recombinant DNA compound that comprises a coding sequence for a desosamine biosynthetic gene or a desosaminyl transferase gene or a beta-glucosidase gene of *Streptomyces venezuelae*.

5. An isolated recombinant DNA compound that comprises a coding sequence for a picK hydroxylase gene of *Streptomyces venezuelae*.

6. An isolated DNA compound of any of claim 1 that further comprises a promoter operably linked to said coding sequence.

7. The isolated recombinant DNA compound of claim 6, wherein said promoter is a promoter derived from a cell other than a *Streptomyces venezuelae* cell.

8. The isolated recombinant DNA compound of claim 7 that is a recombinant DNA expression vector.

9. The recombinant DNA expression vector of claim 8 that expresses a PKS in *Streptomyces* host cells.

10. The recombinant DNA expression vector of claim 9 that encodes a hybrid PKS comprising at least a portion of a narbonolide PKS gene and at least a portion of a second PKS gene for a macrolide aglycone other than narbonolide.

11. The recombinant DNA compound of claim 10, wherein said second PKS gene is a DEBS gene.

12. The recombinant DNA compound of claim 11, wherein said hybrid PKS is composed of a loading module

and extender modules 1 through 6 of DEBS excluding a KR domain of extender module 6 of DEBS and an ACP of extender module 6 and a thioesterase domain of the narbonolide PKS.

13. A recombinant host cell, which in its untransformed state does not produce 10-deoxymethynolide or narbonolide, that comprises a recombinant DNA expression vector of claim 9 that encodes a narbonolide PKS and said cell produces 10-deoxymethynolide or narbonolide.

14. The recombinant host cell of claim 13 that further comprises a picB gene.

15. The recombinant host cell of claim 13 that further comprises desosamine biosynthetic genes and a gene for desosaminyl transferase and produces YC17 or narbomycin.

16. The recombinant host cell of claim 15 that further comprises a picK gene and produces methymycin, neomethymycin, or picromycin.

17. The recombinant host cell of any of claim 16 that is *Streptomyces coelicolor* or *Streptomyces lividans*.

18. A recombinant host cell other than a *Streptomyces venezuelae* cell that expresses a picK hydroxylase gene of *S. venezuelae* encoded by the DNA compound of claim 5.

19. A recombinant host cell other than a *Streptomyces venezuelae* host cell that expresses a desosamine biosynthetic gene or desosaminyl transferase gene of *S. venezuelae* encoded by the DNA compound of claim 4.

20. A method for increasing the yield of a desosaminylated polyketide in a cell, which method comprises transforming the cell with a recombinant expression vector that encodes a functional beta-glucosidase gene.

* * * * *